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Chapter 1
Summary
Nowadays, computational-aided investigations become an essential part in the chemical, bio-
chemical or pharmaceutical research. With increasing computing power, the calculation of
larger biological systems becomess feasible. In this work molecular mechanical (MM) and
quantum mechanical approaches (QM) and the combination of both (QM/MM) have been
applied to study several questions which arose from different working groups. Thus, this work
comprises eight different subjects which deals with chemical reactions or proton transfer in
enzymes, conformational changes of ligands or proteins and verification of experimental data.
In chapter 3 an introduction to enzymes and its classification is given to the reader. In this
connection only enzymes are described which are part of this work. Additionally, the kinetic
of enzymes as well as their inhibition are considered.
The theoretical background of used MM or QM approaches are described in chapter 4. Com-
putational details about the simulations or calculations can be found in chapter 5. The
following chapters refer to the different investigated subjects. If the reader wants to obtain a
general overview to a specific topic, he (or she) may be advised that each chapter ends with
a short summary which comprises the aim of the investigation and results of the respective
study.
Chapter 6 deals with reaction mechanisms of aromatic inhibitors of cysteine proteases which
can be found in many organisms. These enzymes are responsible for various cancer or diseases
as for example Human African Trypanosomiasis (HAT) or the Chagas disease. Aromatic
SNAr-type electrophiles might offer a new possibility to covalently modify these proteases.
Quantum mechanical calculations on Hartree Fock (HF), post-HF or DFT (density functional
theory) level have been performed to gain insights into the energetics and possible mecha-
nisms. Results show that different possible reaction products do not play an important role
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and that DFT approaches are insufficient to describe the reaction energy of these inhibitors.
The next chapter 7 also deals with Trypanosomiasis but the focus was set on a different
enzyme. The particularity of Trypanosomiasis is the thiol metabolism which can also be
modified by covalent inhibitors. In this context, the wild type and point mutations of the
enzyme tryparedoxin have been investigated via molecular dynamic (MD) simulations to ex-
amine the influence of specific amino acids in regard to the inhibitor. The focus was also set
to different protonation states of relevant cysteine residues in the active site. Experimental
data showed that a dimerization of the enzyme occurs if the inhibitor is present. Simulations
revealed that the stability of the dimer decreases in absence of the inhibitor and thus confirms
these experiments.
Further investigations concerning cysteine proteases such as cruzain and rhodesain have been
conducted in chapter 8 with respect to experimental kinetic data of covalent vinylsulfone in-
hibitors. Several approaches such as QM or QM/MM calculations and docking, MD or
MMPBSA/MMGBSA simulations have been applied to reproduce these data. The utiliza-
tion of force field approaches resulted in a qualitatively accurate prediction.
The kinase AKT (also known as protein kinase B) is involved in a range of intrinsic or ex-
trinsic cell survival signals. A dysregulation of AKT leads to a series of diseases and plays
an important role in the formation of cancer. Novel covalent-allosteric inhibitors have been
developed and crystallized in complex with AKT. It was shown that depending on the in-
hibitor a different cysteine residue is modified. To investigate these differences in covalent
modification computational simulations have been applied in chapter 9. As only negatively
charged cysteine residues can react covalently, amino acids have been investigated which can
stabilize the thiolate of cysteines or which might be responsible for a proton transfer.
Enoyl-(acyl carrier) (ENR) proteins are essential in the last step of the fatty acid biosynthe-
sis II (FAS) and represent a good target for inhibition. The diphenylether inhibitor SKTS1
which was originally designed to target the ENR’s of Staphylococcus aureus was also crys-
tallized in InhA, the ENR of Mycobacterium tuberculosis (TB). Crystal structures indicate
a change of the inhibitor’s tautomeric form. This subject was investigated in chapter 10 via
MD simulations. Results of these simulations confirmed the tautomerization of the inhibitor.
Furthermore, environmental effects on the tautomeric form were investigated by conducting
QM calculations in vacuum or solution. Also, another possible inhibitor was probed and its
stability in complex with InhA was analyzed.
Chapter 11 deals with the development of a covalent inhibitor originating from a non-covalent
ligand. The target FadA5 is an essential enzyme for the degradation of steroids in TB and
is responsible for chronic tuberculosis. This enzyme was crystallized in complex with a
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non-covalent ligand which served as starting point for this study. Computations on QM or
QM/MM level and docking and MD simulations have been applied to evaluate potential
candidates. Although no “hit” was obtained, insights into possible warheads, reactivity or
docking procedures were gained.
Chapter 12 focuses on the modification of the product spectrum of Bacillus megaterium levan-
sucrase, a polymerase which catalyzes the biosynthesis of fructans. The covalent modification
of the wild type or mutants of the enzyme lead to an accumulation of oligosaccharides but
also to polymers with higher polymerization degree. To understand these changes in product
spectra MD simulations have been performed. They revealed on the one hand interactions
between the modifier and important amino acids in the active site which are responsible for
the enzyme’s activity, on the other hand offered a possible explanation for the elongation
process of the polymers.
Finally, the proton transfer in catalytic cysteine histidine dyads was investigated in chap-
ter 13. The focus was set on the influence of the relaxation of the protein environment to
the reaction. Calculations of the enzymes FadA5 and rhodesain revealed that the preferred
protonation state of the dyade depends on the protein environment and has an impact on
the reaction barrier. Furthermore, the adaptation of the environment to a fixed protonation
state was analyzed via MD simulations. Dynamics reveal that at least one nanosecond is
required until the relaxation of the surroundings to the respective protonation state occurs.
9
Chapter 2
Zusammenfassung
Heutzutage sind computergestu¨tzte Untersuchungen ein essentieller Teil in der chemischen,
biochemischen oder pharmazeutischen Forschung. Durch die in den Jahren gestiegene Rechen-
leistung ist die Berechnung biologischer Systeme mo¨glich. Im Rahmen dieser Arbeit wurden
molekularmechanische (MM) und quantenmechanische (QM) Methoden sowie die Kombina-
tion beider (QM/MM) fu¨r verschiedene Studien eingesetzt, die teilweise aus Fragestellungen
verschiedener Arbeitsgruppen hervorgegangen sind. Dadurch umfasst diese Arbeit acht ver-
schiedene Themenkomplexe, bei denen chemische Reaktionen, aber auch der Protonentransfer
in Enzymen, Konformationsa¨nderungen von Liganden oder Proteinen und die Verifizierung
experimenteller Daten im Fokus standen.
In Kapitel 3 soll dem Leser eine Einfu¨hrung in Enzyme und deren Klassifizierung gegeben
werden. Hierbei werden nur Enzyme genauer beleuchtet, welche Bestandteil dieser Arbeit
sind. Ebenfalls wird auf die Kinetik von Enzymen und auch auf deren Inhibition eingegan-
gen.
Die theoretischen Grundlagen der hier verwendeten MM oder QM Methoden werden in Kapi-
tel 4 erla¨utert. Generelle Informationen zu den Simulationen oder Berechnungen ko¨nnen in
Kapitel 5 gefunden werden. Die darauffolgenden Kapitel beziehen sich auf die verschiede-
nen Themenkomplexe, welche untersucht wurden. Sofern der Leser lediglich einen groben
U¨berblick zu einer bestimmten Thematik erhalten will, wird darauf hingewiesen, dass das
Ende jedes Kapitels eine kurze Zusammenfassung beinhaltet, welche Fragestellung und Ergeb-
nisse umfasst.
Kapitel 6 befasst sich mit Reaktionsmechansimen aromatischer Inhibitoren fu¨r Cysteinpro-
teasen, Enzyme, welche in vielen Organismen enthalten sind. Diese Enzyme sind fu¨r ver-
schiedene Karzinome oder Krankheiten wie der Afrikanischen Trypanosomiasis oder der
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Chagas-Krankheit verantwortlich. Aromatische SNAr-Elektrophile bieten hierbei eine neue
Mo¨glichkeit der kovalenten Modifikation dieser Proteasen. Quantenmechanische Berech-
nungen auf Hartree Fock (HF), post-HF oder DFT (Dichtefunktionaltheorie) Niveau wur-
den durchgefu¨hrt, um Einblicke in die Energetik und mo¨gliche Mechanismen zu erhalten.
Die Ergebnisse zeigen, dass hierbei verschiedene mo¨gliche Produkte ausgeschlossen werden
ko¨nnen. Ebenfalls kristallisierte sich heraus, dass oft verwendete DFT Ansa¨tze die Reaktion-
senergie solcher Inhibitoren unzureichend beschreiben.
Das darauffolgende Kapitel 7 befasst sich ebenfalls mit Trypanosomiasis, setzt aber den Fokus
auf ein anderes Enzym. Die Besonderheit von Trypanosomiasis ist der Thiol Metabolismus,
welcher durch kovalente Inhibitoren modifiziert werden kann. In diesem Kontext wurden der
Wildtyp und Punktmutationen des Enzyms Tryparedoxin mittels Molekulardynamik Simu-
lationen untersucht, um Interaktionen einzelner Aminosa¨uren mit dem kovalenten Inhibitor
C1 zu evaluieren. Auch die verschiedenen Protonierungszusta¨nde relevanter Cysteine im ak-
tiven Zentrum standen im Fokus. Experimentelle Daten zeigten, dass eine Dimerisierung des
Enzyms in Anwesenheit des Inhibitors stattfindet. Durch MD-Simulationen konnte gezeigt
werden, dass die Stabilita¨t des Dimers in Abwesenheit des Inhibitors sinkt, wodurch experi-
mentellen Daten besta¨tigt wurden.
Weitere Untersuchungen zu Cysteinproteasen wie Cruzain und Rhodeasin wurden in Kapitel
8 durchgefu¨hrt, um experimentelle kinetische Daten von kovalenten Vinylsulfon Inhibitoren
zu reproduzieren. Hierbei wurden Methoden wie QM oder QM/MM Rechnungen aber auch
Docking, MD und MMPBSA/MMGBSA Simulationen angewandt, um diese Daten zu repro-
duzieren. In den Untersuchungen zeigte sich, dass die Verwendung der Kraftfeld-basierten
Methoden zu qualitativ richtigen Vorhersagen fu¨hrte.
Die Kinase AKT (auch bekannt als Protein Kinase B) ist in einer Reihe von Krankheiten
involviert und spielt eine wichtige Rolle bei der Entstehung von Krebs. Neue kovalent-
allosterische Inhibitoren wurden entwickelt und im kovalenten Komplex mit AKT kristallisiert.
Die Kristallstrukturen zeigten, dass je nach Inhibitor ein anderes Cystein adressiert wurde.
Um diese Unterschiede zu untersuchen, wurden in Kapitel 9 computergestu¨tzte Simulationen
verwendet. Da erst ein negativ geladenes Cystein kovalent reagieren kann, wurden ebenfalls
Aminosa¨uren untersucht, welche entweder stabilisierend auf die Thiolate der Cysteine wirken
ko¨nnen oder fu¨r die Deprotonierung zusta¨ndig sein ko¨nnen.
Enoyl-(acyl carrier) (ENR) Proteine sind essentiell fu¨r den letzten Schritt in der Fettsa¨ure-
biosynthese II (FAS) und bilden ein gutes Target zur Inhibition. Der Diphenylether Inhibitor
SKTS1, welchen man urspru¨nglich als Target fu¨r den ENR von Staphylococcus aureus ent-
warf, wurde auch in InhA, dem ENR von Mycobacterium Tuberculosis (TB), kristallisiert.
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Die Kristallstrukturen weisen je nach Protein auf einen Wechsel der tautomeren Form des
Inhibitors hin. In Kapitel 10 wurde dieser Sachverhalt mittels MD Simulationen unter-
sucht. Hierbei zeigten die Ergebnisse eine U¨bereinstimmung mit den experimentellen Daten.
Ebenfalls wurden Umgebungseffekte, welche Einfluss auf die tautomere Form haben ko¨nnen,
mittels QM Rechnungen im Vakuum oder im Solvens untersucht. Zusa¨tzlich wurde ein weit-
erer mo¨glicher Inhibitor getestet und seine Stabilita¨t im Komplex mit InhA analysiert.
Kapitel 11 befasst sich mit der Entwicklung eines kovalenten Inhibitors ausgehend von einem
nicht-kovalenten Liganden. Das Target FadA5 ist ein integrales Enzym zur Degradation von
Steroiden in TB und ist fu¨r die chronische Tuberkulose verantwortlich. Dieses Enzym wurde
im Komplex mit einem nicht-kovalenten Liganden kristallisiert, welches als Startpunkt dieser
Untersuchungen diente. QM, QM/MM, Docking und MD Simulationen wurden hierbei ver-
wandt, um potentielle Kandidaten zu evaluieren. Obgleich kein
”
Hit“ erzielt wurde, konnten
wichtige Erkenntnisse hinsichtlich mo¨glicher Warheads, Reaktivita¨t oder Docking Prozeduren
gewonnen werden.
Das Kapitel 12 befasst sich mit der Modifikation des Produktspektrums von Bacillus mega-
terium Levansucrase, eine Polymerase, welche die Biosynthese von Fruktanen katalysiert.
Durch kovalente Modifikatoren im Wildtyp oder bei Mutanten des Enzyms konnte sowohl eine
Anreicherung von Oligosacchariden, aber auch von Polymeren mit ho¨herem Polymerisation-
sgrad erzielt werden. Um diese A¨nderungen im Produktspektrum zu verstehen, wurden MD
Simulationen durchgefu¨hrt. Diese zeigten einerseits Wechselwirkungen zwischen den Modi-
fikatoren und wichtigen Aminosa¨uren in der aktiven Tasche, welche fu¨r die Enzymaktivita¨t
verantwortlich sind, andererseits bieten sie eine mo¨gliche Erkla¨rung des Elongationsprozesses
der Polymere.
Schließlich wird in Kapitel 13 die Untersuchung des Protonentransfers in katalytischen Cys-
tein Histidin Dyaden beschrieben. Hierbei stand der Einfluss der Relaxation der Proteinumge-
bung auf diese Reaktion im Fokus. Berechnungen in den Enzymen FadA5 und Rhode-
sain zeigten, dass der pra¨ferierte Protonierungszustand der Diade von der Proteinumgebung
abha¨ngt und einen großen Einfluss auf die Reaktionsbarriere hat. Um dynamische Effekte
einzubeziehen, wurde die Adaption der Umgebung auf einen fixierten Protonierungszus-
tand mittels MD Simulationen analysiert. Die Simulationen zeigten, dass mindestens eine
Nanosekunde notwendig ist, bis die Relaxation der Umgebung hinsichtlich des Protonierungszu-
standes stattfindet.
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Chapter 3
Introduction
3.1 The history of enzymes – a brief overview
At the end of the 17th century it was already known that the transformation of starch to sugar
is due to plant extracts or that the digestion of meat is caused by intestinal secretions, still
the mechanism responsible for these reactions was unidentified [1]. Louis Pasteur conducted
investigations in the 19th century in regard to the fermentation of sugar to alcohol in starch.
At that time these unknown substances which promote this reaction were called “ferments”
and it was assumed that they are solely active in living organisms [1].
In the year 1877 the term “enzyme” was used by Wilhelm Ku¨hne to describe the fermentation
process for the first time. The word “enzyme” is derived from the Greek language (en = in
and zyme = yeast) and was used to describe the reaction of ethyl alcohol to carbon dioxide,
which is catalyzed by the enzyme zymase [1]. 20 years later Eduard Buchner was able to show,
that this yeast extract can also ferment sugar outside of the cells and thus he disproved the
assumption that ferments are only able to show activity in living organisms [2]. He named
ferments or more precisely this enzyme zymase. 1907, 10 years after he conducted these
experiments for the cell-free fermentation he was awarded with the Nobel Prize in chemistry.
In these days, the enzymatic activity was related to proteins, however, most of the people
presumed that proteins solely serve as carriers for enzymes and are not the catalysts itself
which was also believed by the Nobel Prize laureate Richard Willsta¨tter [1]. In the 1930s
Northrop and Stanley were able to prove that this assumption was wrong. In their work,
they revealed that pure proteins as pepsin, trypsin and chromotrypsin can indeed be enzymes
[3]. Another milestone in the history of enzymes was set in 1965 by David Chilton Phillips
and co-workers who performed the crystallization and structural elucidation of lysozyme via
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X-ray [4]. This technique is still of relevance nowadays for the structural elucidation of novel
proteins, the understanding of their catalytic reactions and in this respect the development
of new drugs.
To understand the nature of proteins itself, it is of necessity to obtain an overview of the
general structure and functions of proteins. Therefore, the next section is dedicated to this
topic.
3.2 Structural features and functions of proteins
Proteins are one of the most important macromolecules which can be found in living organ-
isms. They have a variety of different and decisive functions in nearly all biological processes.
They play a role in the transport or the storage of other molecules, possess mechanical func-
tions, are responsible for the immunity, are involved in the signal transduction by transferring
nerve impulses or control the growth and cell differentiation [5].
Proteins consist of monomeric sub units, so called amino acids, which can be linked hence
forming peptides (oligomeric/polymeric) and resulting in a chain. This is exemplary shown
for the tripeptide consisting of serine, glycine and leucine in Figure 3.1-A. If one solely sets
his focus on the linear chain one refers to the primary structure. Still, proteins are able to
form a three-dimensional structure which can take, depending on the amino acid sequence,
different shapes. The secondary structure can be obtained if amino acids interact with each
other due to close interactions as hydrophilic ones (e.g. hydrogen bonds) or hydrophobic in-
teractions (Coulomb interactions or pi-stacking) (Figure 3.1-B). The existence of these alpha
helices and beta sheets were already proposed in 1951 as primary motif of proteins by Paul-
ing Corey and Branson [1]. If above mentioned interactions are formed at larger distances
one obtains the tertiary structure (Figure 3.1-C). For some proteins a quaternary structure is
also possible when a group of monomers (tertiary structures) interact with each other (Figure
3.1-D). The manifold possibilities to combine amino acids give the specific shape of proteins
which is deterministic for the function of the protein. The resulting structures can differ in
form and flexibility. Rigid structures serve as structural components in the cytoskeleton or in
connective tissues while flexible proteins allow a merger between proteins or other molecules.
These interactions result in an exchange of signals or information between cells by signal
transduction and thus evoke different effects.
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A B
C D
Figure 3.1: A – Primary structure of tripeptide Ser22, Gly23, Leu24 in FadA5 C93S variant
(pdb code = 4UBT). B – Secondary structure of FadA5 C93S variant. C – Tertiary structure
of FadA5 C93S variant D – quaternary structure of of FadA5 C93S variant (dimer).
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Figure 3.2: Chemical structures of proteinogenic amino acids at physiological pH 7.4.
The flexibility of proteins is determined by the functional groups of the amino acid side
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chain (e.g. thiols, alocohols, carbon acids or amines). This set of amino acids differs in size,
shape, hydrophilicity, hydrophobicity or charge (Figure 3.2). The spectra of interactions
depend on the connection of these amino acids and thus dictate the structure of the protein.
Apart from the structural role, side chains determine the catalyzed chemical reaction and its
reactivity and are responsible for the function of enzymes.
3.3 The enzyme classes
Due to the variety of enzymes and their different catalytic characteristics the International
Union of Biochemistry founded the Enzyme Commission in the year 1955 to classify these
enzymes [1]. If one takes a look at the swissprot database one can find over 6000 different
enzymes today which proves the relevance of the classification (https://enzyme.expasy.org/).
Enzyme classes are organized by the enzyme commission number (EC) depending on the
chemical reaction which they catalyze. The six main classes are:
 EC1: Oxidoreductases which catalyze the oxidation or reduction.
 EC2: Transferases which catalyze the transfer of groups.
 EC3: Hydrolases which promote the transfer of functional groups to water by a hydrol-
ysis reaction.
 EC4: Lyases which add or remove groups to support the development of double bonds.
 EC5: Isomerases which lead to intramolecular transfer of groups (isomerization).
 EC6: Ligases which catalyze the ligation of two substrates due to ATP-hydrolysis.
In the following only enzymes are described which are part of this work. A more compre-
hensive description of the specific investigated enzyme can be found in each chapter.
3.3.1 Proteases
The metabolism of proteins in living organisms is an important process which leads to the
“recycling” of proteins. Unnecessary proteins are degraded to amino acids which can be used
for resynthesis of new proteins. This proteolytic process is catalyzed by proteases (EC 3.4).
The general mechanism of proteases is subject of hydrolytic reactions, depicted in Figure 3.3,
which can be described as the addition of a water molecule to a peptide.
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Figure 3.3: General reaction mechanism of proteases due to hydrolytic reactions.
The reaction is thermodynamically favored but the reaction rate is low. Due to the
resonance structure of the peptide bond a resistance towards hydrolytic cleavages occurs
[5]. The electrophilic character of the carbon is lowered by the partial double bond between
the α-C atom and the nitrogen. In consequence, the reactivity of the nucleophilic reaction
is decreased. Therefore, proteases are of necessity to activate these non-reactive carbonyl
groups to favor the cleavage process of the peptide.
This large group of protease can be divided by two factors: the location where they act or
the residue which they address. Endopeptidases (EC 3.4.21-99) split internal peptide bonds,
while exopeptidases (EC 3.4.11-19) catalyze reactions at the N- or C-terminus. Furthermore,
one can find serine (EC 3.4.21), cysteine (EC 3.4.22), aspartic (EC 3.4.23), metallo (3.4.24)
and threonine proteases (EC 3.4.25).
In the course of this work rhodesain from Trypanosoma brucei (T.b.) rhodesiense, cruzain
from Trypanosoma cruzei and cathepsin L have been investigated which belong to the class
of cysteine proteases. Cysteine proteases can be found in many organisms such as viruses,
bacteria or protozoa. Especially in the latter case most of the isolated proteases belong to the
parasitic protozoa. A cysteine is located in the active center which is activated by a nearby
histidine functioning as nucleophile. In contrast to serine proteases the histidine residue is
sufficient and no catalytic triad is necessary (5).
3.3.2 Glycosyltransferases
Glycosltransferases (EC 2.4) are a subgroup of transferases which favor the production of
complex carbohydrates. It becomes clear that a multitude of enzymes are needed since
manifold glycosidic bonds can be formed. One can differentiate glycosyltransferases into
three different groups: hexosyltransferases (EC 2.4.1), pentosyltransferases (EC 2.4.2) and
transferases which transfer different glycosyl gropus (EC 2.4.99). In all examined organisms,
glycosyltransferases solely account for 1-2% of the gene products (5).
The catalytic reaction of these enzymes can be schematically depicted as in Figure 3.4. Often,
glucose is bound to nucleotides to achieve an increase of the molecules’ energy conversation
[5]. This monosaccharide nucleotide UDP-Glucose (uridine diphosphate) transfers a carbo-
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hydrate to an acceptor substrate as amino acid residues of proteins (e.g. serine, threonine or
asparagine), lipids or other carbohydrates (5). In this work the glycosyltransferase levansu-
crase (EC 2.4.1.10), a hexosyltransferase from Bacillus megaterium has been investigated.
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Figure 3.4: Transfer of glucose from UDP-glucose to acceptor substrate XH catalyzed by
glycosyltransferase. This figure is adapted from [5].
3.3.3 Proteinkinases
Proteinkinases are another class of transferases and shall be considered in more detail. In
eukaryotic cells the phosphorylation serves as regulatory mechanism for metabolic processes.
It is known that 30% of the eukaryotic proteins are phosphorylated [5]. These phosphoryla-
tion reactions are catalyzed by protein kinases. These enzymes belong to one of the largest
protein families with 100 homologous enzymes in yeast and over 500 enzymes in humans. Due
to the variety of enzymes it is possible to ensure the precise regulation of place (specific tis-
sue), time or substrate. Protein kinases are divided as tyrosine (EC 2.7.10), serine/threonine
kinases (EC 2.7.11), dual-specifity kinases which act on serine/threonine and also tyrosine
(EC 2.7.12), histidine kinases (EC 2.7.13), arginine kinases (EC 2.7.14) and other kinases
(EC 2.7.15-99).
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The reaction which is catalyzed by these enzymes is the transfer of a terminal phospho-
ryl group from adenosine triphosphate (ATP) to the respective amino acid of the acceptor
protein. In eukaryotes a transfer to an alcohol group occurs as it is in serine, threonine or
tyrosine (Figure 3.5). The serine/threonine kinase AKT1 (EC 2.7.11.1) was investigated in
this work and will be further discussed in chapter 9.
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Figure 3.5: Transfer of phosphoryl group of ATP to residue (Ser, Thr, Tyr) catalyzed by
protein kinase resulting in adenosine diphosphate (APD) and phosphorylated residue. This
figure is adapted from [5].
3.3.4 Acetyltransferases
Acyltransferases are another representative of the group of transferases. One can split them
in transferases which do not transfer amino-acyl groups (EC 2.3.1), aminoacyltransferases
(EC 2.3.2) or such which convert acyl groups into alkyl groups on transfer (EC 2.3.3). In this
work, FadA5 was investigated, an Acetyl-CoA C-acyltransferase (EC 2.3.1.9) or also known
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as thiolase from Mycobacterium tuberculosis. Thiolases catalyze the reaction of 3-ketoacyl-
CoA with CoA. On this occasion the thiol group of CoA reacts with 3-ketoacyl-CoA leading
to a 2 C-atom shortened Acyl-CoA by cleavage (Figure 3.6).
Studies on the thiolase of Zoogloea ramigera showed that this reaction underlies a so-called
ping-pong reaction [6]. In this case, the nucleophilic Cys89 reacts with the 3-ketoacyl-CoA
and forms a covalent Acyl-CoA intermediate [7]. Due to another CoA the product is cleaved
from the enzyme [8]. These reactions play an important role in the steroid synthesis or in
the degradative pathways of the β-oxiation of fatty acids [9], [10].
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3-ketoacyl-CoA two-carbon shortened acyl-CoA
Figure 3.6: Degradation of 3-ketoacy-CoA to two-carbon shortened acyl-CoA catalyzed by
thiolase.
3.3.5 Oxidoreductases
Oxidoreductases catalyze the electron transfer from one molecule (reductant) to the electron
doner (oxidant) as depicted in Figure 3.7. Substrates can be various organic compounds as ke-
tones, amines, or alcohols, anorganic molecules as sulphites or metals as mercury [11]. In most
cases these enzymes utilize nicotinamide adinine dinucleotide cofactors as NADP+ or NAD+
to transfer a hydride (H-) group to oxidize a substrate [11], [12], [13]. A prominent example is
the mitochondrial electron transport chain which is essential for the respiratory chain in liv-
ing organisms. In this case, electrons are transferred from NADH to oxygen by four different
oxidoreductases: NADH-Q-oxidoreductase, Q-cytochrome-c-oxidoreductase, cytochrome-c-
oxidase and the succinate-Q-reductase [14]. Tryparedoxin (TPX) of Trypanosoma brucei
belongs to the class of reductases which catalyzes reactions where disulfide acts as an accep-
tor. It is part of a redox-cascade and will be further discussed in chapter 7.
A B+ BA +
Figure 3.7: Catalyzed reaction of oxidoreductases by oxidation of one species and simultane-
ously reduce the other.
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3.3.6 Oxidoreductases acting on the CH-CH group of donors
The enoly-(acyl-carrier-protein) reductase (EC 1.3.1.9) or abbreviated as ENR, belongs to the
main enzyme class of the oxidoreductases and is an essential enzyme in the type II fatty acid
synthesis (FAS) system [15]. It catalyzes the reduction of a trans-2-acyl-ACP (acyl carrier
protein) to an acyl-ACP species by means of NADH or NADPH which act as reducing agent
(Figure 3.8). These enzymes are a good target for the development of new antibiotics as they
play an important role in the metabolism of many bacteria. Additionally, the bacterial ENR
sequence is differently compared to the mammalian fatty acid biosynthesis, thus a selective
targeting via drugs is possible. In chapter 10 the ENR of staphyloccocus aureus FabI and of
mycobacterium tuberculosis InhA are further discussed.
S
O
ACP S
O
ACP
NADPH NADP+
ENR
Figure 3.8: Catalyzed reduction of trans-2-acyl-ACP to a saturated acyl-ACP species.
3.4 Michaelis-Menten kinetic
Enzymes catalyze different reactions and lower reaction barriers to enable faster processes.
To investigate the reaction rate of enzymes the best way is to observe the increase of reactands
in the course of time. To achieve this experimentally one can determine the concentration
of the substrate S and the over time increasing concentration of product P . At some point
no change of S or P is observable. In this occasion the substrate is still converted into
the product by the enzyme, though the backward reaction occurs contemporary so that one
reaches a reaction equilibrium.
If one focuses on the forward reaction, one can define the reaction velocity V0 which stands
for the emerging mol of product per second at the beginning of reaction (t ≈ 0) (Figure
3.9-A). In this case, we assume that the backward reaction is negligible thus the amount of
available enzyme remains constant. When V0 is applied to the substrate concentration one
obtains the curve depicted in Figure 3.9-B. This behavior is observed in many enzymes [5].
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Figure 3.9: A - Amount of products obtained at different concentrations of substrate in the
course of time. V0 refers to the initial rate which is obtained by the slope of each curve at the
beginning of the reaction. B – The reaction velocity V0 obtained from the slopes at different
concentrations plotted against the substrate concentration. This figure is adapted from [5].
An explanation for these kinetic properties of enzymes was proposed in 1913 by Leonor
Michaelis and Maud Menten [16]. The crux of this matter is the consideration of an enzyme-
substrate complex (ES) which occurs as an intermediate in the catalysis:
E + S E P+
k1 k2
k
-1 k-2
ES
As one can see in this chemical equation the ES complex is build with a rate constant
k1. This complex can be degraded back to E + S again or be converted to E and P . Still in
the latter case it can degrade back to the ES complex. Since we are solely considering the
reaction rate at the beginning, we can set the rate constant k−2 to zero due to the fact that
the concentration of the product has to be very low. This results in the following equation:
E + S E P+
k1 k2
k
-1
ES
Consequently, one has to measure the reaction velocity V0 (at different substrate concen-
trations) right at the beginning before the accumulation of P occurs. As a result, one obtains
the kinetic of enzymes which obey the rules of the Michaelis-Menten kinetic (Figure 3.10).
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Figure 3.10: The reaction velocity V0 plotted against the substrate concentration. The
Michaelis constant KM is the substrate concentration in which the reaction rate is half of
Vmax, whereas Vmax is the maximum reaction rate. This maximum rate can be estimated by
evaluating the value in the asymptotic limit. This figure is adapted from [5].
The graph depicted in Figure 3.10 can be described with the following equation, the
Michaelis-Menten equation:
V0 = Vmax
[S]
[S] +KM
(3.1)
By means of equation 3.1 important properties can be derived. In this context V0 stands
for the reaction rate, Vmax refers to the maximal possible reaction rate, KM the Michaelis-
Menten constant and [ ] represents the concentration, in this case of the substrate.
At low substrate concentrations ([S] << KM) one acquires V0 = (Vmax/Km)/[S] and thus
obtains a first-order reaction, since reaction rate and substrate concentration are proportional.
If the substrate concentration is larger than KM ([S] >> KM) one obtains a reaction of
zeroth order as V0 = Vmax and in consequence the reaction is independent from the substrate
concentration.
In case of [S] = KM we get V0 =
Vmax
2
and on this occasion the reaction rate reaches half of its
maximum value at the substrate concentration KM . The Michaelis constant is an important
characteristic in enzyme-catalyzed reactions and plays substantial role in the quantification
of enzyme kinetic [5].
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3.5 Inhibition of enzymes
Enzymes regulate various and important processes in organisms as in humans but as well as
in bacteria, protozoa or in viruses. In case of humans, a defective function or a dysregulation
of enzymes can result in diseases. If one disturbs enzymes of viruses or bacteria it is possible
to contain these diseases (virostatic or bacteriostatic) or cure them (virucide or bactericide).
Therefore, it is of importance to understand the function of each enzyme to modulate them
respectively to e.g. counteract dysfunctions or specifically inhibit bacterial enzymes to gain
a therapeutic benefit.
3.5.1 Different ways of inhibition
The inhibition of enzymatic catalysis can be divided into two different types. On the one
hand, one refers to the reversible inhibition in which the inhibitor develops weak interactions
with the enzyme to form an enzyme-inhibitor (EI) complex. This complex is not stable and
dissociation can occur. On the other hand, the dissociation of the EI complex is weak or
non-existent in case of an irreversible inhibition.
The reversible inhibition of enzymes can occur as competitive, uncompetitive or noncompet-
itive inhibition. If one determines the enzyme kinetics it is possible to draw conclusions in
terms of the inhibition type. The irreversible inhibition of enzymes can be achieved by the
formation of a covalent bond between inhibitor and enzyme. In this occasion, one distin-
guishes between different groups. Group-specific reagents modify the amino acide side-chain
covalently which is located in the active site and also essential for the catalysis. Reactive
substrate analogs also bind at the active site but additionally mimic the native enzyme sub-
strate. Suicide inhibitors bind as substrate-analog at the active site and lead due to catalysis
to an auto-inactivation of the enzyme [5].
Beside orthosteric inhibitors which interact with the active site of an enzyme, allosteric in-
hibitors have to be mentioned which can bind at a different location [17]. These inhibitors
have two different mechanisms: In the first case one can consider the following scenario. If
no allosteric inhibitor is bound to the active site, the substrate can bind and thus the enzyme
can catalyze the formation of the product. If the allosteric inhibitor binds to the enzyme,
the active site can be blocked so that the inhibitor hinders the entrance of the substrate. In
the second case, the binding of the allosteric inhibitor modulates the active site and through
this modulation the active site cannot be targeted by the substrate [18].
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Reversible inhibition
Competitive inhibition – In case of the competitive inhibition a blockade of the enzyme’s
active site occurs due to the binding of the inhibitor. Consequently, no natural substrate can
form a complex with the enzyme and the catalysis of the enzyme is reduced. As a concurrent
binding of substrate and inhibitor is not possible, one can neutralize the inhibition by excess
of substrate, since the developed E − I complex solely forms weak interactions. The degree
of dissociation of the E − I complex can be measured by the dissociation constant Ki.
Ki =
[E][I]
[EI]
(3.2)
If one looks at equation 3.3, it is evident that strong inhibitors possess a low dissociation
constant. In this context KappM refers to the apparent KM of the reaction. Furthermore, an
increase of KM occurs due to a competitive inhibitor although Vmax remains the same in a
saturated substrate-enzyme complex [5].
KappM = KM + (1 +
[I]
Ki
) (3.3)
Uncompetitive inhibition – One refers to uncompetitive inhibition if the inhibitor solely
binds to an enzyme-substrate complex. Thus, a neutralization of inhibition cannot be
achieved by an excess of substrate. In contrast to competitive inhibition KappM as well as
Vmax can be modified.
Noncompetitive inhibition – This form of inhibition occurs if a concurrent binding of
substrate and enzyme occurs. Thus, the inhibitor can bind to the enzyme to form the EI
complex or it binds to the ES complex. An excess of substrate cannot lower the inhibi-
tion. Although KM remains the same after inhibition a reduction of Vmax can occur and in
consequence one obtains a new variable V appmax which is defined as:
V appmax =
Vmax
1 + [I]/Ki
(3.4)
Irreversible inhibition
The irreversible inhibition which is evoked by a covalent binding of an inhibitor and a
aminoacid side chain of an active side residue, can be differentiated into two categories.
The first describes a covalent binding which results from a preceeding interaction of inhibitor
and enzyme. Consequently, the inhibition is a two step mechanism which can be described
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by the following chemical equation:
E + I
kinact
E  I E-I
KI
In a first step a reversible enzyme-inhibitor (E · I) complex is formed which can be
quantified by the binding constant KI . KI describes the necessary concentration of inhibitor
to achieve half of the maximum potential rate of covalent bond formation [19]. This should
not to be mixed up with the dissociation constant Ki. The second step is the formation of a
covalent E − I complex which depends on the concentration of the E · I complex. If solely
the reversible E · I complex is available and no free enzyme remains, the observed rate of
inactivation is kinact. This rate describes the formation of a covalent E − I complex and is
defined as the first-order rate constant [19]. To describe the overall reaction from unbound
enzyme to the covalent enzyme-inhibitor complex one uses the ratio of both, resulting in
kinact/KI .
The second category of covalent-irreversible inhibition follows a different mechanism: by
an immediate covalent formation without the presence of a non-covalent complex. In this
occasion, the reactivity of the nucleophile of the enzyme and the electrophilic part of the
inhibitor (also known as warhead) is so high that the efficiency of the reaction is equivalent
to kinact/KI . This inhibition can be described with the following chemical equation:
E + I
kinact/KI
E-I
Covalent-reversible inhibition
Covalent-reversible inhibitors take a different approach. These inhibitors form a covalent
bond with the enzyme but the activity of the enzyme can be regained if the bond is cleaved.
Although the covalent binding is reversible, the binding affinity is about three magnitudes
larger compared to non-covalent inhibitors [20]. One can divide covalent-reversible inhibitors
in two types: The first one show a reversible inhibition because of their chemical mechanism
which results in a weak bonding. Thus, the covalent complex can dissociate to the non-
covalent complex or even the free enzyme. The second type are described as “slow substrates”
which are rather recognized as substrates. The cleavage of the covalent bond results from a
catalyzed reaction by the enzyme and leads to the release of a product which does not serve
as an inhibitor anymore. This kind of reaction occurs at lower rates hence one refers to “slow
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substrates” if such inhibitors are described [21].
Covalent-reversible inhibitors contain different groups as e.g. an aldehyde as electrophilic
group which can form a hemiacetal with nucleophilic residues in the active site [22]. Beside
aldehydes, there are other functional groups which can form a reversible covalent bond.
Bortezomib, a proteasome inhibitor, undergoes a reversible boronic ester transesterification
due to its boronic acid [22], [23]. Nitriles can also act as warheads to form a reversible
covalent bond [24]. In case of Michael acceptors, α,β-unsaturated carbonyl systems, react
with different nucleophiles which are carbon-, nitrogen-, sulfur- or oxygen-based [22]. To
utilize them as covalent-reversible inhibitors one can change the electron density of the double
bond to increase or decrease the reactivity to tune these kinds of warheads [25].
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Theoretical background
4.1 Molecular Mechanics
As biochemical systems are usually large (e.g macromolecules, organelles or cells), calcula-
tions applying quantum mechanical methodologies for the whole system are unfeasible. This
is why one makes use of force field (FF) methods (also known as molecular mechanics). In
contrast to quantum mechanics, the electronic energy is written as a parametric function of
the nuclear coordinates which is parametrized by experimental data or high-level quantum
mechanical calculations [26]. Additionally, force field methods use atoms and do not consider
electrons as individual particles so that the binding information has to be explicitly speci-
fied. The dynamics of these atoms are described with classical mechanics, i.e. Newtons law
of motion. If one connects these atoms to form a molecule one uses the “ball and spring”
model. Atoms differ in this case by their size and the “softness” and the binding results from
the bond’s length and rigidity [27], [28].
Force field methods make use of the fact that molecules consist of subunits which show the
same properties independent from the molecule which they are contained with. If one con-
siders at the linear alkane chain CH3(CH2)nCH3 the amount of energy contribution for the
heat of formation is practically the same for all CH2 subunits [26]. The concept of molecules
comprising structural similar subunits is realized in force field methods by the introduction
of so-called atom types.
4.1.1 Molecular mechanical energy term
To describe the energy of molecules, the calculation of the force field energy Eff is necessary.
Eff is the total energy of a system and can be described as a sum of different terms which
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expresses the distortion of atoms and intermolecular interactions:
Eff = Estr + Ebend + Etors + Evdw + Eel + Ecross (4.1)
The individual terms are:
 the energy function for stretching the bond between two atoms (Estr)
 the energy which needs to be provided to bend an angle (Ebend)
 the torsional energy resulting from a rotation around a bond (Etors)
 non-bonded inter- and intramolecular interactions of the Van der Waals and Coulomb
parts (Evdw und Eel)
 the coupling of the first three terms (Ecross)
As the energy sub-terms depend on the atomic position and yield an energy with respect
to the atomic coordinates Ri, it is also possible to determine the derivatives of the energy
with respect to R. This is necessary in order to perform geometry optimization.
Figure 4.1: Illustration of force field energy terms of the A – stretch term, B – bending term,
C – torsional term, D – non-bonded terms.
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The stretch energy term
The energy function Estr describes the stretching of a bond between two atoms as depicted
in Figure 4.1-A. Estr is expressed as a Taylor series expansion around the equilibrium bond
length R0 which is terminated after the second order resulting in the following equation:
Estr(R
AB −RAB0 ) = E(0) +
dE
dR
(RAB −RAB0 ) +
1d2E
2dR2
(RAB −RAB0 )2 (4.2)
The first term of equation 4.2 is usually set to zero, as this is the zero point of the energy
scale [26]. In consequence Estr can be simplified to:
Estr(R
AB −RAB0 ) = kAB(RAB −RAB0 )2 = kAB(∆RAB)2 (4.3)
In this context kAB represents the parametrized force constant between two atoms. The equa-
tion is written in the form of a harmonic oscillator, in which the potential for displacement
around the equilibrium has a quadratically form. R0 is parametrized within each molecular
subunit and does not reflect the equilibrium pair distance for every molecule, as variations
may occur during a minimization. It is possible to extend the Taylor expansion by including
higher-order terms. However, this leads to a concurrent increase of parameters which need
to be fitted. Furthermore, such an extension does not necessarily lead to an improvement
especially in case of the description of distorting bond lengths [26]. Another problem in the
harmonic approximation are the energies obtained for large bond displacements far away
from the equilibrium arrangement. For such cases it is of importance to determine a function
which describes the convergence of the dissociation energy at infinite distortion of the bond.
With the help of a morse potential this criterion can be fulfilled.
EMorse(∆R) = D(1− e−α∆R)2 (4.4)
α =
√
k
2D
(4.5)
In this context D represents the dissociation energy and α is also related to the force constant
k. Despite this, problems can occur by using a morse potential because of weak forces in
long bonds [26]. Thus, a slow convergence result for obtaining the equilibrium bond length
if poor (non-meaningful e.g. very long bond-lengths) starting structures are used.
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The bending energy term
The bending energy can be described as the necessary energy to vary the angle between three
atoms (ABC) (Figure 4.1-B). As it is the case for the stretch energy, a taylor expansion is
applied up to second order:
Ebend(θ
ABC − θABCβ ) = kABC(θABC − θABC0 )2 (4.6)
where kABC is the bending parameter, θABC the bending angle and θABC0 the ideal angle for
the ABC triple of concerned atoms.
Out of plane bending energy term
A special case in terms of the bending energy is the out of plane bending energy. Looking
at the angle of three atoms ABC of a molecule ABCD and assuming that B is a sp2-
hybridized atom, it is understandable that a huge amount of energy is needed to obtain
a pyramidalization [26]. To describe this distortion, an out-of-plane energy bending term
(Eoop) is introduced as a quadratic function of the out of plane bending angle. This energy
term depends on the angle χ or on the quadratic function of the distance d (Figure 4.2).
Eoop(χ) = k
Bχ2 Eoop(d) = k
Bd2 (4.7)
The force constant kB has to be individually determined for each sp2-hybridized atom. The
force constants can be very large to ensure the non-bending out of plane which is not often in-
cluded in standard FFs. A balanced description with respect to the other bending/stretching
parameters is needed.
Figure 4.2: Illustration of out of plane variables (angle χ or distance d).
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The torsional energy term
The rotation around dihedrals is best described by periodic functions i.e. the rotation within
a full circle (360°) or half circle (± 180°) needs to be captured well. Thus, the rotation by 360°
has to result in the same value. The torsional energy Etors differ from Estretch and Ebend in
further aspects. The rotation barrier does not only depend on Etors but also on non-binding
interactions, i.e. electrostatic or Van der Waals terms. Also, the variation of these torsions
leads to low energetic differences [26]. Therefore, Taylor expansions are not suitable for the
torsional energy as they lead to big changes of the minimum structure [26]. Etors is usually
incorporated as a Fourier series which accounts for the above mentioned periodicity:
Etors(ω
ABCD) =
1
2
V ABCD1 [1 + cos(ω
ABCD)]
+
1
2
V ABCD2 [1− cos(2ωABCD)]
+
1
2
V ABCD3 [1 + cos(3ω
ABCD)]
(4.8)
To describe the torsional energy correctly, the torsional parameters V ABCD1 , V
ABCD
2 and
V ABCD3 have to be determined for each combination of the four atom types A, B, C and D.
These parameters reflect the height of barrier for a rotation around a dihedral [26].
Van der Waals energy term
The Van der Waals energy Evdw describes non-bonding interactions between atoms, i.e. repul-
sive or attractive forces. On this occasion, electrostatics do not play a role and it can rather
be described as non-polar interactions between atoms. At intermediate distances attractive
dipole-dipole interactions can arise which are referred as dispersion or as “London” forces
[29]. As a consequence, Evdw approaches zero for large pair-distances and shows a minimum
if atoms “touch” each other and increases at short distances. To describe these repulsive and
attractive interactions the Lennard Jones potential is often used which possesses a R−6 and
a R−12 dependence.
ELJ(R
AB) =
C1
(RAB)12
− C1
(RAB)6
(4.9)
C1 and C2 are constants which are needed to define this energy function. The application
of the exponent 12 and 6 is due to an enhanced computational performance, although the
exponent of 9 or 10 can give better results [26].
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Electrostatic energy
The other non-bonded interactions arise due to (partly) positively and negatively charged
atoms. This can be accomplished by the assignment of partial charges to each atom. The
interaction of each atom is described by the Coulomb potential:
Eel(R
AB) =
QAQB
RAB
(4.10)
QA and QB refer to the partial charges of atom A and B, RAB expresses the distance between
both atoms and  stands for the dielectric constant.
Cross terms
Cross terms describe the coupling of the previous mentioned terms. They are hence an
interplay of these terms to provide a correct description when e.g. the bond depends on the
angle (and vice versa). The Ecross terms are expressed as a product of a first order Taylor
expansion. Exemplary the stretch/bend term is shown:
Estr/bend = k
ABC(θABC −RABC0 )[(RAB −RAB0 )− (RBC −RBC0 )] (4.11)
These constants do not depend on all atoms but mostly from the central atom, in case of
equation 4.11 of atom B (kABC = kB).
4.1.2 Molecular Dynamic simulations
To describe mechanisms and interactions of biological systems, it is necessary to include
dynamical effects. Proteins for example can show motions of several to hundreds of A˚ngstro¨m
[26]. Some biological mechanisms can only be fully understood by inclusion of a dynamic
description. The binding of oxygen to myoglobin or haemoglobin for example can only
occur due to dynamical changes of these proteins [30]. Molecular Dynamic (MD) simulations
are advantageous to perform investigations of such biological systems. The term Molecular
Dynamics refers to the simulation of the motion of molecules but they are also used as as
a tool to refine crystal structures or NMR data [30]. For these simulations it is of great
importance to have a satisfactory description of the interactions between the particles, hence
a valid description of the inter- and intramolecular forces is needed. Once calculated, these
forces are applied in the equation of motion. In most cases the classical Newtonian equations
of motion are sufficient to describe the movement of these particles. MD simulations start
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with the acquisition of the system’s energy as a function of the atom coordinates. The forces
which act on the atoms are the first derivatives of the potential energy with respect to the
atomic coordinates. These forces can be used to solve the Newtonian equation of motion and
thus one obtains the motion of each particle as a function of time. For certain problems this
technique can offer a deeper insight and delivers ready to use interpretation.
One can run simulations for the period of several picoseconds up to microsecond timescale
to simulate the properties like densities but the cost ratio is comparably low and so it can be
conducted within a time period of less than one day on server computer system. Simulations
of a homogenous system such as a water cluster in a box with periodic boundaries can be
calculated within seconds to determine structural or dynamic properties [31]. Taking a closer
look at proteins, one has a heterogeneous system, hence an increased amount of computational
effort is needed. Naturally the size of the examined system is also of importance in terms of
computational costs. To perform these simulations one usually uses an X-ray structure as a
starting point. The general procedure can be described as follows:
At the beginning preliminary calculations are carried out to obtain the relaxation of the
system. Firstly, one starts by applying an optimization algorithm to minimize ”local stress”
which arise due to close atoms or bond length or angle distortions [30]. Afterwards a random
velocity ϑ is assigned to the atoms which results from a maxwellian distribution at low
temperature and the simulation is conducted for a few picoseconds [30]. In this context one
uses the Newton equation
Fi = miai (4.12)
where ai represents the acceleration of an atom which is determined by the force Fi of the
particular atom. Fi is calculated by the derivatives of equation 4.1 and depends on the
position of the atom while mi stands for the respective atomic mass. By obtaining the
acceleration ai it is possible to calculate the position ri at a specific time t:
ri(t+ ∆t) = ri(t) + ϑi∆t+
1
2
ai(∆t)
2 (4.13)
The time step ∆t is usually set to one to two femtoseconds. By alterating the assigned
velocity obtained from a maxwelian distribution at a chosen temperature the equilibration is
continued. The temperature T can be measured by the mean of kinetic energy of the system:
1
2
N∑
i=1
mi
〈
ϑ2i
〉
=
3
2
NkbT (4.14)
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In equation 4.14 N represents the number of atoms, 〈ϑ2i 〉 refers to the square of mean velocity
of the ith atom and kb stands for the Boltzmann constant. If the temperature stays stable
for a certain amount of time, one can assume that the atomic momenta are governed by a
Maxwell distribution and each region of the protein has the same temperature [30].
To control the course of simulation one can calculate the root mean square deviation (RMSD)
of the protein backbone which is mostly a “distance RMSD” [32]. The RMSD is a single-
number measure which quantifies differences of structures A (e.g. starting structure) and
B (structure after a certain amount of simulation time). It can be described as average
distance of simulated structures in relation to a reference position rrefi (e.g backbone of
crystal structure or starting structure of simulation) according to the following equation:
RMSD =
√√√√ 1
n
N∑
i=1
(ri − rrefi )2 (4.15)
On the one hand the RMSD value can show the stability of the crystal structure and on the
other hand it can evaluate the convergence of the MD simulation analyzing the fluctuations
in the course of simulation time.
4.1.3 Docking
To model interactions between small molecules and a protein, docking simulations can be
conducted. This model is used to investigate the binding of molecules (e.g. drugs) in the
binding site and thus one can draw conclusions on biochemical processes [33]. To perform
these docking simulations two steps are needed: Firstly, one predicts the ligands confor-
mation, position and also orientation in the binding site of the protein (referred as pose).
Secondly, one evaluates the stability of docked poses by applying scoring functions. Both
steps are known as sampling and scoring in literature. If the binding site is well described
the prediction is rather accurate. The first docking approaches were initially based on Fis-
cher’s lock-and-key theory [34], [35]. To obtain a better description, one can think of a rigid
model which includes the flexibility of the protein. This can be related to the ligand-protein
interaction as described in the “induced-fit” theory of Koshland [36]. Nowadays, the usage
of a flexible ligand and a rigid protein is a popular method to perform docking simulations
[37]. This procedure is used because it is not as time consuming as the simulation of a
flexible ligand and a flexible protein. Still, a huge number of possible poses occurs because
of the large number of internal as well as translational and rotational degrees of freedom.
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Therefore, different algorithms have been developed to give the best prediction. This section
summarizes the most common algorithms used in docking programs.
Matching algorithms (MA) [38], [39]
MA uses the ligands’ molecular shape map to insert it into the active site of a protein, while
both are represented as pharmacophores (the part which is responsible for the pharmacolog-
ical effect). The match is hence calculated by the distances of each pharmacophore while
chemical properties such as hydrogen-bond acceptors or donors are included in the mapping
procedure.
Incremental construction (IC) [40]
This methodology splits the ligand into fragments while rotational bonds are broken. Usually
the largest fragment (or the one with the most significant role) is initially docked to serve as
an anchor. Afterwards the remaing fragments are attached incrementally. The flexibility of
the ligand is thus guaranteed by the generation of different orientations which are supposed
to fit into the active site.
Genetic Algorithms (GA) [41], [42], [43]
Genetic algorithms are well-known stochastic methods. Inspired by genetic information of
living organisms’, genes in GA refer to the ligand’s degree of freedom which are described by
binary strings. The pose of the ligand is therefore represented by the “chromosome” which
are made up of these genes. Two different operators are of importance for GA. One is enabled
to insert mutations randomly to evoke changes of the genes. The other performs crossover
which leads to a change between two chromosomes and both leading to a new ligand. After-
wards the resulting ligands are scored and those who pass the scoring will be used for the
next evaluation. This algorithm is also used in the Gold docking program package [42].
As mentioned before, it is of necessity to evaluate the resulting poses, hence scoring func-
tions are used to differentiate between correct or incorrect poses. These function estimate
the binding affinity between ligand and protein. They can be divided in force-field-based,
empirical or knowledge based scoring functions. The empirical ChemPLP function which is
the default scoring function in the Gold program package uses a piecewise linear potential
(fPLP ) to evaluate steric complementarity of protein and ligand [44]. The implementation of
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ChemPLP in the Gold program package is realized by the following equation:
fitnessPLP = −(WPLP · fPLP +Wlig−clash · flig−clash
+Wlig−tors · flig−tors + fchem−cov +Wprot · fchem−prot
+Wcons · fcons)− (fchem−hb + fchem−cho + fchem−met)
(4.16)
The equation considers the heavy atom clash potential or the torsional potential of the
ligand (flig−clash and flig−tors). Additionally, the fitness function includes covalent docking
(fchem−cov), flexible side chains or explicit water molecules (fchem−prot) and also constraints
(fcons). The second part of the equation refers to the distance- and angle dependent hydrogen
or metal bonding terms (fchem−hb, fchem−cho and fchem−met). These functions are additionally
weighted by Wi, where i stands for the different potentials.
4.1.4 MMPBSA / MMGBSA
The methodologies MM/PBSA and MM/GBSA are a combination of molecular mechanic,
the Poisson-Boltzman equation or generalized Born model and the surface area continuum
solvation. The main goal of both methods is estimating the binding affinities of ligands in
biological macromolecules, i.e. proteins. MM/PBSA or MM/GBSA rely on sampling but the
focus is set on the end states resulting in a decrease of computational effort. The calculation
of the free binding energy Gbind can be described by the following equation:
∆Gbind = 〈GPL〉 − 〈GP 〉 − 〈GL〉 (4.17)
The ensemble averages are indicated by the brackets, PL refers to the protein-ligand complex,
P for the protein and L for the ligand. The free energy of each part can be calculated as a
sum of different terms [45], [46].
G = Ebnd + Eel + EvdW +Gpol +Gnp − TS (4.18)
The first three terms of equation 4.18 refer to the MM energy terms for bond, angle, torsion,
electrostatic and van der Waals interaction. The polar contributions which result from the
generalized Born model (or by solvation of the Poisson Boltzman equation) are represented
by Gpol. The non-polar term Gnp is estimated from a linear relation to the solvent accessible
surface area (SASA). Furthermore, T stands for the temperature and the entropy S can be
obtained by the normal-mode analysis of vibrational frequencies [47].
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In the Poisson Boltzman (PB) approach one tries to solve the Poisson Boltzman equation
which consists of two parts. On the one hand, it describes the change of the electrostatic
potential in a medium consisting of a constant dielectric in relation to the charge density.
On the other hand it contains the Boltzman distribution which is responsible for the ion
distribution in the respective system [48]. The basis of this approach is the solvation of the
partial differential Poisson equation [49], [50], [51]:
∇(r)∇θ(r) + 4piρ(r) = 0 (4.19)
In equation 4.19 ∇θ(r) represents the electrostatic potential, (r) a dielectric function which
depends on the coordinates. The charge density caused by the solute is expressed as ρ(r).
The generalized Born approach is an approximation of the Poisson Boltzman equation and
is expressed as follows [52]:
∇GGBBorn = (1−
1

)
∑
ij
qiqj
r2ij + α
2
ijexp(−Dij)0.5
(4.20)
where αij = (αiαj)
0.5 and Dij =
r2ij
2α2ij
The atomic partial charge is represented by qi and qj while the double sum runs over every
atom pair, also in the case i = j. The effective Born radius of an atom i is expressed by αi
while the ∇GGBBorn term approximates the dielectric part of Coulomb’s law, when atoms move
beyond the contact distance of their Born radii. Atoms are modeled as charged spheres with
a lower internal dielectric compared to the environment [45]. The screening of each atom is
therefore regulated by the local environment, i.e. the more atoms surround e.g. atom i the
larger it will be descreened (less of its electrostatic will be screened). Due to the descreening
the Born radius α is therefore obtained for each atom. A large α value refers to a strong
electric field, thus it is described with a strong electric field and reflects the situation of an
atom in vacuum. In contrast to that, a small α value represents the opposite situation as if
the atom was surrounded by a bulk of water [45]. Depending on the applied GB model the
atomic descreening is calculated differently.
The MM/PBSA or MM/GBSA can be classified between docking and scoring and alchemical
perturbation (AP) methods. Docking and scoring have low computational costs but are in
many cases not as accurate in their prediction of the binding affinity. AP methods calculate
the free energy difference between two states but contrary to MM/PBSA or MM/GBSA they
do not set the focus only on the end states but also on the reaction coordinate connecting
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both states. Just like MM/PBSA or MM/GBSA, AP methods are very accurate but the
bottleneck of these methods is that an extensive sampling is needed. This leads to higher
computational costs [47], [53].
4.2 Quantum mechanics
All quantum mechanical methods try to find a solution of the Schro¨dinger equation. The
basic expression in that respect is the time-independent Schro¨dinger equation:
Hˆψ = Eψ (4.21)
Hˆ is the Hamilton operator (also called Hamiltonian) which acts on a wave function ψ so
that one obtains the eigenenergy E. All information about the system is comprised in the
wave function ψ as the total energy. The non-relativistic Hamilton Operator for molecular
systems can be described as a sum of potential and kinetic energy operators of nuclei and
electrons [26]:
Hˆ = Tn + Te + Vne + Vee + Vnn (4.22)
Tn and Te stand for the kinetic operator of the nuclei or the electrons, Vne, Vee and Vnn for
the potential operators of the nuclei-electron, electron-electron or nuclei-nuclei, so that one
can write the Hamilton operator explicitly as:
Hˆ = −1
2
N∑
i=1
∇2i −
1
2
M∑
A=1
1
MA
∇2A −
N∑
i=1
M∑
A=1
ZA
riA
+
N∑
i=1
N∑
j>1
1
rij
+
M∑
A=1
M∑
B>A
ZAZB
RAB
(4.23)
in atomic units.
In equation 4.23 i and j refer to the N electrons, A and B for the M nuclei, R for the distance
between the nuclei and r for the distance between electron-electron or electron-nuclei. The
charge of the nuclei is expressed by Z. The two first terms contain the laplacian operator
which is a differential operator and is connected to the kinetic energy of electrons respectively
nuclei.
∇2 = ∂
2
∂x2
+
∂2
∂y2
+
∂2
∂z2
(4.24)
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If one applies the Hamiltonian on the exact wave function the total energy of the system is
yielded. The expectation value of the Hamiltonian is:
〈E〉 = 〈ψ| Hˆ |ψ〉 ≡
∫
ψ∗HˆψdV (4.25)
One central aspect in quantum chemistry is the Born-Oppenheimer approximation. The mo-
tion of nuclei is much slower compared to electrons as they are much heavier [54]. Thus, one
can think of a molecule where electrons move in the field of nuclei which are fixed. There-
fore, the kinetic energy operator for the nuclei is not included in the electronic Hamiltonian
description. Hence, one can often neglect the second term of equation 4.23 (the kinetic en-
ergy of the nuclei), while the repulsion of the nuclei can be seen as a constant (last term of
equation 4.23). Therefore, the electronic Hamiltonian can then be written as:
Hˆ = −1
2
N∑
i=1
∇2i −
N∑
i=1
M∑
A=1
ZA
riA
+
N∑
i=1
N∑
j>1
1
rij
(4.26)
Thus, the solution to a Schro¨dinger equation is the electronic wave fuction ψel if an electronic
Hamiltonian is applied:
Hˆelψel = Eelψel (4.27)
The electronic wave function ψel describes the electron’s motion and depends parametrically
on the coordinates of the nuclei but explicitly on the coordinates of the electrons. The
electronic energy Eel contains the approximated total energy of the system. QM calculations
aim to find the wave function, usually for the ground state wave function, which is an
eigenfunction of the Hamiltonian (in this context, the electronic Hamiltonian) to obtain
relevant information of the system. The exact solution is only possible for an one-electron
system, thus further approximations have to be made. One starts with a trial wavefunction
ψtrial and applies the variational principle which states that the energy expectation value of
this trial wave function is larger or the same as the actual energy of the ground state [26]:
E0 = 〈ψ0| Hˆ |ψ0〉 ≤ Etrial = 〈ψtrial| Hˆ |ψtrial〉 (4.28)
The search of this (closest to the exact) wave function is conducted within a subsets of possible
wave functions. In the Hartree Fock (HF) model these subsets are Slater determinants which
are made up of one electron functions (orbitals). They consider one important factor: The
total electronic wave function has to be antisymmetric due to the spin of electrons. The
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reason why two electrons cannot have the same quantum number results because of the
antisymmetry which is anchored by the Pauli principle. This antisymmetry is enabled by
Slater determinants.
ψ0 ≈ ΦSD = 1√
N !

χ1(
−→χ 1) χ2(−→χ 1) . . . χN(−→χ 1)
χ1(
−→χ 2) χ2(−→χ 2) . . . χN(−→χ 2)
...
...
...
...
χ1(
−→χ N) χ2(−→χ N) . . . χN(−→χ N)
 (4.29)
In equation 4.29 χ(−→χ ) represents a spin orbital and is expressed as:
χ(−→χ ) = φ(−→r )σ(s) σ = α, β (4.30)
The spin orbital contains a spatial part φ(−→r ), while the spin is represented by σ(s) and can
be α or β. Another approximation is the assumption that the trial wave function consists of
a single Slater determinant. This has the consequence that the electron-electron repulsion is
included as an average effect. If one uses this single-determinant trial wave function one can
apply the variational principle to minimize the energy using the Fock equation. Therefore,
one expresses the energy in the HF method (in consideration of the Born-Oppenheimer
approximation) by the following equation:
E =
N∑
i
〈φi|hi |φi〉+ 1
2
N∑
ij
(〈φj| Ji |φj〉 − 〈φj|Ki |φj〉) + Vnn (4.31)
In equation 4.31 hi represents the one-electron operator, J is the Coulomb operator describing
the electrostatic repulsion between two electrons and K refers to the exchange operator. Both
operators J and K are written as:
Ji |φj(2)〉 = 〈φi(1)| g12 |φi(1)〉 |φj(2)〉 (4.32)
Ki |φj(2)〉 = 〈φi(1)| g12 |φjj(1)〉 |φi(2)〉 (4.33)
where g12 is a two-electron operator which accounts for the electron-electron repulsion.
The next step is the determination of a set of molecular orbitals (MO) which minimizes
the energy or make it stationary in regard to a change in the orbitals. A requirement of
these variations is that the MOs has to remain orthonormal after change. These constrained
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optimizations can be realized by Lagrange multipliers (λij )
δL = δE −
N∑
ij
λij(〈δφi |φj〉+ 〈φi |δφj〉 = 0 (4.34)
where L is the Lagrange function [26]. If one inserts the Fock Operator Fi one obtains
δE =
N∑
i
(〈δφi|Fi |φi〉+ 〈φi|Fi |δφi〉) (4.35)
with
Fi = hi +
N∑
j
(Jj −Kj) (4.36)
Fi is an effective one electron operator which describes the kinetic energy of an electron
and the interaction with all nuclei (attraction) and all other electrons (repulsion) realized by
the J and K operators. If one combines the equations 4.34 and 4.35 and also diagonalizes
the Lagrange multipliers one obtains Fock equations which are a set of pseudo-eigenvalue
equations:
Fiφ
′
i = iφ
′
i (4.37)
In equation 4.37 φ′i refers to canonical MOs, while i stands for the for the corresponding
MO energies. This set of functions can be employed to determine the solution of one orbital
φ′i under the premise that all other orbitals are known. Hence, one electron feels the mean
field of the other electrons (also referred as mean-field approximation).
Usually for investigating chemical problems one invokes a further approximation, the linear
combination of atomic orbitals (LCAO) approximation. Therein, the orbitals are expanded
as a linear combination of atomic centered basis functions:
φi =
M∑
α
cαiχα (4.38)
where M stands for the number of basis functions. By inserting these basis functions, multi-
plying them from the left side and integrating equation 4.37, one obtains the Roothaan-Hall
equation:
FC = SC (4.39)
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The Fock matrix elements are present in the F matrix, overlap integrals between basis func-
tions are included in the S matrix. The matrix C contains the coefficients of the expansion
of the molecular orbitals into the atomic basis. The solution of the Roothan-Hall equation
is accomplished by an iterative way. One starts with an initial guess of matrix C. Out of it
the Fock matrix is built, diagonalized whereby a new set of better coefficients results. These
new coefficients are used to built up a new Fock matrix which is diagonalized and hence
optimized, until the change of the coefficients is below a given convergence criterion.
4.2.1 Møller Plesset perturbation theory
To further improve the solution of the Schro¨dinger equation, i.e. to come closer to the exact
solution, one can expand the HF equations with further determinants. One possibility is the
utilization of the Møller Plesset pertubation theory of second order (MP2) [55]. Originating
from Hartree Fock the Hamiltonian Hˆ0 is extended with the perturbation operator Hˆ
′.
Hˆ = Hˆ0 + λHˆ
′ (4.40)
This operator refers to the correlation energy and scales with λ [26]. The reference Hamil-
tonian Hˆ0 can be obtained if λ = 0, i.e. if no perturbation is present. This perturbation can
be extended from zeroth order (MP0), first order (MP1) up to n-th order (MPn).
E(MP0) + E(MP1) + E(MP2) = E(HF ) + E(MP2) (4.41)
MP0 is merely the summation of the orbital energies.
MP0 = E(MP0) =
Nelec∑
i=1
i (4.42)
In the sum of the orbital energies the electron-electron repulsion is counted twice. The
first-order energy correction fixes the problem of the electron-electron repulsion at zeroth
order.
W1 = 〈Φ0|H ′ |Φ0〉 = 〈Vee〉 − 2 〈Vee〉 = −〈Vee〉 (4.43)
In consequence the sum of the energies of MP0 and MP1 result in the Hartree Fock energy.
MP1 = E(MP0) + E(MP1) = E(HF ) (4.44)
44
4.2. QUANTUM MECHANICS
Most of the correlation energy is already recovered in MP2 (80-90%) and it scales only to
the fitfth power, thus it has an excellent cost-benefit ratio (in relation to the system’s size).
In case of MP3 which accounts 90-95 % of the correlation energy, the computational effort
increases to sixth power and worsen the ratio [26].
4.2.2 Coupled Cluster approaches
In Coupled Cluster (CC) methods corrections are included to the reference wave function in
an infinite order [26]. The excitation operator Tˆ generates all possible electronic excitations
of the order i (number of electrons which are present in the system) by acting on the reference
wave function. Besides the Hartree Fock determinant, the CC wave function also includes
additionally excited determinants on i-th order.
Tˆ = Tˆ1 + Tˆ2 + Tˆ3 + ...+ Tˆi (4.45)
Tˆ1, Tˆ2, etc. are excitation operators for single, double or higher excitations respectively. Tˆ1
for example can be written as:
Tˆ1ΦHF =
occupied∑
j
virtual∑
k
tjkΦjk (4.46)
i.e. it describes all single excitations from the occupied orbitals j to all virtual orbitals k.
Usually these excitation operators act on HF reference wave functions ΦHF . Thereby a set
of excitations is generated which contain the expansion coefficients tjk (in this context also
called amplitudes) are later determined by solving the coupled cluster equation. The coupled
cluster wave function is written as follows:
ψCC = e
TˆΦ0 (4.47)
eTˆ = 1 + Tˆ +
1
2
Tˆ 2 +
1
6
Tˆ 3 + ... =
∞∑
k=0
1
k!
Tˆ k (4.48)
The abbreviation CCS, CCSD, etc. give the form of the excitation operator Tˆ which contain
only single (Tˆ = Tˆ1) or single and doubly (Tˆ = Tˆ1 + Tˆ2), etc. excitation. Inserting its form
in the exponential ansatz we obtain for example for the CCS:
ψCCS = e
TˆΦ0 = e
Tˆ1Φ0 = [1 + Tˆ1 +
1
2
Tˆ 21 +
1
6
Tˆ 31 + ...]Φ0 (4.49)
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From equation 4.49 it is clear that ψCCS does not only contain single excitation but because
of the Tˆ k1 expression also all higher excitations which are obtained if Tˆ1 is applied twice (Tˆ
2
1 ),
three times (Tˆ 31 ) and so on. If one focuses on the term Tˆ
2
1 it becomes clear that the CCS
wavefunction does not contain all double excitation but only the so-called unlinked clusters,
i.e. those which can be generated by a double application of Tˆ1. Due to the inclusion of
these unlinked cluster excitations, coupled cluster has some very favorable properties, e.g. it
is size-consistent.
The disadvantage of these methods is that even CCSD (coupled cluster single double exci-
tations) calculations scale with a power of 6 (in relation to the number of basis functions);
calculation applying CCSDT, i.e. including triplet excitations scale with a power of 8 [56],
[57]. Thus, this methodology is unfeasible for larger systems in terms of computational costs.
One possibility to reduce the costs is to treat triplet excitations by perturbation theory. This
method is called CCSD(T) which only scales with a power between 6 and 7 but still delivers
precise results provided that a large basis set is used [58], [59]. The brackets in CCSD(T)
indicate that the triplet excitation is treated with perturbation theory. CCSD(T) is one of
the most important methods in CC approaches, as errors in energy calculations are of 1
kcal/mol and it is thus often referred as gold standard of quantum chemistry [60]. In this
context one can mention the CC2 method, which is an approximation of the CCSD model
and is also based on the perturbation theory [61]. This method is comparable to the MP2
method in terms of the precision as well as in scaling [26], [62], [63].
4.2.3 Spin component scaled calculations
The concept of the spin component scaling (SCS) is based on the separate scaling of the
correlation energy of anti-parallel spin components E↑↓ and the parallel spin components
E↑↑+↓↓. In this occasion two scaling factors are used [64].
 pS is associated with dynamical correlation effects (short-ranged, pS =
6
5
)
 pT for non-dynamical ones (long-ranged, pT =
1
3
)
ESCS = pSE↑↓ + pTE↑↑+↓↓ (4.50)
As solely empirical numbers are used, the scaling procedure can easily be integrated in
many quantum mechanical computations without an increase in computational costs. With
the SCS procedure one can improve results of MP2 as well as of CC2 [64], [65].
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4.2.4 Density functional theory
Density functional theory (DFT) is an alternative to wave function-based approaches. The
basis of DFT is the description of the ground state energy by the electron density ρ [66].
DFT methods do not calculate the energy as the expectation value of the wave function but
as a functional of the electron density. In contrast to functions, which generate a number
from a set of variables, functionals produce a number from a function.
In wave function approaches, one has 4N variables for each wave function (in a N-electron
system): three spatial ones and one for the spin for each electron. Thus, wave functions
become more complicated as the number of electrons increases. In contrast the electron
density it is solely dependent on three spatial coordinates i.e. its complexity does not increase
with the size of the system. However, while the one-to-one correspondence of wave function
and energy is given by the Schro¨dinger equation, the corresponding relationship between the
density and the ground state energy of a given nuclei orientation (the so-called external field)
were only proven by the Hohenberg-Kohn theorem.
The problem which nowadays still remains is the connection between the electron density
and the energy by an unknown functional. This is still an important topic in research [26],
[67], [68]. If one starts to formulate an energy functional E[ρ] it can be divided in three
parts, the kinetic energy T [ρ], the nuclei-electron interaction Ene[ρ] and the electron-electron
repulsion Eee[ρ] which can be split into the Coulomb and exchange part J [ρ] and K[ρ].
E[ρ] = T [ρ] + Ene[ρ] + Eee[ρ] (4.51)
with
Eee[ρ] = J [ρ] +K[ρ] (4.52)
In an uniform electron gas T [ρ] and KD[ρ] can be described as
T [ρ] = CF
∫
ρ
5
3 (r)dr (4.53)
KD[ρ] = −CX
∫
ρ
4
3 (r)dr (4.54)
with
CF =
3
10
(3pi2)
2
3 (4.55)
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CX =
3
4
(
3
pi
)
2
3 (4.56)
The nuclei-electron interaction Ene[ρ] as well as the Coloumb part J [ρ] can be written as:
Ene[ρ] = −
Nnuclei∑
a
∫
Za(Ra)ρ(r)
|Ra − r| dr (4.57)
J [ρ] =
1
2
∫ ∫
ρ(r)ρ(r′)
|r − r′| drdr
′ (4.58)
The resulting energy functional is known as Thomas-Fermi theory [26].
E[ρ] = T [ρ] + Ene[ρ] + J [ρ] (4.59)
If one includes the exchange part KD[ρ] of Dirac (equation 4.54) one obtains the Thomas-
Fermi-Dirac model. Still both models fail to predict chemical bonding as the assumption of
the uniform electron gas seems to be too crude. The applicability of DFT in computational
chemistry is due to the introduction of orbitals stated by Kohn and Sham [69]. In orbital-
free models the kinetic energy is not well described thus the idea of this formalism is to split
the kinetic energy functional into two parts: an exact calculable one and a correction term.
Similar to HF method the formulas for the kinetic, Coloumb electron-electron and nuclei-
electron energies are identical and the following general DFT energy expression results:
EDFT [ρ] = TS[ρ] + Ene[ρ] + J [ρ] + Exc[ρ] (4.60)
In a hypothetical system, where electrons do not interact, TS[ρ] is the exact kinetic energy
functional which calculates the kinetic energy from a Slater determinant (indicated by the
subscript S), i.e. as HF.
TS =
Nelec∑
i=1
〈φi| − 1
2
∇2 |φi〉 (4.61)
In real systems electrons do interact, thus equation 4.61 does not result in the total kinetic
energy, still it is an improvement with respect to the uniform electron gas expression. The
remaining part of equation 4.60 lies in the exchange correlation term Exc[ρ] which is composed
of the kinetic energy connection term, the electron correlation and exchange energy terms.
Exc[ρ] = (T [ρ]− TS[ρ])(Eee[ρ]− J [ρ]) (4.62)
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Although the DFT formalism is exact in principle, the crux of this approach is that the form
of the exchange part is unknown thus it needs to be approximated by empirical functionals.
The quality of DFT methods is described by Jacob’s ladder of density functional approxima-
tions for the exchange-correlation energy [70]. Local Density Approximations (LDA) is the
simplest approach and provides only a moderate accurate description, in terms of molecules.
Generalized gradient approximation (GGA) methods offer an improvement to LDA as they
include not only the electron density but also the derivatives of the density.
Generally, GGA methods approximate Exc by the following equation:
Exc = −1
2
∑
σ
∫
ρ
4
3
σKσd
3r (4.63)
with the dimensionless coefficient Kσ. Kσ is described by another dimensionless coefficient
xσ with
xσ =
|∇ρσ|
ρ
4
3
σ
(4.64)
The main difference of GGA exchange functionals results from on the dependence of Kσ
and on xσ [71]. The first GGA exchange functionals was introduced by Becke in 1988 as a
correction of the LDA exchange energy LDAX [72].
B88X = 
LDA
X + ∆
B88
X (4.65)
B88X = −β
∑
σ
∫
ρ
4
3
σ
x2σ
1 + 6βxσsinh−1xσ
(4.66)
The parameter β was specifically determined to fit best to the exchange energy of the six
noble gas atoms [72].
Meta-GGA methods are the next step to improve the DFT methodology. These methods
include the dependency of exchange and correlation functionals on the second derivative of
the electron density (∇2ρ). Hybrid-GGA tackle another important problem of DFT which
is the self-interaction, i.e. electrons interacting with each other. For HF this problem does
not occur, as classical and non-classical electron-electron interactions negate each other for
the same electron, which is not the case in KS-DFT [73]. To minimize resulting errors, HF
exchange (often named exact exchange in a DFT context), is mixed in [73]. In general, those
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hybrid functionals can be described by the following equation:
EGHxc = cxE
HF
x + (1− cx)EDFTx + EDFTc (4.67)
with cx as “tunable” parameter. One of the most popular hybrid-GGA methods is the
functional B3LYP after Becke, Lee, Yang and Parr [72], [74], [75], [76].
EB3LY Pxc = (1− a)ELDAx + aEexactx + b∆EB88x + (1− c)ELDAc + cELY Pc (4.68)
B3LYP already belongs to the semi-empirical hybrid GGA’s, as the parameters a, b and
c are fitted to experimental data. Hybrid-GGA methods can additionally be extended to
hybrid-meta GGA as in the Minnesota functionals, e.g. M05, M06, M08 or M011 [77], [78],
[79], [80].
One of an important improvement to DFT methods is the dispersion correction introduced
by Grimme in the year 2004, which has been further improved in the course of years [81],
[82], [83]. As many gradient-corrected functionals describe dispersive interactions poorly he
introduced a model-dependent empirical quantity which describes the missing dispersion [84],
[85], [86]. This additional empirical dispersion energy is described as:
Edisp = −s6
N−1∑
i=1
N∑
j=i+1
Cij6
R6ij
fdmp(Rij) (4.69)
and
fdmp(R) =
1
1 + e−α(R/R0−1)
(4.70)
In the equations 71 and 72 N refers to the number of atoms, Cij6 to the dispersion coefficient
between the atoms ij, s6 to scaling factors referring to the specific atom type and Rij to the
interatomic distance, while R0 stands for the atomic van der Waals radii [81]. The improved
performance of DFT due to this correction has been tested in various cases and is always
recommended to include in calculations [87], [88], [89], [90].
4.2.5 COSMO
The inclusion of explicit solvent molecules can be computationally demanding as an increase
of system size occurs. One solution is offered by continuum solvent models which describe the
embedding of a solute molecule by a dielectric continuum with the permittivity of  forming a
cavity within the dielectric. They are also referred as implicit solvent models. This interface
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between dielectric and cavity is also known as solvent accessible surface (SAS)and can be
obtained by applying probe spheres which consider the size of the solvent molecules [91].
Due to the charge distribution of the solute a polarization of the dielectric medium occurs
resulting in the generation of screening charges on the surface as response of the medium.
In COSMO the polarizable continuum is defined as a perfect conductor, by setting  = ∞
[92]. Hence, surface charges are screened perfectly and additionally electrostatic problems at
the boundary are simplified. The introduction of an empirical scaling function f() enables
a subsequent scaling of surface charges from an ideal screened density σ(s)ideal to consider
the actual solvent permitivitty  [91]. Thus one obtains the apparent surface charge σ(s)app.
σ(s)app = f()σ(s)ideal =
− 1
+ k
σ(s)ideal (4.71)
In equation 4.71 k refers to an empirical factor which is obtained by experimental data
[92].
4.3 QM/MM Methodologies
In 1975 Warshell and Levitt introduced the QM/MM (quantum mechanical/molecular me-
chanics) concept, which is still essential for the calculation of enzymatic reactions [93]. In
1990 the coupling between semi-empircal QM methods and the CHARMM (Chemistry at
Harvard Macromolecular Mechanics) force field has been conducted and compared with
ab initio and experimental data with respect to the precision and effectiveness [94], [95].
Nowadays QM/MM methods are established, and one does not only find them applied in
biomolecular systems but also in inorganic/organometallic or solid state systems [96].
4.3.1 QM-MM partitioning
In the QM/MM approach the system (e.g. protein-ligand complex) is generally divided into
two parts. The “inner” part is described with quantum mechanical methods, the “outer” one
with molecular mechanics (Figure 4.3). Within the inner part the atoms which are involved
in reactions are included, so that bond breaking and forming can be treated by using QM
methods in a sufficient accurate way. The outer part, treated e.g. by a force field, folds in
the influence of the environment on the reaction. Due to the severe interaction between both
parts, the energy cannot be calculated as a sum of both subsystems and therefore coupling
terms are needed. Especially at the boundary one has to be cautious, as covalent bonds are
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cut. The QM part can be extended with so called “link atoms” which are not part of the
system and will be described later on.
Figure 4.3: QM/MM partitioning of a protein ligand complex. The whole system (S) consists
of two parts: The outer region (O) depicted in gray and the inner region (I) depicted in green.
4.3.2 QM/MM energy Expression
Subtractive and additive QM/MM schemes
To describe the QM/MM energy one has two different possibilities: the subtractive and
additive QM/MM scheme. In case of the subtractive scheme one needs a MM calculation of
the whole system as well as of the inner subsystem and a quantum mechanical one of the
inner part. Hence, the energy is calculated by the following equation:
EsubQM/MM(S) = EMM(S) + EQM(I + L)− EMM(I + L) (4.72)
S refers to the whole system, I to the inner part and L for the link atoms. The advantage
of the subtractive procedure is the simplicity as no QM/MM coupling terms are needed, so
that standard QM and MM methods can be applied without any modifications [96]. As long
as MM force terms and link atoms do provide acceptable QM potentials, artifacts which are
caused by the link atoms are corrected by the subtraction. The disadvantage of this method
is that a good parametrization of the inner MM part is needed. Additionally, the coupling
of both parts is only performed on MM level. Especially in the latter case the problem of
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electrostatic interactions arises, which are caused by the Coulomb interactions between fixed
atomic charges in the QM and MM areas. Still, the application of electrostatic embedding
enables the inclusion of MM charges into the QM Hamiltonian so that a better description
is possible [96].
Another option to obtain the QM/MM energy is by using the additive QM/MM scheme.
EaddQM/MM(S) = EMM(O) + EQM(I + L)− EQM−MMI, O (4.73)
In contrast to the subtractive procedure the MM calculation is only performed for the outer
part and one uses explicitly a coupling term, in this case EQM−MM(I, O), which gathers the
interaction of both terms [96]. The inner part including link atoms are described as in the
subtractive scheme by quantum mechanical approaches. The coupling term can be described
by the following equation:
EQM−MM(I, O) = EbQM−MM + E
vdW
QM−MM + E
el
QM−MM (4.74)
and contains besides bonded interactions also van der Waals and electrostatic interactions
between the QM and MM region.
Electrostatic QM/MM interaction
The coupling between the QM charge density and the charge model of the MM region can
be accomplished by mechanical embedding, electrostatic embedding or polarized embedding.
The mechanical embedding treats the QM-MM electrostatic interactions at the same basis
as MM-MM electrostatics. That means that the charge model of the MM part (in most cases
atomic point charges) is transferred to the QM part [96]. The computational costs are low
but disadvantages do occur. Charges of the outer part do not interact with the QM density,
which are in consequence not directly polarized by the electrostatic environment [96]. If
a change in the charge distribution of the QM region occurs (e.g due to a reaction) it is
necessary to update the charges, though it would lead to large fluctuations in the potential
energy surface. Also, MM point charges of the inner region have to be described well. These
disadvantages can be avoided if a QM calculation is performed in the presence of the MM
charge models.
In the electrostatic or electronic embedding scheme the electronic structure of the inner
region is adapted to the changes of the charge distribution of the environment, so that they
are automatically polarized by it. This can be calculated by inserting MM point charges as
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one-electron terms into the QM-Hamiltonian.
HˆelQM−MM = −
N∑
i
L∑
JΦ
qJ
|ri −RJ | +
M∑
aI
L∑
JΦ
qJQa
|Ra −RJ | (4.75)
The MM point charges qJ are located at RJ , while the nuclear charges Qa of the QM atoms
are placed at Ra. The positions of the elctrons are described with ri. The double sum runs
over i, J and a of N electrons, L point charges and M QM nuclei. As mentioned before, one
has to be cautious if boundaries run through covalent bonds. In this instance, MM charges
are set to the close proximity of the QM electron density and this leads to overpolarization.
Electrostatic embedding schemes include the polarization of the QM part by the MM part
but neglects variation arising from the polarization of the MM part by the QM part. This
can be included by the usage of polarizable force fields.
Non-bonded and bonded QM/MM interactions
The non-bonding van der Waals interaction of the QM part are described by a Lennard Jones
potential; hence suitable parameters are needed. Often one uses the atom types of the force
field but problems might occur if QM atoms change their character during a reaction. In
most cases this does not represent a problem as short-ranged interactions are involved. Still,
this can be solved by moving the QM-MM boundary further away from the QM atoms.
Overview of Boundary schemes
As mentioned before within QM/MM the treatment of covalent bonds which crosses the
QM/MM boundary is an critical point. In case of enzymatic reactions in biological system
this is inevitable and can result into problems. Firstly, the affected QM atom has to be capped
and this cannot be achieved by heterolytically or homolytically cleavage. The overpolarization
between the QM density and the MM charges has to be prevented, especially if link atoms
are used. Also, double-counting of the interactions of both parts has to be circumvented.
It is of importance to cut a unipolar bond which is possible for an aliphatic C-C bond but
should be avoided in case of an amide bond. In general, three approaches can solve these
problems:
In the link atom scheme an additional artificial atomic center L is included which is usually
a hydrogen atom. The calculation of the inner part takes the link atom into account (I +
L), while the generated bond is described on MM level. The problem is that due to the
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insertion of the link atom three artificial degrees of freedom are generated. Also, the link
atom is close to the QM electron density so that overpolarization can occur. Additionally, in
chemical and electronical terms the link atom differs from the replaced atom. The problem of
overpolarization can be reduced by deleting one-elctron integrals which are associated with
the link atoms [94]. Another possibility is to delete the M point charges in the link region
of the Hamiltonian or to shift/distribute the point charges in the link region [97], [98]. By
these techniques the handling of link atoms improves so that they are widely used [96].
The boundary-atom scheme replaces the MM atom of the bond by a special boundary atom
which occurs in the QM and MM calculation. On the MM side it is viewed as a normal MM
atom, while in the QM calculation it represents the cleaved bond and the electronic character
of the MM part attached to the QM atom.
In the localized-orbital scheme hybrid orbitals are set to the boundary and frozen. Hence,
they cap the QM region and represent the cleaved bond.
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Computational details
5.1 MD simulations
The MD simulations were conducted using the AMBER14 software package [99]. Protein
monomers or dimers were described by the AMBER forcefield ff14SB [100]. Ligands, in-
hibitors and cofactors have been parameterized by utilizing the generalized AMBER forcefield
(GAFF) with the program antechamber [101], [102]. Electrostatic potential (ESP) charges of
non-protein solutes have been calculated by the Gaussian 03 pgroam package on Hartree Fock
level, employing the 6-31G(d) basis set, except for one case, which is explicitly mentioned in
Chapter 7 [103], [104]. The protein(-inhibitor) complex was solvated in an octahedral shell
in a 10 A˚ radius around the system employing the TIP3P water model [105]. Charges have
been neutralized by Na+ or Cl− ions. The solvent was minimized for 1000 cylces while re-
straining the complex. Subsequently, another 2500 cycles were run without restraints on the
solute. After gradually heating to 300 K over 100 ps and fixating the solvent, the simulation
was continued at constant temperature (300 K) and pressure (1 atm). The duration of the
simulation were adopted to the given question and is explicitly mentioned in the respective
chapters. Time steps of 1 fs were chosen. Bonds involving hydrogen were constrained with
the SHAKE algorithm and simulations were performed under periodic boundary conditions.
5.2 QM calculations
QM calculations as single point calculations or optimzations of investigated structures were
performed by employing the TURBOMOLE V6.6 or Gaussian09 software package [106],
[107], [108], [109]. 3d model structures were prepared with the Avogadro program package
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[110]. Nudged elastic band (NEB) calculations have been performed with the CAST program
package which utilized the MOPAC 2016 energy interface [111], [112].
5.3 QM/MM calculations
QM/MM calculations have been conducted by utilizing the Chemshell [113], [114]. Geome-
tries have been optimized by the DL-Find geometry optimizer [115]. The QM part was
calculated with the TURBOMOLE V6.6 software package while the MM part was described
by the AMBER14 force field. The shift embedding scheme was utilized to describe the
coupling. In all calculations the optimization of the MM part solely included atoms in an
inner layer of 10 A˚ around the reactive thiol group, whereas the rest of the system was not
optimized. The QM part is described in respective sections.
5.4 Graphics and data evaluation
The presented graphics have been prepared with the Origin 2016 software package [116]. The
visualization of presented structure as well as the calculation of RMSD values were conducted
by the molecular visualizationion program VMD [117]. Structural formulas wre generated
with the Chemdraw software. In presented figures the color code of 3d visualized atoms are
as follows: light blue refers to carbons, yellow to sulfurs, red to oxygens, blue to nitrogens
and white to hydrogens.
The mean absolute error (MAE) has been calculated as
MAE =
∑n
i=1 |C − xi|
n
(5.1)
where n is the number of data points, C the reference value and x the calculated values.
The standard deviation has been determined by the following equation:√∑n
i=1(x¯− xi)2
n
(5.2)
The number of data points is given with n, x¯ is the mean of all values and xi refers to the
calculated value.
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Chapter 6
Theoretical investigations of aromatic
warheads for cysteine cathepsin
protease inhibitors employing
quantum mechanical calculations
6.1 Introduction
Cysteine cathepsin proteases are involved in nearly all proceses of lysosymes as for example
the degradation of proteins, metabolism of lipids and proteins, antigen presentation, cellular
stress signalling and lysosome-mediated cell death [118]. Cathepsin belongs to the C1 family
(papain family) of the clan CA as most of cysteine proteases [119], [120]. They influence
additionally the activation, processing or degradation of chemokines, cytokines or different
growth factors [120], [121].
One can find 11 different members of the cathepsin family among humans [118]. Except for
two representatives, cysteine cathepsins are mostly endopeptidases located within endolyso-
mal compartments [118]. There is on the one hand cathepsin C (CTSC) or also known as
dipeptidyl peptidase I and on the other hand cathepsin Z, a carboxymonopeptidase which
cleaves dipeptides of the C terminus of substrate proteins [122], [123]. Still some extracel-
lular functions can be found for specific cysteine cathepsins as e.g. cathepsin K, which is
responsible for the bone remodeling by osteoclasts [124].
It is known for a long time that cathepsin expression is increased in tumor tissues compared
to normal ones [125]. The prognosis for survival of cancers e.g. colorectal, head, neck breast
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and lung cancer is related to the cathepsin expression [126], [127]. Cathepsins have a big
contribution in respect to the progression of tumors in various cancer by different mechanisms
[118]. Secreted cathepsins are potent effectors which can modify the environment of the tu-
mor by turnover or degradation of the extracelluar matrix (ECM). Those secreted cathepsins
bind on the cell membrane aft specific regions and are localized at endolysomal vesicles [128].
Depending on the region one obtains different substrates or functions [128].
Beside the progression another important effect of these cysteine proteases has to be men-
tioned. It was shown that they are involved in the response of anticancer therapy in the
tumor microenvironment and thus, are of relevance in the development of resistance [129],
[130].
Still, an increased expression is not only observable in tumor cells but also in tumor-associated
cells e.g. endothelial cells or macrophages [124]. Additionally, dysfunctional cathepsin activ-
ity is not restricted to induce cancer but also various diseases as parasitic and viral pathogen-
sis, cystic fibrosis, cardiovascular or neurodegenerative diseases, osteoporosis or arthritis [131],
[132], [133], [134], [135], [136]. Therefore, it is understandable why cysteine cathepsins pro-
teases represent good targets not only for the therapy of cancer but also for a lot of other
diseases.
One strategy to modify these cathepsins is addressing them by means of covalent inhibitors.
These inhibitors consist of a recognition unit which is responsible for the non-covalent inter-
actions and a warhead which form a covalent bond with the respective protein. Residues as
cysteine, serine or threonine side chains are often covalently modified by Michael acceptor
systems as vinyl sulfones, unsaturated esters, nitrioles or ketones [22], [137], [138], [139], [140],
[141], [142]. In contrast to that, one can rarely find warheads which react by electrophilic
aromatic substitution (SNAr) [143], [144].
The group of Opatz and Schirmeister from the University Mainz conducted investigations in
terms of these warheads for cysteine proteases of the papain family, as cathepsin. They used
a (S)-Phe-(S)-Leu-OBn dipeptide sequence as a recognition unit and added various aromatic
SNAr-type electrophiles at the N-terminus to obtain the covalent inhibitor (Figure 6.1). It
was shown in the past, that this dipeptide sequence is suitable for cathepsin-like cysteine pro-
teases [141], [142], [145]. Additionally, to various aromatic SNAr-type electrophiles chloro-
or nitrile-subsituted 1,4-naphtoquinones (compound 4 and compound 8) have been used as
warheads by Schirmeister and Opatz group (Figure 6.2). As known in literature quinone,
which are maleimide derivatives, can react with nucleophiles as thioles in proteins. Thus, a
nucleophilic addition reaction at the Cβ-atom of the α,β-unsaturated carbonyl function with
the sulfur of an active site cysteine residue is likely [146]. N-ethylmaleimide for example is
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useful for the titration of thiole groups as the reaction occurs rapidly and is specific to these
groups [147].
In this study experimental data indicate that both compounds inhibit cathepsin L in a com-
petitive way and furthermore, dilutaion assays proven that the inhibition of cathepsin is
reversible. As one can see in Figure 6.3 different reaction products are conceivable and there-
fore QM calculations have been performed to identify the product in lowest energy. As no
crystal structure of the protein-inhibitor complex was available environmental effects were
considered by employing the COSMO approach.
O
O H
N
O
N
H
R
Figure 6.1: Dipeptide sequence (S)-Phe-(S)-Leu-Obn recognition unit. Aromatic warheads
are attachaed at R.
O
O
Cl
O
O
CN
compound 4 compound 8
R R
Figure 6.2: Chloro-subsituted 1,4-naphtoquinones (compound 4) and nitrile substituted
(compound 8)
6.2 Benchmark of ab initio and DFT methods for ge-
ometry optimization
The initial step of the investigations started with the geometry optimization of reactants and
possible reaction products of compound 4 and 8 with methanethiol (Figure 6.3). Therefore,
different approaches like ab initio methods as HF and MP2 or the DFT approach B3LYP with
Grimme’s dispersion correction D3 were applied. These calculations employed the def-TZVP
basis set and considered implicit solvation by COSMO (=78) [148]. To reduce computational
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costs solely the 1,4-napthoquionone moiety (warhead) in connection to the methylamine of
the recognition unit was considered.
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Figure 6.3: Reactans and products of the reaction of methanethiol with the inhibitor 8. The
corresponding products for inhibitor 4 are obtained by replacing CN with Cl.
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As one can see in Table 6.1 the calculated RMSD values of reactants and possible products
of both investigated inhibitors are shown in relation to MP2 optimized structures. In case of
HF the largest MAE of 0.242 A˚ is observed, mainly because of III b or IV b for inhibitor 4
and IV b for inhibitor 8. In contrast to these findings the calculated MAE of RMSD values
for B3LYP optimized structures is lower by a value of 0.129 A˚. The largest deviation was
observed for III a-4 (inhibitor 4) with a value of 0.341 A˚ or IV b (inhibitor 8) with a value of
0.334 A˚. In terms of structure optimization B3LYP appears to be an adequate methodology.
Table 6.1: RMSD values in relation to MP2 optimized structures employing the def-TVZP basis
set. B3LYP-D3/def-TZVP shows a MAE of 0.129 A˚, HF/def-TZVP a MAE of 0.242 A˚. Structure
optimizations employed the COSMO approach (=78). All values are given in A˚.
compound 4 B3LYP-D3 HF compound 8 B3LYP-D3 HF
educt 0.116 0.114 educt 0.153 0.172
III a-1 0.096 0.169 II 0.161 0.207
III a-2 0.109 0.196 III a-1 0.162 0.143
III a-3 0.086 0.139 III a-2 0.122 0.12
III a-4 0.341 0.463 III a-3 0.112 0.138
III b 0.127 0.967 III a-4 0.127 0.326
IV a-1 0.115 0.166 III b 0.224 0.151
IV a-2 0.089 0.146 IV a-1 0.160 0.173
IV a-3 0.172 0.203 IV a-2 0.088 0.390
IV a-4 0.097 0.127 IV a-3 0.175 0.146
IV b 0.162 0.854 IV a-4 0.120 0.148
IV b 0.334 0.834
CH3SH 0.013 0.011
H2NCH3 0.009 0.009
HCl 0.007 0.002
HCN 0.008 0.020
MAE1 0.129 0.242
1 Mean average error of RMSD with respect to MP2 optimization averaged of all compounds.
Although the optimized geometries are comparable by their RMSD values for B3LYP
and MP2, a significant difference can be seen in terms of the calculated reaction energy
∆Ereac. As shown in Table 6.2 product IV b for compound 4 was predicted as most stable
product applying HF or B3LYP showing up with a reaction energy of -5.2 or -5.8 kcal/mol.
Additionally, the reaction energies ∆Ereac of the remaining products resulting in positive
values. This contrasts with the results from MP2 calculations. In this case III a-1 was the
most energetically stable product with a value of -15.7 kcal/mol. Furthermore, only III b was
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positive in reaction energy. These differences are also observable for compound 8. HF shows
only positive reaction energies, whereas B3LYP reveals for product II a difference in energy
by -0.7 kcal/mol between product and reactants which is in the error of the method. In all
other cases positive values are obtained. Again, MP2 calculated energies predict product III
a-1 as lowest in energy by a value of -10.6 kcal/mol. Only products III a-4, III b and IV a-1
are described higher in energy compared to the reactants. Thus, the question arises if those
discrepancies in the reaction energy occur due to the difference in optimized structure or being
caused by the methodology. Therefore, single point energy calculation employing B3LYP and
BHLYP in combination with Grimme’s dispersion correction or ab initio methods as MP2,
CC2 and SCS-CC2 have been conducted. Additionally, the basis set has been increased
to Truhlar’s basis set aug-cc-pVDZ. Environmental effects have been described by COSMO
(=78) again.
If one takes a closer look at Table 6.3 and Table 6.4 a similar trend to previous calculations
can be seen. Single point energy calculations which employ DFT methodologies predict
product IV b for compound 4 as lowest in reaction energy. In this case an abstraction of the
chlorine by a SN2 reaction is described as favorable. In contrast to that ab initio methods
show that product III a-1 is lower by≈ 2-3 kcal/mol in energy compared to IV b. Interestingly
all these results are independent from the employed methodology of structure optimization.
Differences in single point energy which occur due to the usage of a different optimization
method are below 2.0 kcal/mol (Table 6.7). Still, the trend in prediction is in line with the
robusteness for the used methods.
This behavior can also be observed for single point energies of compound 8. In terms of
B3LYP or BHLYP only the nucleophilic attack on the nitrile group on compound 8 leads to
negative values of ∆Ereac. Once more, calculations on ab initio level predict different results.
Reaction energies of product III a-1 are about 2-3 kcal/mol lower independent of the applied
methodology for geometry optimization. And again, if one compares single point energies
of the same method by varying B3LYP or MP2 for geometry optimization differences are at
most of 2.0 kcal/mol (Table 6.7).
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Table 6.2: Summary of the reaction energies (∆Ereac) of possible reaction products of compound
4 or 8 with methanethiol (Figure 6.3) obtained from geometry optimization. All calculations were
performed with a def-TZVP basis sets and employing the COSMO approach (=78) to mimic
environmental effects. All energy values are depicted in kcal/mol.
compound 4 HF B3LYP-D3 MP2
III a-1 5.7 1.8 -15.71
III a-2 7.8 4.9 -12.0
III a-3 6.9 4.2 -13.2
III a-4 9.0 6.6 -10.0
III b 9.1 11.9 5.0
IV a-1 6.9 3.6 -14.1
IV a-2 7.3 4.2 -12.9
IV a-3 8.7 6.2 -10.2
IV a-4 11.2 8.9 -7.8
IV b -5.21 -5.81 -10.9
compound 8 HF B3LYP-D3 MP2
II 13.4 -0.71 -2.3
III a-1 13.11 7.2 -10.61
III a-2 14.1 8.0 -8.1
III a-3 18.4 14.1 -4.9
III a-4 22.0 17.1 0.2
III b 18.0 16.5 9.9
IV a-1 23.0 18.4 0.9
IV a-2 13.6 11.8 -5.7
IV a-3 17.8 15.1 -5.0
IV a-4 15.1 13.0 -6.8
IV b 17.2 14.9 8.3
1 Lowest reaction energy ∆Ereac of calculated reaction products of compound 4 or 8 with methanethiol.
65
6.2. BENCHMARK OF AB INITIO AND DFT METHODS FOR GEOMETRY
OPTIMIZATION
Table 6.3: Reaction energies (∆Ereac) of possible reaction products for the reaction of compound
4 with methanethiol (Figure 6.3) obtained from singlepoint energies on ab initio or DFT level
employing the COSMO approach (=78) with an aug-cc-pVDZ basis set. Energies calculated from
B3LYP-D3/def-TZVP + COSMO (=78) optimized structures. All energy values are presented in
kcal/mol.
compound
4
B3LYP-D3 BHLYP-D3 MP2 CC2 SCS-CC2
III a-1 0.7 -3.5 -15.51 -15.11 -12.11
III a-2 3.6 -1.0 -12.6 -12.3 -9.2
III a-3 3.1 -1.1 -12.9 -12.7 -9.9
III a-4 5.6 1.3 -10.0 -9.7 -7.0
III b 11.9 12.3 6.3 7.1 7.1
IV a-1 2.3 -1.3 -13.5 -13.6 -10.5
IV a-2 3.1 -0.6 -12.5 -12.6 -9.8
IV a-3 5.0 0.7 -10.3 -10.0 -7.3
IV a-4 7.6 3.3 -8.2 -7.8 -5.3
IV b -5.91 -6.21 -11.4 -11.7 -9.8
1 Lowest reaction energy ∆Ereac of possible reaction products of compound 4 with methanethiol.
Table 6.4: Reaction energies (∆Ereac) of possible reaction products for the reaction of compound
4 with methanethiol (Figure 6.3) obtained from singlepoint energies on ab initio or DFT level
employing the COSMO approach (=78) with an aug-cc-pVDZ basis set. Energies calculated from
MP2/def-TZVP + COSMO (=78) optimized structures. All energy values are given in kcal/mol.
compound
4
B3LYP-D3 BHLYP-D3 MP2 CC2 SCS-CC2
III a-1 0.6 -4.1 -16.81 -16.51 -12.91
III a-2 3.4 -1.6 -14.0 -13.8 -10.1
III a-3 2.8 -2.1 -14.4 -14.2 -11.0
III a-4 5.1 0.3 -11.8 -11.7 -8.5
III b 11.4 11.9 5.8 6.5 6.6
IV a-1 2.2 -2.0 -15.1 -15.2 -11.6
IV a-2 2.8 -1.6 -14.0 -14.1 -10.8
IV a-3 5.1 0.4 -11.5 -11.3 -8.0
IV a-4 7.3 2.5 -9.4 -9.1 -6.1
IV b -6.21 -6.21 -11.8 -12.3 -10.0
1 Lowest reaction energy ∆Ereac of possible reaction products of compound 4 with methanethiol.
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Table 6.5: Reaction energies (∆Ereac) of possible reaction products for the reaction of compound
8 with methanethiol (Figure 6.3) obtained from singlepoint energies on ab initio or DFT level
employing the COSMO approach (=78) with an aug-cc-pVDZ basis set. Energies calculated from
B3LYP-D3/def-TZVP + COSMO (=78) optimized structures. All energy values are given in
kcal/mol.
compound 8 B3LYP-D3 BHLYP-D3 MP2 CC2 SCS-CC2
II -4.41 -4.21 -7.0 -8.6 -3.7
III a-1 5.9 3.1 -9.91 -10.11 -6.61
III a-2 6.5 3.7 -8.7 -9.1 -5.4
III a-3 12.5 9.1 -4.4 -4.4 -1.5
III a-4 15.4 12.5 0.2 0.0 2.8
III b 16.3 17.6 11.0 11.2 11.5
IV a-1 17.1 13.5 1.1 1.2 4.0
IV a-2 10.6 6.7 -5.5 -5.3 -2.7
IV a-3 13.7 10.1 -3.9 -3.8 -1.1
IV a-4 11.6 7.5 -6.0 -5.7 -3.3
IV b 15.5 15.9 9.8 8.9 10.0
1 Lowest reaction energy ∆Ereac of possible reaction products of compound 8 with methanethiol.
Table 6.6: Reaction energies (∆Ereac) of possible reaction products for the reaction of compound
8 with methanethiol (Figure 6.3) obtained from singlepoint energies on ab initio or DFT level
employing the COSMO approach (=78) with an aug-cc-pVDZ basis set. Energies calculated from
MP2/def-TZVP + COSMO (=78) optimized structures. All energy values are shown in kcal/mol.
compound
8
B3LYP-D3 BHLYP-D3 MP2 CC2 SCS-CC2
II -4.11 -4.51 -6.4 -7.8 -3.0
III a-1 6.7 3.3 -11.41 -11.81 -7.71
III a-2 7.0 3.5 -10.1 -10.5 -6.4
III a-3 12.8 9.0 -6.1 -6.2 -2.8
III a-4 15.4 11.9 -1.4 -1.6 1.6
III b -16.2 17.7 -6.4 -7.8 -3.0
IV a-1 17.2 13.4 -0.7 -0.7 2.6
IV a-2 10.6 6.4 -7.0 -6.9 -3.8
IV a-3 14.0 10.0 -5.5 -5.4 -2.2
IV a-4 11.7 7.4 -7.5 -7.3 -4.3
IV b 15.2 15.9 8.8 7.8 9.4
1 Lowest reaction energy ∆Ereac of possible reaction products of compound 8 with methanethiol.
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Table 6.7: Differences (∆Ediff ) in DFT or ab initio calculated reaction energies (∆Ereac) between
B3LYP-D3 and MP2 optimized structures of possible reaction products for compound 4 or 8 with
methanethiol. Singlepoint calculations employed the COSMO approach (=78) and an aug-cc-pVDZ
basis set. All energy values are given in kcal/mol.
compound 4 ∆EB3LY P−D3diff ∆E
BHLY P−D3
diff ∆E
MP2
diff ∆E
CC2
diff ∆E
SCS−CC2
diff
III a-1 0.1 0.6 1.3 1.5 0.9
III a-2 0.2 0.6 1.4 1.6 1.0
III a-3 0.3 1.0 1.5 1.6 1.1
III a-4 0.5 1.0 1.9 2.0 1.5
III b 0.5 0.4 0.5 0.6 0.5
IV a-1 0.1 0.7 1.6 1.6 1.1
IV a-2 0.3 1.0 1.4 1.4 1.0
IV a-3 0.1 0.4 1.2 1.3 0.7
IV a-4 0.3 0.8 1.2 1.3 0.8
IV b 0.3 0.1 0.5 0.6 0.3
compound 8 ∆EB3LY P−D3diff ∆E
BHLY P−D3
diff ∆E
MP2
diff ∆E
CC2
diff ∆E
SCS−CC2
diff
II 0.3 0.3 0.6 0.8 0.8
III a-1 0.8 0.2 1.6 1.6 1.1
III a-2 0.5 0.2 1.4 1.4 1.0
III a-3 0.3 0.2 1.7 1.8 1.2
III a-4 0.0 0.6 1.5 1.6 1.2
III b 0.1 0.1 0.5 0.5 0.4
IV a-1 0.1 0.1 1.8 1.9 1.4
IV a-2 0.1 0.3 1.5 1.6 1.1
IV a-3 0.3 0.0 1.5 1.7 1.1
IV a-4 0.1 0.2 1.4 1.6 1.0
IV b 0.3 0.0 1.0 1.0 0.5
MAE1 0.3 0.4 1.3 1.4 1.0
1Mean average error with respect to MP2/def-TZVP optimized structures averaged of both compounds.
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Moreover Table 6.7 shows, energies which are calculated with B3LYP or BHLYP have a
lower MAE of 0.3 or 0.4 kcal/mol. In terms of ab initio methods SCS-CC2 shows the lowest
MAE with a value of 1.0 kcal/mol, followed by MP2 and CC2 with 1.3 and 1.4 kcal/mol.
In this case the difference in prediction of the most stable product does not result from
the methodology for optimization but rather from the methodology employed for reaction
energy evaluation. Thus, the next step was a benchmark of ab initio methods in comparison
to CCSD(T) the gold standard for reaction energies.
6.3 Comparison of reaction energies for ab initio meth-
ods compared to CCSD(T) in vacuo
In the previous section differences in the prediction of possible reaction products were re-
vealed which depend on the usage of whether ab initio, post-HF or DFT methods were used.
Usually one can expect that MP2 or CC2 results are more reliable to B3LYP or BHLYP
calculations. Still, it is of necessity to prove this statement for this specific case. Therefore, a
benchmark was conducted using CCSD(T) as reference. As no COSMO implementation was
available for the Turbomole program package, single point calculations were performed in
vacuo. Additionally, the def-TZVP basis set was employed to decrease computational costs
with respect to CCSD(T) calculations. Only for product III a-1 calculations on CCSD(T)
level with the augmented basis set aug-cc-pVDZ (double-zeta, polarized and augmented )
were conducted [149]. For the remaining ab initio methods solely the aug-cc-pVDZ basis set
was used as well as MP2 optimized geometries.
Firstly, one can see that the results of the CCSD(T) calculations lead to the same conclusions
as before: product III a-1 shows the lowest reaction energy. For compound 4 this product is
8 kcal/mol more stable compared to IV b which was described by DFT methods as energeti-
cally lowest product, for compound 8 it is ≈ 6 kcal/mol lower in energy compared to product
II (Table 6.8). This confirms the assumption of the reliability of MP2 and CC2 calculated
energies as the results reflect the same trend as determined by former calculations.
However, how do the remaining ab initio methods perform? In terms of MP2 and CC2
one obtains a MAE of 2.6 and 2.8 kcal/mol compared to CCSD(T)/def-TZVP calculations.
Both methodologies describe the reaction energy quite similar, as they differ by at most 0.6
kcal/mol. Only once a difference of 1.3 kcal/mol is obtained for product II of compound 8.
By employing the spin-component scaling approaches the MAE decreases. SCS-MP2 shows
a MAE of 0.3 kcal/mol, SCS-CC2 a slightly higher one by 0.4 kcal/mol. If one compares
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both methods, one can see that the calculated energies differ by a largest value of about
0.8 kcal/mol. Although the differences in MAE are below the accuracy of the calculations
(methods/basis set), SCS-MP2 was chosen as reference for further calculations due to its
lower MAE. Still it is to be expected that SCS-CC2 could also be utilized.
Table 6.8: Reaction energies (∆Ereac) of possible reaction products of compound 4 or 8 with
methanethiol from different ab initio calculations compared to CCSD(T)/def-TZVP calculations
(for reaction product III a-1 the aug-cc-pVDZ basis set was additionally considered, marked as 3).
All reaction energies are calculated in vacuum employing the aug-cc-pVDZ basis set. All energy
values are shown in kcal/mol.
method CCSD(T) MP2 CC2 SCS-MP2 SCS-CC2
compound 4
III a-1 -16.22 / -17.12,3 -19.42 -19.32 -16.12 -15.72
III a-2 -10.1 -13.9 -13.9 -10.6 -10.2
III a-3 -12.9 -15.6 -15.5 -12.7 -12.4
III a-4 -10.3 -13.3 -13.4 -10.5 -10.1
III b 6.7 6.5 7.0 6.7 7.3
IV a-1 -12.9 -16.0 -16.3 -12.9 -12.7
IV a-2 -12.6 -15.2 -15.4 -12.3 -12.2
IV a-3 -11.0 -14.1 -14.1 -11.0 -10.7
IV a-4 -7.9 -10.8 -10.7 -8.0 -7.6
IV b -8.2 -10.8 -11.3 -8.8 -9.0
compound 8
II -6.8 -10.9 -12.2 -7.0 -7.4
III a-1 -12.72 / -13.52,3 -15.82 -16.32 -12.42 -12.32
III a-2 -10.0 -13.7 -14.3 -10.3 -10.2
III a-3 -6.8 -9.5 -9.8 -6.6 -6.4
III a-4 -2.2 -4.8 -5.1 -2.2 -2.0
III b 9.4 8.9 9.0 9.3 9.6
IV a-1 -2.5 -5.5 -5.6 -2.7 -2.3
IV a-2 -8.2 -11.0 -11.0 -8.3 -7.9
IV a-3 -7.6 -10.0 -10.0 -7.3 -6.9
IV a-4 -9.6 -12.1 -12.0 -9.6 -9.1
IV b 7.5 8.0 7.0 9.1 8.6
MAE1 2.6 2.8 0.3 0.4
1Mean average error with respect to CCSD(T)/def-TZVP averaged of all compounds. 2 Lowest calculated
reaction energy ∆Ereac of possible reaction products of compound 4 or 8 with methanethiol.
3 CCSD(T)
calculation employing the aug-cc-pVDZ basis set.
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To evaluate the errors caused by the usage of different basis sets, additional calculations
of the reaction energies have been conducted by employing the def-TZVP basis set. As one
can see in Table 6.9 a decrease of 1-2 kcal/mol occurs for most of the products calculated
with SCS-MP2 if aug-cc-pVDZ is used. A similar trend can be seen for CCSD(T). Products
III a-1 for compound 4 and 8 are lower in energy if a larger basis set is used.
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Table 6.9: Calculated reaction energies (∆Ereac) of possible reaction products of compound 4 or
8 with methanethiol in vacuum employing the def-TZVP or aug-cc-pVDZ basis set. For CCSD(T)
solely product III a-1 has been calculated with an aug-cc-pVDZ basis set. All energy values are
given in kcal/mol.
method CCSD(T) CCSD(T) SCS-MP2 SCS-MP2
basis set aug-cc- def- aug-cc- def- ∆SCS−MP2basisset
pVDZ TZVP pVDZ TZVP
compound 4
III a-1 -17.12 -16.22 -16.12 -14.62 1.4
III a-2 NA -10.1 -10.6 -8.4 2.2
III a-3 NA -12.9 -12.7 -11.3 1.4
III a-4 NA -10.3 -10.5 -8.6 1.9
III b NA 6.7 6.7 6.4 0.3
IV a-1 NA -12.9 -12.9 -11.6 1.3
IV a-2 NA -12.6 -12.3 -11.0 1.3
IV a-3 NA -11.0 -11.0 -9.5 1.5
IV a-4 NA -7.9 -8.0 -6.2 1.8
IV b NA -8.2 -8.8 -7.6 1.2
compound 8
II NA -6.8 -7.0 -2.7 4.3
III a-1 -13.52 -12.72 -12.42 -11.22 1.3
III a-2 NA -10.0 -10.3 -8.1 2.2
III a-3 NA -6.8 -6.6 -5.2 1.4
III a-4 NA -2.2 -2.2 -0.3 1.8
III b NA 9.4 9.3 9.1 0.1
IV a-1 NA -2.5 -2.7 -1.0 1.8
IV a-2 NA -8.2 -8.3 -6.7 1.6
IV a-3 NA -7.6 -7.3 -6.5 0.9
IV a-4 NA -9.6 -9.6 -8.5 1.1
IV b NA 7.5 9.1 8.6 0.6
MAE1 = 1.5
1Mean average error with respect to SCS-MP2/aug-cc-pVDZ averaged of all compounds in relation to
SCS-MP2/def-TZVP. 2 Lowest calculated reaction energy ∆Ereac of possible reaction products of compound
4 or 8 with methanethiol. ∆SCSMP2basisset represents E(SCS-MP2/def-TZVP)− E(SCS-MP2/aug-cc-pVDZ).
Additionally, there is a need to prove the reliability of the results of CCSD(T) which
represents the Gold standard for ground state closed shell systems. In case of open shell or
biradical systems, Multi-Reference approaches are needed to describe the reaction correctly.
In these systems one can exclude Multi-Reference character in the CCSD(T) computations.
72
6.4. INFLUENCE OF SOLVATION EFFECTS ON REACTANTS, PRODUCTS AND
REACTION ENERGY
The D1 diagnostics show values below 0.08 and thus reaction energies obtained via the couple
cluster approach can be considered as valid (Table 6.10).
Table 6.10: Summary of CCSD D1 diagnostic of reactants and possible reaction products for
the reaction of compound 4 or 8 with methanethiol. All calculations were performed with the
CCSD(T)/def-TVP or CCSD(T)/aug-cc-pDVZ approach.
basis set compound 4 8 compound
def-TZVP educt 0.0767 0.0779 CH3SH 0.0190
II 0.0779 HCl 0.0101
III a-1 0.0588 0.0612 HCN 0.0306
III a-2 0.0577 0.0625 H3CNH2 0.0156
III a-3 0.0597 0.0582
III a-4 0.0571 0.0611
III b 0.0675 0.0706
IV a-1 0.0640 0.0587
IV a-2 0.0603 0.0601
IV a-3 0.0577 0.0581
IV a-4 0.0578 0.0591
IV b 0.0783 0.0779
basis set compound 4 8 compound
aug-cc-pVDZ educt 0.0754 0.0770 CH3SH 0.0208
III a-1 0.0578 0.0603
6.4 Influence of solvation effects on reactants, products
and reaction energy
As no implementation of COSMO was available for CCSD(T) calculations in Turbomole,
previous single point energy calculations were conducted in vacuum. To investigate the effects
of implicit solvation, COSMO has been applied on MP2, CC2 or their spin-component scaled
variants with an -value of 78.
If one compares Table 6.8 and Table 6.11 one can observe that the use of COSMO leads to
a decrease in reaction energy for nearly all possible products. The effect of the solvation is
larger for compound 8 as differences are in the range of ≈ 3-5 kcal/mol for products II, III a-1
to III a-4 and IV a-1 to IV a4. For products of the SN2 reaction III b and IV b the influence
is smaller. The values are of about 1.7 and 0.8 kcal/mol. This trend can also be seen for
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compound 4 educt compound 4 product III a-1
compound 8 educt compound 8 product III a-1
Figure 6.4: Orientation of the water molecules around the carbonyl moieties of educt and
product III a-1 of compound 4 and 8 after geometry optimization with B3LYP-D3/def-TZVP
employing COSMO (=78).
compound 4. In case of III b and IV b implicit solvation increases the reaction energy by
0.7 or 1.0 kcal/mol. For most of the remaining cases reaction energies are slightly higher
compared to vacuum calculated values by 1.5 to 2.8 kcal/mol. Interestingly, one can observe,
that the difference due to implicit solvation varies only by 0.1 kcal/mol for the above applied
ab initio methods. Hence the decrease or increase in reaction energy by solvent effects is
independent of the employed ab initio methodology.
To gain further insight on the influence of the solvent, additional calculations employing
an -value of 4 have been conducted to simulate a non-polar environment (e.g protein).
Additionally, four explicit water molecules have been considered for the reaction of compound
4 and 8 to product III a-1. SCS-MP2 was used for calculation as it leads to the lowest MAE
value in comparison to the CCSD(T)/def-TZVP reaction energies.
As one can see in Table 6.12 the reaction energy decreases by about 1-3 kcal/mol with
increasing permittivity. The only exceptions are the products III b and IV b of compound 4.
The SN2-reaction products reveal the opposite trend as their reaction energy increases by 0.9
to 1.6 kcal/mol as the stabilization via COSMO is larger on the product site. Additionally,
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Table 6.11: Calculated reaction energies (∆Ereac) of possible reaction products of compound 4
or 8 with methanethiol with COSMO (=78) employing the def-TZVP or aug-cc-pVDZ basis set.
CCSD(T) has been calculated in vacuum employing the def-TZVP basis set (except for product III
a-1 which has been calculated with an aug-cc-pVDZ basis set , marked as 3). All energy values in
kcal/mol.
method CCSD(T) MP2 CC2 SCS-MP2 SCS-CC2
compound 4
III a-1 -16.22 / -17.12,3 -16.82 -16.52 -13.52 -12.92
III a-2 -10.1 -14.0 -13.8 -10.7 -10.1
III a-3 -12.9 -14.4 -14.2 -11.5 -11.0
III a-4 -10.3 -11.8 -11.7 -8.9 -8.4
III b 6.7 5.8 6.5 5.9 6.6
IV a-1 -12.9 -15.0 -15.2 -11.9 -11.6
IV a-2 -12.6 -14.0 -14.0 -11.1 -10.8
IV a-3 -11.0 -11.5 -11.3 -8.5 -8.0
IV a-4 -7.9 -9.3 -9.1 -6.6 -6.1
IV b -8.2 -11.8 -12.3 -9.8 -10.0
compound 8
II -6.8 -6.4 -7.8 -2.5 -2.9
III a-1 -12.72 / -13.52,3 -11.42 -11.82 -7.92 -7.72
III a-2 -10.0 -10.1 -10.5 -6.6 -6.4
III a-3 -6.8 -6.1 -6.2 -3.1 -2.7
III a-4 -2.2 -1.4 -1.6 1.3 1.6
III b 9.4 10.6 10.7 10.9 11.2
IV a-1 -2.5 -0.7 -0.7 2.1 2.6
IV a-2 -8.2 -6.9 -6.9 -4.3 -3.8
IV a-3 -7.6 -5.5 -5.4 -2.7 -2.2
IV a-4 -9.6 -7.5 -7.3 -4.8 -4.3
IV b 7.5 8.8 7.8 9.9 9.4
MAE1 1.5 1.4 2.7 2.9
1Mean average error with respect to CCSD(T)/def-TZVP averaged of all compounds. 2 Lowest calculated
reaction energy ∆Ereac of possible reaction products of compound 4 or 8 with methanethiol.
3 CCSD(T)
calculation employing the aug-cc-pVDZ basis set.
a decrease of reaction energy is observable if four explicit water molecules are considered
which are in the vicinity of each carbonyl moiety (Figure 6.4). To conclude this section, it is
observable, that an increased solvent polarity leads to a decrease of the reaction energy. Dif-
ferences of up to 6 kcal/mol were observable depending on environmental effects. This shows
that the enzyme environment will influence the results. But as stated before experimental
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information regarding orientation of the compound in enzyme is missing thus no calculations
in that direction have been performed.
Table 6.12: Summary of the reaction energies (∆Ereac) of possible reaction products for the re-
action of compound 4 and 8 with methanethiol (see Figure 6.3) as a function of the environment.
All calculations were performed with the SCS-MP2/aug-cc-pVDZ approach. All energy values in
kcal/mol. The orientation of the water molecules is given in Figure 6.4.
compound 4 =1 (vacuum) =4 =78 e=78 & 4 H2O
III a-1 -16.1 -14.5 -13.5 -10.6
III a-2 -10.6 -10.7 -10.7
III a-3 -12.7 -11.9 -11.5
III a-4 -10.5 -9.6 -8.9
III b 6.7 6.1 5.9
IV a-1 -12.9 -12.4 -11.9
IV a-2 -12.3 -11.5 -11.1
IV a-3 -11.0 -9.5 -8.5
IV a-4 -8.0 -7.1 -6.6
IV b -8.8 -9.5 -9.8
compound 8 =1 (vacuum) =4 =78 e=78 & 4 H2O
II -7.0 -4.3 -2.5
III a-1 -12.4 -9.8 -7.9 -4.2
III a-2 -10.3 -8.2 -6.6
III a-3 -6.6 -4.6 -3.1
III a-4 -2.2 -0.2 1.3
III b 9.3 10.1 10.9
IV a-1 -2.7 0.0 2.1
IV a-2 -8.3 -5.9 -4.3
IV a-3 -7.3 -4.6 -2.7
IV a-4 -9.6 -6.8 -4.8
IV b 9.1 9.6 9.9
6.5 Benchmarking – comparison of DFT/COSMO with
SCS-MP2/COSMO
The applied DFT methods described product IV b for compound 4 or product II of compound
8 as lowest in terms of the reaction energy instead of product III a-1. The question arises
if this discrepancy usually occurs for DFT methodologies or just in case of B3LYP and
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BHLYP. Therefore, calculations have been extended by using further hybrid functionals as
M06 and M06-2X or long-range-corrected functionals as CAM-B3LYP or ωB97-xD [150],
[151]. As those methods were not available in the Turbomole 6.6 program package, the
following calculations have been conducted by using the Gaussian09 program package. As
mentioned before implicit solvation was included using COSMO with an epsilon value of 4 or
78. Furthermore SCS-MP2/aug-cc-pVDZ//COSMO results were used as reference as they
showed the lowest MAE compared to the CCSD(T)/def-TZVP calculation.
As indicated in the previous calculations the applied DFT methods are not sufficient to
describe the reaction energy. For compound 4 and a dielectric constant value of 78 one can
see a positive thus endothermic description of the reaction in case of B3LYP and CAM-
B3LYP except for product IV b with values of -6.2 or -4.1 kacl/mol (Table 6.13). Only the
Minnesota functional MO6-2X predicts a reaction energy of -7.5 kcal/mol for product III a-1
and describes it as most stable as the SCS-MP2 calculations. Still, it has to be mentioned
that IV b is only lower by 0.5 kcal/mol thus the separation between these two values is very
low. For the other DFT methods IV b is still described falsely as the most stable reaction
product is of about 1-2 kcal/mol lower in energy than III a-1 (except for B3LYP which is
lower by ≈ 6 kcal/mol). If one applies a less hydrophilic environment a slight decrease in
terms of energetics is observable for nearly all products except for most of the results of IIIb
or IV b (Table 6.14). In contrast to this, a slight increase in reaction energy is observable
leading to a stabilization of III a-1 for BHLYP which becomes less stable by 0.1 kcal/mol
compared to IV b. Additionally, the separation in energy between these products is larger
for M06-2X by applying a smaller value for the permittivity.
Contrary to these results, product II of compound 8 is always described as lowest in terms
of the reaction energy. For a hydrophilic implicit solvation only M06-2X describes III a-1
and III a-2 exothermic but still not favorable as products. The remaining calculated reaction
energies are positive. In contrast to compound 4 the difference in reaction energy compared
to II is larger. The deviation ranges from 6 to 10 kcal/mol if one compares II and III a-1.
As mentioned before the largest energetic difference between IV b and III a-1 of compound
4 was 6 kcal/mol in case of B3LYP. This leads to the conclusion that applied DFT methods
are not sufficient and can not properly describe the reaction of compound 8. By including a
nonpolar environment, the reaction energies decrease in a range of 0.5 to 2 kcal/mol mirroring
the same trend as obtained from the post HF calculations. Furthermore, no destabilization
of the SN2-reaction products III b or IV b occurred as for compound 4 and the predicted
trend remains the same regardless of the environment.
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Table 6.13: Calculated reaction energies (∆Ereac) of possible reaction products of compound 4 or
8 with methanethiol in COSMO (=78) employing the aug-cc-pVDZ basis set. All energy values in
kcal/mol.
method SCS- B3LYP- BHLYP- CAM- M06 M06-2X ωB97-XD
MP2 D3 D3 B3LYP
compound 4
III a-1 -13.52 0.6 -4.1 2.9 -3.9 -7.52 -4.7
III a-2 -10.7 3.4 -1.6 4.7 -2.0 -5.7 -2.8
III a-3 -11.5 2.8 -2.1 4.2 -2.0 -5.6 -3.5
III a-4 -8.9 5.1 0.3 5.6 -0.2 -4.2 -1.5
III b 5.9 11.4 11.9 12.6 11.0 10.4 11.9
IV a-1 -11.9 2.2 -2.0 3.7 -2.3 -5.5 -3.4
IV a-2 -11.1 2.8 -1.6 3.7 -2.5 -5.3 -3.2
IV a-3 -8.5 5.1 0.4 5.3 -0.7 -3.8 -1.3
IV a-4 -6.6 7.3 2.5 7.1 1.6 -1.9 1.1
IV b -9.8 -6.22 -6.22 -4.12 -5.32 -7.0 -6.32
compound 8
II -2.5 -4.02 -4.52 -3.12 -7.82 -7.62 -7.72
III a-1 -7.92 6.7 3.3 7.8 0.8 -1.8 0.7
III a-2 -6.6 7.0 3.5 8.0 0.7 -1.9 1.1
III a-3 -3.1 12.8 9.0 13.5 6.7 3.4 5.8
III a-4 1.3 15.4 11.9 16.2 9.3 6.6 9.1
III b 10.9 16.2 17.7 17.8 15.5 15.8 17.2
IV a-1 2.1 17.2 13.4 17.6 11.5 7.2 9.9
IV a-2 -4.3 10.6 6.4 10.2 4.3 1.6 4.0
IV a-3 -2.7 14.0 10.0 13.5 7.9 4.5 6.7
IV a-4 -4.8 11.7 7.3 11.9 5.8 2.5 5.1
IV b 9.9 15.2 15.9 17.0 15.1 12.3 15.0
MAE1 12.1 9.0 13.0 8.0 5.3 7.5
1Mean average error with respect to SCS-MP2/aug-cc-pVDZ averaged of all compounds in relation. 2Lowest
calculated reaction energy ∆Ereac of possible reaction products of compound 4 or 8 with methanethiol.
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Table 6.14: Calculated reaction energies (∆Ereac) of possible reaction products of compound 4 or
8 with methanethiol in COSMO (=4) employing the aug-cc-pVDZ basis set. All energy values in
kcal/mol.
method SCS- B3LYP- BHLYP- CAM- M06 M06-2X ωB97-XD
MP2 D3 D3 B3LYP
compound 4
III a-1 -14.52 -0.6 -5.7 2.2 -4.6 -8.22 -5.4
III a-2 -10.7 3.3 -1.7 4.8 -1.9 -5.6 -2.8
III a-3 -11.9 2.2 -2.7 3.9 -2.2 -5.8 -3.7
III a-4 -9.6 4.3 -0.5 5.2 -0.5 -4.6 -1.9
III b 6.1 11.5 12.1 12.6 11.0 10.4 11.8
IV a-1 -12.4 1.7 -2.6 3.4 -2.5 -5.8 -3.7
IV a-2 -11.5 2.2 -2.1 3.5 -2.7 -5.5 -3.4
IV a-3 -9.5 4.0 -0.7 4.8 -1.1 -4.3 -1.8
IV a-4 -7.1 6.7 1.9 6.9 1.4 -2.1 0.8
IV b -9.5 -5.82 -5.82 -4.02 -5.22 -6.9 -6.22
compound 8
II -4.3 6.22 -6.62 -4.42 -9.02 -8.72 -9.02
III a-1 -9.82 4.5 0.9 6.5 -0.5 -3.1 -0.7
III a-2 -8.2 5.2 1.6 6.9 -0.3 -2.8 0.1
III a-3 -4.6 10.9 7.1 12.4 5.7 2.4 4.7
III a-4 -0.2 13.8 10.2 15.1 8.3 5.6 8.1
III b 10.1 15.3 16.8 17.2 15.0 15.2 16.5
IV a-1 0.0 14.7 10.8 16.0 10.0 5.7 8.4
IV a-2 -5.9 8.6 4.3 9.1 3.2 0.5 2.9
IV a-3 -4.6 11.8 7.8 12.3 6.7 3.3 5.4
IV a-4 -6.8 9.4 4.9 10.5 4.5 1.1 3.7
IV b 9.6 14.7 15.4 16.6 14.7 12.0 14.7
MAE1 12.0 8.8 13.2 8.3 5.6 7.8
1Mean average error with respect to SCS-MP2/aug-cc-pVDZ averaged of all compounds in relation. 2Lowest
calculated reaction energy ∆Ereac of possible reaction products of compound 4 or 8 with methanethiol.
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6.6 Conclusion and discussion
This chapter comprises the results of the theoretical study of the chloro- or nitrile-substituted
1,4-naphtoquinones 4 and 8 (see Figure 6.2) and their reaction products with methanethiol.
The group of Schirmeister and Opatz from the University Mainz used these structures as
warheads to target cysteine proteases of the papain family. In this study the performance
of the methods in terms of structure optimization, energy computations and the influence
of the environment has been evaluated. Firstly, possible structures have been modeled and
optimized on different QM levels (products and their naming shown in Figure 6.3). In terms
of geometry optimization, the performance of B3LYP is comparable to MP2 and shows a
MAE of 0.129 A˚, while geometries obtained by applying HF show a MAE of 0.242 A˚ (Table
6.1). It was observable that the energy evaluation is not very sensitive with respect to the
used geometry optimization methods. The energy difference was at most 2 kcal/mol whether
B3LYP or MP2 optimized structures were used while the resulting trends were the same. In
these initial calculations it was observable that applied DFT methods revealed a different
prediction in the stability of possible reaction products compared with wave function-based
approaches. Therefore, it was necessary to conduct further investigations in this matter.
In benchmark calculations in vacuo employing CCSD(T)/def-TZVP as reference the results
of SCS-MP2/aug-cc-pVDZ showed the lowest MAE with 0.3 kcal/mol followed by SCS-CC2
with 0.4 kcal/mol (Table 6.8). As no Multi-Reference character was observed for CCSD(T)
calculations, obtained results can be accepted as valid. The question arises if DFT approaches
in general lead to a different result compared to ab initio methods. Therefore, caculations
have been extended to Minnesota and long-range corrected functionals. In these cases, SCS-
MP2 was used as reference due to its low MAE. The difference in prediction was seen for
nearly all functionals. In case of compound 4 the SN2 product IV b was overestimated in
stability while for compound 8 product II instead of III a-1 was described as lowest in reac-
tion energy. The only exception is MO6-2X which described product III a-1 of compound 4
like SCS-MP2 as lowest in energy (Table 6.13).
Additionally, environmental effects have been investigated by employing the COSMO ap-
proach at different epsilon values and by inclusion of explicit water molecules (depicted in
Figure 6.4). Ab initio calculations revealed a decrease in reaction energy by 1-3 kcal/mol
with increasing dielectric constant values. Only reaction energies of the SN2 products showed
an opposite behavior as an increase of 1-2 kcal/mol. Additionally, explicit water molecules
were considered and a further decrease of about 3 kcal/mol was observable. These find-
ings indicate environmental effects will likely influence the results. But as no experimental
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information regarding the orientation of the inhibitor within the active site was available
corresponding computations couldn’t be conducted.
But one question still remains. How do these results fit with the experimental findings? As
one can see in Figure 6.3 except for the SN2 products III b and IV b it is to be expected that
the remaining products occur due to a reversible reaction as long as the exothermicity of the
addition reaction remains small. The reaction to the products III b and IV b is followed by
the abstraction of a leaving group, in these cases methylamine or hydrogen cyanide. As a
dissociation of these groups is to be expected and a reattack appears unlikely one can con-
sider that these products result from an irreversible reaction. In terms of DFT calculations
they are only excluded in case of inhibitor 8 as one obtains positive reaction energies. For
compound 4 the SN2 product IV b was described as the most stable product. These findings
indicate that DFT based approaches must be handled with care as they often overestimate
stabilities due to the aromaticity.
In terms of the prediction of the formation it is not possible to distinguish between product
III a or IV as the deviation of the reaction energy is relatively low. Still, in comparison to
the experimental findings computations could exclude the formation of products which would
lead to an irreversible inhibition. These findings are in line with experimental data.
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Chapter 7
Analysis of protonation state and
protein-inhibitor interactions of C1 in
tryparedoxin monomer, dimer and
mutants
7.1 Introduction
The Human African Trypanosomiasis (HAT, or known as African sleeping sickness) is mostly
located in sub-saharan Africa and belongs to the so called neglected tropical diseases (NTD)
[152]. The occurrence of HAT in this region is due to tsetse fly, which is a suitable habitant
for its vector. Within the past years a change in the prevalence occurred caused by increased
controls. Although the disease was nearly eradicated in the middle of the 1960s, cases of
HAT increased in the 1990s. The number of actual cases nowadays (50.000 – 70.000) appears
in global context in a negligible magnitude. Still, untreated HAT ends fatal for the infected
patients and the negatively socialeconomic effects on affected areas are not to be underesti-
mated [152].
The source of HAT is reasoned by kinetoplastids, a group of flagellated protozoans, single-
celled eukaryotes, which are hidden in the kinetoplast, a DNA-rich region [153]. These pro-
tozon parasites are transmitted via different insect vectors and change within their life cycle
between the insect vector and the mammalian host, while contemporaneous huge changes
appear in their mitochondrial morphology or metabolism [154]. Besides of HAT, which is
caused by the infection of the kinetoplastides Trypanosoma brucei (T.b.) gambiense or T.b.
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rhodensie, also the Chagas disease (known as south-american trypanosomiasis) should be
mentioned, induced by Trypanosoma cruzei [152].
The particularity of trypanosomias is the thiol redox metabolism which is different from the
human body and thus represents a promising target. In T.b. the peroxide damage of the par-
asite is prevented due to a cascade of enzyme reactions, with NADPH as main electron source
[155]. The delivery of reducing equivalents is carried out by the flavoenzyme trypanothione
reductase (TR), trypanothione (T(SH)2), tryparedoxin (Tpx) and finally by a peroxidase
(Px) which lead to the detoxification of hydroperoxide substrates (Figure 7.1) [156], [157].
Additionally, this cascade plays an important role in the synthesis of DNA precursors and
consequently in the replication of the parasite [158].
The medication of these diseases is limitied to a few number of drugs which go along with
high toxicity and additionally increased drug resistances are observable [159]. This shows
the relevance of the development of new drugs for the medication of HAT. In the course
of a high-throughput screening approach with nearly 80.000 chemicals by Fueller et. al the
molecule 2-(chloromethyl)-5-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4(3H)-one (compound 1,
C1) was identified as a Tpx targeting drug, which interacts covalently with Tpx active site
residue Cys40 of the active site WCPPC motif (Figure 7.2) [159].
NADPH
NADP
TRox
TRred
T(SH)2
TS2
Tpxox
Tpxred
Px red
Px ox
ROOH
ROH
Figure 7.1: Detoxifiaction of hydroperoxides (ROOH) in African trypanosomias by a cascade
of a peroxidase (Px), trypareodixin (Tpx), trypanothione (T(SH)2) and the trypanothione
reductase (TR).
The group of Hellmich from the University in Mainz was able to crystallize the first struc-
ture of Tpx in complex with C1 in covalent complex with the protein. The X-ray structure
did not contain the leaving group hydrochloride which indicates that it diffuses after the nu-
cleophilic reaction. After covalent modification of Tpx with C1, a dimerization of the protein
was observable which was experimentally proven while Tpx wild type (oxidized or reduced
form) stays in absence of the inhibitor in a monomer form. Chemical induced dimerization
(CID) which is caused by so called dimerizers, is able to affect e.g. signal transmission and
therefore stimulate target gene activation [160]. On this occasion dimerizers as rapamycin,
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which is used as immunosuppressant, coumermycin or gibberlin are to mention [161], [162],
[163]. Generally dimerizers are large molecules but in case of C1 it is so far one of the smallest
known.
Thus, crystallization of Tpx with C1 offers the opportunity to conduct further investiga-
tions on computational side. Questions like inhibitor-protein interactions in the monomer
or inhibitor-inhibitor or protein-protein interactions in Tpx dimer can be tackled via MD
simulations and will be discussed in detail in the following sections.
N N
S
F
CH2
O
H
compound 1 / C1
Cl
Figure 7.2: Chemical structure of compound 1 / C1 identified by Fueller et al. [159]
. Pyrimidone unit of C1 is colored in red.
7.2 Motivation
To investigate C1 in complex with Tpx, MD simulations have been conducted to analyze the
dynamics and the interactions with the surrounding protein environment. At the same time
interactions between the cysteine residues Cys40 and Cys43 have been considered. Further-
more, nearby amino acids which might establish non-covalent interactions between inhibitor
and protein have been included in the analysis as well.
Firstly, two different binding modes of C1 (pose I and pose II) were observed in case of the
covalent protein-inhibitor crystal structure. The crystal structure consists of three different
chains (A - C) where chain A and B form a dimer and C is present as a monomer. Pose
I of the inhibitor C1 was obtained by considering solely chain A of the dimer, while pose
II results from chain C. The initial question was to figure out which pose is more rigid and
what kind of interactions are established in the course of simulation. Therefore, one can
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conclude which pose is more likely in enzyme and additionally, these computations served as
reference for the following investigations. The group of Hellmich mutated specific residues in
the active site of Tpx and these variants have also been computed to analyze possible effects
on the inhibitor-protein interaction and thus, orientation of the inhibitor in Tpx. Another
point of interest was the computation of the non-covalent complex of C1 in wild type Tpx.
The group of Opatz from the University of Mainz modified C1 by exchanging the chlorine
with a hydrogen, thus no covalent reaction of the C1 derivative and Tpx was to be expected.
Experimental data showed, that no decrease of the activity of Tpx was observable and in
consequence, leading to the conclusion that non-covalent protein-inhibitor interactions should
be weak. Therefore, the non-covalent complex of C1 with TPX was computed to gain further
insight on this matter. Finally, dynamics of the dimer complex in presence and absence of
C1 were studied to analyze drug-drug, protein-drug and protein-protein interaction which
are of importance for the dimerization.
The protein environment was described via the AMBER14 force field whereas C1 was de-
scribed by the GAFF force field. In terms of the simulations of the non-covalent complex,
the description of the ESP charges was performed differently which will be discussed later
on. The protocol of minimization and equilibration was conducted in the same manner as
decribed in section 5.1. The duration of each production run consists of 30 ns, except for the
MD simulations of the non-covalent complex which were performed for 10 ns.
7.3 C1 in covalent complex with Tpx in pose I or pose
II
First of all, chain A of the X-ray structure obtained by Hellmichs group has been used as
pose I, chain C of the same pdb structure for pose II. The difference between both binding
modes is that C1 in pose II is exposed to the solvent whereas in pose I is parallel to the
second inhibitor in chain B (Figure 7.3).
The MD simulation of both poses revealed several findings. First of all, C1 in pose I was
more stable during the simulation. If one looks at the RMSD values one can see that in case
of that pose that the RMSD value increases up to ≈ 2-3 A˚. At certain times (for example
during 6 and 7 ns) it decreases to 1 A˚ (Figure 7.5-A).
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Figure 7.3: Covalent protein-inhibitor complex of inhibitor C1 and Tpx. Initial structure of
pose I (green) and pose II (blue) of inhibitor C1 depicted in licorice representation.
This can be explained by the rotation of the pyrimidone ring of C1 (depicted in red in
Figure 7.2) which will later one be discussed. In pose II the values increased up to 6 A˚ and
show larger fluctuations. This is understandable as a movement of the inhibitor in direction
of the protein is observable (Figure 7.4-C). Still C1 occasionally returns to a pose comparable
the one at the beginning of the MD simulation accompanied by a decrease of RMSD values
to 1.5 A˚ (Figure 7.5-B).
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A B C
Figure 7.4: A – Snapshot from MD simulation of C1 after 30 ns of Tpx in pose I (green). B
– Initial location of C1 in pose II (blue). C – Snapshot from MD simulation of C1 after 30
ns of Tpx in pose II (blue).
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Figure 7.5: Course of RMSD values versus time plots are given for inhibitor C1 in covalent
complex with Tpx in A – C1 in pose I or B – C1 in pose II during the 30 ns production run.
To understand the fluctuations of C1 in pose II one has to analyze interactions with the
protein surrounding (Figure 7.6). In case of the first pose one can see that backbone nitrogen
and oxygen of Ile109 is of importance. Both can establish hydrogen bonds with the nitrogen
or oxygen of the pyrimidone ring of the inhibitor.
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N N(1)
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Figure 7.6: Interaction of covalent protein-inhibitor complex of C1 and Tpx depicted with
dashed lines. Location of amino acids and C1 serves for clarification and does not reflect
actual position in MD simulations.
A
0 6 12 18 24 30
2
3
4
5
6
7
8
9
2
3
4
5
6
7
8
9
 
di
st
an
ce
 [Å
]
time [ns]
 Ile109-O(2) to C1-N(1)H in pose I
 
 
di
st
an
ce
 [Å
]
 Ile109-N(2)H to C1-O(1) in pose I
B
0 6 12 18 24 30
2
3
4
5
6
7
8
9
2
3
4
5
6
7
8
9
 
di
st
an
ce
 [Å
]
time [ns]
 Ile109-O(2) to C1-N(1)H in pose II
 
 
di
st
an
ce
 [Å
]
 Ile109-N(2)H to C1-O(1) in pose II
Figure 7.7: The variation in distance as a function of simulation time for inhibitor C1 in Tpx
corresponding to Figure 7.6 during a 30 ns production run. A – Distance between Ile109-
N(2)H to C1-O(1) or Ile109-O(2) to C1-N(1)H in pose I. B –Distance between Ile109-N(2)H
to C1-O(1) or Ile109-O(2) to C1-N(1)H in pose II.
In terms of pose I the distance between backbone-N(2)H and C1 oxygen O(1) has a mean
of 2.1 A˚ and shows a good interaction (Figure 7.7-A). Fluctuations which occur at ≈ 6 and
12 ns are due the change of orientation of C1 which will be discussed under the section 7.4.
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For pose II this is not the case. As one can see in Figure 7.7-B the mean distance between
Ile109-N(2)H and C1-O(1) is 4.6 A˚ and no water-mediated interaction can be observed. Still
in pose II one can see a large decrease right at the beginning of the simulation from 7.4 A˚
to a mean of 4.6 A˚. This is explained by the fact of the interaction of Ile109’s oxygen and
C1’s pyrimidon nitrogen. For the interaction between Ile109-O(2) and C1-N(1) both poses
show similar mean values, while the standard deviation of pose II is slightly larger. Another
observation can be made in terms of the RMSD value of the inhibitor in pose II and its in-
teraction with Ile109. The decrease of distance between C1 and Ile109 and therefore increase
of the RMSD value shows a relation between these two quantities (Figure 7.8).
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Figure 7.8: Course of RMSD values versus time plots are given for inhibitor C1 in covalent
complex with Tpx during the 30 ns production run (top plot). The variation in distance
as a function of simulation time for inhibitor C1 in Tpx between Ile109-N(2)H and C1-O(1)
corresponding to Figure 7.6 during a 30 ns production run (bottom plot). Both plots are
shown for clarification in terms of their relation.
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Figure 7.9: The variation in distance as a function of simulation time for inhibitor C1 in Tpx
between Cys40 and Cys43 corresponding to Figure 7.6 during a 30 ns production run. A
–Distance between Cys40-S(1) and Cys43-S(2) in pose I. B –Distance between Cys40-S(1)
and Cys43-S(2) in pose II. C – Distance between Cys40-S(1) and Cys43-S(2)H in pose I. D
– Distance between Cys40-S(1) and Cys43-S(2)H in pose II.
In terms of the interactions between the cysteine residues 40 and 43 nearly no differences
are observable. The mean of distance between the two sulfurs of Cys40 and Cys43 as well as
the standard deviation are the same. Only in case of the distance between Cys40 sulfur and
Cys43 SH-group the mean and the standard deviation are slightly higher (see Table 7.1).
In regard of further possible interactions the backbone oxygen of Glu107 can be relevant. The
distance between the fluorine of C1 and Glu107-O(3) has a mean of 3.8 A˚ and by variation of
the substituents of the phenyl ring further interactions might be established (Figure 7.10-A).
Especially the standard deviation of this distance is only 0.6 A˚, indicating a possible stable
interaction. Still, for pose II those interactions can’t be seen as it shows a mean of distance
of 10.2 A˚ although rarely a decrease to ≈ 4 A˚ does occur.
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Figure 7.10: The variation in distance as a function of simulation time for inhibitor C1 in Tpx
between Glu107-O(3) and C1-F(1) corresponding to Figure 7.6 during a 30 ns production run.
A – Distance between Glu107-O(3) to C1-F(1) in pose I. B – Distance between Glu107-O(3)
to C1-F(1) in pose II.
Table 7.1: Mean and standard deviation of RMSD values or distances during a 30 ns production
run of C1 in covalent complex with wild type Tpx. Mean and standard devations are calculated
from 10,000 data points. All values are given in A˚.
wild type C1 covalent pose I C1 covalent pose II
mean / SD mean / SD
RMSD C1 2.1 / 0.6 5.2 / 1.4
distance Ile109-N(2)H to C1-O(1) 2.1 / 0.4 4.6 / 1.1
distance Ile109-O(2) to C1-N(1)H 2.6 / 0.6 2.3 / 0.8
distance Glu107-O(3) to C1-F(1) 3.8 / 0.6 10.2 / 2.2
distance Cys40-S(1) to Cys43-S(2) 3.6 / 0.2 3.6 / 0.2
distance Cys40-S(1) to Cys43-S(2)H 2.6 / 0.5 2.7 / 0.8
7.4 Influence of point mutations of Tpx on the binding
mode of C1
The focus of the following MD simulations lies on the mutation of specific amino acids which
might have an effect on the binding mode of C1 in Tpx. Crystal structure revealed that C1
is embedded in the hydrophobic side chains of Trp39, Trp70 and Ile109. Furthermore, Cys43
is of importance in terms of the redox activity of TPX. Therefore, the residues have been
modified at each time, i.e. Trp39, Cys43, Trp70 or Ile109 have been mutated to alanine. In
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the previous MD simulation of the monomer it was shown that C1 in pose I has lower RMSD
values and thus a higher rigidity in Tpx. Hence, chain A has been used for the simulations
with respect to the mutants. The duration of the MD simulations consists of 30 ns and have
been performed for each point mutation.
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Figure 7.11: Course of RMSD values versus time plots are given for inhibitor C1 in covalent
complex with Tpx mutants during the 30 ns production run. A – RMSD values of C1 in
W39A. B – RMSD values of C1 in C43A. C – RMSD values of C1 in W70A. D – RMSD
values of C1 in I109A.
The RMSD values of C1 in Figure 7.11 show that the mutation of these amino acids leads
to a decrease in the standard deviation and lessened fluctuations compared to the simulation
of C1 in wild type Tpx. In terms of the mean of the RMSD values the modification of Trp39
and also Ile109 to alanine are lower by 0.9 and 0.5 A˚. The change of Cys43 or Trp70 to ala-
nine leads to an increase of the mean RMSD value of C1. This shows that in case of Trp39
and Ile109 less fluctuations in the orientation of C1 occurs with respect to the crystallized
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inhibitor.
To understand this situation, one has to take a look at Figure 7.12. In terms of Figure 7.12-A
one can see that Trp39 in wild type Tpx is able to interact with C1 in a T-shaped stacking
which leads to a change of the inhibitor’s orientation. In this case the distances between C1
and Ile109 also decrease. Furthermore, it occasionally can have another orientation which
is shown in Figure 7.12-B. In this case no interaction between Trp39 and C1 occur, thus
allowing the inhibitor to rotate. At the same time the distance to Ile109 increases. This is
the explanation for the increase of RMSD in the previous simulation of C1 in pose I in wild
type Tpx (compare Figure 7.7-A). While one has a T-shaped stacking between Trp39 and
C1 RMSD values of C1 are about 3 A˚ in the other case they are about 1.5 A˚. These findings
correlate with the RMSD plots in Figure 7.11.
The mutants C43A and W70A are comparable to the simulation of wild type Tpx. Both
simulations show solely the T-shaped stacked orientation (Figure 7.12-C and Figure 7.12-D).
For these cases the distance to Ile109 are of the same amount as in the previous simulation of
the wild type. Of course, there is also the possibility that C1 might rotate in both mutants,
but this event was not observable in performed simulations.
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A B
C D
E F
Figure 7.12: A – Snapshot of C1 (pose I) in wild type Tpx at 6 ns. B – Snapshot of C1
(pose I) in wild type Tpx at 12.6 ns C – Snapshot of C1 (pose I) in Tpx C43A mutant at 30
ns. D – Snapshot of C1 (pose I) in Tpx W70A mutant at 30 ns. E – Snapshot of C1 (pose I)
in Tpx W39A mutant at 30 ns. F – Snapshot of C1 (pose I) in Tpx I109A mutant at 30 ns.
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Figure 7.13: The variation in distance as a function of simulation time for inhibitor C1 in
Tpx mutants corresponding to Figure 7.6 (in case of I109A it is Ala109) during a 30 ns
production run. A –Distance between Ile109-N(2)H to C1-O(1) or Ile109-O(2) to C1-N(1)H
inW39A. B – Distance between Ile109-N(2)H to C1-O(1) or Ile109-O(2) to C1-N(1)H in
C43A. C –Distance between Ile109-N(2)H to C1-O(1) or Ile109-O(2) to C1-N(1)H in W70A.
D –Distance between Ala109-N(2)H to C1-O(1) or Ala109-O(2) to C1-N(1)H in I109A.
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Figure 7.14: The variation in distance as a function of simulation time for inhibitor C1 in
Tpx between Cys40 and Cys43 corresponding to Figure 7.6 during a 30 ns production run. A
–Distance between Cys40-S(1) and Cys43-S(2) in W39A. B –Distance between Cys40-S(1)
and Cys43-S(2) in W70A. C – Distance between Cys40-S(1) and Cys43-S(2) in I109A. D
–Distance between Cys40-S(1) and Cys43-S(2)in W39A. E –Distance between Cys40-S(1)
and Cys43-S(2)H in W70A. F - Distance between Cys40-S(1) and Cys43-S(2)H in I109A.
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The simulation of the variant W39A in complex with C1 shows an orientation in which
the RMSD values are lower and the distance to Ile109 is increased in contrast to the wild
type simulation (Figure 7.13-A). This is understandable as no interaction was possible now
since the bulky side chain of Trp39 was missing.
Also, in case of I109A the RMSD value is slightly lower because of a similar reason. As one
can see in Figure 7.12-F the mutation of isoleucine to alanine lead to increased space which
allowed the inhibitor to move further into the pocket. At the same time one can observe a
movement of Trp39 towards the solvent.
In terms of the distance between Cys40 and Cys43 (except for the C43A mutant) the mean
values of the sulfur-sulfur distance are comparable (Figure 7.14). The hydrogen-sulfur inter-
action is comparable in all three mutants as they show differences below 0.2 A˚ for the mean
and below 0.3 A˚ for the standard deviation (Table 7.2).
Just as in the simulations before the distance between the fluorine and Glu107 backbone
oxygen has been measured. For the variants W39A, W70A and I109A the mean distances
are slightly lower compared to the wild type simulation whereas C43A shows a slightly larger
mean distance of 4.2 A˚ (see Figure 7.15 and Table 7.2).
97
7.4. INFLUENCE OF POINT MUTATIONS OF TPX ON THE BINDING MODE OF C1
A
0 6 12 18 24 30
2
3
4
5
6
7
di
st
an
ce
 [Å
]
time [ns]
 Glu107-O(3) to C1-F(1) in W39A
B
0 6 12 18 24 30
2
3
4
5
6
7
di
st
an
ce
 [Å
]
time [ns]
 Glu107-O(3) to C1-F(1) in C43A
C
0 6 12 18 24 30
2
3
4
5
6
7
di
st
an
ce
 [Å
]
time [ns]
 Glu107-O(3) to C1-F(1) in W70A
D
0 6 12 18 24 30
2
3
4
5
6
7
di
st
an
ce
 [Å
]
time [ns]
 Glu107-O(3) to C1-F(1) in I109A
Figure 7.15: The variation in distance as a function of simulation time for inhibitor C1 in Tpx
mutants between Ile109-N(2)H and C1-O(1) (in case of I109A it is Ala109) corresponding
to Figure 7.6 during a 30 ns production run. A –Distance between Glu107-O(3) to C1-F(1)
in W39A. B – Distance between Glu107-O(3) to C1-F(1) in C43A. C – Distance between
Glu107-O(3) to C1-F(1) in W70A. D – Distance between Glu107-O(3) to C1-F(1) in I109A.
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Table 7.2: Mean and standard deviation of RMSD values or distances during a 30 ns production
run of C1 in covalent complex with Tpx mutants. Mean and standard devations are calculated from
10,000 data points. All values are presented in A˚.
mutants Trp39 Ala Cys43 Ala Trp70 Ala Ile109 Ala
mean / SD mean / SD mean / SD mean / SD
RMSD C1 1.2 / 0.4 3.1 / 0.5 2.7 / 0.4 1.6 / 0.6
distance Ile109-N(2)H to 2.5 / 0.5 2.0 / 0.2 1.9 / 0.2 2.1 / 0.3
C1-O(1)
distance Ile109-O(2) to 3.2 / 0.5 2.1 / 0.3 2.3 / 0.3 3.0 / 0.4
C1-N(1)H
distance Glu107-O(3) to 3.4 / 0.4 4.2 / 0.7 3.7 / 0.5 3.5 / 0.5
C1-F(1)
distance Cys40-S(1) to 3.6 / 0.2 - / - 3.6 / 0.2 3.6 / 0.3
Cys43-S(2)H
distance Cys40-S(1) to 2.5 / 0.5 - / - 2.6 / 0.7 2.7 / 0.8
Cys43-S(2)H
7.5 Stability of the non-covalent complex of C1 in wild
type Tpx
Another aspect, which has been examined, was the stability of the non-covalent protein-
inhibitor complex. These investigations are conducted to gain further insight on the course
of inhibition, as the crystal structure only consists of the final state of reaction. Chain B of
the pdb structure Tpx wt inh cc463a pos1 final.pdb has been used as starting point as C1
in absence of chlorine was present. It is suspected that due to the radiation of the X-ray a
cleavage of the covalent bond occurred and this lead to the crystallized non-covalent form. In
this case, a methyl group instead of a chloromethyl group was at position 2 of the pyrimidin-
4(3H)-one ring. Additionally, no chlorine was located in the vicinity of the binding site. It is
to be expected that after formation of the covalent bond chlorine diffuses out of the binding
pocket.
In order to analyze the non-covalent complex of C1 in Tpx it was of necessity to replace the
hydrogen of the crystallized structure by chlorine. The parametrization has been changed
in this case as the HF/6-31G(d) obtained charges showed one possibly incorrect value: the
electrophilic carbon of C1 had a charge of -0.359 (see Figure 7.16). Because of that the
method was changed and the basis set was expanded to M06-2X/aug-cc-pVDZ. This led to
more meaningful values as the charge of electrophilic carbon changed to 0.382. The non-
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covalent complex has been investigated for three different protonation states of Cys40 and
Cys43 depicted in Figure 7.17. Additionally, the distance between the nucleophilic sulfur of
Cys40 and the electrophilic carbon of C1 has been measured to estimate the possibility of
covalent modification. Another difference regarding the other simulations is the production
run time. This was reduced to 10 ns for each state. In these simulations solely the wild type
was considered.
A B
Figure 7.16: A – Calculated charges of inhibitor C1 using HF and the 6-31G(d) basis set.
B – Calculated charges of inhibitor C1 using DFT functional M06-2X and the aug-cc-pVDZ
basis set.
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Figure 7.17: Interaction of non-covalent protein-inhibitor complex of C1 and Tpx depicted
with dashed lines. Location of amino acids and C1 serves for clarification and does not
reflect actual position in MD simulations. Variation of protonation states of Cys40 and
Cys43 as followed: A – protonated Cys40 and protonated Cys43, B – deprotonated Cys40
and protonated Cys43, C – protonated Cys40 and deprotonated Cys43.
If one takes a look at the RMSD plots (Figure 7.18), all three protonation states show
higher RMSD values compared to the simulation of the covalent complex. This is to be
expected, as the non-covalent complex should show more fluctuations, it was observable that
in case of a deprotonated Cys43 and especially for the neutral state (protonated Cys40 and
Cys43) the RMSD values have a mean of 5.9 A˚ or 7.5 A˚ and are much larger in relation to
the covalent complex. For the simulation of a deprotonated Cys40 the mean is of 4.2 A˚ and
revealing a lower standard deviation of 0.9 A˚.
In terms of the neutral system (Figure 7.17-A) the RMSD value increases strongly after 2 ns
and at the same time the distance between Cys40-S(1) and C1-C(1) increases up to 16 A˚ due
to a movement into a flipped orientation. Also, in case of the deprotonated Cys43 system
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(Figure 7.17-C) an increase to 6 A˚ in RMSD is observable after 1 ns which lowers to 3 A˚ at
9 ns.
Although the simulation with the deprotonated Cys40 (Figure 7.17-B) showed the lowest
mean in respect to the RMSD values, the distance between Cys40-S(1) and the electrophilic
carbon C1-C(1) increases up to 12 A˚ (mean of simulation = 7.4 A˚) and therefore leading to
the conclusion that the covalent modification only occurs if the deprotonated sulfur is close
enough to the electrophilic carbon of C1 to bind irreversible.
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Figure 7.18: Course of RMSD values versus time plots are given for inhibitor C1 in non-
covalent complex with wild type Tpx during the 10 ns production run. A – RMSD values
of C1 in protonation state Cys40-SH and Cys43-SH. B – RMSD values of C1 in protonation
state Cys40-S− and Cys43-SH. C – RMSD values of C1 in protonation state Cys40-SH and
Cys43-S−.
The findings in terms of the course of RMSD values are in relation to the interactions
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with Ile109. If one compares the distances depicted in Figure 7.20 with the RMSD plots in
Figure 7.18 one can see that the variations in value behave similarly. While the RMSD value
increases one can observe an increase in distance thus weakening of the hydrogen bonds. The
lowest mean in distance can be seen for the simulation with the deprotonated Cys40. Still,
these interactions might not be sufficient for a stable non-covalent protein-inhibitor complex
which would already lead to a deactivation of TPX.
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Figure 7.19: The variation in distance as a function of simulation time for inhibitor C1 in
Tpx between Cys40-S(1) and C1-C(1) corresponding to Figure 7.17 during a 10 ns production
run. A – Distance between Cys40-S(1) and C1-C(1) n the protonation state Cys40-SH and
Cys43-SH. B – Distance between Cys40-S(1) and C1-C(1) in the protonation state Cys40-
S− and Cys43-SH. C – Distance between Cys40-S(1) and C1-C(1) in the protonation state
Cys40-SH and Cys43-S−.
Therefore, the simulations are in line with the experimental findings of C1’s derivative
(chlorine was exchanged with hydrogen). The simulations showed solely in one case hydrogen
103
7.5. STABILITY OF THE NON-COVALENT COMPLEX OF C1 IN WILD TYPE TPX
interactions between C1 and the active site of Tpx. Still, the course of RMSD reveals larger
fluctuations compared to the covalent complex of wild type Tpx or its mutants, leading to the
conclusion that the non-covalent complex is low in stability. In consequence, no inhibition is
to be expected, as mirrored in the experimental data.
Table 7.3: Mean and standard deviation of RMSD values or distances during a 10 ns production
run of C1 in non-covalent complex with Tpx (in different protonation states for Cys40 and Cys43)
corresponding to section 3. Mean and standard devations are calculated from 10,000 data points.
All values are in A˚.
non C1 in Cys40-SH / C1 in Cys40-S− / C1 in Cys40-SH /
covalent Cys43-SH Cys43-SH Cys43-S−
mean / SD mean / SD mean / SD
RMSD C1 7.5 / 1.9 4.2 / 0.9 5.9 / 1.5
distance C1-C(1) to 13.8 / 3.3 7.4 / 1.4 8.6 / 2.0
Cys40-S(1) l
distance Ile109-N(2)H 6.7 / 1.8 3.0 / 1.5 7.3 / 2.0
to C1-O(1)
distance Ile109-O(2) 10.7 / 2.6 5.4 / 1.8 8.6 / 2.1
to C1-N(1)H
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Figure 7.20: The variation in distance as a function of simulation time for inhibitor C1 in
Tpx corresponding to Figure 7.17 during a 10 ns production run. A – Distance between
Ile109-N(2)H to C1-O(1) or Ile109-O(2) to C1-N(1)H In the protonation state Cys40-SH and
Cys43-SH. B – Distance between Ile109-N(2)H to C1-O(1) or Ile109-O(2) to C1-N(1)H in the
protonation state Cys40-S− and Cys43-SH. C – Distance between Ile109-N(2)H to C1-O(1)
or Ile109-O(2) to C1-N(1)H in the protonation state Cys40-SH and Cys43-S−.
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PROTONATION STATES
7.6 Wild type Tpx in absence of inhibitor in different
protonation states
In this section interactions of both active site cysteine residues have been analyzed in absence
of the inhibitor C1. Crystal structures do not contain hydrogens and thus the protonation
state is not known. Still, this information is needed to get further insights as only a depro-
tonated cysteine can be modified. Therefore, MD simulations were conducted to determine
the most likely protonation state of Cys40 and Cys43. The system was prepared by removal
of the inhibitor and preparation of three different protonation states (see Figure 7.21). Af-
terwards, hydrogen bonds and sulfur-sulfur distances have been calculated based on the 30
ns production runs.
A
Cys40
S(1)
S(2)Cys43
H
H
B
Cys40
S(1)
S(2)Cys43
H
C
Cys40
S(1) S(2)
Cys43
H
Figure 7.21: Interaction of Cys40 and Cys43 in wild type Tpx in absence of inhibitor depicted
with dashed lines. Location of amino acids serves for clarification and does not reflect actual
position in MD simulations. Variation of protonation states of Cys40 and Cys43 have been
conducted as followed: A – protonated Cys40 and protonated Cys43. B – deprotonated
Cys40 and protonated Cys43. C – protonated Cys40 and deprotonated Cys43.
The distance plots show that the strongest interactions between both Cys residues are
obtained for the neutral state as the standard deviations are below 0.5 A˚ (Figure 7.22). Also,
the sulfur-sulfur distance (depicted in Figure 7.21) with a mean of 3.6 A˚ is comparable to
the MD simulations of the covalent complex (wild type and mutants). For a deprotonated
Cys40 the mean values are slightly higher compared to the neutral state and they also show
fluctuations (Table 7.4). The increase in distance which can be seen in Figure 7.22-B occurs
due to the movement of Trp39 towards the water shell. It is not clear if the weaker interaction
leads to that motion or the movement itself weakens the interaction of both cysteine residues.
For the last protonation state, the behaviour is completely different. Firstly, the deprotonated
Cys43 orientates towards Tyr80’s hydroxyl group at ≈ 5 ns. This leads to an increase in
distance to Cys40 and thus weaker interactions. Subsequently, Cys40 starts to orientate
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towards the solvent at the same time as Trp39 and a return to its initial position was not
observable. In consequence, no hydrogen bond to Cys43 was established again.
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Figure 7.22: The variation in distance as a function of simulation time for wild type C1
in absence of Tpx between Cys40 and Cys43 corresponding to Figure 7.21 during a 30 ns
production run. A –Distance between Cys40-S(1) and Cys43-S(2)H (black curve), Cys40-
S(1)H to Cys43-S(2) (red curve) or Cys40-S(1) to Cys43-S(2) (green curve) for protonated
Cys40 and Cys40. B – Distance between Cys40-S(1) and Cys43-S(2)H (black curve) or Cys40-
S(1) to Cys43-S(2) (green curve) for deprotonated Cys40. C –Distance between Cys40-S(1)H
to Cys43-S(2) (red curve) or Cys40-S(1) to Cys43-S(2) (green curve) for deprotonated Cys43.
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Table 7.4: Mean and standard deviation of RMSD values or distances during a 30 ns production
run of C1 in non-covalent complex with Tpx (in different protonation states for Cys40 and Cys43).
Mean and standard devations are calculated from 10,000 data points. All values are given in A˚.
Tpx in absence Cys40-SH / Cys40-S− / Cys40-SH /
of inhibitor C1 Cys43-SH Cys43-SH Cys43-S−
mean / SD mean / SD mean / SD
distance Cys40-S(1) to 2.5 / 0.5 2.7 / 0.9 -
Cys43-S(2)H
distance Cys40-S(1)H to 4.7 / 0.4 - 6.0 / 1.8
Cys43-S(2)
distance Cys40-S(1) to 3.6 / 0.2 3.9 / 0.8 5.8 / 1.2
Cys43-S(2)
7.7 Analysis of the dimerization of Tpx in covalent
complex with C1 and in absence of C1
Experimental data reveal that the dimer formation of Tpx solely occurs in presence of a
covalently bound C1 with a high affinity as no monomer was detected after the drug was
added. Furthermore, the dimer appears to be stable as dilution experiments did not reverse
the dimerization. To probe the stability of the Tpx dimer, two different simulations have
been conducted. On the one hand in presence of two C1 molecules which are in covalent
complex with Tpx and on the other in absence of both inhibitors. In the latter case both
cysteine residues were protonated.
At first, investigations focused on interactions of C1 with Tpx dimer as well as on drug-drug
interactions in the dimerized Tpx. The dynamics show that both C1 inhibitors have a mean
RMSD value of 1.1 A˚ along with a standard deviation of 0.4 A˚ which is lower compared to
C1 in pose I monomer. These findings are understandable as both molecules interact with
Tpx as well as with each other due to pi-stacking, thus leading to increased stability. In terms
of distance of C1 to backbone-NH group of Ile109 in chain A and chain B, a slight increase in
mean by 0.3 A˚ or 0.6 A˚ is observable if one compares the values with C1 (pose I) in covalent
complex with Tpx monomer.
Interactions between both C1 molecules to the carbonyl group of Ile109 are reduced as mean
distances of 3.4 A˚ or 3.6 A˚ are obtained in the course of the simulation. This is understand-
able as due to the intermolecular pi-pi interactions of both C1 molecules (which apparently
appear to be stronger than the interactions to Ile109’s backbone) their positions are more
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restricted compared to C1 bound to the Tpx monomer.
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Figure 7.23: Course of RMSD values versus time plots are given for inhibitor C1 in covalent
complex with Tpx dimer. (Left) C1 covalently bound to Cys40 of chain A. (Right) C1
covalently bound to Cys40 of chain B during the 30 ns production run.
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Figure 7.24: The variation in distance as a function of simulation time for inhibitor C1 in
Tpx dimer corresponding to Figure 7.6 during a 30 ns production run. A – Distance between
Ile109-N(2)H to C1-O(1) or Ile109-O(2) to C1-N(1)H in chain A. B –Distance between Ile109-
N(2)H to C1-O(1) or Ile109-O(2) to C1-N(1)H in chain B.
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These interactions are observable if one calculates the variation in distance of perpendic-
ular atoms of C1 in chain A to atoms of chain B (Figure 7.25 and Table 7.6). Interactions
between both thiophene rings of C1 in chain A and chain B show a mean in distance of 3.7
A˚ or 3.8 A˚ with a low standard deviation of 0.2 A˚ or 0.3 A˚ (Table 7.6). This indicates that a
stable pi-pi interaction between these two heterocycles is present. In case of the flourophenyl-
rings of both C1 the flexibility is slightly higher as the standard deviation is larger. These
differences might occur due to the sandwich conformation of both thiophene rings while the
flourophenyl-rings are stacked in a parallel displaced manner. These findings reveal a sta-
ble intermolecular interaction of both C1 molecules as well as an appropriate interaction to
Ile109’s backbone which results into lower mean RMSD values of both inhibitors compared
to C1 in Tpx monomer as mentioned before. Additionally, the distance of the fluorine of
both molecules to Glu107’s backbone oxygen show slightly lower distances and fluctuations
compared to the results of Tpx monomer in complex with C1. This can also be explained by
the increased immobility of both inhibitors.
Figure 7.25: Selected perpendicular atoms of two C1 molecules in covalent complex with
chain A or chain B of Tpx depicted with dashed lines.
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Figure 7.26: The variation in distance as a function of simulation time for both C1 molecules
in chain A or chain B of Tpx corresponding to Figure 7.25 during a 30 ns production run. A
– Distance between C1-C(2) in chain A to C1-S(2) in chain B. B – Distance between C1-C(3)
in chain A to C1-C(6) in chain B. C – Distance between C1-C(4) in chain A to C1-C(7) in
chain B. D – Distance between C1-C(5) in chain A to C1-C(8) in chain B.
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Figure 7.27: The variation in distance as a function of simulation time for inhibitor C1 in Tpx
between Glu107-O(3) and C1-F(1) corresponding to Figure 7.6 during a 30 ns production run.
Distance between Glu107-O(3) to C1-F(1) in chain A (left). Distance between Glu107-O(3)
to C1-F(1) in chain B (right).
Another point of interest was the stability of the Tpx dimer. To probe the necessity of
C1 in terms of dimer stabilization the simulation was relaunched in absence of the inhibitor.
If one compares the mean and especially the standard deviation of the RMSD of both chains
one can see larger fluctuations if C1 is not covalently bound to Tpx (Figure 7.28). If one
looks at Table 7.7, chain A and B show low fluctuations with a standard deviation of 0.2 A˚
with a mean of 1.8 A˚ or 1.9 A˚. Contrary to these results larger means of 2.8 A˚ (for chain A)
or 3.1 A˚ (for chain B) are obtained in absence of the inhibitors and an increase of about 0.8
A˚ in standard deviation is observable. Moreover, after 24 ns an increase of ∼ 2 A˚ occurs if
no inhibitor molecules are present.
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Figure 7.28: Course of RMSD values versus time plots are given for chain A and chain B of
Tpx dimer in A – presence of two covalently bound C1 molecules or in B – absence of both
C1 molecules during the 30 ns production run.
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Figure 7.29: Interaction of Lys102 (chain A) and Glu107 (chain B) or Lys102 (chain B) and
Glu107 (chain A) of Tpx dimer depicted with dashed lines. Location of amino acids and C1
serves for clarification and does not reflect actual position in MD simulations.
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Figure 7.30: The variation in distance as a function of simulation time for A - Glu107 (chain
A) to Lys102 (chain B) and B – Glu107 (chain B) to Lys102 (chain A) in presence of two C1
molecules or C – Glu107 (chain A) to Lys102 (chain B) and D – Glu107 (chain B) to Lys102
(chain A) in absence of both C1 inhibitors in Tpx corresponding to Figure 7.29 during a 30
ns production run.
Table 7.5: Mean and standard deviation of RMSD values or distances during a 30 ns production
run of two C1 in covalent complex with chain A or chain B of wild type Tpx dimer. Mean and
standard devations are calculated from 10,000 data points. All values are in A˚.
wild type dimer chain A chain B
mean / SD mean / SD
RMSD C1 1.1 / 0.4 1.1 / 0.4
distance Ile109-N(2)H to C1-O(1) 2.7 / 0.5 2.4 / 0.4
distance Ile109-O(2) to C1-N(1)H 3.6 / 0.5 3.4 / 0.4
distance Glu107-O(3) to C1-F(1) 3.5 / 0.4 3.3 / 0.3
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To gain further insight into this increase in RMSD intermolecular protein-protein inter-
actions have been analyzed. It was observable that Lys102 of chain A and Glu107 of chain B
(and vice versa) can establish hydrogen bonds in the course of simulation (Figure 7.30). In
presence of C1 hydrogen bonds are formed between Glu107 (chain A) and Lys102 (chain B)
for the first 5 ns and after 16 ns. In the other case, a stable interaction is only maintained
for the first 6 ns. In comparison to these observations one obtains interaction for Glu107
(chain A) and Lys102 (chain B) from 9 to 24 ns or for the first 12 ns in case of the interaction
of Glu107 (chain B) and Lys102 (chain A). After 24 ns an increase to 18 A˚ occurs as both
chains are moving apart. This motion is in correlation with the course of RMSD values and
indicates the dissociation of the dimer. Hence, one can conclude that the stability of Tpx
dimer is maintained due to the presence of covalently bound C1 and the resulting drug-drug
and drug-protein interactions.
Table 7.6: Mean and standard deviation of intermolecular distances of both C1 molecules during
a 30 ns production run in covalent complex with wild type Tpx dimer as depicted in Figure 7.25.
Mean and standard devations are calculated from 10,000 data points. All values are in A˚.
wild type dimer mean / SD
distance C1-C(2) to C1-S(2) 3.7 / 0.3
distance C1-C(3) to C1-C(6) 3.8 / 0.2
distance C1-C(4) to C1-C(7) 4.1 / 0.5
distance C1-C(5) to C1-C(8) 3.7 / 0.4
Table 7.7: Mean and standard deviation of RMSD values of chain A or B in presence or absence of
C1 during a 30 ns production run. Mean and standard devations are calculated from 10,000 data
points. All values are in A˚.
wild type dimer RMSD chain A chain B
presence of inhibitor mean / SD 1.8 / 0.2 1.9 / 0.2
absence of inhibitor mean / SD 2.8 / 0.9 3.1 / 1.0
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Table 7.8: Mean and standard deviation of intermolecular distances of both Glu107 in chain A and
Lys102 in chain B (and vice versa) in presence (*) and absence (**) of two C1 molecules during
a 30 ns production run in covalent complex with wild type Tpx dimer as depicted in Figure 7.29.
Mean and standard devations are calculated from 10,000 data points. All values are in A˚.
wild type Glu107 of Glu107 of Glu107 of Glu107 of
dimer chain A chain B chain A chain B
to Lys102 to Lys102 to Lys102 to Lys102
of chain B* of chain A* of chain B** of chain A**
mean / SD mean / SD mean / SD mean / SD
distance Glu107-O4 to 5.9 / 3.3 8.0 / 3.0 7.0 / 4.7 8.2 / 5.3
Lys102-N(1)
distance Glu107-O5 to 6.0 / 3.2 7.9 / 3.0 7.3 / 4.6 8.3 / 5.4
Lys102-N(1)
7.8 Conclusion
The focus of this chapter lies on the investigation of tryparedoxin (TPX) which is part of the
thiol redox metabolism in Trypanosoma brucei and its modification by the covalent inhibitor
C1 (Figure 7.2). MD simulations have been conducted to gain insight on the drug-protein
interaction pattern, the influence of point mutations on C1, the protonation state of TPX
and the dimerization of the enzyme.
First of all, the dynamics of the covalent protein-inhibitor complex of the wild type for two
different poses have been investigated which were present in the crystal structure. The mean
RMSD value of the inhibitor in pose I is 3.1 A˚ lower than in pose II (see Table 7.1). C1
in pose II shows a movement towards the active site and interactions with Ile109 backbone
oxygen increased. For pose I, two different orientations are observed which are caused by the
movement of Trp39. In terms of the interaction between Cys40 and Cys43 both poses show
similar mean values in distance. Also a possible interaction with backbone oxygen of Glu107
might be established if different polar substituents are introduced to the phenyl ring of C1.
The MD simulations of the Tpx variants (based on the covalent protein-inhibitor complex
of C1 in pose I) revealed that the orientation of the inhibitor can change in two directions
depending on the mutant. As mentioned before two different orientations were observed for
pose I in wild type Tpx. The C43A and W70A variant revealed a T-shaped stacked confor-
mation of C1 to Trp39 which was observable for most parts of the wild type simulation. In
case of W39A that interaction is missing and does not cause a rearrangement of the inhibitor.
The Tpx variant I109A offers more space in the active site. Due to this fact it enabled a
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motion of C1 into the pocket and in consequence lessened the interaction with Trp39 which
orientates towards the water shell. The mean RMSD values of W39A and I109A are lower
than in case of the wild type calculations as they do not change their orientation because
of above mentioned findings (Table 7.2). For C43A and W70A these values are higher as
they solely show the second orientation which occurs due to the interaction of C1 and Trp39.
Contrary to that, C1 in pose I wild type shows both conformations leading to a mean RMSD
value which is in between. Still, it is to be expected that C1 in C43A and W70A might also
change its conformation though it was not observed in these simulations.
The investigations of the non-covalent complex (wild type) revealed that the MD simulation
containing a deprotonated Cys40 and a protonated Cys43 show the lowest mean RMSD val-
ues. Still, the mean distance between the Cys40-S(1) and C1-C(1) was 7.4 A˚ in that case.
Therefore, one would not conclude a covalent modification as the distance for a nucleophilic
attack was too far away. In consequence, one can suggest that the formation of the covalent
bond is not determined by the non-covalent complex but rather occurs randomly. In terms
of interactions with Ile109 backbone NH, an interaction can be seen for most times. For
the other two protonation states C1 shows larger RMSD values and the distances were not
reasonable for covalent modification or interaction with Ile109. This is in line with observa-
tions of Hellmichs group as no inhibition occurred in absence of chlorine in C1 thus, a weak
non-covalent protein-inhibitor complex was expected.
Also, the wild type was investigated in absence of the inhibitor by varying the protonation
states of Cys40 and Cys43. These simulations showed that the lowest fluctuations are ob-
tained if both cysteine residues are protonated (see Table 7.4). The distances measured for
the deprotonated Cys40-S system are similar to the neutral state but the mean values and
standard deviations are slightly higher. The third investigated protonation state Cys40-SH
and Cys43-S- shows the largest mean in distance or standard deviation with respect to the
Cys40-Cys43 interaction. The movement of deprotonated sulfur of Cys43 towards Tyr80
leads to a destabilization of the interaction and a movement of Trp39 and Cys40 in direction
of the water shell. Therefore, it is to be expected, that this protonation state is unlikely. This
is in line with the crystal structure of Tpx in covalent complex with C1. Only a modification
of Cys40 was observed and simulations showed that a deprotonated Cys43 is unlikely and in
consequence, no nucleophilic attack is to be expected at this residue.
Lastly, the stability of the Tpx dimer has been evaluated in presence and in absence of C1.
The obtained RMSD values show that the stability of both Tpx chains is decreased if the
inhibitor is missing. This goes along with a rise in distance of both chains after 24 ns which
indicates the dissociation of the protein dimer. This is in agreement with experimental find-
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ings as no dimerization process occurred if inhibitor molecules were absent. Furthermore,
simulations show that drug-drug interactions as pi-pi interactions are maintained in the course
of simulation. Additionally, drug-protein interactions with Ile109 appear weaker compared
to the monomer but due to the pi-stacked conformation of both inhibitors a decrease in
RMSD values for both C1 molecules is observable in the course of simulation time. In terms
of protein-protein interaction, both chains show occasionally intermolecular hydrogen bonds
due to Lys102 and Glu107 side chains which can be preserved for a certain period of time.
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Chapter 8
Comparison of Docking and combined
classical and quantum mechanical
approaches for evaluation of kinetic
data
8.1 Introduction: Rhodesain and cruzain– family and
pathogenetic
The death of thousands of people in Sub-Saharan Africa is attributable to the infectious dis-
ease HAT, as mentioned in the previous chapter. Here, one differentiates between different
subspecies of the protozoan parasite. Its transmission to humans occurs due to the tsetse fly,
a specific species of the genus Glossina.
The temporal course of symptoms and the life expectancy is strongly related to the sub-
species by which the patient is infected [164]. T.b. rhodesiense, which leads to the acute
form, can progress to a lethal end during months or even within weeks, due to the infestation
of the parasites in the central nervous system (CNS) [165]. The subspecies T.b. gambiense is
the cause for the chronical form which can be asymptomatic for months or years [164]. The
perfidious thing in this respect is the fact that symptoms occur after infection of the CNS.
In the first stage, infected humans show symptoms such as headache, fever or joint pains.
The second stage is more severe as a cerebral infection is developed after invasion of the
blood-brain-barrier [164]. The symptoms in the second stage are worse because the CNS is
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affected. Tremors of the tounge, hands or feet, severe headaches, mental disorientation and
neurological psychiatric manifestations are the consequences. Lastly, infected patients fall
into a coma and die because of the infection [166].
Another famous representative of the Trypanosomias family is T. cruzi the cause of Chagas
disease. Even after 100 years of its discovery, Chagas disease is still leading to an increased
morbidity in Central and South America [167]. Although the distribution of this disease
is sterned due to increased measures, still millions of humans remain, who are chronically
infected. Especially for patients with human immunodeficiency virus (HIV) Chagas disease
is an opportunistic infection [168]. Acute infections usually are asymptomatic or can lead
to mild symptoms which still can be accompanied with anemia or thrombocytopenia. After
an incubation time of 1-2 weeks patients show non-specific febrile illness [167]. Additionally,
symptoms as chills, vomiting, diarrhea or conjunctivitis can occur [169].The insidious cir-
cumstance about the infection is its detection: T. cruzi -specific antibodies can be negative
during acute infection [170]. In the indeterminate state of the Chagas disease chronic com-
plications can developed due to the infection with a probability of 15-30 %. The entry in the
chronic stage of this disease can occur over a period of decades which is presented by cardiac
or gastrointestinal complications. Heart diseases caused by the chronic Chagas stadium lead
to arrhythmias, thromboembolic events or even heart failure [171].
Treatment of Chagas disease is carried out by chemotherapy with benznidazole or nifurtimox,
which is under medical supervision due to the increased toxicity and the occurrence of ma-
lignant lymphomas in experimental animals [172], [173]. The chance of success in terms of
both drugs is 60% in case of acute infection but they are not used for the medication of the
chronic form of Chagas [172]. This shows the importance of the development of novel drugs
for the medication of Chagas disease.
By dint of the development of the cysteine protease inhibitor (CPI) K777 (also known as
K11777) a possible foundation stone was laid for the treatment of parasitic diseases [172].
Engel et. al were able to treat mice in the acute or chronic phase of infection in absence of
toxicity by the mammalian host. This CPI was efficacious in preclinical trials in which even
immunocompetent and immunodeficient mice and dogs have been treated [174], [175]. Classic
CIPs compromise di- or tripeptides in combination with a warhead, which binds covalently
(reversible or irreversible) at the active-site cysteine side chain. Bryant et al. developed
further possible CIPs (originating from the K11777 scaffold) and evaluated the IC50 values of
these compounds in cruzain, rhodesain and TbCatB (cathepsin B-like protease in T.brucei)
[176]. Additionally, experimental Kiapp and kinact values were available in case of rhodesain
(Table 8.2).
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The main focus of the investigation described in this chapter lies in the reproduction and
evaluation of kinetic data for K11777 and three selected derivatives (3a, 7a and 7b) via
computational methodologies (Figure 8.1). The question arises whether it is possible to
qualitatively reproduce the kinact values computationally for the above mentioned inhibitors
and also to transfer these findings to predict kinact values for cruzain.
Why is this of interest? By establishing a protocol for the prediction of kinetics or generally
speaking the suitability of novel CPIs one can beforehand filter out candidates and therefore
pick the best compounds.
Firstly, the idea was to calculate the reaction energy and also the height of barrier for the re-
actions by using various QM/MM methodologies. It is understandable that the reaction rate
of the reaction is determined by the energy of the transition state and therefore conclusions
can be drawn in respect to kinact. Computational details will be discussed in the following
sections.
Table 8.1: Experimental IC50 values of the protease inhibition of cruzain and rhodesain by K11777
and different vinylsulfone derivatives measured by [176] are listed.
compound protease In-
hibition IC50
[µM]
protease
Inhibition
IC50 [µM]
Cruzain Rhodesain
K11777 0.004 0.007
3a 10 < 0.006
7a 0.05 0.1
7b > 100 56
Table 8.2: Experimental inhibition kinetics obtained for different vinylsulfone inhibitors for rhode-
sain measured by [176].
compound kinact/Ki(M
1 s1) Kiapp(µM) kinact(s
1)
K11777 555 0.78 0.029
3a 84 0.32 0.0018
7a 9750 0.80 0.00051
7b 2160 7.9 0.0007
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Figure 8.1: Inhibitors of cruzain and rhodesain of the vinylsulfone class. Solely the structures
of K11777, 3a, 7a and 7b were investigated. The positions of P1’-P3’ are depicted for K11777
for clarification.
8.2 System preparation and MD simulation
The first step of the investigation consists in the conduction of MD simulations to obtain
relaxed structures which serve as starting points for QM/MM calculations. For K11777
in complex with cruzain the pdb structure 2OZ2 was used. As no crystal structure was
available for 3a, 7a or 7b in complex with the proteins a manual modification was needed.
Therefore, another crystal structure containing inhibitor 8a has been manually modified to
respective ligands (pdb code 3HD3). Especially in case of 7a and 7b it was advantageous to
use this crystal structure due to the similarity of 8a’s structure to both (Figure 8.1). The
protein-inhibitor complex of K11777 and rhodesain was prepared by employing the existing
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crystal structure (pdb code 2PZU). The remaining inhibitors have been manually created by
modification of K11777 as no crystal structure was available.
The proteins cruzain and rhodesain were parameterized using the AMBER14 force field
ff14SB while the inhibitor K11777, 3a, 7a and 7b by the generalized AMBER force field
(GAFF). For all cases a covalent protein-inhibitor complex has been prepared to calculate
the backwards reaction to the non-covalent complex. The duration of each production run
contained 10 ns resulting in a total simulation time of 80 ns. As the interest lies on the creation
of relaxed structures as starting points for QM/MM calculations no detailed investigations
have been conducted with respect to the MD simulations.
8.3 QM/MM calculations
In the first place, snapshots have been extracted of the MD simulations preparation runs
mentioned in section 8.2 which serve as starting point for QM/MM calculations. The prepa-
ration of these computations will be explained in the following. As shown in Figure 8.2 the
QM area consists of the ligand as well as cysteine and histidine. The importance of both
residues is given by the fact that the nucleophilic sulfur of cysteine form a covalent bond to
the ligands and histidine acts as proton acceptor (in case of the backwards reaction). Ensur-
ing that the computations are still feasible within a reasonable time only the side chain has
been included into the QM part. In regard to the inhibitors only QM atoms were selected
which are available in all inhibitors to ensure comparability of the results.
Firstly, a local optimization has been conducted by the usage of the described QM/MM
scheme. The software package ChemShell 3.6.0 was utilized applying electrostatic embed-
ding and the charge shift method. The MM part was treated by the AMBER14 force field
while the QM part was optimized employing B3LYP in combination with the def-TZVP
triple- basis set. Due to computational costs, only molecules in a radius of 10 A˚ around the
active site cysteine residue were optimized, while the rest of the system was kept fix.
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Figure 8.2: Selected QM area for QM/MM optimization. A – QM part of His162 and in-
hibitor K11777 covalently bound to Cys25 in licorice representation. B – Selected QM area,
red dashed lines indicate C-C bond cuts. Blue dashed lines indicate variation of distance
for 2-dimensional relaxed scan by increasing the distance of Cys25’s sulfur and K11777’s
electrophilic carbon and decreasing the distance between His162 nitrogen and K11777’s hy-
drogen.
To obtain the reaction energy and the height of barrier (of the backward reaction) the
distance between Cys25’s sulfur and the ligands electrophilic carbon has been widened while
the distance between His162’s nitrogen and the ligands hydrogen was decreased which is
depicted in Figure 8.2-B by highlighting the related distances with blue dashed lines. As all
resulting potential energy surfaces show a similar profile. Therefore, the pathway only for the
K11777-cruzain complex is exemplary shown (Figure 8.3-A). The formation of the covalent
bond is computed by decreasing the distance of the nucleophilic sulfur related to the cysteine
and the electrophilic carbon of K11777. Afterwards a proton transfer occurs from the doubly
protonated histidine to K11777 (Figure 8.3-B).
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Figure 8.3: A - Potential energy surface obtained from 2-dimensional relaxed scan of K11777
in cruzain from covalent to non-covalent protein inhibitor complex. Variation of distance of
selected atoms is depicted in Figure 8.2-B. B – Reaction coordinate of nucleophilic attack
of K11777 indicated by red dotted arrows. Energies are obtained by QM/MM optimization
employing B3LYP-D3/def-TZVP with Grimme’s dispersion correction and the AMBER14
force field. Energies are in relation to the non-covalent protein-inhibitor complex of the
relaxed scan. All energy values are in kcal/mol.
The summary of obtained reaction energies and height of barriers is given in Table 8.3.
The energy of the transition state in relation to the non-covalent protein-inhibitor complex
of 7a is lowest by a value of 1.6 kcal/mol, followed by 3a (3.3 kcal/mol) and K11777 (5.8
kcal/mol). For inhibitor 7b the largest barrier is predicted which is of 6.6 kcal/mol. As
one can see the results are contrary to experimental findings with respect to rhodesain. As
shown in Table 8.2, K11777 has the largest kinact value which consequently should lead to
the smallest height of the barrier which is not the case. Additionally, 7a and 7b differ by 5
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Table 8.3: Reaction energies and transition state energies of K11777 and its derivatives 3a, 7a
and 7b obtained from QM/MM optimization employing B3LYP-D3/def-TZVP and the AMBER14
force field are summarized. Energies are in relation to the non-covalent protein-inhibitor complex
corresponding to Figure 8.3. All energy values are given in kcal/mol.
protein compound transition state reaction energy
cruzain K11777 6.1 -21.2
3a 0.6 -37.8
7a 1.7 -34.4
7b 7.5 -27.6
rhodesain K11777 5.8 -31.6
3a 3.3 -33.1
7a 1.6 -38.0
7b 6.6 -30.0
kcal/mol and 7a’s barrier is predicted as to be the lowest in energy. These findings conflict
with the experimental data. The trend of the kinetic data could not be reproduced by
these computations. Therefore, singlepoint calculations applying different DFT or ab initio
methods have been conducted to shed some further light on these findings.
8.4 QM benchmark calculations
In this section, benchmark calculations applying different wavefunction and density func-
tional based methods were conducted and referenced to CCSD(T) energies. The calculations
initially started on QM level in absence of the protein environment. Due to the size of the
QM region previously defined within the QM/MM calculations, computational costs using
CCSD(T) would be too high. Therefore, solely the reaction energy of the QM region of
the vinylsulfone-inhibitor scaffold and methanethiol (representative for cysteine) has been
computed to evaluate the best methodology (Figure 8.4). It must be mentioned that the
energetically description of the transition state is not considered in these computations.
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Figure 8.4: Reactans and product of the reaction of methanethiol with the vinylsulfone
scaffold.
Firstly, the vinylsulfone scaffold, methanethiol and the resulting product has been opti-
mized with B3LYP-D/def-TZVP. Two cases have been considered: the optimization in vacuo
as well as an implicit solvent by using the COSMO approach, with water parameters (=78)
simulating a hydrophilic environment. Afterwards singlepoint energy calculations were com-
puted for both cases. As no COSMO implementation is available for the couple cluster
approach in the Turbomole V6.6 program package solely singlepoint energy computations of
CCSD(T) in vacuo were used for comparison.
As one can see in Table 8.4 best results are achieved by SCS-CC2 and are underpinned by
the smallest MAE values of 0.1 and 0.2 kcal/mol (Figure 8.5). For ab initio methods the
application of spin-component scaling leads to an improvement of results. In case of the DFT
approaches BP86 performs best and lead to a comparable result as SCS-CC2 (and a better
one than SCS-MP2) which might appear due to error compensation. Especially the tested
hybrid GGA methods show larger MAE values compared to PBE or BP86 while they only
outperform LDA. Figure 8.5 shows that MAE values compared to CCSD(T)/aug-cc-pVDZ
single point energies, do not differ largely despite of the presence or absence of implicit solva-
tion within the structure optimization procedure. In contrast to that it is observable that a
decrease in reaction energy of 5-6 kcal/mol occurs by applying COSMO (if the same settings
for structure optimization are utilized). Lastly, it is of importance to have a closer look
on the D1 diagnostic of all computations on CCSD(T)/aug-cc-pVDZ level to ensure that
no multi-reference character within the wavefunctions description plays a role. As shown in
Table 8.5 all values of the D1 diagnostic are below 0.065 and are in an acceptable range.
127
8.4. QM BENCHMARK CALCULATIONS
Table 8.4: QM reaction energies of vinylsulfone scaffold with methanethiol. For all methods the
aug-cc-pVDZ basis set was applied. For * marked reaction eneriges ∆Ereac singlepoint energy
calculation were performed on vacuo optimized structures or for ** marked on COSMO (=78)
optimized structures. Grimme’s dispersion correction was applied for B3LYP and BHLYP. All
energy values in kcal/mol and with to the non-covalent complex.
method * ∆Ereac * ∆Ereac ** ∆Ereac ** ∆Ereac
(vacuo) (COSMO) (vacuo) (COSMO)
CCSD(T) -32.5 NA -32.8 NA
MP2 -36.0 -30.8 -36.3 -30.6
CC2 -37.7 -32.7 -38.1 -32.5
SCS-MP2 -31.4 -26.3 -31.7 -26.1
SCS-CC2 -32.3 -27.3 -32.7 -27.1
LDA -39.3 -34.0 -39.4 -33.5
PBE -30.0 -25.0 -30.5 -24.8
BP86 -31.8 -26.7 -32.4 -26.7
B3LYP -27.0 -21.8 -27.4 -27.4
BHLYP -28,1 -22.6 -28.4 -28.4
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Figure 8.5: Mean average error with respect to CCSD(T)/aug-cc-pVDZ reaction energy.
Singlepoint energy calculation were performed on vacuo optimized structures for * marked
reaction ∆Ereac or on COSMO ( = 78) optimized structures for ** marked. Grimme’s
dispersion correction was applied for B3LYP, B3LYP G and BHLYP. All MAE values in
kcal/mol.
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Table 8.5: Summary of CCSD D1 diagnostics of educt, methanethiol and product of nucleophilic
attack of methanethiol and vinylsulfone scaffold. All calculations were performed applying the
CCSD(T)/aug-cc-pDVZ approach.
Optimization CCSD D1 Optimization with CCSD D1
in vacuum diagnostics COSMO (=78) diagnostic
educt 0.0585 educt 0.0647
methanethiol 0.0211 methanethiol 0.0212
product 0.0608 product 0.0612
8.5 QM/MM benchmark calculations
QM benchmark calculations showed that spin-component scaled CC2 is the most suitable
methodology in terms of the description of the reaction energy in comparison with CCSD(T).
As mentioned before QM/MM singlepoint computations applying the 2nd order coupled clus-
ter approximated triples approach is too costly and therefore SCS-CC2 has been used as
reference for the following QM/MM benchmark. In the previous section it was not possi-
ble to reproduce the experimental kinact values qualitatively by the QM/MM computations
on B3LYP-D3 level. Therefore, different DFT and ab initio approaches have been applied
to the QM/MM optimized structures of the transition state as well as on the non-covalent
protein-inhibitor complex. Additionally, the augmented triple-ζ basis aug-cc-pVDZ was uti-
lized instead of the def-TZVP basis set, while the QM region and the force field description
remained the same as it was for geometry optimization.
The results of the benchmark given in Table 8.6 show a similar trend in prediction of the
kinetics for the tested inhibitors in rhodesain as obtained with B3LYP-D3/def-TZVP. All
ab initio methods describe the reaction barrier for K11777 as highest in energy followed by
inhibitor 7b while the transition states of 3a and 7a are about 3-4 kcal/mol lower in energy.
In case of the DFT approaches barriers were also predicted in the wrong order. Especially
computations on LDA, PBE and BP86 level resulted in transition state energies which are
lower compared to the non-covalent complex. Therefore, it is not possible to make a state-
ment concerning the order of the kinetics in terms of the tested inhibitors and transfer these
findings to cruzain.
In terms of the MAE values, DFT approaches show an error which is of about 2-3 kcal/mol
larger compared to the wave function-based methods. Interestingly, it is observable that the
MAE values of B3LYP are lower if the def-TZVP basis set is used instead of the aug-cc-
pVDZ. Although the order of kinetics could not be reproduced by the application of higher
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ranked methods and basis sets one can see that ab initio methods are with respect to MAE
values superior compared to the tested DFT approaches.
Table 8.6: QM/MM reaction energies and transition state energies of K11777 and its derivatives
3a, 7a and 7b obtained from single point calculations employing wave function-based and DFT
methodologies in rhodesain. For all tested methods the aug-cc-pVDZ basis set was applied. In case
of the * marked method energies were obtained from QM/MM geometry optimization employing
B3LYP-D3/def-TZVP and the AMBER14 force field. All energy values are in kcal/mol and in
relation to the non-covalent complex.
compound K11777 3a 7a 7b
method TS ∆Ereac TS ∆Ereac TS ∆Ereac TS ∆Ereac
MP2 6.2 -38.1 2.6 -40.2 1.8 -44.3 5.1 -36.5
CC2 3.2 -37.6 0.7 -39.0 -0.6 -43.6 2.7 -35.8
SCS-MP2 8.1 -37.7 3.6 -40.6 3.7 -43.4 7.4 -36.1
SCS-CC2 5.9 -37.1 2.2 -39.5 1.9 -42.6 5.8 -35.3
LDA 1.5 -31.2 0.4 -31.7 -3.1 -39.1 -2.3 -31.6
PBE 2.6 -31.3 1.1 -32.2 -1.5 -37.6 3.8 -29.0
BP86 1.6 -31.3 0.6 -31.9 -2.1 -37.4 3.1 -28.6
B3LYP 5.2 -31.6 2.5 -33.4 1.3 -37.0 6.3 -29.4
BHLYP 11.2 -32.6 6.0 -36.0 7.0 -38.2 7.9 -33.7
B3LYP* 5.8 -31.6 3.3 -33.1 1.6 -38.0 6.6 -30.0
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Table 8.7: QM/MM reaction energies and transition state energies of K11777 and its derivatives
3a, 7a and 7b obtained from single point calculations employing wave function-based and DFT
methodologies in cruzain. For all tested methods the aug-cc-pVDZ basis set was applied. In case
of the * marked method energies were obtained from QM/MM geometry optimization employing
B3LYP-D3/def-TZVP and the AMBER14 force field. All energy values are in kcal/mol and in
relation to the non-covalent complex.
compound K11777 3a 7a 7b
method TS ∆Ereac TS ∆Ereac TS ∆Ereac TS ∆Ereac
MP2 3.8 -27.9 0.9 -43.5 5.5 -40.9 5.7 -34.2
CC2 1.2 -27.7 0.4 -42.3 -0.9 -40.8 3.1 -33.6
SCS-MP2 6.6 -26.9 -0.8 -43.6 -4.0 -44.6 8.0 -33.8
SCS-CC2 4.7 -26.6 -0.6 -42.2 -1.8 -41.6 6.1 -33.1
LDA -1.5 -31.2 1.5 -36.4 -1.5 -34.2 2.2 -27.0
PBE 1.7 -22.2 1.3 -34.6 -0.2 -32.9 4.1 -27.1
BP86 1.0 -22.2 1.0 -34.8 -1.1 -32.9 3.4 -26.7
B3LYP 5.5 -21.0 0.4 -31.8 1.6 -33.8 6.7 -27.4
BHLYP 12.0 -20.4 0.6 -38.7 7.2 -35.2 12.3 -29.6
B3LYP* 6.1 -21.2 0.6 -37.8 1.7 -34.4 7.5 -27.6
1.3 1.5 1.4
4.8
4.3
4.6
3.8
4.6
3.4
M
P2
C
C
2
SC
S-
M
P2
LD
A
PB
E
B
P8
6
B
3L
YP
B
H
LY
P
B
3L
YP
*
0
2
4
6
M
AE
 [k
ca
l/m
ol
]
Figure 8.6: Mean average error with respect to SCS-CC2/aug-cc-pVDZ averaged of all re-
action energies and reaction barrier of all investigated inhibitors in rhodesain and cruzain.
For all tested methods the aug-cc-pVDZ basis set was applied. In case of the * marked
method, energies were obtained from QM/MM geometry optimization employing B3LYP-
D3/def-TZVP and the AMBER14 force field. All MAE values in kcal/mol.
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8.6 MD Simulation of non-covalent protein-inhibitor
complex after relaxed scan
As the computations of the backward reaction were not able to reproduce the right order of
the experimental kinetic data a different approach was tested in this part. The non-covalent
complex obtained from the relaxed scan has been used as starting point for a classical MD
simulation. Aim of these simulations is to measure the distance of the nucleophilic sulfur of
the cysteine residue and the electrophilic carbon of the vinylsulfone inhibitors in the course
of simulation time. It is understandable that the height of barrier for a nucleophilic attack
should increase at the same time as the distance although it has to be mentioned that
observations are of course qualitatively. To obtain meaningful results each inhibitor-protein
complex has been simulated thrice and for 10 ns.
Table 8.8: Calculated mean and standard deviations of the distance between electrophilic
carbon of respective inhibitor and nucleophilic sulfur of Cys25 in cruzain and rhodesain
during a 10 ns MD simulation are given. Mean and standard deviations are calculated from
10,000 data points. All values are presented in A˚.
cruzain
compound K11777 3a 7a 7b
mean SD mean SD mean SD mean SD
MD1 3.5 0.2 5.6 1.9 3.5 0.2 3.6 0.3
MD2 3.5 0.2 3.8 0.6 3.5 0.2 3.5 0.3
MD3 3.5 0.2 4.8 0.7 4.2 0.7 3.5 0.2
rhodesain
compound K11777 3a 7a 7b
mean SD mean SD mean SD mean SD
MD1 3.6 0.3 6.1 2.9 3.7 0.4 3.5 0.3
MD2 3.4 0.2 3.6 0.2 3.8 0.4 3.4 0.2
MD3 3.4 0.2 10.1 2.2 4.1 0.5 3.5 0.3
In contrast to the prediction in the QM/MM calculations MD simulations indicate that
K11777 and 7b would result in the lowest barrier as the mean distance of both inhibitors (in
both proteins) are about 3.5 A˚ with a standard deviation of 0.2-0.3 A˚. Slightly larger mean
values are obtained for 7a while 3a appears to be more unstable in terms of the distance.
Therefore, mean distances of 6.1 A˚ or 10.1 A˚ occur with larger standard deviations of about
2-3 A˚. One might conclude that K11777 and 7b would react at the same speed due to the
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same mean distance and thus the same height of barrier. Also, the nucleophilic reaction of
7a would be slightly slower, while 3a kinetics would be worse. These findings still do not fit
to the experimental data and a different solution is needed.
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Figure 8.7: The variation in distance as a function of simulation time is shown for A – K11777,
B – 3a, C – 7a and D – 7b to Cys25’s sulfur in non-covalent complex with rhodesain during
10 ns production run. Calculated mean and standard deviation are summarized in Table 8.8.
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Figure 8.8: The variation in distance as a function of simulation time is shown for A –
K11777, B – 3a, C – 7a and D – 7b to Cys25’s sulfur in non-covalent complex with cruzain
during 10 ns production run. Calculated mean and standard deviation are summarized in
Table 8.8.
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8.7 Docking of K11777 and 7a in rhodesain
Up to this point all computations were not able to predict the right order of experimental
rates. As a result, a different strategy is needed. Firstly, QM/MM computations starting
from the covalent protein-inhibitor complex were conducted. Therefore, it is conceivable
that the protein environment is relaxed to the covalent state and overestimates its stability.
Secondly, MD simulations of the non-covalent complex utilized the end point of the relaxed
scan as initial structure. It is possible that the original non-covalent complex is differently
in terms of conformation and position. Therefore, the idea is to start from the non-covalent
complex by using docking approaches. Additionally, the focus of investigated inhibitors was
laid on K11777 and 7a for a specific reason. If one looks at the experimental kinetic data
in Table 8.2 not only differences in kinact values can be seen but also different Kiapp values.
Solely K11777 and 7a have nearly the same Kiapp value and thus computations should be
more comparable. To obtain a proof of concept the focus was brought on rhodesain.
The evaluation of the docking process was realized by redocking of K11777 in rhodesain
in cooperation with the Sotriffer group, University of Wu¨rzburg, utilizing the GOLDv5.2.2
software package. The typical preparation starts with the removal of all crystal water and the
assignment of hydrogen atoms at pH=6.0, which was reported for the crystal structure (pdb
code 2OZ2) employing the MOE software package [177]. In case of Cys25 a deprotonated
form was considered while His162 was doubly protonated. Before the docking procedure was
performed both inhibitors were protonated by the MOE software package and afterwards
minimized with a convergence criterion of 0.05 kcal/mol. In order to receive a sufficient
amount of poses the number of genetic algorithms runs was increased to the number of 50.
GA settings have additionally been set to be very flexible and no constraints were applied.
The variable was the specification of the approximate radius r of the binding site. Cys25’s
sulfur has been selected as center of the active site and four different values for r were
assigned (10, 15, 20 and 30 A˚). The definition of r is crucial as it should be big enough
to enable complementary fitting points between protein and ligand. But by selecting too
large radii unusable information are included in the docking process due to the fact that
more atoms are defined as active site. This can lead to worse docked poses. The scoring of
obtained poses was conducted with the CHEMPLP fitness function and the best 10 poses
were rescored by DSX with CSD pair-potential utilizing the python script of Dr. Michael
Hein and Maximilian Kuhn [178]. Afterwards RMSD values of the non-covalent inhibitor
were calculated in comparison to the covalent one from the crystal structure.
The results of the redocking in Table 8.9 show that the choice of a r-value of 20 A˚ leads
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to seven poses with RMSD values below 3 A˚ while three of them are ranked in the top 3
poses. Slightly worse results are obtained if a r-value of 10 A˚ is used although it should be
mentioned that one pose with this setting lead to a pose with a RMSD value below 2 A˚. In
case of r=15 A˚ or 30 A˚ only poses were obtained in which K11777 was flipped thus leading
to RMSD values larger than 5 A˚. Therefore, one can conclude that best results are obtained
by the usage of r=20 A˚.
If one takes a closer look at the top ten poses one can see that there are six different ones
(Figure 8.9). Flipped structures occur in conformation II, IV and V while I, III and VI are in
the right position for a nucleophilic attack. For these flipped structures the distance between
the sulfur of Cys25 and the electrophilic carbon is larger than 5 A˚ so that a reaction is not
possible.
conformation I conformation III conformation V
conformation II conformation IV conformation VI
Figure 8.9: Comparison of different conformations of K11777 obtained from redocking com-
pared to X-ray structure of K11777 in covalent complex with rhodesain (orange licorice
representation). Poses refer to Table 8.10.
The same setting has been utilized for the docking of inhibitor 7a as the application of a
r-value of 20 A˚ leads to the best results. As shown in Figure 8.10 three different poses were
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Table 8.9: Docking results of K11777 in rhodesain by varying r to 10 A˚, 15 A˚, 20 A˚ and 30 A˚. The
poses were scored by CHEMPLP and rescored by DSX. Order of conformations on the basis of DSX
ranking. Negative DSX values are shown for clarity. Distance is measured between electrophilic
carbon center of warhead and Cys25 sulfur. RMSD is calculated in relation to crystal structure of
K11777 in covalent complex with rhodesain. Distance is given in A˚.
r 10 A˚ 15 A˚
Ranking dist- RMSD -DSX PLP dist- RMSD -DSX PLP
ance ance
1 6.4 10.9 140.893 78.12 5.7 10.8 130.455 77.9
2 3.4 1.9 140.194 78.02 6.5 5.1 129.129 73.75
3 3.4 2.9 137.149 75.89 7.1 10.8 128.749 72.01
4 4.9 10.0 132.86 77.06 5.9 10.1 127.432 72.67
5 5.6 7.1 129.754 77.8 7.2 10.5 125.867 73.29
6 3.2 2.6 129.376 76.69 6.1 9.6 123.267 72.69
7 4.7 6.7 125.634 78.25 6.0 9.6 122.309 74.57
8 3.7 6.3 123.95 78.11 10.2 11.5 121.116 71.9
9 4.1 2.3 120.297 78.15 8.0 5.9 119.41 72.13
10 4.1 3.2 119.64 75.72 7.7 4.9 118.231 73.71
r 20 A˚ 30 A˚
Ranking dist- RMSD -DSX PLP dist- RMSD -DSX PLP
ance ance
1 3.2 2.7 139.898 77.3 6.9 11.0 140.149 75.28
2 3.4 2.0 138.298 84.64 5.5 7.0 135.426 81.61
3 3.4 2.0 138.178 82.79 5.5 6.7 131.762 73.58
4 6.2 7.0 134.109 79 5.7 7.0 130.681 74.78
5 3.8 2.5 132.747 79.53 6.2 10.1 130.028 74.05
6 3.1 2.7 129.126 78.13 5.7 6.8 126.79 75.98
7 5.1 10.1 128.359 77.31 7.1 10.8 124.754 73.89
8 5.3 6.6 128.083 79.64 5.0 6.8 124.68 74.05
9 4.0 2.4 125.3 77.57 11.5 10.1 113.024 75.53
10 4.1 2.5 125.285 77.58 6.8 4.5 112.766 74.56
obtained by the docking procedure. As no crystal structure of 7a in complex with rhodesain
was available solely the distance between Cys25 nucleophilic sulfur and 7a’s electrophilic
carbon was calculated. The top four poses (conformation I) showed a distance of about 5
A˚ while the remaining were closer for a nucleophilic attack (conformation II and III, see
Table 8.10). This indicates that 7a appears to be farther away for a nucleophilic attack and
in consequence should react slower compared to K11777. To evaluate the findings of the
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docking procedure, MM-PB(GB)SA calculations have been performed and will be discussed
in the next section.
conformation I conformation II conformation III
Figure 8.10: Different conformations obtained from docking of inhibitor 7a in rhodesain.
Poses refer to Table 8.10.
Table 8.10: Docking results of K11777 and 7a in rhodesain by using r value of 20 A˚. The poses
were scored by CHEMPLP and rescored by DSX. Order of poses are on the basis of DSX ranking.
Negative DSX values are shown for clarity. Distance is measured between electrophilic carbon of
inhibitor and Cys25’s sulfur. Distance is given in A˚.
inhibitor K11777 7a
Ranking distance -DSX PLP confor- distance -DSX PLP confor-
mation mation
1 3.2 139.898 77.3 VI 5.1 130.666 74.05 I
2 3.4 138.298 84.64 I 5.1 128.787 73.82 I
3 3.4 138.178 82.79 I 5.1 128.363 73.77 I
4 6.2 134.109 79.00 IV 5.1 128.171 73.35 I
5 3.8 132.747 79.53 III 3.1 128.142 74.91 II
6 3.1 129.126 78.13 III 5.1 128.141 73.11 I
7 5.1 128.359 77.31 V 3.1 127.238 75.87 II
8 5.3 128.083 79.64 II 3.5 126.643 74.89 III
9 4.0 125.3 77.57 III 5.1 126.633 73.13 I
10 4.1 125.285 77.58 III 3.3 126.189 75.19 II
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8.8 MM-PB(GB)SA calculations
In order to verify the differences between the obtained conformations of K11777 and 7a, in-
vestigations in terms of the free binding energy (∆Gbind) have been performed by utilizing the
MM-PB(GB)SA approach which is implemented in the AMBER14 program package. Solely
the highest ranked pose of each conformation was considered. Firstly, the gas phase topology
and coordinates were created for the inhibitors, the protein and the protein-inhibitor complex
for the MM-PBSA calculation as well as the solvated protein-inhibitor complex for the MD
simulations. The protein was described with the AMBER14 force field while the inhibitor
was parametrized via GAFF. Afterwards the solvated complex was equilibrated by a short
minimization containing 1000 steps, 50 ps of heating and 50 ps of density equilibration while
restraining the protein-inhibitor complex by a value of 2 kcal·mol−1·A˚−2. An equilibration at
constant pressure was conducted at 300K for 2 ns. The production run was performed at the
same conditions as the equilibration for 5 ns while each 10 ps the coordinates were recorded
to obtain uncorrelated structures. The estimation of the binding free enthalpy was conducted
by the calculation of the interaction and solvation energy for the inhibitors, the protein and
the protein-inhibitor complex. It has to be mentioned that the results do not reflect the true
free energy rather the free binding enthalpy, as the entropy contribution was not considered.
Still, these values should be comparable as long as similar systems are compared (in this case
different docking poses of the same system).
Table 8.11 shows the calculated free binding enthalpies for all six poses of K11777 obtained
from the previous docking simulation. The flipped conformations II, IV and V which resulted
in larger RMSD values than 6 A˚ in the docking also showed more unfavorable ∆Hbind values
as these conformations range from -11.7 to -23.0 kcal/mol for the generalized Born model or
from 1.0 to 10.5 kcal/mol if the Poisson-Boltzman equation was employed. In contrast to
that, conformation I, III and VI were described as more stable with free binding enthalpies
of -36.7 to -42.3 kcal/mol while conformation III was lowest in energy for MM-PBSA or MM-
GBSA. These results strengthen the validity of applied calculations as docked structures with
low RMSD values also show more exothermic free binding enthalpies. If the prediction would
be the other way around flipped structures would be preferred which cannot react covalently
and this would be in contradiction to experimental findings.
The corresponding calculations have also been conducted for the three conformations of
inhibitor 7a which were predicted by the docking procedure. Contrary to the results of the
rescoring, conformation II was described lowest in free binding enthalpy despite of the used
methodology. Conformation I which was scored in the top four poses is highest in free binding
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Table 8.11: Calculated free binding enthalpies, standard deviations and standard error of mean
of K11777 in rhodesain employing the generalized Born model or Poisson-Boltzmann equation.
Conformations refer to docking procedure. All values in kcal/mol.
conformation I conformation II
average std. dev std. err. average std. dev std. err.
∆Hbind of mean ∆Hbind of mean
GB -36.7 3.4 0.5 -11.7 3.1 0.4
PB -2.4 4.2 0.6 10.5 3.5 0.5
conformation III conformation IV
average std. dev std. err. average std. dev std. err.
∆Hbind of mean ∆Hbind of mean
GB -42.3 2.8 0.4 -23.0 2.3 0.3
PB -8.2 4.8 0.7 1.0 2.5 0.3
conformation V conformation VI
average std. dev std. err. average std. dev std. err.
∆Hbind of mean ∆Hbind of mean
GB -15.9 2.7 0.4 -40.0 3.2 0.4
PB 7.5 3.7 0.5 -6.7 4.1 0.6
enthaply values regarding the applied generalized Born model as pose III and also about 10
kcal/mol higher in relation to conformation II concerning the ∆Hbind value if the Poisson
Boltzmann equation is utilized.
The MM-PBSA and MM-GBSA calculations of K11777 and 7a showed that the ∆Hbind value
of the flipped conformations are always less exothermic. In case of K11777 these results are in
line with the docking simulations as VI and I are best ranked. For 7a the flipped conformation
I was scored as best pose. However, MM-PBSA and MM-GBSA calculations showed that
this conformation is less exothermic as the conformation I which is lower in distance for a
nucleophilic attack. Up to this point the question about rates remained unanswered as 7a’s
conformation II shows a distance between nucleophilic sulfur and electrophilic carbon of 3.1
A˚ which is 0.7 A˚ closer than the pose used for conformation III of K11777.
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Table 8.12: Calculated free binding enthalpies of 7a in rhodesain employing the generalized Born
model or Poisson-Boltzmann equation. Conformations refer to docking procedure. All values in
kcal/mol.
conformation I conformation II
average std. dev std. err. average std. dev std. err.
∆Hbind of mean ∆Hbind of mean
GB -17.5 2.0 0.3 -33.0 2.5 0.4
PB 12.8 4.9 0.7 2.3 3.5 0.5
conformation III
average std. dev std. err.
∆Hbind of mean
GB -24.4 2.2 0.3
PB 11.9 4.5 0.6
8.9 MD Simulation of docked structures
In consequence of the MM-PB(GB)SA calculations, MD simulations of the conformation with
the lowest ∆Hbind value have been conducted for both inhibitors to evaluate fluctuations in
distance between Cys25’s sulfur and the electrophilic carbon of the vinylsulfone inhibitor.
The same poses employed in the MM-PB(GB)SA calculations have been utilized as start-
ing point for the simulations. The sytem preparation as well as minimization, heating and
production run have been conducted in the same manner as in the section 5.1. Each MD
simulations were performed thrice with a duration of 10 ns.
As mentioned before, the distance between the electrophilic carbon of the vinylsulfone in-
hibitor and the nucleophilic sulfur of cysteine strongly influences the kinetics of the reaction
because either the inhibitor or cysteine moiety or both have to move to reach distances at
which the interaction between both reacting centers is strong enough to initiate the chemical
reaction leading to the bond formation. This is obvious as the larger the distance is, the
slower the reaction takes place. The resulting mean distances of K11777’s MD simulations
(Figure 8.11-A) show that they are between 3.5 to 3.7 A˚ which is slightly smaller than the
distance of 3.8 A˚ of the docked conformation (Table 8.13). Still fluctuations in distance occur
in the course of simulation leading to standard deviations of about 0.3 A˚ (Figure 8.11-A). In
contrast to K11777, inhibitor 7a reveals two different scenarios (Figure 8.11-B). In the first
MD simulation the distance between both reacting centers fluctuates either around 3.5 or
around 4.5 A˚, thus leading to a slightly larger mean in distance compared to K11777 (Figure
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8.11 and Table 8.13). Still, due to the flucutations the standard deviation is of 0.5 A˚. In the
remaining simulations the mean in distance is 4.5 A˚ with low fluctuations (standard devia-
tion of 0.2 A˚). These findings explain the experimental kinetics, as inhibitor 7a shows mostly
larger distances to Cys25 compared to K11777. Thus, the nucleophilic attack is favored for
K11777 due to the dynamic of the non-covalent enzyme-inhibitor complex.
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Figure 8.11: The variation in distance is plotted as a function of simulation time for A –
K11777’s electrophilic carbon to Cys25’s sulfur starting from pose III and B – 7a’s elec-
trophilic carbon to Cys25’s sulfur starting from pose II in non-covalent complex with rhode-
sain during 10 ns production run. The related calculated mean and standard deviation are
summarized in Table 8.13.
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Figure 8.12: Frequency of the measured distance between A – K11777’s or B – 7a’s elec-
trophilic carbon and Cys25’s sulfur. The related calculated mean and standard deviation are
summarized in Table 8.13.
Table 8.13: Calculated mean and standard deviation of the distance between the electrophilic
carbon of K11777 or 7a to Cys25’s sulfur in rhodesain. Mean and standard devations are calculated
from 10,000 data points. All values are given in A˚.
K11777 MD run 1 MD run 2 MD run 3
mean 3.54 3.64 3.71
standard deviation 0.31 0.31 0.33
7a MD run 1 MD run 2 MD run 3
mean 3.77 4.53 4.49
standard deviation 0.48 0.18 0.19
8.10 Conclusions
Aim of this study was to qualitatively reproduce experimental kinetic data (kinact values)
obtained by Bryant et. al [176]. The investigation focused on the vinylsulfone inhibitor
K11777 and three selected derivatives (7a, 7b and 8a, see Figure 8.1) which target cysteine
proteases such as rhodesain of Trypanosoma brucei rhodensie and cruzain of Trypanosoma
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cruzi. Therefore, different computational approaches on MM, QM or QM/MM level have
been conducted. Why are kinact values of interest? If these values are computationally
accessible (or at least differences between inhibitors can be estimated) one can predict the
suitability of novel covalent vinylsulfone inhibitors or would be able to differentiate between
acceptable or unsuitable ones.
Investigations started with MD simulations which have been conducted to obtain relaxed
structures for each covalent protein-inhibitor complex. For each simulation a certain snapshot
has been extracted and the backward reaction from the covalent to non-covalent complex has
been calculated via a QM/MM relaxed scan on B3LYP-D3/def-TZVP level and applying the
ff14SB force field. Results indicate that 7a and 3a are superior in respect to the kinetics
compared to K11777 or 7b in rhodesain which is contrary to experimental values. Thus,
it was not possible to transfer these results to cruzain. The question arised if the applied
methodology and basis set was sufficient to describe the reaction. Therefore, a suitable QM
methodology was evaluated by a benchmark, in which CCSD(T) was used as reference and
additionally the basis set size was increased to aug-cc-pVDZ. The spin-component scaled CC2
approach showed the lowest MAE values in relation to CCSD(T). The benchmark calculations
also revealed that the application of implicit solvation does not affect the resulting optimized
geometries but decreases reaction energies by a value of 5-6 kcal/mol.
In a next step the energetics of the transition state as well as the non-covalent state have
been computed on QM/MM level by different ab initio or DFT approaches and have been
compared to SCS-CC2, as computational costs of CCSD(T) were too high. The order of
the transition state energies remained the same for all tested inhibitors in rhodesain like
in the case of the B3LYP-D3/def-TZVP computations. Consequently, it was not possible
to transfer these findings to cruzain. The next attempt was to perform MD simulations of
the non-covalent protein-inhibitor complex obtained from the relaxed scan. Aim of these
simulations was to probe the variation in distance between Cys25’s nucleophilic sulfur and
the inhibitors electrophilic carbon to gain insight into kinetic data. The lowest mean in
distance was obtained for K11777 which is in line with experimental findings, but for 7b,
too which does not reflect the experimental data. Inhibitor 7a shows higher mean distances,
while 3a appear to be the most unstable in terms of the distance.
The focus of investigation was shifted on the one hand to the analysis of K11777 and 7a in
rhodesain as both showed similar Kiapp values but different kinact values. On the other hand,
the simulations started from the non-covalent complex. The first step was the redocking of
K11777 and the docking of 7a to obtain the best poses. To validate these findings MM-
PB(GB)SA calculations have been conducted for each conformation to filter out the best
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pose. Lastly MD simulations of the best pose have been carried out to assess the variation
of distance between Cys25’s sulfur and K11777’s or 7a’s electrophilic carbon. The results
indicate that the distance of K11777 is in most cases shorter while 7a is for the longest peroid
about 1 A˚ farther apart. In terms of the kinetics results of the MD simulations do reflect
qualitatively experimental data with respect to the kinact value.
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Chapter 9
Investigations on the proton transfer
and covalent modification of kinase
AKT1
9.1 Introduction kinase AKT1
More than 30 years ago the v-AKT oncogene of AKT8 transforming retrovirus was iden-
tified by Stephen Staal [179]. Four years later, three different groups have characterized
independently the cellular homolog of v-AKT as a Ser/Thr protein kinase [180], [181], [182].
Woodgett and Coffer used library screening and named the identified protein kinase because
of the analogy to the protein kinases A and C (PKA and PKC) protein kinase B (PKB) [182].
Nowadays it is known that AKT/PKB is conserved in three isoforms in mammalian genomes:
AKT1 (PKBα), AKT2 (PKBβ) und AKT3 (PKBγ) [183]. Cantley et al. showed that the
activity of AKT is induced by the phosphoinositide 3-kinase (PI3K), a lipid kinase which
is activated by an extracellular stimulus [184]. A range of intrinsic or extrinsic cell survival
signals are induced by the PI3K/AKT pathway which leads to an increased proliferation, the
loss of the apoptosiss signal or cell growth and additionally is in relation with the insulin
response [185], [186], [187].
The signal transduction starts with the stimulation of receptor tyrosine kinases (RTK) or G
protein-coupled receptors (GPCRs), whereby PI3K isoforms are recruited and activated at
the plasma membrane (Figure 9.1). By the class I PI3K a phosphorylation of the 3’hydroxyl
of the inositol head group of phosphoinositides occurs. Thus, the production of lipid second
messenger PtdIns-3,4,P2 (PI3,4P2) and PtdIns-3,4,5-P3 (PIP3) which results from the phos-
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phorylation of PI4,5P2 by PI3K, is increased [183], [188]. The binding of PIP3 to AKT is
enabled by the kinase’s pleckstrin homology (PH) domain. This PH domain is present in
many proteins and plays an important role for intracellular signalling or is also an essential
component of the cyto skeleton [189], [190], [191], [192], [193], [194], [195]. At endomembranes
PI3,4P2 is produced after the reaction of PIP3 with 5’phosphatase SH2-domain containing
inosotol 5’phosphatase (SHIP), which can interact with the PH domain of AKT [196], [197].
This shows that PI3K and its lipid products are necessary for interaction with AKT and
in consequence are rate limiting for proper AKT activation. Regardless of the membrane,
the relocalization of inactive AKT in the cytosol after synthesis of PIP3 or PI3,4P2 and in
consequence recruitment to the membrane is needed.
After activation of AKT via PI3K, phosphorylation of two “key residues” are necessary to
enable the maximal activity. On the one hand, Thr308 (T-loop) of the catalytic protein
kinase core has to be phosphorylated and on the other Ser473 of the C-terminal hydrophobic
motif [198]. Thr308 is phosphorylated by the phosphoinositide-dependent protein kinase 1
(PDK1). This modification occurs by relocalization of AKT and PDK1 to the membrane
site of PIP3 or by PI3,4P2 synthesis induced change of conformation which enables the phos-
phorylation of AKT’s Thr308 residue by PDK1 [199], [200]. The activity of AKT is strongly
reduced in absence of a Ser473 phosphorylation because this modification stabilizes Thr308’s
phosphorylation [198], [201]. The phosphorylation of Ser473 occurs by mTORC2, although
the role of PI3K activation and hence PIP3 is not clarified yet.
The termination of AKT’s signal can happen in several ways. On the one hand a reduced
AKT activity is indirectly evoked by the tumor suppressor PTEN, a PIP3 phosphatase which
leads to a dephosphorylation of PIP3 to PI4,5P2. On the other hand, AKT can be regulated
directly at the “key residues”. Protein phosphatase 2A (PP2A) dephosphorylates AKT at
Thr308 and in consequence leads to inactivation of AKT [202]. Furthermore, PH domain
leucine-rich repeat protein phosphatases (PHLPP1 and PHLPP2) have been identified as
physiological AKT Ser473 phosphatases [203], [204].
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Figure 9.1: Signal transduction of AKT regulation at the plasma membrane adapted from
[183].
The phosphorylation of further enzymes by AKT shows that a vast range of cellular
functionalities are modulated. The main aspects are depicted in Figure 9.2. The glycogen
synthase kinase 3 (GSK3) was the first substrate of AKT which was identified as multi-
functional serine and threonine protein kinase. The phosphorylation by AKT leads to a
hampered binding for substrates of GSK3. GSK3 has a vital role in cellular metabolism by
e.g. the inhibition of metabolic enzymes as its substrate glycogen synthase [205], [206].
The phosphorylation by AKT can also supress the expression of Forkhead Box O Family
Transcription Factors (FoxO) targets, which usually induce apoptosis, growth inhibition or
tissue-specific metabolic changes [207], [208]. Furthermore, AKT can also modulate the
tuberous sclerosis complex 2 (TSC2/tuberin), which is inactived by phosphorylation and
thus enables an activation of mTORC1 [209], [210], [211]. Consequently, mTORC1’s activity
leads to an increased range of anabolic processes as the synthesis of protein, lipid and nu-
cleotides and also an inhibition of autophagy [212].
Due to the diverse modulation induced by AKT it becomes evident that changes or dysregu-
lation of the PI3K/AKT signalling pathway leads to manifold diseases. In this occasion, mis-
cellaneous carcinomes as lung, prostate, endometrial or breast cancer arise from a disturbed
signalling pathway [185]. In particular, some breast carcinomes show an overexpression or
mutation of AKT which is associated with the progress in disease and additionally increased
resistances to chemo- or radiotherapy [213], [214]. Also, a disturbance of AKT termination
is related to cancer, as for a reduced or non-existent PHLPP1/PHLPP2 expression [215].
Furthermore, diseases as diabetes mellitus 2, autoimmune diseases, lipodystrophy, chronic
148
9.1. INTRODUCTION KINASE AKT1
inflammatory disease are caused by disturbances of GSK3, FoxO or TSC-mTORC1 [210].
Figure 9.2: Regulation of cellular functions via AKT adapted from [183].
Based on the numerous diseases which result from the dysregulation of AKT, it becomes
clear that AKT is an interesting target for the research of possible inhibitors. In case of pro-
tein kinases, one can find various orthosteric inhibitors, which occupy the active site [216]. In
case of AKT one should mention ipatasertib or afursertib, a thiophenecarboxamide-derivative,
which is already in phase I/II studies [217], [218], [219], [220], [221]. Both mentioned exam-
ples are ATP-competitive small molecules and hence selectivity is a severe problem, as this
binding pocket is ubiquitous in the AGC kinase family. In contrast, allosteric inhibitors which
bind on the protein surface and block the enzyme through an induced conformational change
in the protein binding pocket, are able to enhance the selectivity because their binding sites
are not conserved within the enzyme family. [222], [223].
In the inactive conformation of AKT the PH domain can be inhibited (“PH-in” conforma-
tion), while PI3K products lead to a “PH-out” conformation, enabling the phosphorylation
of PDK1 [224], [225]. By targeting AKT via allosteric inhibitors one can achieve a stabi-
149
9.1. INTRODUCTION KINASE AKT1
lization of the “PH-in” conformation, in which AKT stays inactive [226]. A novel method
was introduced by the development of so called covalent-allosteric inhibitors (CAI’s), which
combine properties of covalent inhibitors and allosteric modulaters [227].
Rauh’s group from the Technical University Dortmund developed different covalent-allosteric
inhibitors and additionally crystallized them in covalent complex with AKT (Figure 9.3).
These complexes show a binding in the interdomain region between the PH-domain or the
kinase-domain due to covalent modification of Cys296 or Cys310. This is quite interesting as
the ligands do not differ strongly. While RL1784 (also known as borussertib) was covalently
bound to Cys296, the other two inhibitors form a covalent bond to Cys310.
While X-ray crystallographic data indicate a bonding to Cys296 or Cys310, mass spectrom-
etry indicated a modification of both cysteine residues for inhibitors RL1784 or RL1780. For
RL2132 no mass spectrometry data are available. The data of mass spectrometry can only
give qualitative results (binding or non-binding) but quantitative data are missing.
Thus, computations were conducted to gain further insight. Each inhibitor was prepared in
a non-covalent complex with AKT and dynamics have been obtained by MD simulations.
Within the simulations distances between the nucleophilic cysteine and the electrophilic war-
head are determined so that one can conclude qualitatively which residue is more likely
modified. To further extend these simulations investigations in regard to the deprotonation
of both cysteine residues were carried out. On this occasion nearby basic amino acids and
their distances to both cysteine residues have also been analyzed.
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Figure 9.3: A - Structure of inhibitors N-(2-oxo-3-(1-(4-(5-oxo-3-phenyl-5,6-dihydro-1,6-
naphthyridin-2-yl)benzyl)piperidin-4-yl)-2,3-dihydro-1H-benzo[d]imidazol-5-yl)acrylamide
(RL1780), B - N-(2-chloro-5-(3-(1-(4-(5-oxo-3-phenyl-5,6-dihydro-1,6-naphthyridin-2-
yl)benzyl)piperidin-4-yl)ureido)phenyl)acrylamide (RL1784, or known as borussertib)
and C – N-(1-methyl-2-oxo-3-(1-(4-(5-oxo-3-phenyl-5,6-dihydro-1,6-naphthyridin-2-
yl)benzyl)piperidin-4-yl)-2,3-dihydro-1H-benzo[d]imidazol-5-yl)acrylamide (RL2132).
9.2 System preparation
The main difference within the system preparation steps compared to the complexes in other
chapters was the need to generate complete pdb structures as residues were missing. For the
crystal structure of RL1784 in covalent complex with AKT1 only the residues 5-109, 145-
188, 200-297 and 308-439, for RL1780 the residues 3-44, 49-112, 144-186 and 205-444 and
for RL2132 the residues 5-45, 50-109, 145-188, 200-297 and 308-439 were available. The first
consideration was to restrain the backbone of existing amino acids and simulate the dynam-
ics. This method failed as the protein still moved, although, a huge force with respect to the
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harmonic restraint was applied. In consequence it was not possible to draw any conclusions
out of these simulations. It was of necessity to add the missing residues to obtain trustworthy
results from MD simulations. Thus, the Modeller 9.18 program package was employed for
the generation of the complete pdb structure [228], [229], [230].
First of all, the sequence information was extracted of the existing crystal structure to obtain
the FASTA code. Afterwards an alignment between the original structure, with gap char-
acters corresponding to the missing residues, and the known full sequence was performed.
Afterwards a model containing all residues was generated while the former incomplete pdb
file was used as a template (Figure 9.4). This resulted in nine different pdb structures. The
structures Ia, Ib and Ic represent the X-ray of AKT1 with covalently bound RL1784, while
structures IIa, IIb and IIc reflect the crystal structure of AKT1 in complex with RL1780
(Figure 9.5 and Figure 9.6). Finally, IIIa, IIIb and IIIc give the structure of RL2132 in
covalent complex with the protein (Figure 9.7).
This analysis of the RMSD values show large differences in generated structures. This in-
dicates the need of a longer simulation time compared to previous simulations to obtain
meaningful results. Therefore, each production run was conducted with duration of 50 ns.
The protein was described with the AMBER14 force field ff14SB as before, while the GAFF
force field was applied to inhibitors RL1784, RL1780 or RL2132. The procedure of minimiza-
tion and gradual heating was carried out as previously explained in section 5.1.
Figure 9.4: Procedure of generating complete pdb file by using incomplete X-ray as template.
152
9.2. SYSTEM PREPARATION
A B
C D
Figure 9.5: A – Incomplete pdb structure of AKT1 in covalent complex with RL1784. B –
complete pdb structure of AKT1 structure Ia (yellow) aligned with incomplete structure. C
– complete pdb structure of AKT1 structure Ib (green) aligned with incomplete structure.
D – complete pdb structure of AKT1 structure Ic (red) aligned with incomplete structure.
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A B
C D
Figure 9.6: A – Incomplete pdb structure of AKT1 in covalent complex with RL1780. B –
complete pdb structure of AKT1 structure IIa (yellow) aligned with incomplete structure. C
– complete pdb structure of AKT1 structure IIb (green) aligned with incomplete structure.
D – complete pdb structure of AKT1 structure IIc (red) aligned with incomplete structure.
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A B
C D
Figure 9.7: A – Incomplete pdb structure of AKT1 in covalent complex with RL2132. B –
complete pdb structure of AKT1 structure IIIa (yellow) aligned with incomplete structure. C
– complete pdb structure of AKT1 structure IIIb (green) aligned with incomplete structure.
D – complete pdb structure of AKT1 structure IIIc (red) aligned with incomplete structure.
To investigate whether Cys296 and Cys310 can interact with the inhibitors, the AKT1-
inhibitor complexes were parameterized as a non-covalent complex as mentioned before. In-
sights if a reaction can take place is given by the distance between the electrophilic center of
the inhibitor and the nucleophilic sulfur of cysteine residue (Figure 9.8). As the distance is
related to the probability of the reaction itself, it is possible to draw qualitative conclusions
concerning the modified cysteine residue. Clearly, this variation in distance cannot be simu-
lated in a covalent protein-inhibitor complex.
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Table 9.1: Calculated RMSD values of protein between generated structures Ia, Ib, Ic, IIa, IIb and
IIc. Mean and standard devations are calculated from 10,000 data points. All values in A˚.
protein [A˚] Ia Ib Ic IIa IIb IIc IIIa IIIb IIIc
Ia 0.00 3.66 3.54 5.19 5.22 5.15 4.50 6.06 7.04
Ib 3.66 0.00 4.13 5.15 5.19 5.12 5.18 6.60 7.52
Ic 3.54 4.13 0.00 5.57 5.62 5.58 4.49 6.02 6.99
IIa 5.19 5.15 5.57 0.00 0.59 0.73 4.05 5.74 5.88
IIb 5.22 5.19 5.62 0.59 0.00 0.68 4.05 5.74 5.89
IIc 5.15 5.12 5.58 0.73 0.68 0.00 4.00 5.70 5.84
IIIa 4.50 5.18 4.49 4.05 4.05 4.00 0.00 3.91 3.96
IIIb 6.06 6.60 6.02 5.74 5.74 5.70 3.91 0.00 4.66
IIIc 7.04 7.52 6.99 5.88 5.89 5.84 3.96 4.66 0.00
Additional simulations have been performed by introducing RL1780 into the environments Ia,
Ib or Ic, RL1784 into IIa, IIb or IIc and also RL2132 into Ia, Ib and Ic to observe the effects
on the complex by inserting the inhibitor into the “wrong” environment. By aligning the
proteins, RL1784 has been placed in the protein environment of IIa, IIb and IIc while RL1780
or RL2132 were inserted into Ia, Ib, Ic. All simulations of the protein-inhibitor complex only
considered protonated cysteine residues. It has to be mentioned that a deprotonated Cys296
or Cys310 might result in different findings but these protonation states were not included
due to computational efforts.
Protonated cysteine residues are not sufficiently reactive for a bond formation, hence the
second question was to figure out responsible amino acids for the deprotonation of Cys296 or
Cys310. In this context, MD simulations of structures Ia, Ib, Ic, IIa, IIb and IIc in absence of
an inhibitor were conducted to investigate possible modulation of Cys296 or Cys310 by basic
aminoacids. If one takes a look at the crystal structure of RL1784 in complex with AKT1
one can observe a distance of 4.4 A˚ between Cys296’s sulfur and Glu85’s oxygen. Therefore,
the analysis of this distance during the course of the production run was conducted. In
case of Cys310 no clear interactions to basic amino acids were observable in respect to the
X-ray structure. Consequently, it was necessary to investigate the production runs in terms
of developing interactions to basic amino acids during the course of simulation.
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9.3 Protein-inhibitor interactions
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Figure 9.8: Interactions of active site Cys296 or Cys310 with RL1784 or RL1780 depicted
with dashed lines, corresponding to the following distance plots. Location of amino acids
and warhead serves for clarification and does not reflect actual position in MD simulations.
The simulations revealed that RL1784 in Ia and Ib show mean distances of 4.3 or 4.0 A˚ to
Cys296 accompanied with low standard devations (0.9 and 0.6 A˚) whereas larger values are
obtained for the structure Ic (Table 9.2). Modification of Cys310 might occur in case of Ia
and during 17 – 33 ns in Ib as the distance decreases below 4 A˚, an appropriate value for
a covalent attack (Figure 9.9-A and B). Still, the mean in distance is lower (especially in
case of Ic) for Cys296 to the inhibitor compared to Cys310 which is observable in all three
MD simulations. This is also the case for the complex of RL1784 in the generated structures
IIa-IIc. The important difference one can observe is that the mean distance between the elec-
trophilic carbon of RL1784 and both cysteine residue is increased compared to simulations in
Ia to Ic. Due to the fact that the inhibitor was placed into the “wrong” protein environment,
i.e. into the structures IIa - IIc which originates from the X-ray of RL1780 in complex with
AKT1, this result is to be anticipated. Interestingly, the same trend is observable: In terms
of the distance to Cys296 one obtains lower values independent of the utilized generated pdb
structure.
For RL1780 in IIa – IIc a clear preference for Cys310 is observable. Mean distances between
the electrophilic carbon of RL1780 and the sulfur of Cys310 are 3.5 or 3.6 A˚ for the structures
IIa or IIb, clearly lower than RL1784 to Cys296 (Figure 9.10). Also, standard deviations of
0.3 A˚ are observable for both structures. Only for the protein-inhibitor complex IIc fluctu-
ations up to 6 A˚ occur leading to a mean distance of 5.3 and a standard deviation of 1 A˚.
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The mean distance to Cys296 is about twofold of value compared to Cys310. A complete
different picture can be seen if RL1780 is inserted into the “wrong” environment (Ia - Ic).
In the cases of Ia to Ic the mean distances to Cys296 are lower as well as the values of the
standard deviation. As a conclusion, one can state that it is significant to have a closer look
at the course of distance.
In case of RL1780 in Ia one can observe during 0 to 12 ns and 48 to 50 ns a distance close
enough for covalent modification of Cys310. At other times the distance increases up to 8 to
10 A˚ and exceeds the distance towards Cys296 which is about 7 A˚ (Figure 9.10-A). Although
the mean distance to Cys296 is lower, the duration of an appropriate distance for covalent
modification is longer for the distance between the inhibitor and Cys310. In terms of RL1780
in the generated pdb structure Ic (Figure 9.10-B), solely for the first 5 ns a modulation of
Cys296 is expected while for Cys310 only few occasions for a covalent modification can be
seen. A whole different picture can be seen for the structure Ib. At first glance it is obvious
that Cys296 is favored in terms of distance and also showing appropriate distances for cova-
lent modification during the course of simulation. Still a decrease in distance is observable
after 10 ns for RL1780 to Cys310 and additionally lower fluctuations after 40 ns.
The crystal structure of RL2132 in covalent complex with AKT1 showed a covalent modi-
fication on Cys310. As one can see in Figure 9.11-D to Figure 9.11-F the inhibitor adopts
a lower distance to Cys310 than to Cys296 if one considers the pdb structures IIIa, IIIb
and IIIc. Fluctuations are lowest in case of IIIa, while in IIIb or IIIc the distance between
RL2132 and Cys310 can increase up to 8 A˚. If one compares the mean of the distance, it is
observable that the distance to Cys296 is larger compared to Cys310 (Table 9.3). This is in
contrast to the results obtained in structure Ia, Ib or Ic (Figure 9.11-A to Figure 9.11-C).
The mean values of the distance between Cys310 to RL2132 are at the one hand larger than
in IIIa, IIIb or IIIc. On the other hand Cys296 show mean distances which are lower than
the one obtained from Cys310 to RL2132. In case of Ia one needs to take a closer look as the
distance for a nucleophilic is given for Cys310 during ∼ 28 ns. Afterwards an increase to 12
A˚ occurs leading to a larger mean value. For Cys296 solely a decrease in distance to ∼ 4 A˚
is observable during 25-30 ns. For Ib the distance for nucleophilic attack increases for both
cysteine residues. Interestingly a complete different picture can be seen in case of Ic. Cys296
shows an appropriate distance for covalent modification while the distance of Cys310’s sulfur
to the electrophilic carbon increases to 12-16 A˚.
To shortly conclude the investigations in this section, MD simulations gave a qualitative an-
swer whether Cys296 or Cys310 was preferably modified by the inhibitors RL1784, RL1780
or RL2132. In section 9.5 results are discussed in detail.
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Figure 9.9: The variation in distance as a function of simulation time for RL1784 with Cys296
or Cys310 in structure Ia (A) and in structure Ib (B) corresponding to Figure 9.8.
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Figure 9.10: The variation in distance as a function of simulation time for RL1780 with
Cys296 or Cys310 in structure Ia (A), in structure Ic (B), in structure IIa (C) and in
structure IIb (D) corresponding to Figure 9.8.
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Figure 9.11: The variation in distance as a function of simulation time for RL2132 with
Cys296 or Cys310 in structure Ia (A), in structure Ib (B), in structure Ic (C), in structure
IIIa (D), in structure IIIb (E) and in structure IIIc (F), corresponding to Figure 9.8.
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Table 9.2: Calculated mean and standard deviation of the distance between Cys296(S1) to RL1784-
C(1) or RL1780-C(1) in protein kinase AKT-1. Mean and standard devations are calculated from
10,000 data points. All values in A˚.
pdb distances Cys296-S(1) to Cys310-S(2) to
RL1784-C(1) RL1784-C(1)
Ia mean / SD 4.3 / 0.9 6.3 / 1.7
Ib mean / SD 4.0 / 0.6 5.8 / 1.5
Ic mean / SD 5.2 / 2.0 13.0 / 2.4
IIa mean / SD 5.5 / 0.6 6.6 / 0.6
IIb mean / SD 5.0 / 0.7 7.0 / 1.3
IIc mean / SD 5.6 / 1.2 10.1 / 1.7
pdb distances Cys296-S(1) to Cys310-S(2) to
RL1780-C(1) RL1780-C(1)
Ia mean / SD 6.7 / 0.9 7.1 / 2.2
Ib mean / SD 4.3 / 1.0 5.4 / 1.5
Ic mean / SD 7.3 / 1.3 8.0 / 1.9
IIa mean / SD 7.3 / 0.7 3.5 / 0.3
IIb mean / SD 7.9 / 0.6 3.6 / 0.3
IIc mean / SD 10.6 / 1.1 5.3 / 1.0
Table 9.3: Calculated mean and standard deviation of the distance between Cys296-S(1) or Cys310-
S(2) to RL2132-C(1) in protein kinase AKT-1. Mean and standard devations are calculated from
10,000 data points. All values in A˚.
pdb distances Cys296-S(1) to Cys310-S(2) to
RL2132-C(1) RL2132-C(1)
Ia mean / SD 6.6 / 1.3 7.2 / 3.4
Ib mean / SD 8.3 / 1.7 8.3 / 2.4
Ic mean / SD 4.6 / 1.0 13.1 / 2.7
IIIa mean / SD 4.9 / 0.5 4.4 / 0.5
IIIb mean / SD 7.3 / 0.5 5.6 / 1.5
IIIc mean / SD 6.7 / 0.9 5.9 / 1.6
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9.4 Interactions of basic amino acids to Cys296 and
Cys310 in non-covalent protein-inhibitor and apopro-
tein complex
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Figure 9.12: Interactions of active site Cys296 with Glu85 depicted with dashed lines, cor-
responding to the following distance plots. Location of amino acids and warhead serves for
clarification and does not reflect actual position in MD simulations.
The next scope of investigation was to determine amino acids which might be able to depro-
tonate the cysteine residues 296 or 310. Why is this of importance? Only a deprotonated
cysteine residue is able to form a covalent bond with an inhibitor. If the deprotonation pro-
cess is understood, one can predict which cysteine residue is more likely modified.
As mentioned in the beginning of this section, a distance of 4.4 A˚ between Cys296 and Glu85
was measured in the crystal structure of RL1784 in AKT1. However, how does this distance
evolve during the simulation time? To consider a possible rotation of the carboxylate group
the distance between both oxygen and the thiol group is measured (Figure 9.12). In this
respect the mentioned mean values are related to the lowest calculated one.
In most cases one can observe a movement of Glu85 opposite directed to Cys296 and thus
to an increased distance towards Cys296. In case of RL1784 in Ib (Figure 9.13) one can
observe a water-mediated interaction with Glu85 leading to distances of ≈ 5 A˚. Similar but
weaker interactions can be seen in RL1780 in IIb which occur infrequently (Figure 9.14). In
case of RL2132 in Ib distances below 3 A˚ are occasionally observable indicating a possible
direct proton transfer. Otherwise distances around 5 A˚ are found, however, because water
molecules are inserted between both centers in the course of the simulation water-mediated
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proton transfers between both amino acids might take place (Figure 9.15-A). This is also
observable for RL2132 in IIIa leading to a similar variation in distance but slightly larger
mean in distance compared to Ib (Figure 9.15-B and Table 9.5). Thus, a proton transfer
might occur but distances for this occurrence are not given in every structure.
In absence of the inhibitors RL1784 or RL1780 mean distances between the investigated
amino acids are partly lower. As in the presence of RL1784 one can see distances in Ib
(Figure 9.16) which are close enough for a water-mediated proton transfer. In contrast to
previous simulations this occurrence can also be seen for the structures IIa. After 5 ns of
fluctuations one can observe a decrease of distance between Cys296 and Glu85 leading to an
appropriate distance for a water-based proton transfer. These occurrences are rarer for IIc
yet it shows possibilities of proton transfer compared to the simulations in presence of an
inhibitor. Therefore, an occurrence of a proton transfer is possible.
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Figure 9.13: The variation in distance as a function of simulation time for Glu85 with Cys296
in presence of RL1784 in structure Ib corresponding to Figure 9.12.
164
9.4. INTERACTIONS OF BASIC AMINO ACIDS TO CYS296 AND CYS310 IN
NON-COVALENT PROTEIN-INHIBITOR AND APOPROTEIN COMPLEX
0 5 10 15 20 25 30 35 40 45 50
2
4
6
8
10
12
14
16
18
20
22
2
4
6
8
10
12
14
16
18
20
22
 
di
st
an
ce
 [Å
]
time [ns]
 Cys296-S(1)H to Glu85-O(1)
 
 
di
st
an
ce
 [Å
]
 Cys296-S(1)H to Glu85-O(2)
Figure 9.14: The variation in distance as a function of simulation time Glu85 with Cys296
in presence of RL1780 in structure IIb corresponding to Figure 9.12.
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Figure 9.15: The variation in distance as a function of simulation time for Glu85 with Cys296
in presence of RL2132 in structure Ib (A) and in structure IIIa (B) corresponding to Figure
9.12.
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Figure 9.16: The variation in distance as a function of simulation time for Glu85 with Cys296
in absence of RL1784, RL1780 or RL2132 in structure Ib corresponding to Figure 9.12.
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Table 9.4: Calculated mean and standard deviation of the distance between Cys296(S1) to
Glu85(O1) or Glu85(O2) in protein kinase AKT-1. Mean and standard devations are calculated
from 10,000 data points. All values in A˚.
pdb distances Cys296-S(1) to Cys296-S(1) to
Glu85-(O1)* Glu85-(O2)*
Ia mean / SD 9.8 / 1.8 9.7 / 1.8
Ib mean / SD 7.0 / 1.7 6.9 / 1.8
Ic mean / SD 10.4 / 2.1 10.6 / 2.3
IIa mean / SD 10.2 / 1.4 10.4 / 1.4
IIb mean / SD 9.7 / 1.5 9.8 / 1.5
IIc mean / SD 10.5 / 2.1 10.8 / 2.1
pdb distances Cys296-S(1) to Cys296-S(1) to
Glu85-(O1)** Glu85-(O2)**
Ia mean / SD 10.6 / 1.6 10.3 / 1.6
Ib mean / SD 10.2 / 2.1 9.9 / 1.8
Ic mean / SD 9.6 / 2.1 9.5 / 2.1
IIa mean / SD 7.9 / 1.3 8.0 / 1.4
IIb mean / SD 7.5 / 1.2 8.0 / 1.2
IIc mean / SD 8.9 / 1.1 8.8 / 1.1
pdb distances Cys296-S(1) to Cys296-S(1) to
Glu85-(O1)*** Glu85-(O2)***
Ia mean / SD 11.7 / 2.2 11.8 / 2.1
Ib mean / SD 5.9 / 1.2 6.3 / 1.3
Ic mean / SD 8.9 / 1.7 9.1 / 1.7
IIa mean / SD 6.7 / 1.5 7.1 / 1.6
IIb mean / SD 9.2 / 1.7 9.4 / 1.4
IIc mean / SD 6.7 / 1.3 6.9 / 1.4
*MD simulation in presence of RL1784. ** MD simulation in presence of RL1780. *** MD simulation in
absence of inhibitor.
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Table 9.5: Calculated mean and standard deviation of the distance between Cys296(S1) to
Glu85(O1) or Glu85(O2) in presence of inhibitor RL2132 in protein kinase AKT-1. Mean and
standard devations are calculated from 10,000 data points. All values in A˚.
pdb distances Cys296-S(1) to Cys296-S(1) to
Glu85-(O1) Glu85-(O2)
Ia mean / SD 7.5 / 1.7 7.5 / 1.8
Ib mean / SD 5.2 / 1.2 5.2 / 1.1
Ic mean / SD 9.1 / 1.8 9.2 / 1.6
IIIa mean / SD 5.9 / 1.2 5.9 / 1.3
IIIb mean / SD 7.5 / 1.8 8.1 / 1.4
IIIc mean / SD 8.6 / 1.2 8.7 / 1.2
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Figure 9.17: Interactions of active site Cys310 with Glu298 depicted with dashed lines,
corresponding to the following distance plots. Location of amino acids and warhead serves
for clarification and does not reflect actual position in MD simulations.
In terms of the deprotonation of Cys310, interactions with two amino acids are established
in the course of the simulation time. A decrease of distance between Cys310 and Glu298 is
observable in the non-covalent complex of AKT with RL1784 as well as in the absence of any
inhibitor. Just as before the distance from Cys310 to both oxygens is measured and the given
mean value is referred to the lower value. The distance between Glu298’s oxygen and Cys310
thiol group in structure Ib shows a steady decrease to values between 2 to 4 A˚ observable
after 35 ns (Figure 9.18-A) leading to a mean of 5.3 A˚. In this case even a direct proton
transfer might occur in contrast to interactions of Cys296 to Glu85. A quite similar behavior
can be seen for structure IIa with the difference that the decrease in distance occurs after
25 ns but still leading to the same mean distance (Figure 9.18-B). This occurrence appears
between 10-30 ns for IIb thus showing a slightly higher mean of 5.8 A˚ and only twice with a
duration of 2 ns in structure IIc explaining the mean distance of 8.4 A˚ (Figure 9.18-C and
D). In contrast to these findings distances which allow a direct or a water-mediated proton
transfer are not found if RL1780’s is present. In case of RL2132 a water-mediated proton
transfer appears possible during 25-40 ns in structure Ib as well as occasionally in IIIc (Figure
9.19-A and Figure 9.19-B).
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Figure 9.18: The variation in distance as a function of simulation time for Glu298 with
Cys310 in presence of RL1784 in structure Ib (A), in structure IIa (B), in structure IIb (C)
and in structure IIc (D), corresponding to Figure 9.17.
170
9.4. INTERACTIONS OF BASIC AMINO ACIDS TO CYS296 AND CYS310 IN
NON-COVALENT PROTEIN-INHIBITOR AND APOPROTEIN COMPLEX
A
0 5 10 15 20 25 30 35 40 45 50
2
4
6
8
10
12
14
16
18
20
22
2
4
6
8
10
12
14
16
18
20
22
 
di
st
an
ce
 [Å
]
time [ns]
 Cys310-S(2)H to Glu298-O(3)
 
 
di
st
an
ce
 [Å
]
 Cys310-S(2)H to Glu298-O(4)
B
0 5 10 15 20 25 30 35 40 45 50
2
4
6
8
10
12
14
16
18
20
22
2
4
6
8
10
12
14
16
18
20
22
 
di
st
an
ce
 [Å
]
time [ns]
 Cys310-S(2)H to Glu298-O(3)
 
 
di
st
an
ce
 [Å
]
 Cys310-S(2)H to Glu298-O(4)
Figure 9.19: The variation in distance as a function of simulation time for Glu298 with
Cys310 in presence of RL2132 in structure Ib (A) and in structure IIc (B) corresponding to
Figure 9.17.
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Figure 9.20: The variation in distance as a function of simulation time for Glu298 with
Cys310 in absence of RL1784, RL1780 or RL2132 in structure IIa (A) and in structure IIb
(B) corresponding to Figure 9.17.
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In absence of the inhibitor, only in the cases IIa, IIb and occasionally in IIc a proton
transfer is to be expected. IIa shows the largest mean for these structures due to the increase
from ≈ 5 to 12 A˚ between 28 – 38 ns (Figure 9.20-A). For IIb the interaction between Cys310
and Glu298 is stable during the course of simulation thus resulting in a small deviation of
1.5 A˚ (in comparison to IIa or IIc) and a mean of 5.5 A˚ (Figure 9.20-B).
Table 9.6: Calculated mean and standard deviation of the distance between Cys310(S2) to
Glu298(O3) or Glu298(O4) in protein kinase AKT-1. Mean and standard devations are calculated
from 10,000 data points. All values in A˚.
pdb distances Cys310-S(2) to Cys310-S(2) to
Glu298-(O3)* Glu298-(O4)*
Ia mean / SD 11.0 / 1.7 11.0 / 1.7
Ib mean / SD 5.3 / 2.2 5.7 / 2.2
Ic mean / SD 11.7 / 2.9 11.8 / 2.9
IIa mean / SD 5.3 / 1.5 5.1 / 1.5
IIb mean / SD 5.8 / 1.7 6.0 / 1.8
IIc mean / SD 8.4 / 1.6 8.4 / 1.6
pdb distances Cys310-S(2) to Cys310-S(2) to
Glu298-(O3)** Glu298-(O4)**
Ia mean / SD 10.6 / 1.6 10.3 / 1.6
Ib mean / SD 10.2 / 2.1 9.9 / 1.8
Ic mean / SD 9.6 / 2.1 9.5 / 2.1
IIa mean / SD 6.4 / 1.0 6.7 / 1.0
IIb mean / SD 6.7 / 1.2 6.8 / 1.2
IIc mean / SD 13.5 / 1.4 13.6 / 1.4
pdb distances Cys310-S(2) to Cys310-S(2) to
Glu298-(O3)*** Glu298-(O4)***
Ia mean / SD 8.7 / 1.7 8.5 / 1.8
Ib mean / SD 9.7 / 1.4 9.9 / 1.4
Ic mean / SD 11.4 / 2.3 11.4 / 2.3
IIa mean / SD 6.9 / 2.7 7.0 / 2.6
IIb mean / SD 5.5 / 1.5 5.5 / 1.5
IIc mean / SD 6.7 / 1.7 6.7 / 1.6
*MD simulation in presence of RL1784. ** MD simulation in presence of RL1780. *** MD simulation in
absence of inhibitor.
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Table 9.7: Calculated mean and standard deviation of the distance between Cys310(S2) to
Glu298(O3) or Glu298(O4) in presence of inhibitor RL2132 in protein kinase AKT-1. Mean and
standard devations are calculated from 10,000 data points. All values in A˚
pdb distances Cys310-S(2) to Glu298-(O3) Cys310-S(2) to Glu298-(O4)
Ia mean / SD 7.7 / 1.0 7.6 / 1.1
Ib mean / SD 8.9 / 3.2 9.0 / 3.3
Ic mean / SD 13.1 / 3.7 13.1 / 3.7
IIIa mean / SD 7.7 / 1.2 7.8 / 1.2
IIIb mean / SD 8.7 / 1.7 8.7 / 1.7
IIIc mean / SD 7.3 / 1.6 7.3 / 1.7
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Figure 9.21: Interactions of active site Cys310 with Arg15 depicted with dashed lines, cor-
responding to the following distance plots. Location of amino acids and warhead serves for
clarification and does not reflect actual position in MD simulations.
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Figure 9.22: The variation in distance as a function of simulation time for Arg15 with Cys310
in presence of RL1784 in structure Ib (A), in structure IIa (B) and in structure IIb (C)
corresponding to Figure 9.21.
Additional to Glu298 interactions further ones are formed between Arg15 to Cys310 dur-
ing the simulations. Again, all hydrogens of Arg15’s guanidine group have been considered to
account possible rotations of the side chain. Interestingly a relationship between Arg15 and
Glu298 are sometimes found. For example, one can observe a similar behavior as in struc-
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ture Ib in complex with Rl1784, as a steady decrease is visible as before (Figure 9.22-A).
For IIa the distance also lowers to values between 3.5 and 4.5 A˚ after 10 ns (Figure 9.22-B).
For IIb the same values are observable. Only during 15-20 ns an increase to 8 A˚ occurs
(Figure 9.22-C). In presence of inhibitor RL1780 only in structure IIc an interaction between
Arg15 and Cys310 is formed revealing the lowest calculated mean in distance of 3.0 A˚ (Fig-
ure 9.23) while no interactions can be observed for the simulations of the protein-inhibitor
complex of RL2132. In absence of an inhibitor distances between 3.5 and 4.5 A˚ are shown for
the structure Ib and twice for Ic during 5 to 6 ns and 20 to 25 ns (Figure 9.24-B and C). In
case of the structures IIa – IIc distances between 8 to 16 A˚ are observed (Figure 9.24-D to F).
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Figure 9.23: The variation in distance as a function of simulation time for Arg15 with Cys310
in presence of RL1780 in structure IIc corresponding to Figure 9.21.
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Figure 9.24: The variation in distance as a function of simulation time for Arg15 with Cys310
in absence of RL1784, RL1780 or RL2132 in structure Ia (A), in structure Ib (B), in structure
Ic (C), in structure IIa (D), in structure IIb (E) and in structure IIc (F), corresponding to
Figure 9.21.
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Table 9.8: Calculated mean and standard deviation of the distance between Cys310(S2) to Arg15-
H(1), Arg15-H(2), Arg15-H(3) or Arg15-H(4) in protein kinase AKT-1. Mean and standard deva-
tions are calculated from 10,000 data points. All values in A˚.
pdb distances Cys310-S(2) to Cys310-S(2) to Cys310-S(2) to Cys310-S(2) to
Arg15-H(1)* Arg15-H(2)* Arg15-H(3)* Arg15-H(4)*
Ia mean / SD 11.8 / 1.8 12.0 / 2.0 9.7 / 1.7 10.9 / 1.9
Ib mean / SD 7.0 / 2.4 6.3 / 2.6 7.1 / 2.2 8.3 / 1.9
Ic mean / SD 16.5 / 2.3 16.4 / 2.1 16.3 / 2.0 16.4 / 1.9
IIa mean / SD 4.8 / 1.8 4.1 / 1.7 5.1 / 1.5 6.3 / 1.4
IIb mean / SD 4.4 / 1.1 4.5 / 1.1 5.1 / 1.4 5.6 / 1.4
IIc mean / SD 7.5 / 1.4 7.1 / 1.4 6.9 / 1.2 7.3 / 1.3
pdb distances Cys310-S(2) to Cys310-S(2) to Cys310-S(2) to Cys310-S(2) to
Arg15-H(1)** Arg15-H(2)** Arg15-H(3)** Arg15-H(4)**
Ia mean / SD 11.5 / 1.8 12.2 / 2.1 14.0 / 2.2 14.7 / 2.0
Ib mean / SD 12.4 / 2.5 12.5 / 2.4 12.6 / 2.1 12.5 / 1.7
Ic mean / SD 12.3 / 2.7 12.3 / 2.7 12.9 / 3.0 13.4 / 3.0
IIa mean / SD 6.7 / 1.1 6.3 / 1.0 7.6 / 1.0 8.9 / 1.0
IIb mean / SD 8.4 / 1.1 8.0 / 1.3 8.9 / 1.4 9.8 / 1.2
IIc mean / SD 3.0 / 1.4 4.5 / 1.3 5.9 / 1.1 5.9 / 1.0
pdb distances Cys310-S(2) to Cys310-S(2) to Cys310-S(2) to Cys310-S(2) to
Arg15-H(1)*** Arg15-H(2)*** Arg15-H(3)*** Arg15-H(4)***
Ia mean / SD 8.5 / 1.0 8.5 / 1.0 8.0 / 1.0 7.4 / 0.9
Ib mean / SD 4.9 / 1.6 5.2 / 1.8 6.3 / 1.6 7.0 / 1.2
Ic mean / SD 6.5 / 1.7 6.8 / 1.6 7.3 / 1.4 7.4 / 1.2
IIa mean / SD 13.6 / 1.8 13.6 / 2.1 13.9 / 2.1 14.2 / 2.0
IIb mean / SD 9.2 / 0.9 9.6 / 1.0 10.5 / 1.0 10.7 / 0.8
IIc mean / SD 16.0 / 0.7 17.1 / 0.8 17.5 / 1.0 16.9 / 1.2
*MD simulation in presence of RL1784. ** MD simulation in presence of RL1780. *** MD simulation in
absence of inhibitor.
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Table 9.9: Calculated mean and standard deviation of the distance between Cys310(S2) to Arg15-
H(1), Arg15-H(2), Arg15-H(3) or Arg15-H(4) in presence of inhibitor RL2132 in protein kinase
AKT-1. Mean and standard devations are calculated from 10,000 data points. All values in A˚.
pdb distances Cys310-S(2) to Cys310-S(2) to
Arg15-H(1) Arg15-H(2)
Ia mean / SD 13.3 / 1.3 13.4 / 1.3
Ib mean / SD 13.2 / 2.1 13.3 / 2.0
Ic mean / SD 14.3 / 1.6 15.0 / 1.8
IIIa mean / SD 8.9 / 0.8 8.2 / 0.9
IIIb mean / SD 9.3 / 1.4 9.0 / 1.4
IIIc mean / SD 8.9 / 1.0 8.5 / 1.2
pdb distances Cys310-S(2) to Cys310-S(2) to
Arg15-H(3) Arg15-H(4)
Ia mean / SD 13.1 / 1.5 12.8 / 1.8
Ib mean / SD 14.3 / 1.9 15.1 / 1.9
Ic mean / SD 15.6 / 1.9 15.3 / 1.7
IIIa mean / SD 7.7 / 0.8 7.9 / 0.7
IIIb mean / SD 9.1 / 1.5 9.4 / 1.3
IIIc mean / SD 8.8 / 1.3 9.3 / 1.1
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Figure 9.25: Interactions of active site Cys296 and Cys310 with Lys20 depicted with dashed
lines, corresponding to the following distance plots. Location of amino acids and warhead
serves for clarification and does not reflect actual position in MD simulations.
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The analysis of the MD simulation of RL2132 in IIIa, IIIb and IIIc revealed another
interaction between Cys296 or Cys310 and the basic amino acid Lys20. As one can see
in Figure 9.26-D to Figure 9.26-F distances of around 5 A˚ are observable leading to the
conclusion of an interaction between these residues. In all cases the mean distances between
Cys310 to Lys20 are lower than between Cys296 and Lys20 (Table 9.10). This kind of
interaction does not appear for the structures Ia, Ib or Ic (in Figure 9.26-A to Figure 9.26-
C). It has to be mentioned, that all simulations considered a protonated Lys20 which cannot
be involved in the deprotonation of cysteine. Still, interactions from lysine to cysteine can
be relevant as as a stabilization of the thiolate after proton transfer can result.
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Figure 9.26: The variation in distance as a function of simulation time for Lys20 with Cys296
(black curve) or Cys310 (red curve) in presence of RL2132 in structure Ia (A), in structure
Ib (B), in structure Ic (C), in structure IIIa (D), in structure IIIb (E) and in structure IIIc
(F), corresponding to Figure 9.25.
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Table 9.10: Calculated mean and standard deviation of the distance between Cys296-S(1) or
Cys310-S(2) to Lys20-N(3) in presence of RL2132 in protein kinase. Mean and standard devations
are calculated from 10,000 data points. All values in A˚.
pdb distances Cys296-S(1) to Cys310-S(2) to
Lys20-N(3) Lys20-N(3)
Ia mean / SD 15.3 / 2.5 9.9 / 1.7
Ib mean / SD 15.5 / 3.6 10.9 / 2.7
Ic mean / SD 21.7 / 3.9 14.5 / 3.2
IIIa mean / SD 5.1 / 1.0 4.7 / 0.7
IIIb mean / SD 7.3 / 1.4 5.1 / 0.9
IIIc mean / SD 6.7 / 1.0 4.7 / 0.8
9.5 Conclusions
The group of Rauh from the Technical University Dortmund crystallized three different
covalent-allosteric inhibitors (RL1784, RL1780 or RL2132) in covalent complex with AKT,
a protein which is involved in the regulation cellular functions (Figure 9.3). This chapter
comprises investigations these inhibitors in AKT1 and focused on two different questions.
Crystal structures revealed a covalent modification of Cys296 in case of RL1784 while the
other two were covalently bound to Cys310. In case of RL1784 and RL1780 mass spec-
trometry indicated that both residues are modified by these inhibitors. However, these
measurements cannot differentiate which residue is more active. Thus, the question arose
which nearby cysteine residue is more likely modified. Therefore, MD simulations of the
non-covalent complex have been conducted to analyze the variation of distance between both
cysteine residues and the warhead. Experimentally these investigations cannot be performed
because only information about the covalent enzyme-inhibitor are available. If a small dis-
tance towards the cysteine residue can be maintained for a longer period of time one can
conclude that the respective residue is more likely modified.
Another point of interest is the deprotonation process of these cysteine residues which is
needed to enable the covalent reaction. In case of Cys296 the crystal structure indicate that
Glu85 is relevant for the abstraction of the proton. Hence, MD simulations in complex with
the inhibitors as well as in absence of the inhibitors have been conducted and residues have
been identified which might be responsible for the deprotonation.
Initially, it was necessary to build up the whole protein using theoretical approaches as many
residues were missing in the crystal structure. The Modeller 9.18 program package which
added the missing residues lead to different protein structures (Figure 9.5to Figure 9.7).
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These structures were used for Molecular Dynamics simulation.
The results of these simulation offer a qualitative answer in respect to the modified cys-
teine residue. In the course of simulation one can observe lower values for the distance from
RL1784 to Cys296 for the generated structures Ia-Ic compared to IIa-IIc. The mean distance
to Cys296 is always lower as to Cys310. Still one can occasionally see appropriate distances
for covalent modification of Cys310 although this does not occur as often as for Cys296. This
explains the possible covalent bond to Cys310. It also explains why in the crystal structure
a covalent bond is only found between RL1784 and Cys296.
For RL1780 the mean and standard deviation of the distance between inhibitor and Cys310 is
lower for the structures IIa to IIc. This indicates that the formation of a covalent complex is
more likely than for RL1784 with Cys296 in their initial crystal structures. Additionally, no
close distance to Cys296 was found. This is not the case for the simulations in the structures
Ia to Ic. In this connection RL1780 is farther away to Cys310 whereas also the frequency of a
proper distance is lower than before. It appears that a certain amount of time is of necessity
until the warhead is directed towards Cys310. Especially in one case Cys296 forms a perma-
nent interaction with the inhibitor. This also is in line with the mass spectrometry revealing
that a modification of Cys296 is also possible. Still, for the other structures the distance to
Cys296 is not sufficiently close or appears infrequently compared to Cys310. These findings
indicate that for RL1780 a modification of Cys310 is more likely.
In case of RL2132 distances for covalent modification of Cys310 are obtained in the struc-
tures IIIa, IIIb and IIIc. For IIIa fluctuations are low (standard deviation of 0.5 A˚) in terms
of the distance between Cys310 and the inhibitor. Still interactions between Cys296 and
RL2132 are also observable with a slightly higher value in distance which indicates possible
modification of both residues. This cannot be observed for IIIb and IIIc as the nucleophilic
sulfur of Cys296 is too far away. Additionally, the distance between Cys310 and the inhibitor
show larger fluctuations in contrast to IIIa. The insertion of RL2132 into the environment
of Ia, Ib and Ic leads to different results. For Ia an appropriate distance for modification of
Cys310 can be maintained for 25 ns and afterwards an increase to 12 A˚ occurs. Dynamics
of the inhibitor in Ib show infrequent appropriate distances for a covalent modification of
Cys310 as well as for Cys296. A complete different picture is obtained for Ic as Cys296 is
closer to RL2132 than Cys310. These results indicate that the modification of Cys310 is
slightly preferred although results are not as clear as for RL1780 or RL1784.
The evaluation of the deprotonation of Cys296 or Cys310 also revealed new findings. In
terms of the interaction of Glu85 with Cys296 it is not as strong as expected from the in-
teraction profile of the crystal structure. Still, it has to be mentioned that distances were
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observed where a water-based abstraction of Cys296’s hydrogen might appear although the
likelihood is not very high. For the cysteine residue 310 two interactions are observed in the
course of simulation. Firstly, Glu298 oriented in several simulations towards Cys310 leading
to distances where an abstraction appears possible. Secondly, Arg15 establishes interactions
to Cys310 and occasionally to Glu298. A deprotonation of the cysteine residue might be
possible, but it is also conceivable that the protonated arginine functions as a stabilizer for
the proton transfer. Another interesting finding is the role of Lys20. Dynamics of AKT1 in
non-covalent complex with RL2132 in the structures IIIa, IIIb and IIIc reveal interactions
of Cys296 and Cys310 to Lys20. This was not observed in case of the other inhibitors. It
becomes clear that this observation was only made by the previous mentioned structures as
they were generated by the crystal structure of RL2132. Thus, one can conclude that Arg15
and especially Glu298 are of importance for the deprotonation process of Cys310 while Lys20
plays an important role for the protein-inhibitor complex of RL2132.
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Chapter 10
The binding mode of non-covalent
diphenylether inhibitors in FabI and
InhA
10.1 Introduction
With the discovery of penicillin in the year 1929 by Fleming the history of humanity en-
tered a turning point [231]. It became clear that diseases caused by bacterial infections were
manageable. But already in the year 1940, before penicillin was available on the market,
bacterial penicillinases have been identified which proved Flemings observation that several
bacteria have not been inhibited by penicillin [232]. With the rational design of methi-
cillin 1959, the problem of penicillinases seemed to be solved. Still, three years afterwards
methicillin-resistant Staphylococcus aureus (MRSA) appeared and in consequence further
multiantibiotic-resitant variants occurred so that the abbreviation MRSA is also referred to
multidrug-resistant S. aureus [233].
This leads to the necessity of the development of new antibiotics. In the period of the 1950s
to the 1970s, many classes of antibiotics as tetracyclines, macrolides, aminoglycosides or
quinolone have been discovered, just to mention a few of them [234]. The mechanism of
antibiotics is manifold, may it be by the disturbance of the protein, RNA, DNA synthesis or
of the bacterial cell wall [235]. The increased development of resistance towards these drugs
was problematic and still is today. MRSA was in the late 1960 endemic in hospitals but
spread out rapidly in the population in the 1990s so that it is prevelant in the world. Today,
we are confronted with community acquired (CA)-MRSA which shows increased virulence
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and distinctive characteristics concerning the transmission [236]. This can be traced back
by the large consumption of antibiotics in medicine but also in agricultural economics and
animal husbandry. Accordingly, resistances rose in alarming heights [237]. Especially the ap-
pearance of resistances of last-resort antibiotic vancomycin by so called vancomycin resistant
S. aureus (VRSA) underlines the urgency of the development of new antibiotics [238].
A lot of bacterial pathogenes which are associated with epidemics, developed a multidrug-
resistant (MDR) form due to the overused application of antibiotics. MDR Mycobacterium
tuberculosis is not only present in the Third World countries but also in industrial countries.
Already in 1944 when streptomycin was introduced as drug targeting tuberculosis (TB; also
known as “the great white plague”), mutated strains have been found which showed resis-
tances against this antibiotic [233].
The treatment of TB often turns out as complicated and includes an intensive initial treat-
ment of two months with a fourfold combination of isoniazid, rifampicin, pyrazinamide and
ethambutol. Subsequently a 4-month period treatment with isoniazid and rifampicin has to
be continued. In case of MDR infections different drugs (depending on the results of resis-
tance at least four effective drugs have to be chosen) have to be applied in combination for
a time period of 18 to 24 months [239], [240]. To win the fight against MDR strains new
targets or concepts have to be developed.
Copeland et al. showed 2006 that an increase in the drug residence time (tr) enhance the
pharmocodynamic activity and alow lower drug concentrations due to elimination processes
[241], [242]. This was also confirmed by studies which investigated the inhibition of ENR
reductases (E.C. 1.3.1.9) via triclosan and different diphenyl ether (DPE) compounds [243].
It was shown that an increase of tr results in a contemporaneous improvement in inhibition.
ENRs catalyze the last step in the elongation in the bacterial fatty-acid biosynthesis (FAS II
pathway) and offer a good drug-target which is addressed by triclosan and also by isoniazid.
The reduction of trans-2-acyl-ACP to a saturated acyl-ACP species is catalyzed by this en-
zyme, while in most cases the cofactor NADH or NADPH serves as reducing agent (Figure
10.1). While the mammalian FAS I synthase executes many functions, the FAS II system of
bacteria, protozoa or plants consists of many individual enzymes which are equipped with a
certain functionality and thus a selective inhibition is possible as it is not found in humans
[244].
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Figure 10.1: Reduction of double bond by addition of hydride ion of NADH (NADPH) of
trans-2-butenoyl-ACP and abstraction of proton of Tyr156’s phenol group in E. coli FabI.
Proton of Tyr156’s phenol group is restored through Lys163, hydroxyl groups of the ribose
moiety of the coenzyme and the surrounding water molecules. Graphic is adapted from [245].
SKTS1 (Figure 10.2), a diphenyl ether (DPE) inhibitor which was originally designed for
targeting the ENR of S. aureus (saFabI), was crystallized by the group of Kisker from the
University of Wu¨rzburg in complex with saFabI and additionally with InhA, the ENR of M.
tuberculosis. In terms of the binding position, SKTS1 occupies the same binding region in
InhA as in FabI. Just like in case of FabI, Kiskers group showed that the measured kinetics
indicate a favorable binding towards InhA. Although the binding mode of SKTS1 in InhA is
similar to FabI, interactions resulting from the pyridone moiety are different. If one takes a
look at the interactions of the pyridone ring of SKTS1 with Ala97 in FabI, distances between
the inhibitors nitrogen or oxygen (of the pyridone ring) in to Ala97’s backbone oxygen are
different compared to SKTS1’s interaction with Met98 in InhA (Figure 10.3). It appears
that a tautomerization of the pyridone ring to a hydroxypyridine is of necessity to establish
more favorable interactions with the protein environment in InhA in contrast to FabI. The
interaction pattern obtained by the crystal structure between SKTS1 and the protein also in-
dicates an interaction between Glu100 (for FabI) or Gln100 (for InhA) and the diphenylether
inhibitor.
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O O
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N OH
Figure 10.2: Pydridone form of SKTS1 (left) and hydroxypyridine form of SKTS1 (right).
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As crystal structures do not contain hydrogen centers computational investigations are
advantageous to shed light into the question of SKTS1’s tautomeric form in the respective
enzyme. QM calculations in vacuum and solution for the pyridone and hydroxypyridine ring
were performed as well as for SKTS1 in both tautomeric forms to analyze the preference state
of the inhibitor itself. Afterwards dynamics of SKTS1 were investigated via MD simulations
with duration of 10 ns have been performed to investigate the different interactions to the
protein environment depending on the tautomeric form. Additionally, a derivative of SKTS1
has been investigated by MD simulations to gain insight in regard of possible novel inhibitors.
As this derivative consists of a 2-aminoimidazole instead of a pyridone ring it might show a
better binding behavior as it is not affected by tautomerization.
A B
Figure 10.3: Interaction of the SKTS1 with Ala97’s backbone in saFabI (A) or of SKTS1
with Met98’s backbone (B).
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10.2 QM calculations of pyridone and hydroxypyridine
in vacuo and solution
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Figure 10.4: Structure of SKTS1 in pyridone or hydroxypyridine form. In case of hydrox-
ypyridine trans- or cis-conformation was considered. Additionally, inclusion of explicit water
molecule to pyridone, trans- or cis-hydroxypyridine is depicted for clarification.
As known from literature a hydroxypyridine ring is energetically favored in vacuum, whereas
a pyridone is lower in energy in aqueous solution which has been shown experimentally or by
QM calculations [246], [247], [248], [249]. To investigate the energetic difference of SKTS1 in
its pyridone or hydroxypyridine form, firstly the methodology of the QM calculations has to
be evaluated. In a first step only the pyridone or hydroxypyridine ring have been calculated
in absence of the diphenylether scaffold to obtain qualitative comparability to results from lit-
erature. In contrast to the work of Galvao et al. the calculations were simplified and instead
of the Gibbs energies only the difference in inner energy U was evaluated. After structure
optimization employing B3LYP-D3 and the def-TZVP basis set in vacuo or with COSMO
(=78,39), single point energy calculation utilizing different DFT or ab initio methods have
been performed on top of these structures with the aug-cc-pVDZ basis set.
Table 10.1 shows that indeed the environment influences the preference of the tautomeric
state. Except for the results obtained with B3LYP-D3 and SCS-CC2, cis-hydroxypyridine is
favored by 1-2 kcal/mol whereas the inclusion of COSMO reveals that pyridone is lower in
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energy by ≈ 2-6 kcal/mol depending on the used methodology. This is in indeed qualitatively
concordant to the literature and therefore the same methodologies were applied to SKTS1. As
shown in Figure 10.4 not only trans-hydroxypyridine but also cis-hydroxypyridine have been
considered as well. Additionally, the system was extended by one explicit water molecule
to further investigate environmental influence on the tautomeric state. The optimization
and single point energy calculation procedure have been performed in the same manner as
described before. Differences in structure due to optimization in vacuum or COSMO can be
measured by a RMSD value of 0.24 A˚ (pyridone), 0.26 A˚ (trans-hydroxypyridine) or 0.26 A˚
(cis-hydroxypyridine). In terms of the inhibitor SKTS1, QM calculations in vacuum or in
COSMO reveal that all methods (except for energies obtained with MP2/aug-cc-pVDZ for
the cis-hydroxypyridine) predict that the pyridone form of SKTS1 is the energetically lower
configuration compared to hydroxypyridine (see Table 10.2 and Table 10.3). Differences in
terms of the presence or absence of COSMO regarding the optimization influence the ob-
tained single point energy. By applying COSMO in the optimization step, energies obtained
from the different single point calculations show a slight increase of energy by 0.5 kcal/mol
or less for SKTS1’s hydroxypyridine compared to its pyridone form. In general terms theory
predicts that the pyridone form of SKTS1 is energetically more stable regardless of the used
method or environment.
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Figure 10.5: Interaction between SKTS1 in its hydroxypyridine form with explicit water
molecule before (left) and after (right) optimization. All values in A˚.
Concerning the cis-hydroxypyridine form DFT methods predict an increase of energy
difference of 0.4 kcal/mol up to ≈ 2-3 kcal/mol if one employs the COSMO approach. The
usage of ab initio methods leads to a decrease of about 0.5 kcal/mol up to ≈ 1 kcal/mol, thus
a destabilization of the pyridone form. If one takes an explicit water molecule into account,
the energetic difference between both tautomeric forms decreases by ≈ 1 kcal/mol but still
describing the SKTS1’s pyridone form to be more stable. For the trans-hydroxypyridine form
of SKTS1 a stabilization of about 4 kcal/mol occurs if one employs implicit solvation for all
used methods. In contrast to the cis-form, the inclusion of an explicit water molecule leads
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to an increase and therefore destabilization of the trans-hydroxypyridine form which can
be explained by Figure 10.5. The optimized structure shows an increased distance between
the hydroxyl group of the ring and the hydrogen of the water and therefore an unfavorable
interaction contrary to the results of cis-hydroxypyridine.
If one compares both forms for hydroxypyridine, one can see that the cis-form is about 5
kcal/mol lower than the trans-from in case of vacuum energies, while these differences decrease
to ≈ 1 kcal/mol by inclusion of COSMO. These findings are also observable in MD simulation
which will be shown in the next section. Also, another observation can be made: The usage
of COSMO and inclusion of one explicit water molecule decreases the stability of SKTS1’s
pyridone tautomer whereas this trend is contrary to the simple pyridone ring. Thus, binding
to InhA might be accompanied by increased constraints applied to the preferred tautomeric
state of the inhibitor itself and may account for a less stable enzyme-inhibitor complex and
shorter residence time.
Table 10.1: Single point energy difference of cis-hydroxypyiridine in relation to pyridone single
point energy obtained from B3LYP-D3/def-TZVP optimized structures in vacuum and COSMO
(=78,39). All calculations were performed using aug-cc-pVDZ basis sets. All energy values are
shown in kcal/mol.
environment vacuum COSMO vacuum COSMO
B3LYP-D3 0.6∗ 5.8∗ 0.3∗∗ 6.4∗∗
BHLYP-D3 -0.9∗ 4.7∗ -1.3∗∗ 5.3∗∗
MP2 -2.3∗ 2.3∗ -2.3∗∗ 3.1∗∗
CC2 -0.2∗ 4.2∗ -0.1∗∗ 5.1∗∗
SCS-MP2 -0.8∗ 3.7∗ -1.0∗∗ 4.3∗∗
SCS-CC2 0.8∗ 5.1∗ 0.8∗∗ 5.8∗∗
* Single point calculation of B3LYP-D3/def-TZVP optimized structures in vacuum. ** Single point
calculation of B3LYP-D3/def-TZVP optimized structures with COSMO.
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Table 10.2: Single point energy difference of SKTS1’s cis-hydroxypyridine in relation to SKTS1’s
pyridone single point energy obtained from B3LYP-D3/def-TZVP optimized structures in vacuum
and COSMO (=78,39). All calculations were performed with aug-cc-pVDZ basis sets. All energy
values are given in kcal/mol.
environment vacuum COSMO vacuum COSMO vacuum/ COSMO/
H2O H2O
B3LYP-D3 3.0∗ 3.1∗ 3.1∗∗ 3.3∗∗ 1.8 ∗∗∗ 2.4 ∗∗∗
BHLYP-D3 1.8∗ 2.0∗ 1.9∗∗ 2.3∗∗ 0.9 ∗∗∗ 1.7 ∗∗∗
MP2 -0.6∗ -0.9∗ -0.3∗∗ -0.6∗∗ -1.2 ∗∗∗ -1.0 ∗∗∗
CC2 1.3∗ 0.8∗ 1.7∗∗ 1.2∗∗ 0.5 ∗∗∗ 0.6 ∗∗∗
SCS-MP2 0.8∗ 0.5∗ 1.0∗∗ 0.7∗∗ 0.1 ∗∗∗ 0.4 ∗∗∗
SCS-CC2 2.3∗ 1.8∗ 2.6∗∗ 2.1∗∗ 1.5 ∗∗∗ 1.6 ∗∗∗
* Single point calculation of B3LYP-D3/def-TZVP optimized structures in vacuum. ** Single point
calculation of B3LYP-D3/def-TZVP optimized structures with COSMO. *** Single point calculation of
B3LYP-D3/def-TZVP optimized structures with COSMO including explicit solvent molecule.
Table 10.3: Single point energy difference of SKTS1’s trans-hydroxypyridine in relation to SKTS1’s
pyridone single point energy obtained from B3LYP-D3/def-TZVP optimized structures in vacuum
and COSMO (=78,39). All calculations were performed with aug-cc-pVDZ basis sets. All energy
values are presented in kcal/mol.
environment vacuum COSMO vacuum COSMO vacuum/ COSMO/
H2O H2O
B3LYP-D3 8.3∗ 4.4∗ 8.5∗∗ 4.6∗∗ 11.9 ∗∗∗ 4.6 ∗∗∗
BHLYP-D3 7.3∗ 3.3∗ 7.6∗∗ 3.6∗∗ 11.4 ∗∗∗ 3.9 ∗∗∗
MP2 4.7∗ 0.3∗ 5.2∗∗ 0.8∗∗ 9.1 ∗∗∗ 1.4 ∗∗∗
CC2 6.6∗ 2.2∗ 7.1∗∗ 2.6∗∗ 10.9 ∗∗∗ 3.2 ∗∗∗
SCS-MP2 6.1∗ 1.7∗ 6.5∗∗ 2.0∗∗ 9.9 ∗∗∗ 2.2 ∗∗∗
SCS-CC2 7.6∗ 3.1∗ 8.1∗∗ 3.4∗∗ 11.4 ∗∗∗ 3.7 ∗∗∗
* Single point calculation of B3LYP-D3/def-TZVP optimized structures in vacuum. ** Single point
calculation of B3LYP-D3/def-TZVP optimized structures with COSMO. *** Single point calculation of
B3LYP-D3/def-TZVP optimized structures with COSMO including explicit solvent molecule.
10.3 MD Simulation of SKTS1 in pyridone and hydrox-
ypyridine form in complex with FabI or InhA
As the interest lies on the tautomeric state of SKTS1 in FabI or InhA molecular dynamic
simulations have been performed. Aim of these simulations is to evaluate the difference in in-
191
10.3. MD SIMULATION OF SKTS1 IN PYRIDONE AND HYDROXYPYRIDINE
FORM IN COMPLEX WITH FABI OR INHA
teractions of the diphenylether inhibitor in each tautomeric form for both proteins compared
to the X-ray structure. If the mean RMSD value of the pyridone unit is lower than that of
the hydroxypyridine unit (or the other way around in case of InhA), one can assume that this
would go along with the interaction pattern obtained from the crystal structure. As the focus
was laid on the tautomeric forms, the RMSD of the pyridone or hydroxypyridone was solely
calculated to decrease the interference of the whole structure. Additionally, the variation of
distances during the MD simulation for interactions with the protein environment has been
investigated to underpin results from the RMSD analysis.
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Figure 10.6: RMSD plot of pydridone or hydroxypyridine unit with ether-oxygen of SKTS1
in complex with FabI or InhA during the 10 ns production run. SKTS1 in FabI shows a
mean of 1.47 A˚ (pyridone) or 2.71 A˚ (hydroxypyridine) whereas in InhA it has one of 2.05 A˚
(pyridone) or 1.32 A˚ (hydroxypyridine). Mean and standard devations are calculated from
10,000 data points.
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As in the section 5.1 the proteins FabI or InhA were described by the Amber14 force
field ff14SB while for SKTS1 (in its pyridone and hydroxypyridine form) and the respective
cofactors (NADP+ in FabI and NAD+ in InhA) the generalized AMBER force field (GAFF)
was employed. The preparation of the inhibitor-protein complex in terms of minimization
and gradual heating were done in the same manner as described in section 5.1. The duration
for each production run was 10 ns. Each tautomer of SKTS1 was simulated once in FabI or
InhA resulting in a total simulation time of 40 ns.
In case of FabI it is expected that SKTS1 shows the most stable interaction with the protein
environment in its pyridone form. In terms of the RMSD values obtained during the 10 ns
simulation time, one can see that the pyridone unit shows a mean of 1.47 A˚ while the hydrox-
ypyridine unit has a mean value of 2.71 A˚ (Figure 10.6) which is in line with experimental
findings. The difference in RMSD values is small if one looks at the distances between the
pyridone or hydroxypyridine ring and the surrounding amino acids.
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Figure 10.7: The variation in distance as a function of simulation time for SKTS1 in pyridone
(A) or hydroxypyridine form (B) in FabI during 10 ns production run.
As one can see in Figure 10.7 the pyridone form of SKTS1 shows distances to Ala97
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backbone NH of ≈ 2.5 A˚ or to Ala97’s carbonyl oxygen with a distances of about 2 A˚.
Occasionally one can observe an increase of distance to Ala97’s backbone carbonyl oxygen
up to 4.5 A˚ due to a water-mediated interaction and in consequence a decrease to Ala95 by a
rotation of the pyridone ring in the simulation time of ≈ 6 – 7.5 ns. Furthermore, a favorable
water-mediated interaction to Met99 can be observed which also weakens during the just
mentioned simulation time. Interestingly all these measured distances are in accordance to
the RMSD plot. An increase in RMSD value is in relation to a weakening of interactions
with Ala97 or Met99.
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Figure 10.8: Interactions of pyridone (left) and hydroxypyridine (right) of SKTS1 in FabI
depicted with dashed lines, corresponding to distance plots of Figure 10.7. Location of
amino acids and SKTS1 serves for clarification and does not reflect actual position in MD
simulations.
For the hydroxypyridone form SKTS1 shows quite the opposite behaviour. Interactions
between Ala97’s backbone carbonyl oxygen or to Met99 are only observable for a few hundreds
of picoseconds while the hydroxypyridine ring is mostly rotated and thus directed towards
Ala95. This kind of movement corresponds well to the increased RMSD values and therefore
a different orientation as in the crystal structure can be observed. Only the interaction of
SKTS1’s ether group and A98 backbone NH are comparable for both tautomeric forms.
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Contrary to the MD simulation of SKTS1 in FabI, the mean RMSD value of the hydrox-
ypyridine unit of SKTS1 in InhA is lower (1.32 A˚) than the calculated one for the pyridone
unit (2.05 A˚). This supports the assumption that a favorable binding of SKTS1 is enabled if
it is in the hydroxypyridine form. Especially, one can observe fewer fluctuations with respect
to the RMSD values compared to the pyridone tautomer of SKTS1 in FabI. This is under-
standable if one looks at the distance plots (Figure 10.7) of SKTS1 in InhA. As one can see
for the hydroxypyridine form the interaction with Met98’s backbone NH or carbonyl oxygen
is quite pronounced. No fluctutations and thus no reorientation of the hydroxypyridine unit
was observed during the 10 ns simulation time.
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Figure 10.9: Interactions of pyridone (left) and hydroxypyridine (right) of SKTS1 in InhA
depicted with dashed lines, corresponding to distance plots of Figure 10.10. Location of
amino acids and SKTS1 serves for clarification and does not reflect actual position in MD
simulations.
For the pyridone form in InhA one can observe a similar behavior to the hydroxypyridone
form in FabI. During ≈ 3.5 to 8 ns simulation time the distance to Gly96 decreases due to a
direct or water-mediated interaction which leads to a reorientation of the ring as observed for
SKTS1’s hydroxypyridine form in FabI to Ala97. This movement in distance also correlates
with its RMSD values, as it is visualized within the RMSD plots given in Figure 10.6. Ad-
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ditionally, the interaction of SKTS1’s ether oxygen with Met98’s backbone NH shows larger
fluctuations although the distance itself is closer during the time course of simulation.
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Figure 10.10: The variation in distance as a function of simulation time for SKTS1 in pyridone
(A) or hydroxypyridine form (B) in InhA during 10 ns production run.
As it is now clarified in which tautomeric form SKTS1 is present in the respective pro-
tein, the next question regarding the interaction to Glu100 (FabI) or Gln100 (InhA) has
been tackled. The distance plot of the MD simulation of SKTS1 in FabI (pyridone form)
shows distances of ≈ 9 A˚ leading to the assumption that no interaction to Glu100 is existing
(Figure 10.11 left). Furthermore, an increase of distance is observable up to 10 – 13 A˚ during
6-7 ns. On the other hand, SKTS1 in InhA (hydroxypyridine form) shows a water-mediated
interaction to Gln100 which is interrupted during 2-6 ns (Figure 10.11-A). Indeed, one can
assume that an interaction towards this amino acid is possible, although, one has to be aware
of its strength as the distance increases.
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Figure 10.11: The variation in distance as a function of simulation time for SKTS1 in pyridone
form and Glu100 in FabI (A) and for SKTS1 in hydroxypyridine form and Gln100 in InhA
(B), during 10 ns production run.
As mentioned in the previous section an analysis in regard of the conformation of hy-
droxypyridine in FabI or InhA has been performed. Aim of it was to figure out if the cis
or trans form is favored during the MD simulation. By measuring the dihedral of SKTS1
in its hydroxypyridine form during the MD simulation (red marked atoms in Figure 10.12)
one obtains a plot which shows that the diphenylether inhibitor in InhA is solely present as
cis-hydroxypyridine (dihedral of -10 to 40°) whereas rarely the trans-form (± 175°) can be
observed in FabI (see dihedral plot in Figure 10.12).
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A B
Figure 10.12: Dihedral plot of red marked atoms of SKTS1 in hydroxypyridine form in
complex with FabI or InhA during a 10 ns MD simulation. In case of FabI occasionally
dihedrals of ≈ ± 175° can be seen, leading to trans-hydroxylpyridine. Dihedrals in the range
of ± 50° result in the structure of cis-hydroxypyridine which mostly occur in FabI and solely
in InhA.
10.4 MD Simulation of SKTS1 derivatives in InhA
O
O
O
N
HN
NH2
Figure 10.13: Structure of SKTS1 derivative on the basis of a diphenylether scaffold by
substituting the pyridone-ring by a 2-aminoimidazol.
To extend the study in respect to diphenylether inhibitors the pyridone ring has been replaced
by a 2-aminoimidazole group (depicted in Figure 10.14). Based on the crystal structure of
the initial inhibitior in complex with InhA, SKT1 has been manually modified to obtain the
derivative. This structure has also been tested in InhA by MD simulations to investigate
its interaction with the protein environment and to make an assumption on its suitability
as possible inhibitor. If one compares the measured distance to Met98 backbone NH with
SKTS1, one can see that both structures show the same strength of interaction. Also, the
imidazole NH group of the derivative reveals the same interaction towards Met98 backbone
carbonyl-oxygen as the hydroxyl-group of SKTS1’s hydroxypyridine ring.
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Figure 10.14: The variation in distance as a function of simulation time for 2-aminoimidazol
derivative in InhA during 10 ns production run (A) and its corresponding interactions rep-
resented in dashed lines (B). Location of amino acids and 2-aminoimidazol derivative serves
for clarification and does not reflect actual position in MD simulations.
Furthermore, the hydrogens of the amino group of the derivative form an additional in-
teraction with Met98 backbone carbonyl-oxygen which appears occasionally water-mediated.
Due to the rotation of the amine one can observe a switch with respect to its hydrogens.
The observed increase in distance for one hydrogen results in a decrease of the other but still
maintaining a favorable interaction to the carboxyl group.
10.5 Conclusions
In this chapter the tautomeric state of the diphenyl ether inhibitor SKTS1 was investigated
which has been crystallized in the enoyl-acyl carrier proteins FabI of S. aureus and InhA
of Mycobacterium tuberculosis (Figure 10.2). The crystal structures indicate that SKTS1
is in a pyridone form in FabI while it is in a hydroxypyridine form in InhA (Figure 10.3).
Furthermore, interactions with Glu100 in FabI or Gln100 in InhA have been observed in the
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X-ray structure. Hence, this study verified their relevance in terms of the inhibitor’s binding.
Finally, a 2-aminoimidazole derivative of SKTS1 was investigated in InhA and its interaction
and stability in this protein was probed. The advantage of this derivative is the lack of tau-
tomerization and thus this structure might offer a similar or more favorable binding behavior
compared to SKTS1. In order to gain insight on these questions, QM calculations as well as
MD simulations have been applied.
Firstly, QM calculations of the simple pyridone or hydroxypyridine ring were found in line
with the literature that pyridone is more stable in polar solution while hydroxypyridine is
more stable in vacuum. Contrary to that, computations predict that the pyridone form of
SKTS1 is always lower in energy independent of the influence of the solvent. Still, one in-
teresting trend can be observed. Solvent effects decrease the stability of the pyridone form
of SKTS1 which is in contrast to the simple pyridone ring. Additionally, QM calculations
revealed a favorable state of SKTS1’s cis-hydroxypyridine compared to its trans-form which
was also confirmed by MD simulation.
In terms of the tautomerization of SKTS1 in FabI or InhA, MD simulations of both tau-
tomeric states in the respective protein have been conducted and results are in a good agree-
ment with the interaction pattern obtained from the crystal structure. The question related
to the most stable binding mode is underpinned by the findings in this study. In FabI the
RMSD values of the pyridone tautomer show indeed a smaller mean RMSD value compared
to the hydroxypyridine form. In the case of InhA the MD simulations also validate that
SKTS1’s hydroxypyridine form is related to be the best possible binding mode. Fluctuations
in terms of the RMSD value are relative to interactions to the protein environment and are in
accordance to the in- or decrease of distance to surrounding amino acids. Another conclusion
concerning SKTS1’s pyridone ring in FabI can be made. Due to its flexibility further inter-
actions by rotation occur and therefore lead to fluctuations of RMSD values in the course of
simulation time. This kind of behavior could not be observed for SKTS1 in InhA.
The expected interaction of SKTS1 to Glu100 in FabI could not be supported as the distance
between the amino acid and the inhibitor was too large to assume an interaction. Opposite
to this finding one can observe a water-based interaction between SKTS1 to Gln100 in InhA,
although, a weakening in interaction occurred during the course of simulation.
The MD simulation of the 2-aminoimidazol derivative show promising results in respect to its
interaction to the protein environment in InhA and are comparable to SKTS1 in its hydrox-
ypyridine form. Especially the additional interaction due the amino-group might strengthen
the interaction and therefore increase the duration of binding. Further theoretical investiga-
tions in terms of free binding energy or docking approaches and also inhibition experiments
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are of need to validate the MD simulations. Still, these findings are encouraging and might
offer an additional possibility for the development of an inhibitor for InhA which should be
further investigated.
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Chapter 11
The first steps in the development of
a covalent inhibitor for FadA5 - a
thiolase of mycobacterium tuberculose
11.1 Introduction
Tuberculosis (TB) exists for millenia and still represents a serious health problem which can
occur all over the world. It belongs to the top ten causes of death in a global context and is
the leading cause of death as an infectious agent for the past years [250]. Hence, the cases
of deaths are even higher compared to HIV/AIDS ( [251]. 6.3 millions of new cases of TB
have been reported for 2016 and thus represent 61% of the estimated 10.4 million. New cases
which occurred in 2016 are located in WHO South-East Asia region (45%), in WHO African
Region (25%) and in WHO Western Pacific Region (17%). A smaller amount can be found
in WHO Eastern Mediterranean Region (7%), in WHO European Region (3%) and in WHO
Region of the Americas (3%). Globally, new treatment outcome data reveal a success rate
off 83% [250]. In contrast to that, the 129.689 cases in which drug-resistant TB is involved
show on global scale a success rate of only 54%. The treatment of HIV-associated TB was
only in 78% successful (2015), while a significant smaller proportion of 30% showed a positive
outcome in treatment (2014) [250]. New forms of diagnostic, drugs and medication plans are
steadily developed, although, the process is a slow one.
Tb is an infectious disease which is caused by bacillus Mycobacterium tuberculosis. In most
cases one has to deal with pulmonary TB which attacks the lungs. The disease is spread by
e.g. coughing, whereby people who are infected with pulmonary TB distribute the airborne
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bacteria. If organs other than the lung are affected, e.g. lymph nodes, skin, abdomen, gen-
itourinary one refers to extra-pulmonary TB [252]. The development of TB disease occurs
only in 5-1 % of the estimated 1.7 billion people who are infected with M. tuberculosis. People
with diabetes who are infected with HIV or are affected by risk factors as alcohol, smoking
or under-nutrition show a higher probability to develop TB disease.
The distribution occurs by inhalation of aerosol bacteria and leads to the infection cycle
(Figure 11.1). The role of the bacteria’s metabolism and its influence to the host lipid is
not fully solved yet [253]. It is known that foamy macrophages which contain lipid droplets
are concentrated in infected mouse lungs and are also concentrated in lung granulomas of
infected humans [254], [255]. MTB is located close to lipid bodies in foamy macrophages and
the bacteria accumulate presumably also in the intracellular lipid bodies [256]. It is possible
that due to the high amount of cholesterol esters in foamy macrophages a binding to MTB
is caused [257], [258]. In case of mycobacterium leprae it is known that one can observe an
accumulation of cholesterol esters in infected macrophages [259].
Pandey et al. were able to show that MTB’s cholesterol metabolism was of necessity and a
disturbed cholesterol transport could hamper the virulence in the mouse model [260]. Dub-
nau et al. investigated genes which are over exprimed in human macrophages after infection
by MTB and identified FadA5 which is up-regulated [261]. This lipidmetabolizing thiolase
FadA5 is necessary to utilize cholesterol as carbon source and is ultimately responsible for
the virulence of MTB in chronic lung infections of mice [253]. FadA5 plays a role in the
β-oxidation of the cholesterol side chain and the thiolysis of acetoacetyl-coenzyme A (CoA)
and consequently is needed in the production of androesterones (Figure 11.2). Hence it is
suggested that the resulting products due to the metabolism of cholesterol in M. tuberculosis
cause the persistence [253].
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Figure 11.1: Infection and transmission of MTB adapted from [262]. I – The inhalation
of bacteria leads to the absorption by alveolar macrophages in the lung. II – MTB causes
proinflammatory reactions, which promotes the formation of macrophage-centric granuloma.
They show a range of heterogenous forms during the latent or chronic phase during the
infection in humans. III – Additionally, it is suggested that migration to the airways by
infected neutrophis or macrophages play an important role in distribution of the bacilli [262].
3-ketoacyl-CoA thiolases are degradative thiolases which catalyze the reaction of 3-ketoacyl-
CoA to a shortened acyl-CoA species and an acetyl-CoA [263], [264], [7]. This reaction was
proposed as a two-step “ping-pong” mechanism by Modies et al. and is depicted in Figure
11.3 [263], [265]. Thiolases contain a conserved active sites with a catalytic dyade which con-
sists a acid/base cysteine and a histidine [266]. Studies of Nesbitt et al. revealed that FadA5
is a degradative thiolase and were able to show the side chain degradation in cholesterol
[253].The degradation is the favored process but still the carbon-carbon cleavage is reversible
[267].
204
11.1. INTRODUCTION
HO HO
O
SCoA
O
HSCoA propionyl-CoA
HO
SCoA
O
FadA5
HO
O
SCoA
O
HO
O
acetyl-CoA
FadA5
HSCoA
O
O
OH
O
+
OH
O
HO
cholesterol 3,24-dioxo-cholest-4-ene-26-oyl-CoA 3-oxo-chol-4-ene-24-oyl-CoA
DOHNAA 3-oxo-pregn-4-ene-20-
carboxyl-CoA (3-OPC-CoA) 3,22-dioxo-chol-4-ene-24-oyl-CoA
HO
O
SCoA
2-hydroxyhexa-2,4-
dienoc acid androsta-4-ene-3,17-dione (AD)
Figure 11.2: C-C cleavage of ketothioester to propionyl-CoA (red) or acetyl-CoA (green) by
FadA5 (blue) into steroid products adapted from [253]. DOHNAA refers to 3-[(3aS,4S,7aS)-
7a-methyl-1,5-dioxo-2,3,3a,4,6,7-hexahydroinden-4-yl]propanoic acid.
Schaefer et al. showed that the production of 3-OPC-CoA and Ac-Coa by FadA5 is
promoted after addition of 3,22-dioxo-chol-4-ene-24-oyl-CoA [267]. Investigations revealed
that 3,22-dioxo-chol-4-ene-24-oyl-CoA is 400-fold more specific compared to AcAc-CoA which
is related to the steroid structure. Thus, a steroid-binding pocked was identified which leads
to the favorable result and might be a potential target. Still, the mechanism of steroid
binding remains unexplained. Two possibilities are discussed by Schaefer. On the one hand
steroid binding might occur along the CoA-binding site and the catalytic triade.
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Figure 11.3: Proposed thiolase reaction mechanism as degradation (A to D) or biosynthesis
(D to A) adapted from [265]. A – Proton abstraction of Cys93 and nucleophilic attack at
ß-ketoacyl-CoA. B – Formation of acyl-cysteine and acetyl-CoA. C – Exchange of acetyl-CoA
by CoA, which attacks acyl-CoA to obtain two-carbon shortened acyl-CoA and free Cys93.
If methyl group is at the α-carbon of ß-ketoacyl-CoA one obtains propionyl-CoA.
Otherwise a reorientation of the steroid binding loops might be conceivable. Nevertheless,
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these results indicate a possible novel target for the treatment of chronic TB. Topic of this
chapter is the development of a possible covalent inhibitor originating from a non-covalent
structure. Due to the crystallization of OPC and CoA in FadA5 by the group of Kisker
from the University of Wu¨rzburg the way was paved for computational investigations and
the design of possible novel inhibitors which will be explained in the following chapters.
11.2 General approach of designing a covalent inhibitor
The first consideration to design a new inhibitor is the active site which one wants to tar-
get. As mentioned in section 3.5.1 the covalent inhibition is an at least two-step mechanism.
First of all, the formation of a non-covalent complex is needed and therefore, one has to
find an appropriate binding-site. The postulated mechanism in terms of degradation starts
with the abstraction of a proton of Cys93 and its covalent attack with 3,22-dioxo-chol-4-ene-
24-oyl-CoA (Figure 11.3). Afterwards the proton of Cys377 is abstracted by the resulting
intermediate. The answer to address FadA5 non-covalently could be found in the first step of
the degradation reaction. First of all, a non-covalent binding site for the coenzyme A as well
as for the steroid is in FadA5 present [267]. Additionally, the catalytic dyade consisting of
Cys93 and His347 can be used for the covalent formation. This leads to the suggestion that
state A of the degradation might serve as starting point for covalent modification of FadA5
(Figure 11.3).
The next question is related to the topic of how to design the scaffold of this new inhibitor.
It is of necessity that it shows an adequate non-covalent binding to the active site as well as
an appropriate warhead for covalent modification. Three different possibilities can tackle this
problem. First of all, one can focus on the binding site of the coenzyme A (Figure 11.4-A).
CoA should able to enter and leave FadA5 rapidly to enable an efficient degradation (Figure
11.3-B/C). Hence, one can place the warhead at the coenzyme A’s thiol group, which is
directed to Cys93 (Figure 11.6-A). But drawbacks occur for this approach as the synthesis
of structures of scaffold A is too complex. Additionally, one has to consider the selectivity
of possible inhibitor candidate. CoA occurs in many biological reactions in human as in
the metabolism of fats or of carbon and proteins. This could lead to many unintended side
reactions. Another problem is the identification of an adequate docking procedure due to its
flexibility. These factors complicate the evaluation of the findings.
Scaffold B employs the steroid moiety to interact with the binding site. Schaefer et al.
were able to crystallize the non-covalent complex of the steroid OPC (3-oxo-preg-4-ene-20-
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carboxylic acid) and CoA in FadA5 (Figure 11.6-B). Therefore, this scaffold contains a steroid
(exemplary progesterone) with a warhead linked to C21 or C22. One advantage is the range
of steroids which are available for purchase. This facilitates experimental work by decreasing
the steps of synthesis. Due to the rigidity of the steroid, docking procedures are easier to
perform and therefore, it is easier to develop a re-docking and afterwards docking protocol.
To mimic the substrate 3,22-dioxo-chol-4-ene-24-oyl-CoA, which is involved in the first step
of degradation (Figure 11.3-A), scaffold C was devised. This scaffold contains the CoA part
as well as steroid structure and the di-keto group would be exchanged by the warhead. Nev-
ertheless, the synthesis of scaffold C is of increased complexity due to the CoA moiety and
the connection of the warhead in between.
Figure 11.4: Interaction of coenzyme A with the protein environment and crystal water
molecules of FadA5 in the X-ray structure.
Considering the aspects on experimental sides and also including the possibility of un-
wanted side effects of CoA, Scaffold B was pursued for further development of a covalent
inhibitor. One important assumption has been made while designing these scaffolds. It is of
importance that the abstraction of the proton of Cys93 by His347 occurs, to provide a re-
active thiolate. This enables the formation of a covalent bond with the electrophilic warhead.
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Figure 11.5: Interaction of OPC with the protein environment and crystal water molecules
of FadA5 in the X-ray structure.
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Figure 11.6: Scheme for general design of a covalent inhibitor for FadA5. A - Insertion of a
warhead on thiol of co-enzyme A (scaffold A). B - Insertion of a warhead on the D-ring of
a steroid, exemplary progesterone (scaffold B). C - Insertion of warhead in between steroid,
exemplary progesterone, and co-enzyme A (scaffold C).
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11.3 MD simulation of OPC and CoA in FadA5 variant
C93S and apoprotein
To investigate the stability of OPC and CoA in FadA5, MD simulations have been performed.
The pdb structure of mutant C93S of FadA5 in complex with OPC and CoA was used as
a starting point (pdb code 4UBT). The pdb file contained four chains of the mutant, while
chain D did not contain OPC. As no huge differences were seen in the active site, chain A
has been chosen for further simulations.
Figure 11.7: Comparision of monomers A (red), B (green) and C (yellow). Comparison
of active site residues Cys93, His347, Cys377 and OPC showed that there is no significant
difference in their position.
The ligand-protein complex has been prepared as described in section 5.1 as well the
applied protocol for minimization and gradual heating. The production run was performed
at 300 K without restraints and with duration of 5 ns.
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Figure 11.8: A – C93S variant of FadA5 in complex with OPC and CoA (complex I). B
– Apoprotein of FadA5 in complex with OPC and CoA (complex II). C – Apoprotein of
FadA5 in complex with OPC and in absence of CoA (complex III). D – Apopotein of FadA5
in complex with CoA and in absence of OPC (complex IV).
Four different simulations have been performed (Figure 11.8). First of all, the variant
C93S containing OPC and CoA have been simulated to serve as a reference system (complex
I). Afterwards Ser93 was changed to Cys93 to obtain the wild type. In this occasion the
system was simulated in presence of OPC and CoA (complex II), absence of CoA (complex
III) and absence of OPC (complex IV) to probe the effect of the co-enzyme on the steroid
(Figure 11.8). RMSD values of OPC and CoA show a complex dependence in their behavior
(Figure 11.9). For complex I the steroid show small fluctuations. The RMSD values of
the co-enzyme remain at 1.5 A˚ for 3 ns but increase to 2.5 A˚ due to the motion of the
3-phosphorylated adenosine part. The modification of the C93S variant to the wild type
(complex II) leads to fluctuations of CoA as in complex I. This time they are related to the
movement of the di-phosphate of CoA. One can observe an increase in mean for the calculated
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RMSD values from 1.76 A˚ to 2.15 A˚ whereas the standard deviation is comparable to complex
I (see Table 11.1). In case of the steroid the RMSD values show a lower calculated mean
while the standard deviation is equivalent for both complexes. In terms of the RMSD plot
of CoA in complex IV one can note that the value is about 1-2 A˚ for 4.5 ns and increases up
to 3 A˚ similar to complex I or II. For OPC in complex III (absence of CoA) one can observe
an increase of the mean RMSD value to 1.87 A˚ and its standard deviation. As the binding
pocket of the co-enzyme became unoccupied a motion of OPC was enabled. Still, one can
assume that the binding site of the steroid moiety ensures sufficient stabilization for OPC
and in consequence declines the necessity of CoA since the ligand remained in the binding
site. Hence, scaffold B might serve as possible draft for designing a covalent inhibitor. It is
of importance to mention that an additional assumption was made: Due to the need of the
release of Ac-CoA and the binding of CoA in the second to third step of degradation (Figure
11.3) this exchange has to occur frequently. The following investigations consider that CoA
is absent and the inhibitor binds at that time period. According to that guess the following
docking and MD simulation of scaffold B have been performed in absence of the coenzyme.
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Figure 11.9: A – RMSD values as a function of time for OPC in complex I (black curve),
complex II (red curve), complex III (blue curve). B - RMSD values as a function of time for
CoA in complex I (black curve), complex II (red curve), complex IV (blue curve).
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Table 11.1: Calculated mean and standard deviation of RMSD values for OPC and CoA during 5
ns production run correspond to Figure 11.9. All values in A˚.
system mean standard deviation
OPC in complex I 1.24 0.27
OPC in complex II 1.16 0.27
OPC in complex III 1.87 0.61
CoA in complex I 1.76 0.52
CoA in complex II 2.15 0.54
CoA in complex IV 1.60 0.45
11.4 Proposed synthesizable structures for docking
For scaffold B, a range of different structures are possible due to the variety of warheads and
steroids and its combination. The choice of warheads was limited to acrylamide, chloromethylke-
tone, cyanamide, carbamate and bromodihydroisoxazole (Figure 11.10). Progesterone, preg-
nenolone, prasterone and estrone which are comparable structures to OPC served as steroid
recognition unit (Figure 11.11). In all investigated inhibitors containing prasterone or es-
trone (except for the carbamat warhead) the steroid was also modified by exchanging the
hydroxyl group of the A-ring with a hydroxymethylether. To ensure the realization of these
structures, a synthesis plan was developed by the Holzgrabe group from the University of
Wu¨rzburg. Because of the combination of different warheads and steroids 36 synthesizable
inhibitors were suggested (Figure 11.12 - Figure 11.15).
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Figure 11.10: Different warheads as A – acrylamide, B – chloromethylketone, C – cyanamide,
D – carbamate or E – bromodihydroisoxazol connected to the steroids after synthesis.
If one takes a closer look at the structures, one can notice that solely the (3-methoxy)estrone
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or (3-methoxy)prasterone scaffold contains bromodihydroisoxazole (EstId, EstIId, PraId,
PraIId) as a warhead. This is due the circumstance that those molecules (except for EstIe)
were initially suggested and probed via docking simulations. Findings of these simulations
lead to development of further structures represented in Figure 11.14 and Figure 11.15. De-
tails on this matter will be discussed in Section 11.6.2.
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Figure 11.11: Different steroids as A – progesterone, B – pregnenolone, C – prasterone or
D – estrone which were used for scaffold B.
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Figure 11.12: A – Estrone steroid structure in combination with selected warheads connected
at the D-ring. B – 3-methoxy-estrone steroid structure in combination with selected warheads
linked to the D-Ring.
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Figure 11.13: A – Prasterone steroid structure in combination with selected warheads con-
nected to the D-ring. B – 3-methoxy-prasterone steroid skeleton in combination with selected
warheads linked to the D-ring.
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Figure 11.14: A – Pregnenolone steroid structure in combination with selected warheads
connected to the D-ring. B – 3-methoxy-prasterone steroid structure in combination with
selected warheads linked to the D-ring.
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Figure 11.15: Progesterone steroid structure in combination with selected warheads con-
nected to the D-ring (A), A-ring (B) or both (C).
11.5 QM calculation of the reaction energy of selected
warheads
The second step of inhibition is the formation of the covalent bond between warhead and
targeted amino acid. As mentioned before Cys93 appears to be appropiate for a nucleophilic
attack since it is involved in the reaction with 3,22-dioxo-chol-4-ene-24-oyl-CoA and is also
part of the catalytic dyade (Figure 11.3). Therefore, an evaluation of the suitability of the
selected warheads is needed. QM computations have been performed to estimate the reaction
energy employing the Turbomole V6.6 program package. DFT and wave function-based
methods have been compared with CCSD(T) to evaluate the best methodology describing
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(reaction)energy. For sake of completeness, environmental effects were included by using
implicit solvation models.
In a first step structures were optimized on B3LYP-D3 level and the basis set def-TZVP.
As a model for implicit solvation the COSMO approach was employed with an -value of 78
to mimic the molecules interaction within a water surrounding. The cysteine residue was
represented as methanethiol to save computational efforts. In case of chloromethylketone
and bromodihydroisoxazole, a methanethiolate was used. The warhead was exteneded by
a methyl group to obtain the same structure used for QM/MM calculations which will be
discussed later on.
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Figure 11.16: Calculated reaction of selected warheads as acrylamide (A), chloromethylke-
tone (B), cyanamide (C), bromodihydroisoxazole (D) and carbamate (E) with methanethiol
or methanethiolate.
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11.5.1 Benchmark calculation in vacuum
To calculate the reaction energy, DFT methods as B3LYP and BHLYP with Grimme’s dis-
persion correction or ab initio approaches as MP2, CC2 or its spin component scaled vari-
ations were used to obtain the relative energetic difference between reactants and products.
CCSD(T) was selected as benchmark reference since it represents the gold standard for ground
state closed shell systems. The application of aug-cc-pVDZ results, since negatively charged
atoms and molecules are involved in the reaction. As mentioned in a previous chapter, no
implementation of CCSD(T) in combination with the COSMO approach was available in
Turbomole V6.6. Hence, all energies had to be calculated in vacuum first, to obtain compa-
rable results to CCSD(T).
The difference in reaction energy is summerized for the investigated warheads in Table 11.2:
Bromodihydroisoxazole shows the highest reaction energy, followed by chloromethylketone.
The difference to acrylamide and cyanamide results due to the fact that both reactions lead
to an abstraction of a halogen and thus most likely to an irreversible inhibition (as a reattack
is unlikely). In case of acrylamide the reaction energy is about 5 kcal/mol lower compared
to chloromethylketone and might lead to an irreversible inhibition, too. The lowest reaction
energies of about -9 kcal/mol or -3 kcal/mol can be observed for cynamide and carbamate
warheads which are in the range of reversible covalent inhibition.
Table 11.2: Reaction energies obtained by QM calculation in vacuum. Aug-cc-pVDZ has been
used as basis set except for * marked method. In that case the def-TZVP basis set was employed.
All energies shown are in kcal/mol.
aug-cc-pVDZ// acrylamide chloro- cyanamide bromodi- carbamate
vacuum methyl- hydro-
ketone isoxazole
CCSD(T) -25.9 -31.4 -8.7 -44.6 -2.7
B3LYP-D3* -22.9 -30.7 -9.4 -46.0 -0.3
BHLYP-D3 -25.7 -32.7 -9.4 -48.9 -2.81
MP2 -28.4 -32.3 -8.51 -45.8 -4.0
CC2 -28.5 -32.3 -9.8 -45.8 -1.6
SCS-MP2 -25.91 -31.6 -4.7 -45.31 -2.5
SCS-CC2 -25.7 -31.51 -5.2 -45.21 -1.4
1Reaction energies with the lowest deviation compared to CCSD(T) calculated energies.
Table 11.3 shows the deviation of calculated reaction energies of the selected warheads.
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Table 11.3: Absolute deviation of reaction energies compared to CCSD(T) energies. Aug-cc-pVDZ
was used as basis set except for * marked methods which employed the def-TZVP basis set. All
deviations shown are in kcal/mol.
deviation acrylamide chloro- cyanamide bromodi- carbamate MAE
methyl- hydro-
ketone isoxazole
B3LYP-D3* 3.02 0.7 0.7 1.4 2.4 1.6
BHLYP-D3 0.2 1.3 0.6 4.22 0,1 1.3
MP2 2.5 0.9 0.21 1.1 1,3 1.2
CC2 2.6 0.9 1.1 1.2 1,2 1.4
SCS-MP2 0.01 0.2 4.02 0.61 0,2 1.0
SCS-CC2 0.2 0.11 3.52 0.61 1,4 1.2
1 Lowest deviation compared to CCSD(T) calculated reaction energies. 2 Deviations which are above 3
kcal/mol compared to CCSD(T) calculated reaction energies.
For acrylamide, chloromethylketone and bromodihydroisoxazole, best results were obtained
by employing the spin-component scaled post-HF methods. DFT methods mostly perform
with a comparable accuracy as MP2 or CC2 except for BHLYP which show similar results as
SCS-CC2 for acrylamide or even better ones for carbamate. Worst results were obtained in
case of B3LYP for acrylamide and BHLYP for bromodihydroisoxazole as they show deviations
of 3.0 and 4.2 kcal/mol. Solely the computed reaction energies of cyanamide are different.
DFT methods outperform SCS-MP2 and SCS-CC2 as deviation of 3.5 and 4.0 kcal/mol
occur. Also CC2 is slightly worse than utilized DFT methods resulting in a deviation of 1.1
kcal/mol. The best result can be achieved by computing the reaction energies with MP2.
In case of the MAE (mean averaged error) MP2 and SCS-MP2 or SCS-CC2 perform best,
although CC2 and applied DFT methods show reasonable results, too (except for above
mentioned occurences).
11.5.2 Influence of the environment on reaction energies
After determining the best method for each warhead in vacuum, the COSMO approach
(=78) has been applied to evaluate environmental influences regarding the reaction en-
ergy. One can observe that the utilization of implicit solvation decreases the reaction energy
of bromodihydroisoxazole slightly by 1 kcal/mol (Table 11.4). In case of acrylamide and
cyanamide an upshift between 1.3 and 1.6 kcal/mol or 2.7 and 3.3 kcal/mol occurs in terms
of the reaction energy. For carbamate it ranges at the same level (-2.8 to -3.2 kcal/mol). The
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highest impact can be seen for chloromethylketone after including environmental effects. By
employing the COSMO approach, the reaction energy decreases by about 6 kcal/mol. This
difference between bromodihydroisoxazle and chloromethylketone is interesting because one
would suggest that both of them would show the same trend.
Table 11.4: Reaction energies obtained by QM calculation in COSMO. Aug-cc-pVDZ has been used
as basis set except for * marked method which employed the def-TZVP basis set was employed. All
energies shown are in kcal/mol.
aug-cc-pVDZ// acrylamide chloro- cyanamide bromodi- carbamate
COSMO methyl- hydro-
ketone isoxazole
B3LYP-D3* -21.6 -36.9 -6.2 -46.6 -5.9
BHLYP-D3 -24.2 -38.8 -6.1 -49.4 -3.61
MP2 -27.0 -38.8 -5.81 -46.3 -5.7
CC2 -27.2 -38.8 -7.0 -46.4 -6.8
SCS-MP2 -24.51 -38.0 -2.0 -45.71 -4.51
SCS-CC2 -24.4 -37.91 -2.5 -45.81 -5.3
1Reaction energies with the lowest deviation compared to CCSD(T) calculated energies.
Table 11.5: Absolute deviation of reaction energies compared to vacuum energies. Aug-cc-pVDZ
has been used as basis set except for * marked method. In that case the def-TZVP basis set was
employed. All deviations shown are in kcal/mol.
deviation acrylamide chloro- cyanamide bromodi- carbamate
vaccum methyl- hydro-
ketone isoxazole
B3LYP-D3* 1.3 -6.2 3.2 -0.9 -3.1
BHLYP-D3 1.5 -6.1 3.3 -0.8 -3.2
MP2 1.4 -6.5 2.7 -1.1 -2.9
CC2 1.3 -6.5 2.8 -1.2 -2.8
SCS-MP2 1.4 -6.4 2.7 -1.0 -2.9
SCS-CC2 1.3 -6.4 2.7 -1.1 -2.8
Therefore, one can take a closer look on each structure and their energies. Table 11.6
shows the differences in energy obtained in vacuum or COSMO of each structure for the
reaction of chloromethylketone with methanethiol. Especially the last two rows are of in-
terest. They show the difference between the deviation of vacuum and COSMO energy in
220
11.5. QM CALCULATION OF THE REACTION ENERGY OF SELECTED
WARHEADS
products and educts for neutral or charged molecules (and atoms). In case of the neutral
structures (educt and product of chloromethylketone) difference in deviation are of about 2
kcal/mol. The most significant differences occur for negatively charged atoms or molecules
of the reaction. Especially chlorine’s absolute energy is about 5 kcal/mol lower compared to
methanethiolate if solvent effects are included. This might by reasoned due to the stabiliza-
tion of its negative charge. This downshift of energy leads to an increased reaction energy of
chloromethylketone if COSMO is applied.
Table 11.6: Absolute deviation of each structure calculated with COSMO compared to vacuum
energy. Differences between deviations of neutral structures (educt = chloromethylketone and
product) and negatively charged atoms/molecules (Cl− and CH3S−) are shown. Aug-cc-pVDZ has
been used as basis set. All energies shown are in kcal/mol.
method educt CH3S− product Cl− reaction ∆(educt/ ∆(Cl-/
energy product) CH3S−)
B3LYP 9.2 66.1 10.9 70.7 6.2 1.7 4.5
BHLYP 9.8 67.3 11.5 71.7 6.1 1.7 4.4
MP2 8.8 66.7 10.5 71.4 6.5 1.7 4.7
CC2 8.6 66.5 10.3 71.3 6.5 1.7 4.8
SCS-MP2 8.8 66.7 10.5 71.4 6.4 1.7 4.7
SCS-CC2 8.7 66.6 10.3 71.3 6.4 1.7 4.7
The same analysis was conducted for bromodihydroisoxazole and the computed energies
in vacuum and in COSMO were compared (Table 11.7). In this occasion neutral molecules
involved in the reaction show similar deviations as for chloromethylketone. In contrast bro-
mide and methanethiol show the same deviation after applying implicit solvation. Hence, the
decrease in reaction energy is explained due to the influence of the neutral molecules. The
stabilization of the negatively charged bromide is therefore about the same as methanethiol
which does not result to a significant influence of the reaction energy.
221
11.6. DOCKING PROCEDURE OF DIFFERENT INHIBITORS OF TYPE SCAFFOLD
B
Table 11.7: Absolute deviation of each structure calculated with COSMO compared to vacuum
energy. Differences between deviations of neutral structures (educt = bromodihydroisoxazole and
product) and negatively charged atoms/molecules (Br- and CH3S-) are shown. Aug-cc-pVDZ has
been used as basis set. All energies shown are in kcal/mol.
method educt CH3S- product Br- reaction ∆(educt/ ∆(Br−/
energy product) CH3S−)
B3LYP 10.9 66.1 12.0 65.9 0.9 1.1 0.2
BHLYP 11.5 67.3 12.8 66.8 0.8 1.3 0.5
MP2 10.4 66.7 11.5 66.6 1.1 1.1 0.1
CC2 10.2 66.5 11.3 66.6 1.2 1.1 0.1
SCS-MP2 10.4 66.7 11.5 66.7 1.0 1.1 0.1
SCS-CC2 10.3 66.6 11.4 66.6 1.1 1.1 0.0
11.6 Docking procedure of different inhibitors of type
scaffold B
11.6.1 Redocking of OPC in C93S variant of FadA5
To evaluate the suitability of the suggested inhibitors, docking approaches have been em-
ployed. In the beginning it is of importance to perform a re-docking of OPC to verify
docking parameters which therefore can be used for the proposed ligands. In consequence,
OPC was removed from the protein ligand complex and was re-docked to the FadA5 C93S
variant. Afterwards, the differences in structure regarding the X-ray structure of OPC were
quantified by calculating the RMSD. If many poses with a low RMSD value are obtained in
the docking, one can assume that used parameters are applicable for the structures of the
type scaffold B. Furthermore, the ranking of the poses was rescored for additional refinement
of the docking results.
The docking procedure was carried out in cooperation with the Sotriffer group, University
of Wu¨rzburg, by employing the program package GOLDv5.2.2. First of all, the protein was
prepared in the following manner: The ligand, co-factor and crystal water were removed
except for two water molecules close to Cys93 and Cys377 since they show interactions with
OPC and the mentioned amino acids (Figure 11.5). As the protein was used from the X-ray
structure, no hydrogen atoms were available. Hence, hydrogens were assigned by utilizing
the MOE software package at a pH of 6.7 at which the C93S variant was crystallized. Addi-
tionally, His347 was protonated at the delta position as this is needed for the proton transfer
depicted in Figure 11.3. The ligand was prepared independently by the MOE software pack-
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age. Hydrogens were also assigned at a pH of 6.7 resulting to a deprotonated carbon acid
which is understandable as its calculated pKa-value is about 4.6 obtained from the Chem-
draw software package. After minimization with a convergence criterion of 0.05 kcal/mol,
the ligand was used for docking. The co-factor A was not considered, as the focus of interest
lies at the scaffold B which is expected to react in absence of CoA. The number of GA runs
was set to 50 to obtain a sufficient number of poses. Additionally, GA settings have been set
to very flexible which increases the computational time but might also increase the quality
of the docking results. In case of the algorithm default settings for the parameters of GOLD
have been employed. To avoid bias of the results no constraints have been applied. One
important aspect has been varied: the specification of the approximate radius r of the bind-
ing site. First of all, a certain atom has to be selected as center of the active site. Because
Cys93’s sulfur atom is the center of proposed reaction it was chosen. Three different r-values
have been used: 10, 20 and 30 A˚. To evaluate the docked structures, the CHEMPLP fitness
function was applied as it is recommended by the GOLD developer. Afterwards the best
ten poses ranked by CHEMPLP have been rescored by DSX with CSD pair-potential by the
python script of Dr. Michael Hein and Maximilian Kuhn. Another important thing is to men-
tion: As shown in section 11.3, MD simulations revealed that OPC remained in the active site
even in absence of the cofactor. For this reason, CoA was not included in the docking process.
As one can see in Table 11.8, a r-value of 10 A˚ results in only two poses (in the top ten)
which show a RMSD value below 0.7 A˚. Especially the CHEMPLP scoring function does not
give the right order of ranking. The second structure was ranked as worst pose although it
has a RMSD value of 0.62 A˚. In this case the DSX scoring leads to the right order of ranking.
The best results were obtained by utilizing a r-value of 20 A˚. All poses show a RMSD value
below 0.70 A˚. In terms of order, the DSX scoring moves the poses with a RMSD value of 0.55
and 0.31 A˚ to the second and third place which are ranked as worst regarding the CHEMPLP
scoring. In case of r = 30 A˚ resulting poses are comparable to findings which employed a
r-value of 10 A˚. Only two poses show a RMSD value below 0.8 A˚. Concerning rescoring,
DSX show worse results than CHEMPLP. As CHEMPLP correctly rank the poses with a
low RMSD value to the first places DSX solely scores the one with the RMSD value of 0.50
A˚ well. The second structure with a RMSD value of 0.78 A˚ is ranked in fourth place. The
results of the re-docking show indeed that it is possible to obtain reliable poses by applying
a r-value of 20 A˚. In conclusion those parameters can be used for the docking of the selected
inhibitor.
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Table 11.8: Docking results of OPC in FadA5 C93S variant by varying r to 10 A˚, 20 A˚ and 30
A˚. The poses were scored by CHEMPLP and rescored by DSX. Order of poses on the basis of the
DSX ranking. Negative DSX values are shown for clarity. RMSD values are calculated in relation
to X-ray structure of OPC in FadA5 C93S variant. All RMSD values are given in A˚.
r = 10 A˚ r = 20 A˚
Ranking RMSD -DSX CHEMPLP RMSD -DSX CHEMPLP
1 0.65 94.423 60.42 0.64 99.487 64.49
2 0.62 93.076 59.1 0.55 99.303 64.23
3 7.53 84.868 59.11 0.31 99.093 63.9
4 7.53 82.27 59.82 0.64 97.403 65.18
5 7.52 81.664 60.05 0.70 97.257 64.81
6 7.55 80.589 59.49 0.60 96.932 64.55
7 7.54 79.191 60.02 0.69 96.874 64.96
8 7.54 78.335 59.93 0.62 95.926 65.34
9 7.53 77.418 59.93 0.64 95.906 64.94
10 7.55 76.985 59.76 0.70 93.546 64.78
r = 30 A˚
Ranking RMSD -DSX CHEMPLP
1 0.50 94.896 62.05
2 7.48 94.476 59.7
3 7.48 94.258 59.62
4 0.78 94.068 62.26
5 7.47 94.027 59.57
6 7.50 92.954 59.59
7 7.49 92.06 59.59
8 7.50 91.429 59.67
9 7.49 91.102 59.59
10 7.10 72.159 61.21
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Figure 11.17: Top ten docked poses of OPC in FadA5 in absence of CoA by applying a r
value of 20 A˚. OPC structure of X-ray is orange colored in comparison to docked structures
for clarity.
11.6.2 Docking of possible inhibitors of type scaffold B
After establishing a reliable docking procedure which performs well in redocking OPC in
FadA5 C93S variant, this docking protocol was employed on the inhibitors of type scaffold B
(Figure 11.12 to Figure 11.15). Just like in the re-docking, CoA was not considered and the
docking was solely performed for the inhibitors. As the focus was laid on the apoprotein’s
modification, the active site contained a protonated Cys93 and doubly protonated His347.
The first suggested structures were built on an estrone or prasterone scaffold and furthermore,
also included a bromodihydroisoxazole as a warhead (Figure 11.12 and Figure 11.13). This
time the RMSD value was not of interest as different steroid scaffolds were used. Instead, the
investigation focused on the distance between the nucleophilic sulfur and the electrophilic
warhead of the respective structure. This is quite obvious as the formation of a covalent
bond is dependent on the distance. Therefore, the scope lies on the identification of possible
ligands whose warheads are close to Cys93’s sulfur (< 4 A˚). These structures were further
probed via MD simulations. Solely the best results are presented in Table 11.9 and Table
11.10, other results will be discussed in the following.
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The docking simulations of prasterone revealed that this scaffold is unable to modify FadA5’s
active site. In terms of distance, these ligands (Pra-Ia to Pra-Id) showed distances of 13 to
15 A˚ due to a “flipped” steroid scaffold compared to OPC (exemplary shown for Est-1d in
Figure 11.18-C). Also the modification of the hydroxyl-group (structures from type Pra-IIX)
show distances in the same range. By exchanging the steroid scaffold to estrone one obtains
different poses, comparable to OPC in the X-ray structure. As one can see in Table 11.9,
Est-Ia has solely one pose which has an appropriate distance of 4.0 A˚, while the other poses
also show the behavior of a “flipped” steroid scaffold (Figure 11.18-C). Still, in terms of DSX
and PLP ranking it was scored better than poses from rank 2 – 10. Hence, it was considered
for MD simulations. The docking Est-Ib resulted in solely one pose with an adequate distance
of 3.4 A˚. Interestingly, PLP ranking predicts that pose as the best one whereas DSX delivers
the opposite result. To gain further insight, MD simulations of this pose were conducted.
The modification of estrone (Est-IIb) lead to solely two flipped orientations. Although one
obtains eight poses with the right directionality towards the catalytic center, the distance
ranges from 4.8 to 6.9 A˚. Because of these docking results Est-IIb was not considered for MD
simulations.
226
11.6. DOCKING PROCEDURE OF DIFFERENT INHIBITORS OF TYPE SCAFFOLD
B
A B
C
Figure 11.18: A – The crystal structure of OPC in FadA5. B – Docked structure of Est-Ia
in FadA5. C – Docked structure of Est-1d in FadA5.
In case of ligands employing bromodihydroisoxazole as warhead, docking simulations re-
vealed that in almost all cases the warhead was directed opposite to the catalytic center, i.e
it showed a “flipped” steroid scaffold compared to OPC leading to distances of ≈ 14 A˚. If one
compares the size of bromohydroisoxazole to acrylamide or chloromethylketone, the warhead
appears to be too large to fit into the binding pocket. In consequence, it was excluded as
warhead in the following design of possible inhibitors.
Prasterone as steroid scaffold is in combination with the selected warheads unsuitable to
obtain acceptable docking results. Therefore, pregnenolone and progesterone were included
as steroid structures. In case of progesterone the warhead could be linked to the A- and D-
ring (or at both locations) and thus lead to structures depicted in Figure 11.15. The design
of structures Pro-IIIa to Pro-IIId was pursued to overcome the flipped pose of the warhead
observed by the previous docking studies. At least one warhead should be directed to the ac-
tive site if they are linked at both positions (“sandwich-structures”). Bromodihydroisoxazole
was neglected as possible warhead for pregnenolone and progesterone, for above mentioned
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Table 11.9: Docking results of Est-Ia, Est-Ib and Est-Ic in FadA5 apoprotein. The poses were
scored by CHEMPLP and rescored by DSX. Order of poses on the basis of DSX ranking. Negative
DSX values are shown for clarity. Distance was measured between electrophilic carbon center of
warhead and Cys93 sulfur. The distance is given in A˚.
Est-Ia Est-Ib
Ranking distance -DSX PLP distance -DSX PLP
1 4.0 96.55 65.03 14.6 94.63 62.21
2 12.3 93.52 61.01 14.6 94.46 62.17
3 12.3 93.22 60.98 14.6 94.21 62.23
4 12.3 93.17 60.87 14.6 93.36 62.32
5 12.3 92.96 60.88 14.5 93.17 62.16
6 12.3 92.89 61.12 14.7 92.79 62.13
7 12.4 92.88 60.88 14.6 92.53 62.35
8 12.4 92.21 61.00 14.6 92.33 62.20
9 12.4 91.68 60.78 14.6 91.57 62.16
10 12.4 89.55 60.79 3.4 76.72 64.01
Est-Ic
Ranking distance -DSX PLP
1 3.4 102.77 60.00
2 3.7 102.44 59.80
3 13.6 85.87 59.56
4 13.5 85.79 59.53
5 13.6 85.52 59.53
6 13.6 85.34 59.54
7 13.6 85.20 59.54
8 13.6 84.38 59.71
9 13.6 84.23 59.44
10 3.4 82.56 59.97
reasons. Distances obtained by the docking simulation of inhibitor Est-Ie are larger than 5 A˚.
In all poses it is directed towards the active site but because of the size of the nitrobenzene it
could not approach the cysteine closer. Structures containing a pregnenolone (Figure 11.14)
showed the same behavior as ligands based on the prasterone scaffold. All docked inhibitors
pointed towards the solvent and revealed distances above 14 A˚.
Inhibitors composed of pregnenolone resulted in different findings. Distances of Pro-Ia and
also Pro-IIa were > 15 A˚ due to flipped poses. If both rings are modified (Pro-IIIa), one
obtains nine poses of chloromethylketone linked to the A ring directed to the active site with
a distance of ≈ 7 A˚. In reverse, the distance of the warhead located at the D ring was > 14
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Table 11.10: Docking results of Est-IIa and Est-IIc in FadA5 apoprotein. The poses were scored
by CHEMPLP and rescored by DSX. Order of poses on the basis of DSX ranking. Negative DSX
values are shown for clarity. Distance was measured between electrophilic carbon center of warhead
and Cys93 sulfur. The distance is given in A˚
Est-IIa Est-IIc
Ranking distance -DSX PLP distance -DSX PLP
1 4.0 97.79 64.47 3.5 109.61 58.38
2 4.0 97.54 65.3 16.6 94.10 58.51
3 4.1 96.84 64.79 3.6 93.58 58.19
4 6.2 96.66 63.80 3.6 92.89 58.28
5 4.0 96.29 64.82 16.6 92.72 58.40
6 4.1 95.77 64.55 7.0 91.43 58.93
7 3.9 95.75 65.28 6.9 90.57 58.62
8 6.2 95.72 63.72 6.8 90.18 58.57
9 3.8 95.62 65.50 7.1 88.25 59.59
10 3.3 80.76 65.85 7.0 87.37 58.96
A˚. Although the distance for covalent modification is insufficient, one still can see that the
concept of “sandwich-structures” result in the right positioning. These conclusions can also
be drawn for the other structures. Docked ligands with cyanamide attached to the D-ring
(Pro-Ib to Pro-IIIb) show solely one pose directed to the active site with a distance of 6 A˚.
Pro-IIIb has seven poses directed to the binding pocket with distance of about 8 A˚. This
can also be observed for Pro-Ic to Pro-IIIc. Only two poses of the singly modified rings are
directed towards the active site with a distance of 6 to 7 A˚.
A slightly different observation was obtained for the structures combining the pregnenolone
scaffold and the carbamate. For Pro-Ia the best four poses show distances of about 5 A˚,
for Pro-IIa all of the best ten poses show distances of 7 A˚. Docked carbamate structures
with a singly modified ring are positioned in the right orientation. In contrast to the other
“sandwich-structures”, Pro-IIId shows eight poses where the carbamate at the D-ring is
placed right. Still these distances are inadequate for covalent modification (5.5 – 7.5 A˚).
Nevertheless, some conclusions can be drawn by comapring the investigated structures. Pras-
terone and pregnenolone are not suitable as a steroid scaffold as all docked poses showed
“flipped” orientations of the warheads. Although the idea of a “sandwich-ligand” overcomes
this problem, the distances for covalent modification were too large. Therefore, structures in
Table 11.9 and Table 11.10 were used for further MD simulations.
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11.7 MD simulations of docked structures of type scaf-
fold B
The docking studies resulted in five structures with poses in which the warhead is directed
towards the active site and also shows an appropriate distance (< 4 A˚) for covalent modifica-
tion. Still one important question needs to be answered: Can these distances be maintained
during a certain amount of time? This question is of importance because the longer a close
distance can be maintained the likelier a covalent modification occurs. To shed light in this
matter and also to verify the docking results MD simulations have been performed and dis-
tances according to Figure 11.19 have been measured.
In contrast to the simulations described in section 11.3, the system was prepared in absence
of the coenzyme and furthermore two different protonation states were considered (Figure
11.19). As depcited in Figure 11.3, the mechanism starts with the abstraction of the proton
from Cys93 to His347. Subsquently, one has the neutral state at the beginning, where Cys93
still harbors the proton (protonation state A) and the zwitterionic state in which His347 is
doubly protonated and Cys93 is negatively charged (protonation state B). Hence, the influ-
ence of the protonation state regarding the distance of the warhead to Cys93 was of interest.
The conducted MD simulations are analog to the simulations of OPC in FadA5 regarding
parameterization, minimizing, heating and production runs. To probe the reproducibility,
the MD simulations have been executed from the same starting point thrice for each pro-
tonation state with duration of 5 ns leading to a total simulation time of 150 ns for the ligands.
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Figure 11.19: Distance between electrophilic carbon of warhead and nucleophilic sulfur of
Cys93 depicted with dashed lines in (A) neutral protonation state of Cys93/His347 dyad
or (B) in zwitterionic state. Location of warhead and amino acids serves for clarification
and does not reflect actual position in docking or MD simulations. R corresponds to steroid
scaffold as shown in Figure 11.12.
Table 11.11: Mean and standard deviation of distances between electrophilic carbon of ligand and
nucleophilic sulfur of Cys93 during a 5 ns production run corresponding to Figure 11.20 - Figure
11.24. MD runs marked with * correspond to protonation state A, MD runs marked with ** to
protonation state B. All values are given in A˚.
Est-Ia Est-Ib Est-Ic Est-IIa Est-IIc
MD run 1* mean / SD 4.2 / 0.5 4.3 / 0.5 5.6 / 1.9 4.2 / 0.5 5.9 / 1.0
MD run 2* mean / SD 3.7 / 0.4 5.6 / 1.3 4.8 / 0.7 5.1 / 0.6 5.0 / 0.6
MD run 3* mean / SD 3.9 / 0.4 6.7 / 1.2 4.8 / 0.7 4.3 / 0.5 6.1 / 1.3
MD run 1** mean / SD 5.3 / 2.3 5.2 / 1.3 5.7 / 0.7 6.1 / 2.5 5.9 / 1.2
MD run 2** mean / SD 4.0 / 0 .7 8.4 / 2.1 5.7 / 1.1 4.3 / 0.8 6.0 / 1.3
MD run 3** mean / SD 4.0 / 0.5 4.4 / 0.6 8.6 / 2.2 4.6 / 0.9 6.0 / 0.9
MD 1 – 3* mean 3.9 5.5 5.1 4.5 5.7
MD 1 – 3** mean 4.4 6.0 6.7 5.0 6.0
The best results were obtained for Est-Ia. In terms of the protonation state A, every
MD simulation showed a mean of distance of 3.9 A˚. By considering the zwitterionic state
one obtains a larger mean value of 4.4 A˚. This is caused by the first MD simulation in pro-
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tonation state B as an increase in distance occurs to 10 A˚ after 4 ns. Consequently, the
mean increases for simulation in this protonation state (Figure 11.20-B). Contrary to this
simulation, the second and third production run show a mean of 4.0 A˚, a sufficient distance
for covalent modification. As this distance is maintained for all simulations during the time
course, a small standard deviation in the range of 0.4 to 0.7 A˚ is obtained (except for the first
MD run in protonation state B). Thus, one can expect a nucleophilic attack by Cys93’s sulfur.
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Figure 11.20: The variation in distance as a function of simulation time for inhibitor Est-
Ia corresponding to Figure 11.19 during three 5 ns production runs. A – Simulation of
docked structure Est-Ia in protonation state A. B – Simulation of docked structure Est-Ia in
protonation state B.
This is not the case for the remaining structures. Although the first MD run of Est-Ib
in the neutral state showed a mean in distance of 4.3 A˚ (due to a fluctuation at 3 ns), this
observation could not be reproduced for the second and also third simulation, leading to a
mean of 5.5 A˚ for all three simulations. Regarding the zwitterionic state, the mean of all
three simulations increases to 6.0 A˚ especially due to the rise in distance to 10 A˚ in the
second MD simulation (Figure 11.21). Comparable results were obtained for Est-Ic. The
calculated mean of distance in the neutral state amounts 5.1 A˚ and even a sperate analysis
of the simulations, values ranges from 4.8 to 5.6 A˚. In consequence, a nucleophilic attack is
unlikely. One might argue that there are certain periods of time in which a reaction can occur
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but from a statistical point of view this occurrence is less likely compared to Est-Ia. The same
conclusion can be made for Est-IIa. In the first and third MD simulation of protonation state
A the distance of about 4.0 A˚ can be maintained for a certain amount of time, still the mean
of these simulations are 4.2 or 4.3 A˚. The trend in the zwitterionic state is just like before.
The mean of simulations in the zwitterionic state are slightly higher compared to state A
resulting in a mean of 5.0 A˚. The only difference to Est-Ia is the exchanged hydroxylgroup
of the estrone. This modification leads to a slight reorientation of the steroid due to lipohilic
interactions to Ile139 which occasionally occur and therefore worsen the results. The analysis
of Est-IIc affirms that this inhibitor is also not suitable for covalent modification by Cys93’s
sulfur. Both mean distances of protonation state A and B are too large that one cannot
expect a nucleophilic attack (Figure 11.24).
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Figure 11.21: The variation in distance as a function of simulation time for inhibitor Est-
Ib corresponding to Figure 11.19 during three 5 ns production runs. A – Simulation of
docked structure Est-Ib in protonation state A. B – Simulation of docked structure Est-Ib
in protonation state B.
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Figure 11.22: The variation in distance as a function of simulation time for inhibitor Est-
Ic corresponding to Figure 11.19 during three 5 ns production runs. A – Simulation of
docked structure Est-Ic in protonation state A. B – Simulation of docked structure Est-Ic in
protonation state B.
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Figure 11.23: The variation in distance as a function of simulation time for inhibitor Est-
IIa corresponding to Figure 11.19 during three 5 ns production runs. A – Simulation of
docked structure Est-IIa in protonation state A. B – Simulation of docked structure Est-IIa
in protonation state B.
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Figure 11.24: The variation in distance as a function of simulation time for inhibitor Est-
IIc corresponding to Figure 11.19 during three 5 ns production runs. A – Simulation of
docked structure Est-IIb in protonation state A. B – Simulation of docked structure Est-IIc
in protonation state B.
11.8 Estimation of reaction energy and barrier
The results of docking and MD simulations lead to the assumption that solely Est-Ia appears
to be a suitable candidate for inhibition. Still, the question of the reaction energy and
barrier has to be considered. In case of the QM calculations only reaction energies of the
warheads were calculated. To account the influence of the steroid further QM calculations in
solution have been performed. Additionally, the reaction energy of Est-Ia was estimated by
nudged-elastic band (NEB) calculations employing the CAST program package. To accelerate
calculations a semi-empirical approach was utilizied and also benchmarked beforehand. In a
last step a relaxed scan on QM/MM level was conducted to investigate the influence of the
protein environment with respect to the reaction barrier and energy of Est-Ia. Also Est-Ic
was included in the investigations which will be discussed in the following.
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11.8.1 Benchmark – Influence of steroid skeleton
The warheads were extended by estrone since Est-Ia showed the best results regarding docking
and MD simulations. For reasons of comparability to the previous calculations, all warheads
including estrone were tested (Figure 11.25). Those structures were optimized on B3LYP-D3
level using the def-TZVP basis set. As before the COSMO approach with a dielectric value
of 78 was employed. Afterwards single point calculations have been carried out. The results
of the reaction energies are presented in Table 11.12.
Table 11.12: Reaction energies obtained by QM calculation in COSMO. Energies marked with
* are energies obtained with the best methodology compared to the CCSD(T). Aug-cc-pVDZ has
been used as basis set. All values are given in kcal/mol.
aug-cc-pVDZ// Est-Ia Est-Ib Est-Ic Est-Id Est-Ie
COSMO
B3LYP-D3 -37.2 -5.1 -20.2 -47.1 -5.3
BHLYP-D3 -39.0 -4.9 -22.6 -49.9 -2.8
MP2 -39.1 -4.7∗ -25.5 -47.3 -5.1
CC2 -39.2 -6.2 -25.8 -47.4 -6.4
SCS-MP2 -38.3 -1.1 -22.9∗ -46.6∗ -3.9
SCS-CC2 -38.2∗ -1.7 -22.9 -46.6∗ -4.8
Table 11.13: deviation of reaction energies including estrone skeleton compared to reaction
energies of warheads in COSMO. Deviations marked with * are deviations obtained with the
best methodology compared to the CCSD(T). All values are given in kcal/mol.
deviation to Est-Ia Est-Ib Est-Ic Est-Id Est-Ie
warhead
B3LYP-D3 0.3 1.1 1.4 0.5 0.5
BHLYP-D3 0.2 1.2 1.6 0.5 0.7
MP2 0.3 1.1∗ 1.5 1.0 0.5
CC2 0.4 0.8 1.4 1.0 0.4
SCS-MP2 0.2 0.9 1.5∗ 0.9∗ 0.6
SCS-CC2 0.3∗ 0.8 1.5 0.9∗ 0.5
The deviations compared to the warheads show low deviations for Est-Ia and Est-Id as
they vary between 0.2 to 1.0 kcal/mol (Table 11.13). For Est-Ib they are around 1 kcal/mol
and for acrylamide about 1.5 kcal/mol. For Est-Ie the difference in reaction energy is also
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below 0.7 kcal/mol and therefore, one can conclude that the steroid does not have a significant
effect on the reaction energy.
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Figure 11.25: Calculated reaction of Est-Ia, Est-Ib, Est-Ic, Est-Id and Est-Ie in reaction with
methanethiol or methanethiolate.
11.8.2 Semiempirical approach and NEB calculations
As above mentioned the NEB approach was selected to calculate the reaction barrier. To
decrease computational costs, the semi-empirical method PM6 including Grimme’s dispersion
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correction D3 was employed for geometry optimization. To evaluate the suitability of this
methodology reactants and products shown in Figure 11.25 were optimized on PM6-D3 level
applying the COSMO approach with an -value of 78. These calculations employed the CAST
program package, which utilized the MOPAC 2016 energy interface. The RMSD values in
Table 11.14 are all below 0.25 A˚ and no significant, structural differences occur. These
findings indicate the suitability of PM6-D3 regarding structure optimization. Afterwards
single point calculations have been conducted using the PM6-D3 optimized structures to
evaluate differences in reaction energy which might occur due to the change of methodology
for structure optimization (Table 11.15).
Table 11.14: Root-mean-square deviation (RMSD) of PM6-D3//COSMO optimized structures
compared to B3LYP-D3/def-TZVP//COSMO structures.
structure RMSD [A˚]
Est-Ic 0.18
CH3S-Est-Ic 0.07
Est-Ia 0.13
CH3S-Est-Ia 0.14
Est-Ib 0.06
CH3S-Est-Ib 0.08
Est-Id 0.25
CH3S-Est-Id 0.08
Est-Ie 0.12
CH3S-Est-Ie 0.18
p-hydroxynitrobenzene 0.03
CH3SH 0.02
CH3S- 0.03
The differences in reaction energy compared to the B3LYP-D3 optimized structures are
shown in Table 11.16. For Est-Ia and Est-Id their deviations are of about 1 to 1.5 kcal/mol.
Est-Ie shows the lowest deviations of < 0.5 kcal/mol for the used DFT functionals, while
ab initio methods are larger than 1.3 kcal/mol. In case of Est-Ib and Est-Ic they have a
larger impact of ≈ 3 to 3.5 kcal/mol. Interestingly, the reaction energy for Est-Ic increases
whereas Est-Ib’s decreases. Still, the trends of inhibition are comparable to previous findings.
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Table 11.15: Reaction energies obtained by QM calculation in COSMO. Energies marked with
* are energies obtained with the best methodology compared to the CCSD(T). Aug-cc-pVDZ has
been used as basis set. All energies shown are in kcal/mol.
aug-cc-pVDZ// Est-Ia Est-Ib Est-Ic Est-Id Est-Ie
COSMO
B3LYP-D3 -36.3 -2.7 -22.9 -48.6 -4,8
BHLYP-D3 -37.8 -2.1 -25.6 -51.0 -2.8
MP2 -38.0 -2.0∗ -29.0 -48.3 -3.8
CC2 -38.2 -3.7 -29.3 -48.4 -4.4
SCS-MP2 -37.3 1.8 -26.2∗ -47.8∗ -2.6
SCS-CC2 -37.2∗ 1.1 -26.2 -47.8∗ -3.0
Table 11.16: Absolute deviation of reaction energies compared to COSMO energies of B3LYP-
D3/def-TZVP//COSMO optimized structures. Deviations marked with * are deviations obtained
with the best methodology compared to the CCSD(T). All deviations shown are in kcal/mol.
deviation PM6-D3 Est-Ia Est-Ib Est-Ic Est-Id Est-Ie
optimization
B3LYP-D3 0.8 2.5 2.8 1.5 0,5
BHLYP-D3 1.1 2.7 3.0 1.1 0,1
MP2 1.1 2.7∗ 3.5 1.0 1,4
CC2 1.0 2.5 3.5 0.9 2,0
SCS-MP2 1.0 2.9 3.3∗ 1.2∗ 1,3
SCS-CC2 0.9∗ 2.8 3.3 1.2∗ 1,8
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Figure 11.26: Extracted structures for optimization and NEB calculations. In case of Cys93
and His347 solely the side chain has been used.
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The next step contained the calculation of the energy barrier of Est-Ia. Four structures
including Est-Ia and the side chains of Cys93 and His347 (Figure 11.26) of the third MD
run of protonation state B were employed for NEB calculations calculations. First of all,
the structures of these frames have been optimized using PM6-D3//COSMO. Afterwards
the covalent structure was modeled using Avogadro in the following way: The distance
between electrophilic carbon of Est-Ia and sulfur was decreased to 1.9 A˚ and a constrained
optimization between these atoms was performed. Subsequently an optimization without
constrains was conducted to obtain a relaxed covalent structure. Thus, one aquires the
starting- and endpoint for the NEB calculation. For each structure 20 NEB images were
generated resulting in four different reaction paths (Figure 11.27). On each of these images
single point calculations have been performed on SCS-CC2/aug-cc-pVDZ//COSMO level
which performed best in benchmark calculations regarding the warhead chloromethylketone.
Table 11.17: Calculated reaction barrier and reaction energy of Est-Ia on SCS-CC2/aug-cc-pVDZ
level employing COSMO. Single point calculations have been conducted on structures obtained by
the NEB run on PM6-D3 level. Four different structures have been employed from the third MD
run of protonation state B of Est-Ia.
aug-cc-pVDZ//COSMO TS product
Snapshot 1 (1 ns) 13.0 -28.3
Snapshot 2 (2 ns) 10.9 -20.6
Snapshot 3 (4 ns) 11.8 -24.8
Snapshot 4 (5 ns) 8.6 -20.7
The computed heights of the barriers of the reaction are ≈ 9 to 13 kcal/mol). The reaction
energy decreases to -20 to -28 kcal/mol which implies that the product is about 10 kcal/mol
less stable compared to previous results. Still, these calculations indicate that the reaction
energy and barrier for covalent modification by Est-Ia is appropriate.
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Figure 11.27: Calculated reaction path by a NEB calculation on PM6-D3 level.
11.9 QM/MM calculations of Est-Ia and Est-Ic
The final step contains the evaluation of Est-Ia’s suitability to inhib FadA5. Thus, QM/MM
calculations aimed to describe the reaction of Est-Ia in enzyme. As a starting point, a
structure of the third MD run of Est-Ia (protonation state B) has been utilized for further
calculations. The first step was the geometry optimization of Est-Ia, Cys93 and His347. The
red colored QM region depicted in Figure 11.28 were optimized on B3LYP-D3 level with the
def-TZVP basis set. The covalent bond cut between QM and MM part of Est-Ia had to be
done as in Figure 11.28, as two C-C bonds could not be saturated. This explains why the
warheads were extended by a methyl group in previous QM benchmark calculations. The
AMBER14 force field was employed to describe the MM part. After optimization, a relaxed
scan has been conducted by decreasing the distance between Cys93’s sulfur and the elec-
trophilic carbon of Est-Ia.
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Figure 11.28: Red coloured lines indicate atoms, which has been described in the QM part
of QM/MM calculation. A - Blue arrow indicates coordinate between nucleophilic sulfur
of Cys93 and electrophilic carbon of Est-Ia, which has been decreased during the relaxed
scan. B – First reaction coordinate (1) is the decrease in distance between nucleophilic
sulfur of Cys93 and electrophilic carbon of Est-Ic. Afterwards the distance between carbon
and hydrogen of His347 has been decreased (2). Location of Est-Ia, Est-Ic and amino acids
serves for clarification and does not reflect actual position in QM/MM calculation.
The resulting reaction barrier of 28.8 kcal/mol is about 15 to 20 kcal/mol higher com-
pared to the ones obtained by NEB calculation (Table 11.18). It is to be expected that this
energetic hurdle is hard to overcome. Furthermore, the reaction energy of 0.1 kcal/mol indi-
cate that the formation of a covalent bond between Est-Ia and Cys93 is not to be expected.
This is in contrast with previous results. In case of reaction energies, the nucleophilic attack
in vacuo is -31.5 for SCS-CC2/aug-cc-pVDZ. The application of COSMO leads to reaction
energies of ≈ 38 kcal/mol. For NEB calculations the reaction energy is in a range of ≈ 20
to 28 kcal/mol. One of the major differences to previous calculations is the stabilization
of the chlorine by implicit solvation. As mentioned in section 11.5.2 the absolute deviation
between chlorine in vacuum and COSMO is larger compared to neutral species. To overcome
this problem, two explicit water molecules were included to the QM region to stabilize the
chlorine. By doing so one obtains a decrease of 12.7 kcal/mol in respect to the transition
state and a reaction energy of -4.0 kcal/mol. In terms of kinetics, one can expect that a
reaction barrier of 16.1 kcal/mol can be overcome if water molecules stabilize the chlorine.
Still, the reaction energy of -4.0 kcal/mol is in contrast to previous findings. This leads to
the question if the QM or QM/MM approach leads to false results.
To tackle this problem, the reaction energy and barrier of Est-Ic was calculated, applying
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Table 11.18: Reaction energy and barrier on QM/MM level obtained by relaxed scan. Geometry
optimization of structures were conducted on B3LYP-D3 level and a def-TZVP basis set. Energy
evaluation was performed by single point calculation of initial structure (non-covalent complex),
transition state (TS) and end of reaction (covalent complex). For Est-Ia SCS-CC2 with the aug-
cc-pVDZ basis set was employed, for Est-Ic the SCS-MP2 method with the aug-cc-pVDZ basis set.
All values are given in kcal/mol.
Est-Ia Est-Ia + 2 H2O Est-Ic
SCS-CC2/ SCS-CC2/ SCS-MP2/
aug-cc-pVDZ aug-cc-pVDZ aug-cc-pVDZ
non-covalent complex 0.0 0.0 0.0
TS 28.8 16.1 16.8
covalent complex 0.1 -4.0 -37.9
the same QM/MM method. Compared to Est-Ib or Est-Ie, the reaction energies are in a range
of ≈ -23 to -26 kcal/mol and therefore lower. Additionally, it harbors poses in the docking,
in which the warhead is directed to the active site. In terms of MD simulations one could see
that the distance between Cys93’s sulfur and Est-Ic electrophilic carbon does increase and
a nucleophilic attack is not likely. To overcome this fact a harmonic distant restraint was
applied on Cys93’s sulfur and the electrophilic carbon to obtain a relaxed structure in which
Est-Ic’s warhead can be covalently modified. Of course one has to keep in mind that this is
an artificial state which has been forced to calculate the reaction energy and barrier. The
QM/MM system was prepared as before but without the inclusion of water molecules to the
QM region. The relaxed scan was devided in two parts. Firstly, the distance between Cys93’s
sulfur and Est-Ic electrophilic carbon was reduced to 1.9 A˚. Afterwards, it was kept fixed
and the distance between His347’s hydrogen was moved to Est-Ic (Figure 11.28). Instead
of SCS-CC2 the spin component scaled variant of MP2 with the aug-cc-pVDZ basis set
was applied, as this methodology was the best in comparison with CCSD(T). The resulting
reaction barrier of 16.8 kcal/mol is comparable with the one obtained of Est-Ia including two
water molecules. Regarding the reaction energy of -37.9 kcal/mol it is much lower compared
to Est-Ia or previous calculation of the warhead or Est-Ic in vacuo or COSMO. These findings
indicate that differences of Est-Ia (in terms of reaction energy) do not occur because of the
application of QM/MM methods, but rather because of the enzyme’s environment.
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11.10 Conclusion
In this chapter first steps have been taken for the development of a covalent inhibitor origi-
nating from a non-covalent ligand for FadA5 (a thiolase of Mycobacterium tuberculosis). The
group of Kisker from the University of Wu¨rzburg crystallized the steroid OPC (3-oxo-preg-
4-ene-20-carboxylic acid) and CoA in non-covalent complex with the C93S mutant of FadA5
and identified a steroid binding pocket. This X-ray structure served as a starting point for
the following computational investigations.
To modify FadA5 covalently, the active site dyad consisting of Cys93 and His347 appear to
be suitable and therefore three different inhibitor scaffolds are considered which could be
expanded by a warhead to result in a covalent inhibitor:
 Scaffold A: A warhead could be attached to the thiol group of CoA (Figure 11.6-A).
 Scaffold B: One can think of linking the warhead to a steroid scaffold (Figure 11.6-B).
 Scaffold C: The warhead could be placed between the steroid and the coenzyme.
(Figure 11.6-C).
As CoA occurs in many biological reactions in human, problems in respect to the selectivity
can arise if scaffold A is used. Furthermore, the synthesis might be very complex as in the case
of scaffold C. Hence, both scaffolds were neglected. Scaffold B offers the advantage of a range
of purchasable steroids which facilitates experimental work by decreasing the steps of syn-
thesis and was further pursued for investigation. In the course of this study, 36 synthesizable
structure related to scaffold B were investigated. These possible inhibitors occur due to the
combination of five different warheads adressing cysteine (acrylamide, chloromethylketone,
cyanamide, carbamate and bromodihydroisoxazole) and six different steroids (progesterone,
pregnenolone, prasterone, 3-methoxy-prasterone, estrone and 3-methoxy-estrone) as depicted
in Figure 11.10 to Figure 11.15.
At the start, MD simulations have been conducted for the C93S FadA5 mutant in complex
with OPC and CoA or for the FadA5 wild type in complex with OPC, CoA or with both
(Figure 11.8). These simulations are needed to probe the stability of OPC in wild type as
well as in absence of CoA. Results showed that the RMSD of OPC does not increase strongly
in wild type but in absence of CoA. Still, OPC remains in the steroid binding pocket so that
one can conclude that an attached warhead can also be directed towards the active site for
covalent modification.
Afterwards, the covalent modification of methanethiol (representing the cysteine side chain)
244
11.10. CONCLUSION
by above mentioned warheads have been calculated on QM level to provide insight on the
reactivity of each warhead and additionally, to determine the most accurate methodology for
selected warheads. In most cases spin-component scaled MP2 or CC2 offer the best results
in comparison to CCSD(T). In terms of cyanamide they show the largest error of about 4
kcal/mol. Furthermore, the application of implicit solvation revealed different results de-
pending on the investigated warhead. In terms of acrylamide and cyanamide one obtains a
decrease in reaction energy. For bromodihydroisoxazole a small increase occurs, while the
reaction energy of the carbamate warhead increases by a value of 3 kcal/mol. The largest
influence of the solvent can be observed for chloromethylketone as a downshift of 6 kcal/mol
is obtained after employing COSMO. This can be explained by the stabilization of the chlo-
rine due to the implicit solvation.
As the warheads appear suitable for covalent modification the next step was to establish a
suitable redocking protocol for OPC which can be transferred to the docking of proposed
inhibitors. This procedure is needed to obtain meaningful poses which can be used for MD
simulations to probe the stability of the inhibitors in complex with FadA5. In this matter
the specification of the approximate radius r of the binding site was crucial. Best results in
the redocking were obtained if a r-value of 20 A˚ was applied leading to high-ranked poses of
OPC with RMSD values below 1 A˚ compared to the X-ray structure.
This setup was used for the docking of the proposed inhibitors. In contrast to OPC, good
poses of the inhibitors were referred to those which showed a small distance between the elec-
trophilic part of the warhead and the nucleophilic sulfur of Cys93. This is understandable,
as the probability for covalent modification is enabled if a sufficient small distance is given.
The docking simulations of the inhibitors revealed different findings. Bromodihydroisoxazole
appears to be unsuitable as warhead for this scaffold, as it is too huge to fit in the active site
resulting in poses which are directed to the solvent. This behavior was observed for many
poses of the remaining inhibitors and thus the idea came up to design “sandwich-structures”
which are modified by two warheads at the A- or D-ring. Although the docking poses of
these “sandwich-structures” did not show sufficient distances for covalent modification, all
poses showed that at least one warhead is always directed towards the active site. Best re-
sults were obtained for five inhibitors which consist of estrone or 3-methoxy-estrone (Est-Ia,
Est-Ib, Est-Ic, Est-IIa and Est-IIc, see Figure 11.12 ). The poses of these inhibitors were
used for MD simulations to probe if the small distance between warhead and sulfur can be
maintained in the course of simulation time. The MD simulations revealed that only Est-Ia
fulfilled this requirement.
The next question which needed to be answered was the covalent reaction of Est-Ia itself. In
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order to do so, preceding calculations had to be conducted. As the first QM benchmark only
focused on the warhead, calculations have been extended by including the steroid scaffold
estrone. This is because docking and MD simulations revealed Est-Ia to be the best candi-
date. Still, all warheads were included for reasons of comparability to previous calculations.
These computations showed that differences in reaction energy are largest by a value of 1.5
and therefore indicate that the attachment of the steroid does not affect the reactivity of the
warheads significantly.
Afterwards, investigations on semi-empirical and QM/MM level have been conducted to gain
insight in regard to the covalent modification. Reaction energies as well as the reaction
barriers of Est-Ia obtained by NEB calculations on semi-empirical level are contrary to the
findings on QM/MM level. In terms of the reaction barrier QM/MM calculations reveal
that it is about 15 kcal/mol higher compared to semi-empirical results. The inclusion of two
explicit water molecules in the QM region decreased the barrier; hence solvents are relevant
for the kinetics of Est-Ia. Also, the reaction energy is overestimated in case of semi-empirical
results as they are of -20 to -28 kcal/mol while they are much smaller for QM/MM com-
putations (0.1 kcal/mol in absence of explicit water molecules or -4.0 kcal/mol in presence
of two explicit water molecules). This shows that the stabilization of the chlorine molecule
is of importance. In terms of the QM or semi-empirical calculations implicit solvation was
applied thus offering a perfect stabilization of the chlorine which is not the case for Est-Ia in
the QM/MM calculation of the protein-inhibitor complex.
To gain further insight on this effect the covalent modification of FadA5 by Est-Ic was also
calculated on QM/MM level. In contrast to Est-Ia, calculations of Est-Ic revealed an ap-
propriate reaction barrier of 16.8 kcal/mol and especially a reaction energy of -38 kcal/mol.
Additionally, results show that acrylamide is not prone to the solvent as chloromethylketone.
However, dynamics show that fluctuations in distance are too large for a nucleophilic attack
for Est-Ic although acrylamide appears to be a fitting warhead.
The last step of this study was conducted by the Tonge group from the Stony Brook Uni-
versity. They tested experimentally the inhibition of Est-Ia, Est-Ic and Est-Ie in FadA5 but
did not see any meaningful inhibition. After two hours of incubation all tested compounds
showed < 50% irreversible inhibition. Additionally, no competitive inhibition was observed
for these structures. This is in accordance with the calculated results. For Est-Ie all docked
poses showed, that the warhead itself is not close enough for covalent modification and there-
fore would not react. For Est-Ic the reaction energy and barrier seems favorable, but the
distance for a nucleophilic attack of Cys93 sulfur cannot be maintained during the MD sim-
ulations. This might explain the experimental results. For Est-Ia one might expect some
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inhibition, although the reaction energy is not very large.
These experimental findings reveal that research is still necessary for the development of a
covalent inhibitor. As mentioned above, no competitive inhibition was observed in the ex-
periments and a way to overcome this problem might be the change of the inhibitor scaffold.
Instead of solely focusing on the steroid scaffold it might be essential to include the CoA moi-
ety as described in Figure 11.6 although the complexity of synthesis increases. This shows
that further research is needed in regard of the development of a covalent inhibitor for FadA5.
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Chapter 12
Theoretical investigations on the
modulation of the product profile of
Bacillus megaterium levansucrase by
ene-reactions
12.1 Introduction
The importance of carbohydrates in living organisms is shown in many forms. On the one
hand, they are of necessity for the structural integrity e.g. as cellulose in cell wands of
plants or as chitin in fungi or bugs [268]. On the other hand, they are essential for energy
storage in form of glycogen in humans. Carbohydrates are classified by their size. If their
polymerization degree (DP) is > 9, they are named polysaccharides, if they consist of 3 to
9 units, they are called oligosaccharides. In terms of smaller units, one refers to mono-, di-
and trisaccharides which are compromised of e.g. glucose, galactose, fructose or xylolose.
The smallest building block of oligo- or polysaccharides are called monosaccharides. They
are organized by number of atoms, carbonyl groups and chirality. Because of the number
of hydroxyl groups, one obtains a variety of possibility of connectivity and by implication a
series of complex structures.
In cosmetics, bacterial polysaccharaides are used as they mostly do not show toxicity and
posess appropriate physicochemical properties for the formulation of cosmetics as well as
good tolerability [269]. To obtain these products, microbacterial fructosyl transferases (EC
2.4.1.99) are used; polymerases which catalyze the biosynthesis of fructans [270]. Two known
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fructan sucrases are levansucrase and inolsucrases. The synthesis of levan occurs by ß-(2,6)-
linked fructosyl residues by levansucrase (EC 2.4.1.10) [271] (Figure 12.1). Inulines are mainly
produced by inolosucrases (EC.2.4.1.9) [272], [273].
O
OH
OHHO
O
n
Figure 12.1: Chemical structure of mono-unit of levan.
The heterologusly exprimed levansucrase of bacillus megaterium (Bm-LS) of the glycoside
hydrolase family GH68 is known to catalyze the synthesis of a number of fructo oligosaccha-
rides. The range of the carbohydrate size ranges from 2 to 20 fructose units [274]. Strube et
al. have performed an extensive mutation study of Bm-Ls, to obtain insight on the elongation
of the carbohydrate polymer and to evaluate relevant interactions in the process of polymer-
ization [275]. The active site of Bm-LS consists three catalytic amino acids Asp95, Asp257
and Glu352. At this Asp95 serves as catalytic nucleophile, while Glu352 acts as acid/base
catalysator [274]. The interaction of the 3- and 4-OH group of the fructosyl unit in the ac-
tive site is attributed to Asp257, which additionally stabilizes the transition state [272], [273].
By the mutation of selected amino acids and the analysis of the synthesized carbohydrates
of Bm-LS variants, it was possible to draw conclusions on the functionality of respective
residues (Figure 12.2). While Asn252 shows an interaction motif for tri-/tetrasaccharides,
Lys373 shows this behavior for penta-/hexasaccharides and Tyr247 for nona/decasaccharides.
In terms of Arg370, this residue is important for the stabilization of the carbohydrate in the
progress of elongation. Therefore, it was possible to predict the direction of Bm-LS poly-
merization progress which appears in a clockwise motion. These insights in respect to the
biosynthesis of levan in Bm-LS are of importance for further investigations.
In the past many attempts of molecular engineering of enzymes showed improvements con-
cerning activity, specifity and stability [276]. E.g. chemical modification of proteins offers a
way for accessing tailored bio-catalysts for different applications. In this manner tyrosine or
tryptophane residues are suitable for conjugation as their occurrence is less than usually con-
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jugated residues as cysteine, threonine, serine and lysine and often are buried when located
at the surface [277], [278], [279], [280], [281], [282], [283]. 25 tyrosine residues can be found
in Bm-LS although only residues 41, 196, 247, 281 and 446 are the most solvent exposed
ones [284]. The group of Seibel from the University of Wu¨rzburg conducted investigations
on the site-selective chemo modification of these tyrosine residues in Bm-LS. In this respect
different scientific issues arose and were additionally investigated by computations which will
be discussed in this section.
In the beginning the bioconjugation of tyrosine residues of wild type Bm-LS have been con-
ducted by introducing modifier 1 (7-((6-aminohexyl)oxy)-2-methyl-2,3-dihydrophthalazine-
1,4-dione with an azine group). The mass spectrometry detected two modified tyrosine
residues although the exact residue could not be determined. In consequence, computations
were necessary to shed light into this matter.
Figure 12.2: Active site residues of levansucrase from Bm-LS, which interacts with the elon-
gation process of the fructooligosacharides.
Afterwards, possible key residues have been mutated experimentally to obtain new ac-
cessible tyrosine residues for bioconjugation. In these cases, modifier 1 or modifier 2 (2-
methyl-6-(pent-4-yn-1-yloxy)-2,3-dihydrophthalazine-1,4-dione with an alkyne group) have
been investigated via MD simulations and have been compared with experimental findings
regarding the change of product spectra.
Lastly, the group of Seibel showed that different levansucrase variants were able to synthesize
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polysaccharides due to the chemical modification of modifier 2 or 2-AzGlc. As mentioned be-
fore the products of wild type Bm-LS are oligosaccharides with a DP of 2-20 and by mutation
and bioconjugation polysaccharides were obtainable. Thus, investigations of these covalent
modifier-protein complexes were also included in the computations (Figure 12.3).
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R= O
modifier 2
R= O
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NN
HO
HO
O
OH
OH
modifier 2-AzGlc
Figure 12.3: Tyrosine targeting structures as 4-phenyl-3H-1,2,4-triazole-3,5(4H)-dione
(PTAD) = modifier 1, 6-(6-azidohexyl)-2-methyl-2,3-dihydrophthalazine-1,4-dione = mod-
ifier 1 methyl-6-(pent-4-yn-1-yloxy)-2,3-dihypdrophthalazine-1,4-dione) = modifier 2 and
methyl-6-(pent-4-yn-1-yloxy)-2,3-dihydrophthalazine-1,4-dione) modified with
”
click reac-
tion“ with 1-azido-1-deoxy-ß-D-glucopyranoside = modifier 2-AzGlc.
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12.2 General Information on MD simulation
One focus of investigation was the determination of the tyrosine residues which were mod-
ified in levansucrase wild type. The actual position of modifier 1 has been investigated by
covalently connecting it to different tyrosine residues (Tyr196, Tyr247 and Tyr446) of Bm-
LS. Afterwards Molecular Dynamic simulations with duration of 10 ns for each investigated
covalent complex have been conducted. As a starting point, the crystal structure of the
D257A Bm-LS mutant has been used (pdb code 3OM2) and mutated to the wild type by
changing Ala257 to Asp257 (Figure 12.4). Modifier 1 was afterwards attached on each of the
above-mentioned tyrosine residues, employing the Avogadro program package. If possible,
the modifier was bound to C3 or C5 of the tyrosine side chain. In the course of this pro-
cedure, the nearby protein environment (5 A˚ radius of the corresponding tyrosine residue)
was considered to avoid atom clashes and unlikely binding modes were neglected. As men-
tioned before mass spectrometry determined two modified tyrosine residues. Therefore, the
simulation considered single and twofold modifications of tyrosine residues by modifier 1.
Additional aspects have to be considered in the simulations because the structure of the
modifier is present as a stereoisomer. In consequence, the 1-azido-5-methoxypentane group
can be present at position 6 or 7 of the phthalazinedione scaffold which also has been taken
into account for most cases (Figure 12.5).
Bm-LS was described by application of the Amber14 force field ff14SB whereas modifier 1, 2
or 2-AzGlc were parameterized by GAFF. The same protocol for minimization and gradual
heating was used described in section 5.1.
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Figure 12.4: Modification of D257A mutant of Bacillus megaterium levansucrase to wild type
protein (dotted circle shows position of Ala257/Asp257). Possible tyrosine residues which
can be modified by modifier 1 are depicted in orange licorice style. Amino acids of the active
site are presented in yellow licorice style.
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Figure 12.5: Stereoisomers of modifier 1. Stereoisomers of modifier 2 and 2-AzGlc are ob-
tained by exchanging the 1-azido-6-methoxyhexane
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12.3 Covalent modification of wild type Bm-LS with
modifier 1
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Figure 12.6: Course of RMSD values versus time plots of modifier 2-1 or 2-2 covalently bound
to Tyr196 in B. megaterium levansacucrase during the 10 ns production run.
First of all, the single modification of Tyr196, Tyr247 or Tyr446 was investigated to gain
insight on the protein ligand interaction. By attaching modifier 1-1 (stereoisomer 1) or 1-2
(stereoisomer 2) on Tyr196 one cannot observe any movement towards the active site. In
contrast the modifier orients itself towards the solvent. Figure 12.6 shows in terms of the
calculated RMSD values larger deviations of stereoisomer 2 than for 1. Still, these variations
do not change the fact that the single modification of Tyr196 does not harbour any effect on
the polymerization reactions in Bm-LS and thus not affecting the product profile of Bm-LS
as no interaction of modifier 1 to any amino acid of the active side can be observed (see
Figure 12.7).
254
12.3. COVALENT MODIFICATION OF WILD TYPE BM-LS WITH MODIFIER 1
A B
Figure 12.7: A – MD simulation of modifier 1-1 covalently bound to Tyr196. B - MD simula-
tion of modifier 1-2 covalently bound to Tyr196. Every ns of the temporal progress presented
from red-coloured (start of simulation) to blue-coloured modifier 1 (end of simulation). Initial
frame of active site residues is shown for clarification in yellow licorice presentation.
For the modification of Tyr247 two different possibilities of the linkage of modifier 1 are
enabled. In Figure 12.8 one can see that the ligand can be attached directing towards the
solvent or in direction of the active site. By including both stereoisomers of the structure,
one has to consider four different simulations in for the covalent modification of Tyr247. A
glance at the variation of RMSD values in Figure 12.9 shows that the stereoisomerism has
a subordinate role in these four complexes. In terms of modifier 1-2 the increase of RMSD
occurs after a certain amount of time (after ≈ 4 ns for pose I or after ≈ 6 ns for pose II)
whereas for modifier 1-1 this is observable in an earlier stage of the molecular dynamics
simulation. Of more importance is the pose of the ligand. In case of pose I the increase
of RMSD value goes along with the movement of the ligand leading away from the active
site. By attaching modifier 1 in pose II to Tyr247 the increase of RMSD values is lower.
Figure 12.10-B and Figure 12.10-D show that despite of the stereoisomerism modifier 1 is
pointing towards the active site. Thus, it is likely that this pose leads to interactions with
the polymerization process of the polysaccharide and therefore has an effect on the product
profile. Still, one has to consider that a certain amount of flexibility in terms of modifier 1 is
available as fluctuations in the RMSD plots are in a range of 8 A˚.
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pose I pose II
Figure 12.8: Possible conformations (pose I or pose II) of modifier 1 covalently bound to
Tyr247 depicted in orange licorice presentation close to amino acids of the active site shown
in yellow licorice presentation.
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Figure 12.9: Course of RMSD values versus time plots of modifier 1-1 or 1-2 in pose I or pose
II covalently bound to Tyr247 in B. megaterium levansucrase during the 10 ns production
run.
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A B
C D
Figure 12.10: A – MD simulation of modifier 1-1 in pose I bound to Tyr247. B – MD
simulation of modifier 1-1 in pose II bound to Tyr247. C – MD simulation of modifier 1-2
in pose I bound to Tyr247. D – MD simulation of modifier 1-2 in pose II bound to Tyr247.
Every ns of the temporal progress presented from red-coloured (start of simulation) to blue-
coloured modifier 1 (end of simulation). Initial frame of active site residues is shown for
clarification in yellow licorice presentation.
The last simulation was of the modified Tyr446 residue. Similar to the covalent modifica-
tion of Tyr196 one can only observe a movement of the ligand into the opposite direction of
the active site. The RMSD plots of both stereoisomers show fluctuations in the same range
and also lead to the conclusion that the stereoisomerism is not of importance in this case.
Therefore, it is likely that the single modification of Tyr446 also has no effect on the product
profile of Bm-LS.
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Figure 12.11: Course of RMSD values versus time plots of modifier 1-1 or 1-2 covalently
bound to Tyr446 in B. megaterium levansucrase during the 10 ns production run.
A B
Figure 12.12: A – MD simulation of modifier 1-1 covalently bound to Tyr446. B - MD simula-
tion of modifier 1-2 covalently bound to Tyr446. Every ns of the temporal progress presented
from red-coloured (start of simulation) to blue-coloured modifier 1 (end of simulation). Initial
frame of active site residues is shown for clarification in yellow licorice presentation.
The next step was the simultaneous modification of two tyrosine residues by modifier 1
to describe the simulations more correctly in relation to experimental findings. The previous
MD simulations revealed that the single modification of Tyr196 or Tyr446 does not appear
to have any influence on the active site thus to a modified production profile. Therefore, a
double modification of both tyrosine residues at the same time was not conducted.
In the following, a twofold modification of Tyr196 and Tyr247 has been performed. Contrary
to the previous simulations solely stereoisomer 1 has been considered as the stereoisomerism
does not have a significant impact on the interaction with the active site in the case of the
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modified Tyr247. More of interest is the pose of the covalent ligand on Tyr247. Thus, only two
simulations resulted in different poses of modifier 1-1 on Tyr247. Interestingly one can observe
a motion in both cases in regard of modifier 2-1 on Tyr196 as it moves to the direction of the
second modifier 1-1 on Tyr247. The reason for this change of position is a pi-pi interaction
between the phthalazinedione scaffold of modifier 1-1 on Tyr196 and Tyr247’s phenyl ring
resulting in a parallel alignment (see Figure 12.14). In contrast to the single modification of
Tyr247, one can observe that modifier 1-1 in pose I shows an increase up to 8 A˚ in RMSD value
(instead of a steady to 14 A˚) and a relatively stable course after 4 ns (black curve in Figure
12.13). This stabilization is caused by the above mentioned pi-pi interaction and additionally
leads to a redirection of modifier 1-1 (on Tyr247) closer to the active site. The second modifier
shows a large increase of RMSD after ≈ 500 ps which goes along with the reorientation
towards the second modifier. In the second case of the simultaneous modification of Tyr196
and Tyr247 in pose II the same movement of 2-1 on Tyr196 also occurs due to the pi-pi
interaction. In the course of RMSD values during the simulation fluctuations of 1-1 on
Tyr196 are larger than before as the pi-stacking at first evolves after 2 ns and requires a
certain amount of time to consolidate. In contrast to the single modification of Tyr247 one
can observe a continuous increase of RMSD of the covalent ligand on this amino acid due to
the flexibility of the 1-azido-5-methoxypentane group. Nevertheless, it is directed towards
the active site and should also lead to an interaction with the polymerization process.
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Figure 12.13: Course of RMSD values versus time plots of modifier 1-1 covalently bound to
A - Tyr196 (black curve) and Tyr247 in pose I (red curve) or B - Tyr196 (black curve) and
Tyr247 in pose II (red curve) in Bm-LS during the 10 ns production run.
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Figure 12.14: Observed pi-pi interaction between phthalazinedione scaffold of modifier 1-1
covalently bound to Tyr196 and phenyl ring of Tyr247 indicated by red dotted lines during
10 ns production run.
A B
Figure 12.15: A - MD simulation of modifier 1-1 covalently bound to Tyr196 and Tyr247
in pose I. B - MD simulation of modifier 1-1 covalently bound to Tyr196 and Tyr247 in
pose II. Every ns of the temporal progress presented from red-coloured (start of simulation)
to blue-coloured modifier 1 (end of simulation). Modified tyrosine residues are depicted in
orange licorice presentation, initial frame of active site residues in yellow licorice presentation
for clarification.
In contrast to these findings, a twofold linkage of 2-1 on Tyr247 and Tyr446 does not lead
to any interaction. As before, only the stereoisomer 1 was considered and two simulations with
the difference of the position of 1-1 on Tyr247 were performed. In terms of the modification
of Tyr446 both cases show RMSD values in the range of 2.5 to 10 A˚ similar to the single
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modification of this residue (black curve in Figure 12.16). As it is shown in Figure 12.17
the modifier is directed to the solvent and does not move towards the active site during the
simulation time. For Tyr247 one can obtain further insights. At first it was expected that the
modification in pose I would not interefere with the active site if Bm-LS is singly modified.
This is not the case for this simulation. In contrast to the previous assumption the ligand in
pose I does move towards the active site and could interact with it. As for pose II modifier 1-1
shows a large motion out of its initial position which is accompanied by an increase of RMSD
to 20 A˚ (red curve in Figure 12.16). This occurency is unlikely attributed to the concurrent
covalent binding of the second ligand on Tyr446 as both are > 25 A˚ apart. Hence, one can
conclude that 1-1 on Tyr247 has a larger flexibility as expected and is capable of motions
into and also out of the active site despite of the pose.
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Figure 12.16: Course of RMSD values versus time plots of modifier 1-1 covalently bound to
A – Tyr446 (black curve) and Tyr247 in pose I (red curve) or B – Tyr446 (black curve) and
Tyr247 in pose II (red curve) in B. megaterium levansucrase during the 10 ns production
run.
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A B
Figure 12.17: A - MD simulation of modifier 1-1 covalently bound to Tyr446 and Tyr247
in pose I. B - MD simulation of modifier 1-1 covalently bound to Tyr446 and Tyr247 in
pose II. Every ns of the temporal progress presented from red-coloured (start of simulation)
to blue-coloured modifier 1 (end of simulation). Modified tyrosine residues are depicted in
orange licorice presentation, initial frame of active site residues in yellow licorice presentation
for clarification.
The first conclusion which can be drawn by the simulations is that the covalent modifica-
tion of Tyr247 with modifier 1-1 is likely to be responsible for the altered product spectrum
of the carbohydrate polymer. Despite the initial assumption of the importance of the pose of
ligand-linkage the simulations revealed for both cases a motion towards the active site due to
the flexibility of the ligand which results in a movement opposite directed to the active site
in one case. In terms of Tyr196, no modification of the product profile is to be expected if a
second ligand is absent. In combination with 1-1 on Tyr247 a motion to the other ligand and
thus a stabilization due to pi-stacking occurs. It appears that 1-1 on Tyr196 has a supportive
role. The covalent binding of modifier 1-1 on Tyr446 is unlikely as no movement towards
the active site occurs, regardless of the presence or absence of a second ligand. Thus, it is to
be expected that Tyr196 and Tyr247 are the modified residues which were detected by mass
spectrometry. Experimental mutations of Bm-LS wild type to the Y196F/Y247F double
variant incubated with modifier 2 confirmed the conclusions from the MD simulations as no
change in product profile was observed.
12.4 Covalent modification of triple mutated Bm-LS
As the determination of the modified tyrosine residues by modifier 1 was successful, the scope
of computations was extended. The interest of investigation lies on the controlled modifi-
cation of the beginning of the elongation process in Bm-LS. Therefore, three novel tyrosine
residues were inserted by triple mutation at possible key positions. At the same time, the
modification of Tyr196 and Tyr247 was prevented by mutating them to phenylalanine. Thus,
three different triple mutations of Bm-LS have been investigated: Y196F/Y247F/N126Y,
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Y196F/Y247F/Q381Y, and Y196F/Y247F/F445Y (Figure 12.18). Additionally, modifier 2
was included into the simulations for the variant Y196F/Y247F/N126Y. The preparation of
the MD simulation was conducted as for the wild type employing the same force fields for
description of the protein and ligand. Moreover, the protocol of system minimization and
equilibration as well as the production and duration are the same as mentioned in section 5.1.
A B
C
Figure 12.18: Triple mutants of B. megaterium levansucrase. A – Y196F, Y247F and N126Y
triple mutation. B – Y196F, Y247F and Q381Y triple mutation. C – Y196F, Y247F and
P445Y triple mutation. Modified residues are presented in orange licorice presentation, initial
frame of active site residues in yellow licorice presentation serves for clarification. Modified
amino acids are depicted in orange licorice presentation. Initial frame of active site residues
is shown in yellow licorice presentation and serves for clarification.
Three different cases have been considered for the Y196F/Y247F/N126Y variant of Bm-
LS. The linkage of modifier 1 on N126Y was created on the C-3 atom (pose I) of the benzyl-
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ring as well as on the C-5 atom (pose II). For the latter both stereoisomers were considered.
Initial frames of the MD simulations of all three cases are depicted in Figure 12.19.
A B
C
Figure 12.19: A – Initial frame of modifier 2-1 covalently bound to N126Y in pose I directed
towards water shell. B - Initial frame of modifier 1-1 covalently bound to N126Y in pose II.
C - Initial frame of modifier 1-2 covalently bound to N126Y in pose II. Active site residues
are depicted in yellow licorice presentation, mutated tyrosine residues in red.
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Figure 12.20: Course of RMSD values versus time plots of A – modifier 1-1 covalently bound
to N126Y in pose I or of B – modifier 1-1 covalently bound to N126Y in pose II (black curve)
or modifier 1-2 (red curve) covalently bound to NY126 in pose II during the 10 ns production
run of the levansucrase Y196F/Y247F/N126Y variant.
The initial position of modifier 1-1 attached on N126Y in pose I is directed to the solvent.
After 600 ps a motion towards the protein occurs leading to a position maintained over
the course of simulation time (see Figure 12.21-A). This goes in hand with the increase in
RMSD which mainly is caused due the first movement and afterwards fluctuations occur due
to the flexibility of the 1-azido-5-methoxypentane group (Figure 12.20-A). The movement
of modifier 1-1 is induced by the mutated tyrosine residue. As the N126Y mutation was
manually inserted, the tyrosine residue was not adapted to the protein environment due to
its enlarged size. Therefore, a movement of the amino acid was observable and in consequence
of the covalent ligand. The attachment of 1-1 in pose II also shows a similar movement of the
mutated residue leading to an increase of the ligand’s RMSD in the first 2 ns. Afterwards,
the modifier is directed towards the active site. Contrary to the Tyr247 modification of wild
type Bm-LS, 1-1 is directed to the starting point of polymer elongation (Figure 12.21-B).
In terms of stereoisomer 2 (in pose II) it is directed in the same manner for the first 8 ns.
Unexpectedly one can observe a movement of 1-2 to the same position as 1-1 in pose I after 8
ns (Figure 12.21-C). This can clearly be comprehended by a glance at the RMSD plot which
also shows a RMSD between 2 and 4 A˚ and a sudden increase to 14 A˚.
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A B
C D
Figure 12.21: A - MD simulation of modifier 1-1 covalently bound to N126Y in pose I. B
- MD simulation of modifier 1-1 covalently bound to N126Y in pose II C - MD simulation
of modifier 1-2 covalently bound to N126Y in pose II. D - Initial and last frame of 1-1 (in
pose I) and 1-2 (in pose II). Every ns of the temporal progress presented from red-coloured
(start of simulation) to blue-coloured modifier 1 (end of simulation). Drawn arrows indicate
movement of modifier during 10 ns production run. Mutated residues are depicted in orange
licorice presentation, initial frame of active site residues in yellow licorice presentation for
clarification.
In respect to the covalent modification of Bm-LS variant Y196F/Y247F/Q381Y only one
pose of the modifier arises. As depicted in Figure 12.22 solely the linkage on the C-3 atom
of the tyrosine residue was feasible due to steric hindrance of the protein environment. In
case of this variant only stereoisomer 1 was considered. During the 10 ns simulation one
cannot notice any indication of interaction with active site amino acids but on the contrary
it remains stable on the surface after 2 ns (Figure 12.23).
266
12.4. COVALENT MODIFICATION OF TRIPLE MUTATED BM-LS
A
B
Figure 12.22: A – Initial frame of modifier 1-1 covalently bound to Q381Y directed towards
the water shell. B – Quick surf presentation of amino acids close to Q381Y. Active site
residues are depicted in yellow licorice presentation.
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Figure 12.23: Course of RMSD values versus time plots of modifier 1-1 covalently bound to
Q381Y during the 10 ns production run of the levansucrase Y196F/Y247F/Q381Y variant.
Figure 12.24: MD simulation of modifier 1-1 covalently bound to Q381Y. Every ns of the
temporal progress presented from red-coloured (start of simulation) to blue-coloured modifier
1 (end of simulation). Mutated residues are depicted in orange licorice presentation, initial
frame of active site residues in yellow licorice presentation for clarification.
The last investigated variant Y196F/Y247F/F445Y enabled modification on the C-3 as
well as on the C-5 atom of F445Y leading to the poses I and II (Figure 12.25). As in the
previous case, only stereoisomer 1 was considered in the simulations. For the MD simulation
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of 1-1 in pose I, the obtained RMSD values are small in relation to pose II (Figure 12.26-A).
In this case the ligand stays steady directed towards the starting point of polymerization.
This is explainable as no movement of Tyr446 occurs and in consequence no motion in regard
of the modifier. For pose II an increase of 1-1 up to 14 A˚ is observable after 500 ps pointing
out to the solvent. In contrast to the other pose Tyr445 forms a T-stacked interaction with
Tyr446 thus ’pulling’ the ligand further away from the active site.
A
B
Figure 12.25: A – Initial frame of modifier 1-1 covalently bound to P445Y in pose I. B -
Initial frame of modifier 1-1 covalently bound to P445Y in pose II. Active site residues are
depicted in yellow licorice presentation, mutated tyrosine residues in red.
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Figure 12.26: Course of RMSD values versus time plots of A – modifier 1-1 covalently bound
to P445Y in pose I or of B – modifier 1-1 covalently bound to P445Y in pose II during the
10 ns production run of the levansucrase Y196F/Y247F/F445Y variant.
A B
Figure 12.27: A - MD simulation of modifier 1-1 covalently bound to P445Y in pose I. B -
MD simulation of modifier 1-1 covalently bound to P445Y in pose II. Every ns of the temporal
progress presented from red-coloured (start of simulation) to blue-coloured modifier 2 (end
of simulation). Mutated residues are depicted in orange licorice presentation, initial frame of
active site residues in yellow licorice presentation for clarification.
By summing up the present results one might expect that the modification of the triple
variant Y196F/Y247F/N126Y and also Y196F/Y247F/F445Y of Bm-LS might change the
product profile. But experimental data lead to a slightly different conclusion. It was shown
that only the triple mutation Y196F/Y247F/N126Y promotes the synthesis of small products.
This leads to the conclusion that pose II is more likely in case of the Y196F/Y247F/F445Y
variant whereas the simulations of Y196F/Y247F/N126Y are in line with the experiments.
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To gain further insights on the mechanism itself sucrose and 6-kestose, output materials of
the elongation have been inserted into the active site and simulated in combination with a
covalent modified N126Y.
Figure 12.28: Alignment of pdb structures 1PT2 to 3OM2 after manual insertion of sucrose
depicted in yellow licorice presentation (from 1PT2) or coloured by atom name (inserted in
3OM2).
By aligning the protein structure of Bm-LS in complex with sucrose (pdb code 1PT2)
and of the triple variant it was possible to transfer the position of sucrose to the mutated
protein-modifier complex of BM-LS (Figure 12.28). The initial simulation contained sucrose
in absence of modifier 1 to estimate its interaction with the active site and afterwards,
the ligand was included in all variations as considered before to investigate the interplay
of these complexes. Firstly, the absence of modifier 1 shows an increase in RMSD values
until 4 ns simulation time due to a slight rotation of the glucose unit. Afterwards the
fluctuations in RMSD are of ≈ 0.5 A˚ thus one can expect a stable non-covalent complex.
By inserting 1-1 in pose I the RMSD value as well as its fluctuations increases for the
disaccharide. Interestingly the same movement of 1-1 towards the active site can be observed
as in absence of sucrose. At the same time interactions between ligand and the disaccharide
occur explaining its increased RMSD value. Modifier 1-1 in pose II also stays directed towards
the starting point of polymerization as in the previous simulation. Especially in presence of
sucrose a stable conformation is maintained which also restraints the movement of sucrose
which is reflected in the small fluctuations and RMSD values in the plot (Figure 12.29).
The last complex contained stereoisomer 2 in pose II in combination with sucrose. In this
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connection a transport of sucrose out of the active site occurs evoked by the ligands movement
which was also observed in absence of the sugar. Contrary to the previous simulation one can
observe a return of the modifier to its initial position after “accompanying” sucrose towards
the solvent.
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Figure 12.29: Course of RMSD values versus time plots of A – sucrose in absence of modifier
2, B – sucrose in presence of modifier 1-1 covalently bound to N126Y in pose I, C - sucrose
in presence of modifier 1-1 covalently bound to N126Y in pose II or of D – modifier 1-2
covalently bound to N126Y in pose II during the 10 ns production run of the levansucrase
Y196F/Y247F/N126Y variant.
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Figure 12.30: MD simulation of sucrose with initial structure (red), after 5 ns (white) or 10
ns (blue) depicted in licorice representation. Initial frame of active site residues are depicted
in yellow licorice presentation for clarification.
A B
Figure 12.31: A - MD simulation of modifier 1-1 covalently bound to N126Y in pose I or B
- MD simulation of modifier 1-1 covalently bound to N126Y in pose II in presence of sucrose
depicted as initial structure (red), after 5 ns (white) or 10 ns (blue) in licorice representation.
Drawn arrows indicate movement of modifier and sucrose during 10 ns production run. Initial
frame of active site residues is depicted in yellow licorice presentation for clarification.
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A B
C
Figure 12.32: A - MD simulation of modifier 1-2 covalently bound to N126Y in pose II
depicted as initial structure (red), after 5 ns (white) or 10 ns (blue) in licorice representation.
B – For- and backward movement of modifier 1-1 during 10 ns production run indicated as
arrow 1 and 2. C – Movement of sucrose out of active site during 10 ns production run
is shown. Initial frame of active site residues is depicted in yellow licorice presentation for
clarification.
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A
Figure 12.33: Alignment of 6-kestose to sucrose in 3OM2. Sucrose is shown in yellow licorice
presentation, 6-kestose in 3OM2 coloured by name.
The last simulations contained the consideration of the second smallest output product
6-kestose. The fructose unit of 6-kestose has been aligned with the same unit of sucrose in
complex with the triple mutant of Bm-LS which was previously created (Figure 12.33). As
the fructose unit of the oligosaccharide is the starting point of polymerization it was chosen
for alignment instead of considering the glucose unit. This becomes clear if one thinks about
the previous simulation of sucrose in absence of the modifier. The change in RMSD value
mainly occurs by the rotation of the glucose and not fructose unit.
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Figure 12.34: Course of RMSD values versus time plots of A – 6-kestose in absence of
modifier 1, B – 6-kestose in presence of modifier 1-1 covalently bound to N126Y in pose I,
C – 6-kestose in presence of modifier 1-1 covalently bound to N126Y in pose II or of D –
modifier 1-2 covalently bound to N126Y in pose II during the 10 ns production run of the
levansucrase Y196F/Y247F/N126Y variant.
If one solely focuses on the 6-kestose Bm-LS complex one can observe an equilibration in
structure. The stabilization of the non-covalent complex occurs after 2 ns due interactions
between the glucose unit of 6-kestose and the N126Y mutant. This leads to a raise of RMSD
value to 6 A˚ implied in Figure 12.34-A. As in the case of sucrose only small fluctuations of
the initial fructose unit are observable. The inclusion of 2-1 in pose I also reveals a similar
motion as in the case of sucrose. A motion of 6-kestose and the covalent ligand occurs as
an interaction between both establishes which leads to an increase of RMSD value of the
trisaccharide after 4 ns. In contrast to the sugar the modifier is not strongly affected by this
interaction as it only shows a single twist of the phthalazinedione scaffold at 6 ns accompanied
by a slight raise in RMSD but a motion back to its equilibrated position. The simulations
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of modifier 1 as stereoisomer 1 or 2 in pose II reveal comparable results. In both cases 6-
kestose is tightly placed in its position as the ligand is directed towards it. This interaction
additionally stabilizes the modifier itself as the course of RMSD reveals lower values compared
to the absence of the trisaccharide. Fluctuations which occur for stereoisomer 2 are related
to the motion of the 1-azido-5-methoxypentane group.
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C D
Figure 12.35: A – MD simulation of 6-kestose in absence of modifier 2. B - MD simulation
of modifier 1-1 covalently bound to N126Y in pose I, C - of modifier 1-1 covalently bound to
N126Y in pose II or D – of modifier 1-2 covalently bound to N126Y in pose II in presence
of sucrose. Temporal progress of simulation time is depicted as initial structure (red), after
5 ns (white) or 10 ns (blue) in licorice representation. Drawn arrows indicate movement of
modifier and 6-kestose during 10 ns production run. Initial frame of active site residues is
depicted in yellow licorice presentation for clarification.
In a next step MD simulations have been conducted to investigate dynamics of the
Y196F/Y247F/N126Y variant of Bm-LS in covalent complex with modifier 2 and in presence
of 6-kestose. The initial positions of modifier 1 have been reused for modifier 2 to obtain
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comparability. In case of modifier 2-1 in pose I a similar behaviour is observable as for
modifier 1-1. Firstly, a movement of modifier 2-1 towards the active site can be seen and
consequently a rise to 8 A˚ in RMSD value is observable (Figure 12.36-A). After 8 ns the
trisaccharide draw closer to the modifier and forms interactions with 2-1 which leads to an
increase in RMSD from 3 A˚ to 6 A˚. In case of modifier 2-1 in pose II a similar movement
of the modifier is observable as for modifier 1-2 in pose II in presence of sucrose. Firstly,
a motion of 2-1 towards the same protein region occurs with a large increase in RMSD to
a value of 16 A˚ which does not affect 6-kestose as no rise in RMSD is observable (Figure
12.36-B). Afterwards 2-1 returns to its initial position ater 7 ns and stays directed towards
the active site.
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Figure 12.36: Course of RMSD values versus time plots of A – 6-kestose in presence of
modifier 2-1 covalently bound to N126Y in pose I, B – 6-kestose in presence of modifier 2-1
covalently bound to N126Y in pose II or of C – modifier 2-2 covalently bound to N126Y in
pose II during the 10 ns production run of the levansucrase Y196F/Y247F/N126Y variant.
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Lastly, dynamics of 2-2 in pose II reveal a stable conformation of the ligand as well as
of 6-kestose. Firstly, a slight motion of 2-2 is observable for the first nanosecond but the
modifier quickly relaxes and stays directed to the active site.
A B
C
Figure 12.37: Snapshots of production run in Y196F/Y247F/N126Y variant of Bm-LS. A
– Modifier 2-1 covalently bound to N126Y in pose I B - Modifier 2-1 covalently bound to
N126Y in pose II C – Modifier 2-2 covalently bound to N126Y in pose II in presence of
sucrose. Every ns of the temporal progress presented from red-coloured (start of simulation)
to blue-coloured modifier 2 (end of simulation). Initial frame of active site residues is depicted
in yellow licorice presentation for clarification.
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12.5 Polymer elongation via modifier 2 and 2-AzGlc of
different Bm-LS variants
Experimental data revealed a change in product profile to polysaccharides for three different
cases: on the one hand for the Bm-LS variant Y247F and the covalent modification of Tyr196
with 2-AzGlc and on the other for the Y196F/Y247F/S125Y mutant with modifier 2 or 2-
AzGlc covalently bound to S125Y. In order to reveal interactions of the protein-modifier
complex MD simulations with duration of 10 ns have been conducted with the same protocol
as mentioned in section 5.1.
A B
Figure 12.38: A – Initial position of modifier 2-AzGlc-1 in pose I (red) or in pose II (green).
B – Position of modifier 2-AzGlc-1 in pose I (red) or in pose II (green) after 10 ns production
run in levansucrase Y247F variant. Initial frame of active site residues is depicted in yellow
licorice presentation for clarification.
Firstly 2-AzGlc has been attached as stereoisomer 1 in two different poses on Tyr196 in
the Y247F variant as depicted in Figure 12.38-A. Afterwards a 10 ns production run has
been performed in presence of 6-kestose. For 2-AzGlc stereoisomer 1 an increase to 15 A˚ in
RMSD value is observable after 2 ns which goes along with a decrease in distance to Lys194
backbone oxygen (Figure 12.39-A and Figure 12.41-B). This interaction was maintained for
2 ns and was re-established after 8 ns. Additionally, intramolecular interactions of 2-AzGlc
are observable after 8 ns leading to a stabilization of RMSD values. For 6-kestose a motion
in the first ns is observable leading to a similar position as in absence of any modifer. Still,
no interactions between the trisaccharide and the modifier was observable as well as a motion
of the modifier towards the active site.
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Figure 12.39: Course of RMSD values versus time plots of A – 6-kestose in presence of
modifier 2-AzGlc-1 covalently bound to Tyr196 in pose I, B – 6-kestose in presence of modifier
2-AzGlc-1 covalently bound to Tyr196 in pose II during the 10 ns production run of the Bm-
LS variant Y247F.
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Figure 12.40: Interaction of covalent protein-inhibitor complex of 2-AzGlc-1 in pose I and
Bm-LS variant Y247F depicted with dashed lines. Location of amino acids and 2-AzGlc
serves for clarification and does not reflect actual position in MD simulations.
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Figure 12.41: The variation in distance as a function of simulation time for modifier 2-AzGlc-
1 (pose I) in Bm-LS variant Y247F corresponding to Figure 12.40 during a 10 ns production
run. A – Distance between 2-AzGlc-1-O(1) to 2-AzGlc-1-O(2)H in pose I. B – Distance
between Lys194-O(4) to 2-AzGlc-1-O(3) in pose I.
N
N
O
O(1)
N
NN
H(2)O
H(3)O
O
OH
O(4)H
O (5)O
HN Asp243
Glu244O
O(6)
Tyr196
Figure 12.42: Interaction of covalent protein-inhibitor complex of 2-AzGlc-1 in pose II and
Bm-LS variant Y247F depicted with dashed lines. Location of amino acids and 2-AzGlc
serves for clarification and does not reflect actual position in MD simulations.
For 2-AzGlc in pose II similar observations have been made. In terms of RMSD values
an increase to 15 A˚ can be seen after 1 ns which drops to 10 A˚ after 5 ns. This course is
correlated with arising interactions of the modifier and Asp243 backbone oxygen and Glu244
carboxylate group. As before, intramolecular hydrogen bonds are established for 2-1AzGlc.
All these points lead to the stabilization in RMSD value thus less fluctuations after 5 ns.
6-kestose shows a steady increase in RMSD value to 10 A˚ and stabilizes after 6 ns. As in
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the previous case, no interactions between the trisaccharide and 2-AzGlc was seen as well as
motions of the modifier into direction of the active site.
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Figure 12.43: The variation in distance as a function of simulation time for modifier 2-AzGlc-
1 (pose II) in Bm-LS variant Y247F corresponding to Figure 12.42 during a 10 ns production
run. A – Distance between 2-AzGlc-1-O(1) to 2-AzGlc-1-O(2)H in pose II. B – Distance
between Asp243-O(5) to 2-AzGlc-1-O(3) in pose II. C - Distance between Glu244-O(6) to
2-AzGlc-1-O(3) in pose II.
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A B
Figure 12.44: A – Initial position of modifier 2-1 in pose I (red) or in pose II (blue) or of
modifier 2-2 in pose I (green) or in pose II (orange). B – Position of modifier 2-1 in pose I
(red) or in pose II (blue) or of modifier 2-2 in pose I (green) or in pose II (orange) after 10 ns
production run. Initial frame of active site residues is depicted in yellow licorice presentation
for clarification.
As experimental findings revealed the production of polysaccharides for the Y196F/Y247F
/S125Y variant of Bm-LS in complex with modifier 2 and 2-AzGlc further simulations have
been conducted. For modifier 2 both stereoisomers and two different poses have been in-
cluded in the computations (Figure 12.44-A). If one takes a look at the RMSD values, a
higher increase is observable for the attachement to S125Y in pose II (Figure 12.45). This
becomes clear as the modifier shows a larger motion during the simulation compared to pose
I. Interestingly, all four variations of attaching modifier 2 lead to a similar position after 10
ns (Figure 12.44-B). Differences can be seen in case of the stereoisomers: lower fluctuations
in RMSD are observable for stereoisomer 2 which is also correlated with the formation of
stable direct hydrogen bonds with Glu170’s amide group (Figure 12.47).
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Figure 12.45: Course of RMSD values versus time plots of A – 6-kestose in presence of
modifier 2-1 covalently bound to Tyr126 in pose I, B – 6-kestose in presence of modifier 2-2
covalently bound to Tyr126 in pose I, C - 6-kestose in presence of modifier 2-1 covalently
bound to Tyr126 in pose II, D - 6-kestose in presence of modifier 2-2 covalently bound to
Tyr126 in pose II during the 10 ns production run of Bm-LS variant Y196F/Y247F/S125Y.
In case of 6-kestose interactions between modifier 2-1 in pose I and the trisaccharide
are established leading to the increase in RMSD value. This was not seen for the three
other cases. Additionally, modifier 2 is not directed towards the active site in the course of
simulation time as modifier 1.
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Figure 12.46: Interaction of covalent protein-inhibitor complex of 2-1 and Bm-LS variant
Y196F/Y247F/S125Y depicted with dashed lines. Location of amino acids and 2 serves for
clarification and does not reflect actual position in MD simulations.
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Figure 12.47: The variation in distance as a function of simulation time for modifier 2-AzGlc-
1 (pose I) in Bm-LS Y196F/Y247F/S125Y variant corresponding to Figure 12.5 during a 10
ns production run. Distance between A – 2-AzGlc-1-O(1) in pose I, B – 2-AzGlc-2-O(1) in
pose I, C – 2-AzGlc-1-O(1) in pose II or D – 2-AzGlc-2-O(1) in pose II and Gln170-NH(1).
Lastly, dynamics of 2-AzGlc in the Y196F/Y247F/S125Y variant of Bm-LS have been
investigated. Due to steric hindrance of the protein environment it was not possible to attach
2-AzGlc-2 in pose II to Tyr125 thus only three different simulations have been performed.
As modifier 2 the extended 2-AzGlc show similar motions towards the same region of Bm-LS
independent from the starting point (Figure 12.48-B). Consequently, the rise in RMSD for
pose II is much larger compared to simulations of 2-AzGlc in pose I as it has to move farther
away from its initial position. In contrast to modifier 2 no interactions to 6-kestose can be
observed resulting in similar trends in RMSD for the trisaccharide. For 2-AzGlc-1 in pose I
interactions between modifier and backbone oxygen of Lys194 are established between 2 and 6
ns. Afterwards hydrogen bonds between Asp251 are formed (Figure 12.51). For stereoisomer
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2 in the same pose interactions between Asp251 are established and maintained in the course
of simulation time (Figure 12.52). Contrary to 2-AzGlc-1 in pose I simulations in pose II
reveal at first an interaction with Asn252 between 2 and 4 ns (Figure 12.53-A). The next
observed formation of hydrogen bonds occurred at 8 ns between Lys194 and the modifier
(Figure 12.53-B). Interestingly, no intramolecular interactions of modifier 2 or 2-AzGlc have
been established in the simulations in the Y196F/Y247F/S125Y variant of Bm-LS.
A B
Figure 12.48: A – Initial position of modifier 2-AzGlc-1 in pose I (red) or in pose II (blue)
or of modifier 2-AzGlc-2 in pose I (green). B – Position of modifier 2-AzGlc-1 in pose I (red)
or in pose II (blue) or of modifier 2-AzGlc-2 in pose I (green) after 10 ns production run.
Initial frame of active site residues is depicted in yellow licorice presentation for clarification.
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Figure 12.49: Course of RMSD values versus time plots of A – 6-kestose in presence of
modifier 2-AzGlc-1 covalently bound to Tyr126 in pose I, B – 6-kestose in presence of modifier
2-AzGlc-2 covalently bound to Tyr126 in pose I, C - 6-kestose in presence of modifier 2-AzGlc-
1 covalently bound to Tyr126 in pose II during the 10 ns production run of Bm-LS variant
Y196F/Y247F/S125Y.
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Figure 12.50: Interaction of covalent protein-inhibitor complex of 2-AzGlc-1 or 2-AzGlc-2 and
Bm-LS variant Y196F/Y247F/S125Y depicted with dashed lines. Location of amino acids
and 2-AzGlc serves for clarification and does not reflect actual position in MD simulations.
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Figure 12.51: The variation in distance as a function of simulation time for modifier 2-AzGlc-
1 (pose I ) in Bm-LS Y196F/Y247F/S125Y variant corresponding to Figure 12.50 during a
10 ns production run. Distance between A – 2-AzGlc-1-O(1)H in pose I and Lys194-O(5) or
between B – 2-AzGlc-1-O(2)H or 2-AzGlc-1-O(3)H in pose I and Asp251-O(6).
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Figure 12.52: The variation in distance as a function of simulation time for modifier 2-AzGlc-
2 (pose I ) in Bm-LS Y196F/Y247F/S125Y variant corresponding to Figure 12.50 during a
10 ns production run. Distance between 2-AzGlc-2-O(3)H or 2-AzGlc-2-O(4)H in pose I and
Asp251-O(6).
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Figure 12.53: The variation in distance as a function of simulation time for modifier 2-AzGlc-
1 (pose II) in Bm-LS Y196F/Y247F/S125Y variant corresponding to Figure 12.50 during a
10 ns production run. Distance between A – 2-AzGlc-1-O(3) in pose II and Asn252-O(7) or
between B – 2-AzGlc-1-O(2)H in pose II and Lys194-O(5).
292
12.6. CONCLUSION AND COMPARISON TO EXPERIMENTAL FINDINGS
12.6 Conclusion and comparison to experimental find-
ings
Investigations on the covalent modification of Bacillus megaterium levansucrase (Bm-LS)
wild type or triple variant by modifier 1, 2 or 2-AzGlc and its effects on the product profile
have been conducted in this chapter (Figure 12.5). Bm-LS polymerizes mono-units of levan
and usually produces oligosaccharides with a polymerization degree of 2-20. The introduc-
tion of modifier 1 lead to a covalent modification of tyrosine residues and thus to an altered
product profile with smaller oligosaccharides. Mass spectrometry verified that two tyrosines
were varied but could not determine the exact ones. Hence, MD simulations were conducted
by linking modifier 1 (if possible both stereoisomers) to Tyr196, Tyr247 or Tyr446 and dy-
namics were investigated. If a motion towards the active site is detectable one can suggest
that a disturbance of the polymerization occurs. In consequence one can conclude which
tyrosine is likely modified.
The first aspect was the determination of the modified tyrosine residues in Bm-LS wild type.
Initial simulations which include a single covalent attachment of modifier 1-1 (modifier 1
stereoisomer 1) showed that for Tyr196 or Tyr446 no interaction to important active site
amino acids can be observed. These findings were independent from the stereoisomer. Only
the linkage of the ligand to Tyr247 revealed a possible disturbance of the elongation pro-
cess. Investigations have further been extended to the combined modification of two tyrosine
residues according to the findings of the mass spectrometry. In the process, the twofold mod-
ification of Tyr196 and Tyr446 was neglected as individual simulations did not lead to active
site interactions. In terms of the concurrent linkage of modifier 1 on Tyr196 and Tyr247 a
pi-pi interaction between the phthalazinedione scaffold of modifier 1-1 on Tyr196 and Tyr247’s
phenyl ring was noticeable leading to a change of orientation of the ligand on Tyr196 towards
Tyr247 (Figure 12.14). Additionally, a stabilization of the second modifier occurred as fluc-
tuations in the RMSD decreased. Simulations of the simultaneous covalent binding of 1-1 on
Tyr247 and Tyr446 strengthen the assumption of the subordinate role of Tyr446 as it was
not directed towards the active site. Yet it became clear that the modifier shows a certain
amount of flexibility as, despite of the pose, motions towards or reverse to the active site
are possible. These findings go along with the experimental analysis of products obtained
by the Y196F/Y247F mutant. No altered oligosaccharide/levan production was obtained by
chemical modification of this variant via modifier 1. This indicates that the different product
profile occurs due the reaction of the modifier and those two tyrosine residues.
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Secondly, investigations on the triple variants of Bm-LS have been carried out. Triple muta-
tions as Y196F/Y247F/N126Y, Y196F/Y247F/Q381Y and Y196F/Y247F/F445Y were con-
ducted and also simulated. The tyrosine residues 196 and 247 have been replaced by pheny-
lalanine to avoid modification. Aim of these changes is to gain control on the polymerization
process by inserting tyrosine residues at critical positions via mutations which should be sol-
vent exposed and accessible for covalent modification. Experimental results concluded indeed
a change of product profile which occurs because of the Y196F/Y247F/N126Y variant. This
leads to the heightening in synthesis of small polymers. In terms of the MD simulation of
the Y196F/Y247F/F445Y mutant the results occur ambiguous. Depending on the pose of
modifier 1 one might or might not expect a disturbance in elongation. On the experimental
side, this event was not confirmed. For the case of the Y196F/Y247F/Q381Y mutant no
interaction with the active site was observed during the simulation as seen in experiments.
Theoretical investigations on Y196F/Y247F/N126Y lead to two possible explanations regard-
ing the changed product profile. Simulations revealed that modifier 1 is directed to the region
of elongation which could lead to disturbances. To further study this Bm-LS variant simula-
tions have been extended by including sucrose or 6-kestose source materials of the elongation
process. In consequence new findings arose as a motion was visible leading to a transport
of sucrose out of the active site. Additionally, a stabilization of the modifier and sucrose or
6-kestose can occur, which is leading to a blockade and thus to a disturbance of the elonga-
tion process. Both occurrences are in line with experimental results and might explain the
increase of small products of the Y196F/Y247F/N126Y variant. Furthermore, investigations
have been extended by conducting simulations of modifier 2 in the Y196F/Y247F/N126Y
variant in presence of 6-kestose. In case of the isomer 2 in pose II one can see a stable
conformation and a occupancy of the active site by modifier 2. In contrast to that isomer
1 shows motions receding and also approaching towards active site residues. These findings
are also in line with experimental results but in contrast to modifier 1 a larger flexibility is
observed.
Lastly, dynamics of modifier 2 and 2-AzGlc have been investigated for Y247F or Y196F/Y247F
/S125Y variants of Bm-LS. The group of Seibel revealed that these variants of Bm-LS in co-
valent complex with modifier 2 or 2-AzGlc lead to a production of polysaccharides. To gain
further insight on the polymerization MD simulations have been conducted.
In all simulations no interactions with active site residues have been observed which goes
along with experimental findings. If the modifier would occupy the active site one can ex-
pect the production of shorter oligosaccharides. This is not the case as polysaccharides
were produced by the mutants of Bm-LS. Additionally, the research gave insight in terms of
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protein-modifier interactions. In case of the Y247F variant polar intermolecular interactions
of 2-AzGlc and Lys194 are established, while for the Y196F/Y247F/S125Y variant Glu170
(for modifier 2) or Lys194 and Asp251 (for modifier 2-AzGlc) hydrogen bonds are formed.
Interestingly, modifier 2 as well as 2-AzGlc are moving to the same region of protein in the
Y196F/Y247F/S125Y despite of the initial position. These findings suggest that the modifier
might act as cap due to increased steric hindrance and thus could prevent an early depart
of the size-increasing oligosaccharides. Still it has to be mentioned that these results only
indicate a possible elongation path. The mechanism is nevertheless not fully understood and
further research is of necessity.
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Chapter 13
Environmental influence on the proton
transfer in cysteine/histidine dyads
13.1 Introduction
Protonation states or the understanding of the proton transfer in enzymes or biological sys-
tems is in nearly all theoretical work of relevance. The proton transfer within the enzyme
is deterministic for a series of processes e.g. peptide cleavage reactions or enabling covalent
modification of inhibitors [285]. Another often investigated problem is the determination
of the pKa value of respective protein residues which is, due to the number of atoms, not
a trivial matter. The pKa predictor PROPKA offers one possibility to solve this problem
[286], [287]. Still, the application of this software can be problematic as it is based on empir-
ical parameters for atomic charge and bond geometries thus might lead to unreliable results
[288]. Another option to obtain pKa values is via pH-titration MD (pHtMD) [289]. The
procedure is comparable to classical wet-lab titration, but a huge amount of simulation time
is necessary.
A lot of studies, which deal with proton transfer in enzymes, are applying QM/MM method-
ologies, whereas the QM part is calculated with density functional methods [285]. Due to
the size of enzymes the choice of QM/MM methodologies is evident, as the description of a
whole protein is still not feasible with pure QM. Therefore, the reaction itself is calculated
with QM approaches, while the environment is described with simpler methods (force field).
The relevance of such investigations can be explained as follows: changes in the pH value is
concurrent involved with a change of the protonation state of amino acids as cysteine, lysine,
histidine etc. Thus the abstraction or addition of a proton at these amino acids leads to a
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change of the charge distribution within the whole protein and can result in conformational
changes. Therefore, binding properties of ligands or the activity of the protein itself might
be affected [289].
In literature plenty of QM/MM studies concerning the proton transfer in enzymes can be
found. Vidossich et al. investigated the water-mediated proton transfer and its role in the
peroxidase catalysis of horseradish peroxidase via MD simulations and QM/MM calculations.
Another theoretical study focused on the reaction mechanism of the peptide-bond formation
in the ribosome and revealed additionally to the direct transfer a proton-shuttle mechanism
via the ribose-2’-OH group.
Among the clarification of enzyme specific mechanisms the understanding of neutral or zwit-
terionic protonation states in cysteine/histidine dyads is an integrial part and in case of
cysteine proteases still subject of controversy [290]. Mladenovic et al. showed the rele-
vance of active side histidine which enables the water-mediated proton transfer to epoxide-
or aziridine-based inhibitors via a relay system and therefore is responsible for the activity
of these inhibitors. In case of the arginine deiminase catalysis the protonation state of the
cysteine nucleophile was determined by comparison with experimental findings [291]. For
KasA, which is involved in the biosynthesis of the cell wall of Mycobacterium tuberculosis,
Lee et al. revealed that the protonation state of the catalytic Cys/His dyade can switch easily
between both protonation states [292]. Of course these are just a few examples which can be
found in literature in regard to the determination of the proton transfer or the protonation
state in enzymes.
Clearly, it is of necessity to probe the reliability of applied quantum chemical method for
the description of the protonation state. One can find a lot of benchmarking studies on this
matter, although they are mostly performed under gas phase conditions [293], [294], [295],
[296], [297]. Further analysis on this matter has been conducted by Paasche et al. In his
benchmark paper, the accuracy of different quantum chemical methods has been probed for
the cysteine-histidine proton transfer [285]. Investigations have been expanded from the gas
phase by mimicking the enzyme environment with continuum models or the explicit inclu-
sion via QM/MM methodologies. These investigations focused solely on the proton transfer
starting from the neutral state and do not include the backwards reaction.
In this chapter similar computational investigations have been conducted to describe the
proton transfer of the catyltic cys/his dyade in FadA5 or in cruzain (T. cruzi) via MD simu-
lations and QM/MM calculations. In contrast to the work of Paasche et al. both protonation
states have been considered as starting points for the proton transfer to detect possible dis-
crepancies in the description. In this matter several post-HF and DFT functionals were
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additionally benchmarked against CCSD(T) to probe the suitability of applied methodolo-
gies. Furthermore, investigations have been extended to analyze the relaxation process of
the protein due to the proton transfer and will be described in the following sections.
13.2 System preparation and MD simulations
As a prerequisite it was necessary to perform MD simulations to obtain equilibrated structures
of the apoprotein of FadA5 and cruzain for QM/MM calculations. In case of FadA5 chain
B of the apoprotein structure (pdb code 4UBW) was used as starting point. In contrast
to chain A, all residues were located in the X-ray structure of chain B. As no apoprotein
structure of cruzain was available a different solution was needed. Therefore, a structure of
a non-covalent inhibitor bound to cruzain has been chosen (pdb code 1ME4) because of its
high X-ray structure resolution of 1.2 A˚. Afterwards the inhibitor was removed to obtain the
artificial apoprotein structure of cruzain.
Just like in section 5.1 the apoprotein complexes of FadA5 and cruzain were described by
the AMBER14 force field ff14SB. In regard to minimization and equilibration the same
protocol was conducted as described in section 5.1. In terms of the proton transfer two
different protonation states are conceivable: (protonation state I) a neutral catalytic dyade
consisting of a protonated cysteine and a singly protonated histidine or (protonation state II)
a zwitterionic catalytic dyade with a deprotonated, negatively charged cysteine and a doubly
protonated positively charged histidine (Figure 13.1). As no proton transfer can take place
during a classical MM simulation both states have to be considered in the MD simulations to
obtain two different starting points for the QM/MM proton transfer calculations. By doing so
it is observable that the protein environment relaxes to the protonation state of the catalytic
dyade and these effects are evaluated in the next sections. The duration of each simulation
was 10 ns leading to a total simulation time of 40 ns by including both protonation states of
the catalytic dyade of FadA5 and cruzain.
In contrast to the other sections a detailed investigation on the MD simulations was not
performed as they were only needed to obtain a relaxed structure as starting point for further
QM/MM calculations.
298
13.3. QM/MM CALCULATIONS AND BENCHMARK
13.3 QM/MM calculations and benchmark
Firstly, a relaxed structure of FadA5 and cruzain in both protonation states has been ex-
tracted from the MD simulation which served as starting point for the QM/MM calculations.
It was paid attention that all structures contained a water molecule located between active
site cysteine and histidine which acts as proton donator and acceptor. By doing so one
achieves comparability for the investigated reaction.
The initial step started with a local optimization by employing QM/MM methodology uti-
lizing the ChemShell 3.6.0 software package and an electrostatic embedding with the charge
shift method. The QM region (depicted in red in Figure 13.1) has been optimized by em-
ploying B3LYP-D3 and the def-TZVP basis set. The rest of the system was treated by the
AMBER14 force field. To decrease computational costs only molecules in a radius of 10 A˚
around the active site cysteine residue were optimized, while the rest of the system was fixed.
Afterwards a relaxed scan on QM/MM level has been conducted resulting in four different
potential energy surfaces (Figure 13.2 and Figure 13.3). In all cases the same methodology
has been used as mentioned before. Interestingly, one can observe a similar trend for both
proteins: the stability of the protonation state is determined by the initial protonation state
of the used snapshot. If the relaxed scan starts from the optimized neutral catalytic state
(protonation state I) it is energetically lower than the zwitterionic state after water-mediated
proton transfer and vice versa. In case of FadA5 the height of barrier is 9.7 kcal/mol while
the zwitterionic state is higher by 8.1 kcal/mol compared to the initial neutral starting point.
These findings are similar to the QM/MM computations of cruzain whereby the obtained
values are lower: the barrier is of 7.9 kcal/mol while the energy difference after the proton
transfer is 3.1 kcal/mol. Contrary to these findings are the results from the zwitterionic
starting point. It is observable that this state is favored if the snapshot of the MD simulation
in the zwitterionic one is used. For FadA5 the barrier increases to 17.0 kcal/mol and the
neutral state is described as less stable compared to the zwitterionic state with difference
in energy of 13.1 kcal/mol. Again, this trend can be seen for cruzain with a barrier of 8.7
kcal/mol and an energetic difference of 4.3 kcal/mol after proton transfer.
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Figure 13.1: Red coloured lines indicate atoms, which has been used in the QM part of a
QM/MM relaxed scan of the proton transfer in FadA5 or cruzain. A – Starting point from
a neutral catalytic dyade of cysteine and histidine (protonation state I). B – Starting point
from a zwitterionic catalytic dyade of cysteine and histidine (protonation state II). Dashed
lines indicate the coordinates which were varied during relaxed scan. Location of amino acids
and water molecule serves for clarification and does not reflect actual position in QM/MM
calculation.
These findings indicate a large influence of the surrounding on the stability of the proto-
nation state which is observable for both proteins. As negatively charged sulfur is present in
the QM region, the necessity of augmented basis sets is obvious for a better description of
the transition as well as the zwitterionic state. Thus, a benchmark has been performed by
conducting QM/MM single point energy calculations on the transition state as well as for
both protonation states employing different wave function-based or DFT approaches summa-
rized in Table 13.1 and Table 13.2 while the description of the MM part remained the same.
The basis set was increased to aug-cc-pVDZ, in case of SCS-MP2 or SCS-CC2 additionally
to aug-ccpVTZ. The results have been compared to the CCSD(T) methodology which is the
gold standard for ground state energy calculations.
If one takes a look at Table 13.1 or Table 13.2, it is observable that the results obtained by
SCS-MP2 or SCS-CC2 in combination with aug-cc-pVDZ agree best with the benchmark val-
ues obtained with CCSD(T)/aug-cc-pVDZ. Slightly worse results are achieved if the basis set
is increased to aug-cc-pVTZ except for SCS-MP2 in cruzain starting from protonation state
I. This might be explainable as only aug-cc-pVDZ was employed for CCSD(T) calculations.
It is possible that an increase of the basis set to aug-cc-pVTZ in case of CCSD(T) might
result in comparable results but was not performed due to computational costs. Additionally,
one can see that the usage of a larger basis set decreases the barrier height while the “final”
state after proton transfer is destabilized. These effects are still not large and do not affect
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the trend in prediction. Computations also show that the usage of the spin-component scaled
electron correlation method constantly improves the results. In terms of the DFT functionals
the same observation as before can be made.
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A
B
Figure 13.2: Relaxed scan of proton transfer in FadA5 depicted in Figure 13.1. A – Starting
from neutral state of cysteine and histidine catalytic dyade. B – Starting from zwitterionic
state of cysteine and histidine catalytic dyade. Energies are obtained by B3LYP-D3/def-
TZVP optimization and are in relation to the starting point of the relaxed scan. All energy
values are given in kcal/mol.
302
13.3. QM/MM CALCULATIONS AND BENCHMARK
A
B
Figure 13.3: Relaxed scan of proton transfer in cruzain depicted in Figure 13.1. A – Starting
from neutral state of cysteine and histidine catalytic dyade. B – Starting from zwitterionic
state of cysteine and histidine catalytic dyade. Energies are obtained by B3LYP-D3/def-
TZVP optimization and are in relation to the starting point of the relaxed scan. All energy
values are given in kcal/mol.
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Table 13.1: QMMM transition state and reaction energies (∆Ereac) of water-mediated proton
transfer in FadA5 employing different ab initio or DFT calculations compared to CCSD(T)/aug-
cc-pVDZ calculations from neutral or zwitterionic starting point. For * marked methods the aug-
cc-pVTZ basis was used, otherwise the aug-cc-pVDZ basis set. All energy values are shown in
kcal/mol.
neutral catalytic dyade starting point
HIDCYS TS zwitterion.
CCSD(T) 12.5 9.2
HF 20.2 10.8
MP2 10.2 8.6
CC2 9.9 8.4
SCS-MP2 12.8 9.7
SCS-CC2 12.5 9.6
SCS-MP2* 12.4 10.1
SCS-CC2* 12.2 10.1
LDA -2.5 -0.4
PBE 4.8 4.9
BP86 4.7 4.7
BLYP 7.5 6.1
B3LYP 8.8 6.4
B3LYP G 9.3 6.9
BHLYP 12.2 7.7
zwitterionic catalytic dyade starting point
HIPCYM TS neutral
CCSD(T) 19.1 14.1
HF 30.2 22.0
MP2 16.9 13.6
CC2 16.2 12.9
SCS-MP2 19.9 14.6
SCS-CC2 19.4 14.1
SCS-MP2* 18.9 14.7
SCS-CC2* 18.5 14.2
LDA 7.3 11.9
PBE 12.5 12.7
BP86 12.6 12.9
BLYP 15.2 13.3
B3LYP 17.1 14.8
B3LYP G 17.6 15.1
BHLYP 21.0 17.2
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Table 13.2: QMMM transition state and reaction energies (∆Ereac) of water-mediated proton
transfer in cruzain employing different ab initio or DFT calculations compared to CCSD(T)/aug-
cc-pVDZ calculations from neutral or zwitterionic starting point. For * marked methods the aug-
cc-pVTZ basis was used, otherwise the aug-cc-pVDZ basis set. All energy values are given in
kcal/mol.
neutral catalytic dyade starting point
HIPCYM TS neutral
CCSD(T) 10.6 3.7
HF 18.5 3.1
MP2 8.2 3.0
CC2 7.9 3.2
SCS-MP2 9.9 3.6
SCS-CC2 9.7 3.8
SCS-MP2* 10.4 3.9
SCS-CC2* 10.2 4.1
LDA -3.3 -2.2
PBE 2.8 1.1
BP86 2.7 0.9
BLYP 5.3 1.8
B3LYP 7.0 1.7
B3LYP G 7.3 2.2
BHLYP 10.6 2.3
zwitterionic catalytic dyade starting point
HIDCYS TS zwitterion.
CCSD(T) 10.4 4.0
HF 17.5 7.5
MP2 8.8 4.2
CC2 8.5 3.9
SCS-MP2 10.5 4.1
SCS-CC2 10.2 3.9
SCS-MP2* 10.2 4.4
SCS-CC2* 9.9 4.2
LDA 2.1 7.6
PBE 5.9 5.6
BP86 6.0 5.6
BLYP 7.8 5.0
B3LYP 9.0 5.8
B3LYP G 8.8 5.6
BHLYP 11.2 6.5
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Except for LDA, the initial protonation state is always lower in energy compared to the
one after proton transfer. Interestingly, BHLYP agrees better with the CCSD(T) value than
MP2 or CC2 in case of the neutral starting point and B3LYP or B3LYP G for the zwitterionic
starting point in FadA5. Still, in all other cases DFT approaches are always worse compared
to spin-component scaled methods as their MAE is larger. If one takes the MAE values of the
transition state and the proton transfer reaction energies into account, it is observable that
the lowest MAE values are achieved if the spin component scaled methodologies is employed
(Figure 13.4). Pure MP2 or CC2 results are about 1 kcal/mol higher in MAE value. As to be
expected Hartree Fock leads to the worst results in terms of the applied ab initio methods.
For DFT results one can clearly see that Jacobs Ladder is reproduced: the accuracy increases
at the same time as the complexity of the applied functional. LDA which is the simplest
approximation leads to a MAE value of 9 kcal/mol while the MAE value of GGA methods
as PBE, BP86 or BLYP are below 5 kcal/mol [298]. The hybrid functional B3LYP (in the
Turbomole and Gaussian implementation) and also BHLYP perform similar to MP2 or CC2
and have a MAE value below 2.2 kcal/mol.
To gain further insight, MAE values of the reaction barrier or of the proton transfer reaction
energy have been calculated (Figure 13.5 and Figure 13.6). Except for the spin-component
scaled methods larger MAE values are obtained for the reaction barrier compared to the
reaction energy. Especially HF, LDA and the GGA methods PBE and PB86 have in this
respect MAE values in the range of 7 to 12 kcal/mol. Comparable results regarding the MAE
values are only obtained if spin-component scaled methods are applied as their MAE values
are below 0.5 kcal/mol for the reaction energy as well as for the reaction barrier.
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Figure 13.4: Mean average error with respect to CCSD(T)/aug-cc-pVDZ averaged of all
proton transfer reaction energies and reaction barrier (neutral and zwitterionic) in FadA5
and cruzain. For * marked methods the aug-cc-pVTZ basis was used, otherwise the aug-cc-
pVDZ basis set. All MAE values are presented in kcal/mol.
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Figure 13.5: Mean average error with respect to CCSD(T)/aug-cc-pVDZ averaged of all
reaction barrier (neutral and zwitterionic) in FadA5 and cruzain. For * marked methods
the aug-cc-pVTZ basis was used, otherwise the aug-cc-pVDZ basis set. All MAE values are
presented in kcal/mol.
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Figure 13.6: Mean average error with respect to CCSD(T)/aug-cc-pVDZ averaged of all
proton transfer reaction energies (neutral and zwitterionic) in FadA5 and cruzain. For *
marked methods the aug-cc-pVTZ basis was used, otherwise the aug-cc-pVDZ basis set. All
MAE values are presented in kcal/mol.
To prove the validity of CCSD(T) it is necessary to analyze the D1 diagnostics. As one can
see in Table 13.3 the CCSD D1 diagnostics show values below 0.06 and thus the description
of the QM part via the coupled cluster approach can be considered as valid as one can see
that multiple configurations in the wave functions’ description is not necessarily needed.
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Table 13.3: Summary of CCSD D1 diagnostic of neutral, transition and zwitterionic state of proton
transfer in FadA5 or cruzain. All calculations were performed with the CCSD(T)/aug-cc-pDVZ
approach.
FadA5 starting point neutral transition state zwitterionic
protonation state I
CCSD D1 0.0405 0.0440 0.0495
diagnostic
starting point zwitterionic transition state neutral
protonation state II
CCSD D1 0.0499 0.0406 0.0402
diagnostic
cruzain starting point neutral transition state zwitterionic
protonation state I
CCSD D1 0.0428 0.0456 0.0505
diagnostic
starting point zwitterionic transition state neutral
protonation state II
CCSD D1 0.0541 0.0447 0.0447
diagnostic
13.4 Change of protein environment and its influence
on proton transfer
Results of the previous section indicate a large influence of the protein environment on the
prevailing protonation state. As results of the benchmark calculations also show that this
observation can be made independent of the applied methodology (except for LDA) further
investigations have been conducted. One can imagine two different protein environments
A and B resulting from the snapshot of the MD simulation in protonation state I (neutral
starting point) or protonation state II (zwitterionic starting point). If one starts from the
neutral state in environment A, this state is clearly preferred as the snapshot is extracted
from a MD simulation in which the protein has adapted to the protonation state. Now the
idea is to insert the QM region of the neutral, transition and zwitterionic state of environment
A into the “wrong” environment B which is adapted to the zwitterionic protonation state II.
By doing so it is to be expected that the zwitterionic state is now stabilized by environment B
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and should be lower in energy compared to the neutral state. This change of environment can
also be done by inserting above mentioned QM regions of environment B into environment
A.
In a first step the optimized QM structures of the neutral, transition and zwitterionic state
including active site cysteine, histidine residue as well as the water molecule involved in
the proton transfer have been extracted from environment A (or B) and were inserted into
environment B (or A). This is exemplary shown for the neutral state in environment A and
B in Figure 13.7. To ensure a connection between the residues, backbone atoms of cysteine
and histidine have also been considered in the exchange. Afterwards a QM/MM optimization
on B3LYP/def-TZVP level including dispersion correction has been performed for all three
states with the same QM region and applied constraints as in environment A (or B) depicted
in Figure 13.1. The MM region was described with the AMBER14 force field. Afterwards
QM/MM single point energy calculations were conducted on SCS-MP2 or SCS-CC2 level
with an aug-cc-pVDZ basis set as these methods show the best results in the benchmark.
A B
Figure 13.7: A – QM/MM optimized structure of neutral catalytic dyade of cysteine and
histidine in cruzain environment A (green). B – QM/MM optimized structure of neutral
catalytic dyade of cysteine and histidine inserted in environment B (red) of cruzain and
reoptimized. The QM/MM optimization employed B3LYP-D3/def-TZVP and the AMBER14
force field.
As initially expected one can see a decrease in reaction energy of the proton transfer after
the exchange (Table 13.4 and Figure 13.8). In case of FadA5 the zwitterionic state decreases
to the same level as the neutral state (if one starts from the protonation state I) while the
height of barrier also lowers by ∼ 2 kcal/mol. In the other case the QM region of the neutral
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state in the “wrong” environment A (extracted from environment B) is 20 kcal/mol more
stable in comparison to the zwitterionic state. Interestingly the previous transition state is
lower than the initial neutral state by 14 kcal/mol. In case of cruzain comparable results are
obtained. In both cases the height of barrier decreases by approximately 3 to 5 kcal/mol while
the endpoint of the proton transfer is lower by 1 or 2 kcal/mol. These findings strengthen the
assumption of the influence of the protein environment regarding the preferred protonation
state.
Table 13.4: QM/MM reaction energies (∆Ereac) of water-mediated proton transfer in FadA5 or
cruzain employing different ab initio method. All calculations used the aug-cc-pVDZ basis set. All
energy values in kcal/mol.
FadA5 SCS-MP21 SCS-CC21 SCS-MP22 SCS-CC22
TS 12.8 12.5 10.1 9.6
zwitterion. 9.7 9.6 -0.2 -0.2
SCS-MP23 SCS-CC23 SCS-MP24 SCS-CC24
TS 19.9 19.4 -13.7 -13.9
neutral 14.6 14.1 -19.9 -20.1
cruzain SCS-MP21 SCS-CC21 SCS-MP22 SCS-CC22
TS 9.9 9.7 6.7 6.5
zwitterion. 3.6 3.8 -1.2 -0.9
SCS-MP23 SCS-CC23 SCS-MP24 SCS-CC24
TS 10.5 10.2 5.7 5.4
neutral 4.1 3.9 -2.2 -2.4
1Calculated energy of transition state and reaction energy from neutral starting point in environment I.
2Calculated energy of transition state and reaction energy from neutral starting point in environment II.
3Calculated energy of transition state and reaction energy from zwitterionic starting point in environment
II. 4Calculated energy of transition state and reaction energy from zwitterionic starting point in
environment I.
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Figure 13.8: Reaction energies of proton transfer obtained by QM/MM single point calcula-
tions employing SCS-MP2 or SCS-CC2 and a aug-cc-pVDZ basis set starting from protona-
tion state I in both environment A and B in A – FadA5 or B – cruzain or from protonation
state II in both environment in C – FadA5 or D – cruzain. Depicted values correspond to
Table 13.4. All values in kcal/mol.
13.5 Dynamics of protein adaptation to the protona-
tion state
Lastly, the investigations focused on the dynamics of the protein adaptation to the protona-
tion state. It is imaginable that the proton transfer itself is a much faster reaction as the
rearrangement of the protein. If one imagines a water dimer, hydrogen bonds can be formed
or broken due to thermal fluctuations alone, thus the shifting of protons along hydrogen
bonds can occur spontaneously at 300 K [299], [300]. In consequence the question arises
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how much time is needed for the adaptation process of the protein. Therefore classical MD
simulations have been performed using the QM/MM optimized structure of the neutral state
in environment A and B (or zwitterionic state in both environments) to gain further insight
on the time scale of environmental relaxation. The difference to previous simulations is the
usage of a harmonical restraint by a value of 2000 kcal mol−1 A˚−2 to prevent large motions
of the QM region. The reason why both environments were considered is due to two circum-
stances. Firstly, both snapshots of the respective protonation state starts from a QM/MM
optimized structure. Therefore it is understandable that a MD simulation is needed to equi-
librate the MM region. Secondly, it is of interest how much time is required for a relaxation
of the “wrong” environment in comparison to the “right” one. To achieve a certain amount
of comparability and validity 2-dimensional RMSD plots were calculated which include the
motion of both MD simulations. In concrete terms 200 snapshots of the MD simulation of
protonation state I (FadA5 and cruzain) in the wrong environment B have been compared
with 200 snapshots of the MD simulation in the right environment A which also has been
done for protonation state II (Figure 13.9). To decrease the computational costs only the
protein environment in a radius of 10 A˚ close to the active cysteine was considered.
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Figure 13.9: 2d-RMSD plot of MD simulation of QM part inserted into different MM region
(x-axis) compared to MD simulation of QM part in original MM region (y-axis). RMSD was
calculated for 10 A˚ protein around Cys25 for cruzain or Cys93 for FadA5. 200 snapshots have
been considered for each MD simulation. A - Neutral QM region of cruzain in environment
A and B. B – Zwitterionic QM region of cruzain in environment A and B. C - Neutral
QM region of FadA5 in environment A and B. D – Zwitterionic QM region of FadA5 in
environment A and B.
To simplify the 2d RMSD plots the mean RMSD values have been calculated by using
the following equation:
meanRMSD =
n∑
b=1
RMSDbt
n
(13.1)
The mean RMSD is the averaged summation of all RMSD values (RMSDbt ) of the MD
simulation in the “right” environment compared to a snapshot in the artifical environment
(Figure 13.10).
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For cruzain in protonation state I (neutral dyad) it is observable that after 4 ns a relaxation of
the environment occurs leading to a decrease in mean RMSD value from ≈ 2.3 A˚ to 1.8 A˚ and
after 7 ns to 1.5 A˚. For the zwitterionic protonation state a reduction in mean RMSD value
takes place after 6 ns from ≈ 2 A˚ to 1.5 A˚. In contrast to protonation state I snapshots in the
wrong environment during 7 – 10 ns show RMSD values below 1 A˚ compared to the snapshots
in the simulation time of 9-10 ns in the right environment (Figure 13.9-B). Additionally, no
increase in mean RMSD value can be seen after 7 ns. For FadA5 in protonation state I
a diminishing in mean RMSD value can be observed after 2 ns. If one compares the 2d
RMSD plot of FadA5 in the neutral state (Figure 13.9-C) to cruzain in in the zwitterionic
state (Figure 13.9-B), it becomes clear that in case of FadA5 only snapshots after 7 ns in
environment A (right environment) are similar to structures in environment B leading to
low RMSD values in the upper part of the 2d-RMSD plot. Lastly, the dynamics of the
zwitterionic state of FadA5 in both environments have been analyzed. In terms of the mean
RMSD value a decrease below 1.5 A˚ can be observed after 1 ns and a rise to 4 A˚ after 8 ns.
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Figure 13.10: Mean RMSD values as a function of time considering protein environment in
a radius of 10 A˚ close to Cys25 for cruzain or Cys93 for FadA5. 200 snapshots have been
considered for each MD simulation. All values are given in A˚.
13.6 Conclusion
Investigations in respect to the proton transfer in cysteine histidine dyads were conducted
in this chapter to gain further insight environmental effects (i.e. enzyme environment). In
this study MD simulations and QM or QM/MM calculations were performed on FadA5 and
cruzain which served as test systems. Why are these investigations of interest? Cysteine
histidine dyads are often located in the active site of e.g. cysteine proteases and can be
adressed by covalent inhibitors. Still, the modification can only be initiated if the cysteine
is deprotonated to act as a nucleophile. Therefore, it is of importance to understand the
mechanism of the proton transfer in enzyme as well as the influence of the surroundings and
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its effects on the reaction.
Initially, MD simulations have been conducted to obtain a relaxed structure for the proton
transfer calculated on QM/MM level. In this context the neutral and zwitterionic proto-
nation states have been considered: a singly protonated cysteine and histidine (protonation
state I) or a deprotonated cysteine and doubly protonated histidine (protonation state II). It
was observable that the preferred protonation state is determined by the used snapshot. If it
is extracted by a MD simulation in the neutral state (Figure 13.1-A), it is favored compared
to the zwitterionic state (Figure 13.1-B) and vice versa. This was shown for all four cases by
a relaxed scan utilizing QM/MM methodologies on B3LYP/def-TZVP level. To benchmark
these results, starting- and endpoint as well as the transition state of the proton transfer have
been benchmarked with different wave function-based or DFT approaches. Additionally, the
basis set was increased to aug-cc-pVDZ to achieve a better description of negative charges.
In comparison to CCSD(T) spin component scaled methods perform best and are always
superior to DFT approaches. Those results reveal barriers in a range of ≈ 10 to 20 kcal/mol
while the state after proton transfer was less stable by values of ≈ 4 to 15 kcal/mol. If one
compares FadA5 and cruzain, the energy values obtained from the latter are always lower in
terms of the height of barrier or the proton transfer reaction energy.
To gain further insight on the influence of the protein environment on the proton transfer the
QM region of starting- and endpoint and also the transition state (from the neutral state )
were inserted in the “wrong” environment, i.e. in the environment of the zwitterionic proto-
nation state and vice versa. By doing so, a decrease in the height of barrier and furthermore,
a stabilization of the state after proton transfer is observable. Especially in case of protona-
tion state II (zwitterionic) of FadA5 no barrier was present and the neutral state after proton
transfer is about 20 kcal/mol more stable. These results show a large influence of the protein
surrounding in respect to the protonation states. This means that the change in environment
leads to the opposite description concerning the preference of the protonation state.
Furthermore, dynamics of the protein environment relaxation regarding the protonation
states have been investigated. It is understandable that the proton transfer itself is a fast
process. But how long does the protein environment need to adapt to the change of protona-
tion state? This question was tackled by classic MD simulations explained in the following:
The simulations included constrained atoms of the active site and considered both environ-
ments to allow an adaptation of the environment while fixing atoms of the QM region. By
doing so, a degree of comparability was ensured. It was observable that the relaxation of
the environment requires at least 1 ns but can also have a duration of 6 ns. Still, it has
to be mentioned that these relaxed structures mostly reveal RMSD values of 1.6 A˚ in the
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2d-RMSD plots. Therefore, it is hard to say how much time is exactly needed for a relaxation
of the environment to the respective protonation state. As mentioned above, however, the
surrounding requires at least 1 ns for relaxation towards the respective protonation state and
therefore revealing a qualitative answer.
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Figure 16.1: The variation in distance as a function of simulation time for RL1784 with
Cys296 or Cys310 in structure Ic (A), in structure IIa (B), in structure IIb (C) and in
structure IIc (D), corresponding to Figure 9.8.
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Figure 16.2: The variation in distance as a function of simulation time for RL1780 with
Cys296 or Cys310 in structure Ib (A) and in structure IIc (B) corresponding to Figure 9.8.
344
A
0 5 10 15 20 25 30 35 40 45 50
2
4
6
8
10
12
14
16
18
20
22
2
4
6
8
10
12
14
16
18
20
22
 
di
st
an
ce
 [Å
]
time [ns]
 Cys296-S(1)H to Glu85-O(1)
 
 
di
st
an
ce
 [Å
]
 Cys296-S(1)H to Glu85-O(2)
B
0 5 10 15 20 25 30 35 40 45 50
2
4
6
8
10
12
14
16
18
20
22
2
4
6
8
10
12
14
16
18
20
22
 
di
st
an
ce
 [Å
]
time [ns]
 Cys296-S(1)H to Glu85-O(1)
 
 
di
st
an
ce
 [Å
]
 Cys296-S(1)H to Glu85-O(2)
C
0 5 10 15 20 25 30 35 40 45 50
2
4
6
8
10
12
14
16
18
20
22
2
4
6
8
10
12
14
16
18
20
22
 
di
st
an
ce
 [Å
]
time [ns]
 Cys296-S(1)H to Glu85-O(1)
 
 
di
st
an
ce
 [Å
]
 Cys296-S(1)H to Glu85-O(2)
D
0 5 10 15 20 25 30 35 40 45 50
2
4
6
8
10
12
14
16
18
20
22
2
4
6
8
10
12
14
16
18
20
22
 
di
st
an
ce
 [Å
]
time [ns]
 Cys296-S(1)H to Glu85-O(1)
 
 
di
st
an
ce
 [Å
]
 Cys296-S(1)H to Glu85-O(2)
E
0 5 10 15 20 25 30 35 40 45 50
2
4
6
8
10
12
14
16
18
20
22
2
4
6
8
10
12
14
16
18
20
22
 
di
st
an
ce
 [Å
]
time [ns]
 Cys296-S(1)H to Glu85-O(1)
 
 
di
st
an
ce
 [Å
]
 Cys296-S(1)H to Glu85-O(2)
Figure 16.3: The variation in distance as a function of simulation time for Glu85 with Cys296
in presence of RL1784 in structure Ia (A), in structure Ic (B), in structure IIa (C), in
structure IIb (D) and in structure IIc (E), corresponding to Figure 9.12.
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Figure 16.4: The variation in distance as a function of simulation time b Glu85 with Cys296
in presence of RL1780 in structure Ia (A), in structure Ib (B), in structure Ic (C), in structure
IIa (D) and in structure IIc (E), corresponding to Figure 9.12.
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Figure 16.5: The variation in distance as a function of simulation time for Glu85 with Cys296
in presence of RL2132 in structure Ia (A), in structure Ic (B), in structure IIIb (C) and in
structure IIIc (D), corresponding to Figure 9.12.
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Figure 16.6: The variation in distance as a function of simulation time for Glu85 with Cys296
in absence of RL1784, RL1780 or RL2132 in structure Ia (A), in structure Ic (B), in structure
IIa (C), in structure IIb (D) and in structure IIc (E), corresponding to Figure 9.12.
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Figure 16.7: The variation in distance as a function of simulation time for Glu298 with
Cys310 in presence of RL1784 in structure Ia (A) and in structure Ic (B) corresponding to
Figure 9.17.
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Figure 16.8: The variation in distance as a function of simulation time for Glu298 with
Cys310 in presence of RL1780 in structure Ia (A), in structure Ib (B), in structure Ic (C),
in structure IIa (D), in structure IIb (E) and in structure IIc (F), corresponding to Figure
9.17.
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Figure 16.9: The variation in distance as a function of simulation time for Glu298 with
Cys310 in presence of RL2132 in structure Ia (A), in structure Ic (B), in structure IIa (C)
and in structure IIb (D), corresponding to Figure 9.17.
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Figure 16.10: The variation in distance as a function of simulation time for Glu298 with
Cys310 in absence of RL1784, RL1780 or RL2132 in structure Ia (A), in structure Ib (B), in
structure Ic (C) and in structure IIc (D), corresponding to Figure 9.17.
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Figure 16.11: The variation in distance as a function of simulation time for Arg15 with
Cys310 in presence of RL1784 in structure Ia (A), in structure Ic (B) and in structure IIc
(C), corresponding to Figure 9.21.
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Figure 16.12: The variation in distance as a function of simulation time for Arg15 with
Cys310 in presence of RL1780 in structure Ia (A), in structure Ib (B), in structure Ic (C),
in structure IIa (D) and in structure IIb (E), corresponding to Figure 9.21.
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Figure 16.13: The variation in distance as a function of simulation time for Arg15 with
Cys310 in presence of RL2132 in structure Ia (A), in structure Ib (B), in structure Ic (C), in
structure IIIa (D), in structure IIIb (E) and in structure IIIc (F), corresponding to Figure
9.21.
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Abbreviations
ADP Adenosine diphosphate
AIDS Acquired immunodefiency syndroms
Ala Alanine
AP Alchemical Perturbation
Arg Arginine
Asn Asparagine
Asp Aspartic Acid
ATP Adenosine Triphosphate
B3LYP Becke, 3-parameter, Lee-Yang functional
B3LYP-D B3LYP with Grimme’s dispersion correction
B3LYP G B3LYP implemented in Gaussian
Bm-LS Bacillus megaterium levansucrase
CAI Covalent allosteric inhibitor
CAST Conformational Analysis and Search Tool
CoA Coenzyme A
CCSD(T) Coupled Cluster with single and double and perturbative triple excitation
CHARMM Chemistry at Harvard macromolecular mechanics
CID Chemical induced dimerization
CNS Central nervous system
CPI Cysteine protease inhibitor
CTSC Cathepsin C
Cys Cysteine
DNA Desoxyribonucleic acid
DFT Density functional theory
DP Degree of polymerization
DPE Diphenylether
EC Enzyme commission
ECM Extracellular matrix
ENR Enoyl-(acyl-carrier-protein)
FAS Fatty acid biosynthesis
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FF Forcefield
GA Genetic algorithm
GAFF Generalized AMBER force field
GB Generalized Born
GGA Generalized gradient approximation
Gln Glutamine
Glu Glutamic acid
Gly Glycine
GPCR G protein-coupled receptors
GSK3 Glycogen synthase kinase 3
HAT Human African Trypanosomiasis
HF Hartree Fock
His Histidine
HIV Human immunodeficiency virus
IC Incremental construction
Ile Isoleucine
LDA Local density approximation
Leu Leucine
Lys Lysine
MA Matching algorithms
MAE Mean averaged error
MD Molecular dynamics
MDR multidrug-resistant
Met Methionine
MM Molecular mechanics
MP2 Møller-Plesset perturbation theory 2
MRSA Methicillin-resistant Staphylococcus Aureus
MTB Mycobacterium tuberculosis
NADPH Nicotinamide adenine dinucleotide phosphate
NADH Nicotinamde adenine dinucleotide
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NEB Nugded elastic band
NMR Nuclear magnetic resonance
NTD Neglected tropical disease
PB Poisson-Boltzmann
PDB Protein data bank
PDK1 Phosphoinositide-dependent protein kinase 1
PH Pleckstrin homology
Phe Phenylalanine
pHtMD pH-titration MD
PKB Protein kinase B
Pro Proline
Px Peroxidase
QM Quantum Mechanics
RNA Ribonucleic acid
RMSD Root mean square deviation
RTK Receptor tyrosine kinases
SAS Solvent accessible surface
SASA Solvent accessible surface area
SCF Self consistent field
SCS Spin component scaling
Ser Serine
SD standard deviation
T.b. Trypanosoma brucei
TB Tuberculosis
Thr Threonine
TPX Tryparedoxin
TR Trypanothione reductase
Trp Tryptophan
Tyr Tyrosine
UDP Uridine diphosphate
Val Valine
WHO World Health Organization
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